EXHIBIT AA

(12) United States Patent

Watanabe et al.

(10) Patent No.:

US 9,079,934 B2

(45) **Date of Patent:**

Jul. 14, 2015

(54) ANTISENSE NUCLEIC ACIDS

(75) Inventors: Naoki Watanabe, Tsukuba (JP); Youhei Satou, Tsukuba (JP); Shin'ichi Takeda,

Tokyo (JP); Tetsuya Nagata, Tokyo (JP)

(73) Assignees: NIPPON SHINYAKU CO., LTD., Kyoto-shi, Kyoto (JP); NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, Kodaira-shi, Tokyo (JP)

Subject to any disclaimer, the term of this (*) Notice: patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

13/819,520 (21) Appl. No.:

(22) PCT Filed: Aug. 31, 2011

PCT/JP2011/070318 (86) PCT No.:

§ 371 (c)(1),

(2), (4) Date: Apr. 10, 2013

(87) PCT Pub. No.: WO2012/029986

PCT Pub. Date: Mar. 8, 2012

Prior Publication Data (65)

US 2013/0211062 A1 Aug. 15, 2013

(30)Foreign Application Priority Data

Sep. 1, 2010 (JP) 2010-196032

(51)	Int. Cl.	
	C07H 21/02	(2006.01)
	C07H 21/04	(2006.01)
	A61K 31/70	(2006.01)
	C12N 15/11	(2006.01)
	C12N 15/113	(2010.01)
	C07H 21/00	(2006.01)
	C12O 1/68	(2006.01)

(52) U.S. Cl.

(2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3525 (2013.01); C12N 2320/33 (2013.01)

(58) Field of Classification Search

See application file for complete search history.

(56)**References Cited**

U.S. PATENT DOCUMENTS

6,653,467 E	31 11/2003	Matsuo et al.
2010/0130591 A	A1* 5/2010	Sazani et al 514/44 A
2010/0168212 A	A1* 7/2010	Popplewell et al 514/44 R
2012/0190728 A	A1* 7/2012	Bennett et al 514/44 A
2013/0109091 A	A1* 5/2013	Baker et al 435/375

FOREIGN PATENT DOCUMENTS

JP	2002-10790	1/2002
WO	2004/048570	6/2004
WO	2006/000057	1/2006
WO	2008/036127	3/2008
WO	2010/048586	4/2010
WO	2011/057350	5/2011

OTHER PUBLICATIONS

Linda J. Popplewell et al., "Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene," Mol. Ther., vol. 17, No. 3, Mar. 2009, pp. 554-561.

Linda J. Popplewell et al., "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human *DMD* gene: Implications for future clinical trials," Neuromuscular Disorders, vol. 20, No. 2, Feb. 2010, pp. 102-110.

Annemieke Aartsma-Rus et al., "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy," Neuromuscular Disorders, vol. 12, 2002, pp. S71-S77.

Steve D. Wilton et al., "Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript," Mol Ther., vol. 15, No. 7, Jul. 2007, pp. 1288-1296. Anthony P. Monaco et al., "An Explanation for the Phenotypic Dif-

ferences between Patients Bearing Partial Deletions of the DMD Locus," Genomics, 1988; 2, pp. 90-95.

Masafumi Matsuo, "Duchenne / Becker muscular dystrophy: from molecular diagnosis to gene therapy," Brain & Development, 1996; 18, pp. 167-172.

International Search Report dated Oct. 11, 2011 in PCT/JP2011/ 070318 filed Aug. 31, 2011.

* cited by examiner


Primary Examiner — Sean McGarry (74) Attorney, Agent, or Firm - Drinker Biddle & Reath LLP

(57)**ABSTRACT**

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.


7 Claims, 19 Drawing Sheets

U.S. Patent Jul. 14, 2015 Sheet 1 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 2 of 19 US 9,079,934 B2

Figure 2




U.S. Patent

Jul. 14, 2015


Sheet 3 of 19

US 9,079,934 B2

Figure 3



U.S. Patent Jul. 14, 2015 Sheet 4 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015

Sheet 5 of 19


US 9,079,934 B2

Figure 5




U.S. Patent Jul. 14, 2015 Sheet 6 of 19 US 9,079,934 B2


Figure 6




U.S. Patent Jul. 14, 2015 Sheet 7 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 8 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 9 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 10 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 11 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 12 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 13 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 14 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 15 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 16 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 17 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 18 of 19 US 9,079,934 B2




Figure 18

U.S. Patent Jul. 14, 2015 Sheet 19 of 19 US 9,079,934 B2




Figure 19

1 ANTISENSE NUCLEIC ACIDS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the National Stage of International Application No. PCT/JP2011/070318, filed Aug. 31, 2011, and claims benefit of Japanese Application No. 2010-196032, filed on Sep. 1, 2010, all of which are herein incorporated by reference in their entirety.

SEQUENCE LISTING

The instant application contains a sequence listing which has been submitted in ASCII format via EFS-Web and is ¹⁵ hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 29, 2013, is named G12_0074_Seq_Listing_revised_Sq_No_64.txt and is 24,294 bytes in size.

TECHNICAL FIELD

The present invention relates to an antisense oligomer which causes skipping of exon 53 in the human dystrophin gene, and a pharmaceutical composition comprising the oli- 25 gomer.

BACKGROUND ART

Duchenne muscular dystrophy (DMD) is the most frequent form of hereditary progressive muscular dystrophy that affects one in about 3,500 newborn boys. Although the motor functions are rarely different from healthy humans in infancy and childhood, muscle weakness is observed in children from around 4 to 5 years old. Then, muscle weakness progresses to the loss of ambulation by about 12 years old and death due to cardiac or respiratory insufficiency in the twenties. DMD is such a severe disorder. At present, there is no effective therapy for DMD available, and it has been strongly desired to develop a novel therapeutic agent.

DMD is known to be caused by a mutation in the dystrophin gene. The dystrophin gene is located on X chromosome and is a huge gene consisting of 2.2 million DNA nucleotide pairs. DNA is transcribed into mRNA precursors, and introns are removed by splicing to synthesize mRNA in which 79 exons are joined together. This mRNA is translated into 3,685 amino acids to produce the dystrophin protein. The dystrophin protein is associated with the maintenance of membrane stability in muscle cells and necessary to make muscle cells less fragile. The dystrophin gene from patients with DMD 50 contains a mutation and hence, the dystrophin protein, which is functional in muscle cells, is rarely expressed. Therefore, the structure of muscle cells cannot be maintained in the body of the patients with DMD, leading to a large influx of calcium ions into muscle cells. Consequently, an inflammation-like 55 response occurs to promote fibrosis so that muscle cells can be regenerated only with difficulty.

Becker muscular dystrophy (BMD) is also caused by a mutation in the dystrophin gene. The symptoms involve muscle weakness accompanied by atrophy of muscle but are 60 typically mild and slow in the progress of muscle weakness, when compared to DMD. In many cases, its onset is in adulthood. Differences in clinical symptoms between DMD and BMD are considered to reside in whether the reading frame for amino acids on the translation of dystrophin mRNA into 65 the dystrophin protein is disrupted by the mutation or not (Non-Patent Document 1). More specifically, in DMD, the

2

presence of mutation shifts the amino acid reading frame so that the expression of functional dystrophin protein is abolished, whereas in BMD the dystrophin protein that functions, though imperfectly, is produced because the amino acid reading frame is preserved, while a part of the exons are deleted by the mutation.

Exon skipping is expected to serve as a method for treating DMD. This method involves modifying splicing to restore the amino acid reading frame of dystrophin mRNA and induce expression of the dystrophin protein having the function partially restored (Non-Patent Document 2). The amino acid sequence part, which is a target for exon skipping, will be lost. For this reason, the dystrophin protein expressed by this treatment becomes shorter than normal one but since the amino acid reading frame is maintained, the function to stabilize muscle cells is partially retained. Consequently, it is expected that exon skipping will lead DMD to the similar symptoms to that of BMD which is milder. The exon skipping approach has passed the animal tests using mice or dogs and now is currently assessed in clinical trials on human DMD patients.

The skipping of an exon can be induced by binding of antisense nucleic acids targeting either 5' or 3' splice site or both sites, or exon-internal sites. An exon will only be included in the mRNA when both splice sites thereof are recognized by the spliceosome complex. Thus, exon skipping can be induced by targeting the splice sites with antisense nucleic acids. Furthermore, the binding of an SR protein to an exonic splicing enhancer (ESE) is considered necessary for an exon to be recognized by the splicing mechanism. Accordingly, exon skipping can also be induced by targeting ESE.

Since a mutation of the dystrophin gene may vary depending on DMD patients, antisense nucleic acids need to be designed based on the site or type of respective genetic mutation. In the past, antisense nucleic acids that induce exon skipping for all 79 exons were produced by Steve Wilton, et al., University of Western Australia (Non-Patent Document 3), and the antisense nucleic acids which induce exon skipping for 39 exons were produced by Annemieke Aartsma-Rus, et al., Netherlands (Non-Patent Document 4).

It is considered that approximately 8% of all DMD patients may be treated by skipping the 53rd exon (hereinafter referred to as "exon 53"). In recent years, a plurality of research organizations reported on the studies where exon 53 in the dystrophin gene was targeted for exon skipping (Patent Documents 1 to 4; Non-Patent Document 5). However, a technique for skipping exon 53 with a high efficiency has not yet been established.

Patent Document 1: International Publication WO 2006/ 000057

Patent Document 2: International Publication WO 2004/ 048570

Patent Document 3: US 2010/0168212

Patent Document 4: International Publication WO 2010/ 048586

Non-Patent Document 1: Monaco A. P. et al., Genomics 1988; 2: p. 90-95

Non-Patent Document 2: Matsuo M., Brain Dev 1996; 18: p. 167-172

Non-Patent Document 3: Wilton S. D., et al., Molecular Therapy 2007: 15: p. 1288-96

Non-Patent Document 4: Annemieke Aartsma-Rus et al., (2002) Neuromuscular Disorders 12: S71-S77

Non-Patent Document 5: Linda J. Popplewell et al., (2010) Neuromuscular Disorders, vol. 20, no. 2, p. 102-10

3

DISCLOSURE OF THE INVENTION

Under the foregoing circumstances, antisense oligomers that strongly induce exon 53 skipping in the dystrophin gene and muscular dystrophy therapeutics comprising oligomers thereof have been desired.

As a result of detailed studies of the structure of the dystrophin gene, the present inventors have found that exon 53 skipping can be induced with a high efficiency by targeting the sequence consisting of the 32nd to the 56th nucleotides from the 5' end of exon 53 in the mRNA precursor (hereinafter referred to as "pre-mRNA") in the dystrophin gene with antisense oligomers. Based on this finding, the present inventors have accomplished the present invention.

That is, the present invention is as follows.

- [1] An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a 20 nucleotide sequence complementary to any one of the sequences consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 56th, the 31st to the 57th, the 31st to the 58th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 58th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 53rd, the 34th to the 54th, the 34th to the 55th, the 34th to the 56th, the 34th to the 30 57th, the 34th to the 58th, the 35th to the 53rd, the 35th to the 54th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 58th, the 36th to the 53rd, the 36th to the 54th, the 36th to the 55th, the 36th to the 56th, the 36th to the 35 57th, or the 36th to the 58th nucleotides, from the 5' end of the 53rd exon in the human dystrophin gene.
- [2] The antisense oligomer according to [1] above, which is an oligonucleotide.
- [3] The antisense oligomer according to [2] above, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified.
- [4] The antisense oligomer according to [3] above, wherein the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group is replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R' is an alkylene).
- [5] The antisense oligomer according to [3] or [4] above, wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond and a boranophosphate bond.
- [6] The antisense oligomer according to [1] above, which is 60 a morpholino oligomer.
- [7] The antisense oligomer according to [6] above, which is a phosphorodiamidate morpholino oligomer.
- [8] The antisense oligomer according to any one of [1] to 65 [7] above, wherein the 5' end is any one of the groups of chemical formulae (1) to (3) below:

[9] The antisense oligomer according to any one of [1] to [8] above, consisting of a nucleotide sequence complementary to the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides from the 5' end of the 53rd exon in the human dystrophin gene.

[10] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 2 to 37.

[11] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 11, 17, 23, 29 and 35.

[12] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by SEQ ID NO: 11 or 35.

[13] A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the antisense oligomer according to any one of [1] to [12] above, or a pharmaceutically acceptable salt or hydrate thereof.

The antisense oligomer of the present invention can induce exon 53 skipping in the human dystrophin gene with a high efficiency. In addition, the symptoms of Duchenne muscular dystrophy can be effectively alleviated by administering the pharmaceutical composition of the present invention.

BRIEF DESCRIPTION OF DRAWINGS

- FIG. 1 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cell line (RD cells).
- FIG. 2 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into human normal tissue-derived fibroblasts (TIG-119 cells) to induce differentiation into muscle cells.
- FIG. 3 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into human DMD patient-derived fibroblasts (5017 cells) to induce differentiation into muscle cells.

5

- FIG. 4 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle cells.
- FIG. 5 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells.
- FIG. 6 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells.
- FIG. 7 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52 or deletion of exons 48-52) to induce 20 differentiation into muscle cells.
- FIG. **8** shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle ²⁵ cells.
- FIG. 9 shows the efficiency of exon 53 skipping (2'-OMe-S—RNA) in the human dystrophin gene in human rhab-domyosarcoma cells (RD cells).
- FIG. **10** shows the efficiency of exon 53 skipping (T-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 11 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 12 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 13 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyo-sarcoma cells (RD cells).
- FIG. 14 shows the efficiency of exon 53 skipping (T-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. **15** shows the efficiency of exon 53 skipping (2'-OMe- 45 S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 16 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 17 shows the efficiency of exon 53 skipping (T-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. **18** shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cells 55 (RD cells) at the respective concentrations of the oligomers.
- FIG. 19 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells) at the respective concentrations of the oligomers.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention is described in detail. The embodiments described below are intended to be presented by way of example merely to describe the invention but not limited only to the following embodiments. The

present invention may be implemented in various ways without departing from the gist of the invention.

All of the publications, published patent applications, patents and other patent documents cited in the specification are herein incorporated by reference in their entirety. The specification hereby incorporates by reference the contents of the specification and drawings in the Japanese Patent Application (No. 2010-196032) filed Sep. 1, 2010, from which the priority was claimed.

0 1. Antisense Oligomer

The present invention provides the antisense oligomer (hereinafter referred to as the "oligomer of the present invention") which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to any one of the sequences (hereinafter also referred to as "target sequences") consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 56th, the 31st to the 57th, the 31st to the 58th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 58th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 53rd, the 34th to the 54th, the 34th to the 55th, the 34th to the 56th, the 34th to the 57th, the 34th to the 58th, the 35th to the 53rd, the 35th to the 54th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 58th, the 36th to the 53rd, the 36th to the 54th, the 36th to the 55th, the 36th to the 56th, the 36th to the 57th, or the 36th to the 58th nucleotides, from the 5' end of the 53rd exon in the human dystrophin gene.

[Exon 53 in Human Dystrophin Gene]

In the present invention, the term "gene" is intended to mean a genomic gene and also include cDNA, mRNA precursor and mRNA. Preferably, the gene is mRNA precursor, i.e., pre-mRNA.

In the human genome, the human dystrophin gene locates at locus Xp21.2. The human dystrophin gene has a size of 3.0 Mbp and is the largest gene among known human genes. However, the coding regions of the human dystrophin gene are only 14 kb, distributed as 79 exons throughout the human dystrophin gene (Roberts, R G., et al., Genomics, 16: 536-538 (1993)). The pre-mRNA, which is the transcript of the human dystrophin gene, undergoes splicing to generate mature mRNA of 14 kb. The nucleotide sequence of human wild-type dystrophin gene is known (GenBank Accession No. NM_004006).

The nucleotide sequence of exon 53 in the human wild-type dystrophin gene is represented by SEQ ID NO: 1.

The oligomer of the present invention is designed to cause skipping of exon 53 in the human dystrophin gene, thereby modifying the protein encoded by DMD type of dystrophin gene into the BMD type of dystrophin protein. Accordingly, exon 53 in the dystrophin gene that is the target of exon skipping by the oligomer of the present invention includes both wild and mutant types.

Specifically, exon 53 mutants of the human dystrophin gene include the polynucleotides defined in (a) or (b) below.

- (a) A polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ
 ID NO: 1; and,
 - (b) A polynucleotide consisting of a nucleotide sequence having at least 90% identity with the nucleotide sequence of SEQ ID NO: 1.

As used herein, the term "polynucleotide" is intended to mean DNA or RNA.

As used herein, the term "polynucleotide that hybridizes under stringent conditions" refers to, for example, a poly-

- 7

nucleotide obtained by colony hybridization, plaque hybridization, Southern hybridization or the like, using as a probe all or part of a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of, e.g., SEQ ID NO: 1. The hybridization method which may be used includes methods described in, for example, "Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor, Laboratory Press 2001," "Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997," etc.

As used herein, the term "complementary nucleotide sequence" is not limited only to nucleotide sequences that form Watson-Crick pairs with target nucleotide sequences, but is intended to also include nucleotide sequences which form Wobble base pairs. As used herein, the term Watson- 15 Crick pair refers to a pair of nucleobases in which hydrogen bonds are formed between adenine-thymine, adenine-uracil or guanine-cytosine, and the term Wobble base pair refers to a pair of nucleobases in which hydrogen bonds are formed between guanine-uracil, inosine-uracil, inosine-adenine or 20 inosine-cytosine. As used herein, the term "complementary nucleotide sequence" does not only refers to a nucleotide sequence 100% complementary to the target nucleotide sequence but also refers to a complementary nucleotide sequence that may contain, for example, 1 to 3, 1 or 2, or one 25 nucleotide non-complementary to the target nucleotide sequence.

As used herein, the term "stringent conditions" may be any of low stringent conditions, moderate stringent conditions or high stringent conditions. The term "low stringent condi- 30 tions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 32° C. The term "moderate stringent conditions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 42° C., or 5×SSC, 1% SDS, 50 mM Tris-HCl (pH 7.5), 50% formamide at 42° C. The term 35 "high stringent conditions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 50° C. or 0.2×SSC, 0.1% SDS at 65° C. Under these conditions, polynucleotides with higher homology are expected to be obtained efficiently at higher temperatures, although multiple 40 factors are involved in hybridization stringency including temperature, probe concentration, probe length, ionic strength, time, salt concentration and others, and those skilled in the art may appropriately select these factors to achieve similar stringency.

When commercially available kits are used for hybridization, for example, an Alkphos Direct Labeling and Detection 8

System (GE Healthcare) may be used. In this case, according to the attached protocol, after cultivation with a labeled probe overnight, the membrane is washed with a primary wash buffer containing 0.1% (w/v) SDS at 55° C., thereby detecting hybridized polynucleotides. Alternatively, in producing a probe based on the entire or part of the nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1, hybridization can be detected with a DIG Nucleic Acid Detection Kit (Roche Diagnostics) when the probe is labeled with digoxigenin (DIG) using a commercially available reagent (e.g., a PCR Labeling Mix (Roche Diagnostics), etc.).

In addition to the polynucleotides described above, other polynucleotides that can be hybridized include polynucleotides having 90% or higher, 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, 99% or higher, 99.1% or higher, 99.2% or higher, 99.3% or higher, 99.4% or higher, 99.5% or higher, 99.6% or higher, 99.7% or higher, 99.8% or higher or 99.9% or higher identity with the polynucleotide of SEQ ID NO: 1, as calculated by homology search software BLAST using the default parameters.

The identity between nucleotide sequences may be determined using algorithm BLAST (Basic Local Alignment Search Tool) by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc. Natl. Acad. Sci. USA 90: 5873, 1993). Programs called BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul S F, et al: J. Mol. Biol. 215: 403, 1990). When a nucleotide sequence is sequenced using BLASTN, the parameters are, for example, score=100 and wordlength=12. When BLAST and Gapped BLAST programs are used, the default parameters for each program are employed.

Examples of the nucleotide sequences complementary to the sequences consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 55th, the 31st to the 57th, the 31st to the 55th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 55th, the 32nd to the 57th, the 32nd to the 55th, the 33rd to the 57th, the 33rd to the 55th, the 33rd to the 55th, the 33rd to the 57th, the 33rd to the 55th, the 33rd to the 57th, the 33rd to the 55th, the 34th to the 57th, the 34th to the 55th, the 34th to the 57th, the 34th to the 55th, the 35th to the 53rd, the 35th to the 57th, the 35th to the 55th, the 35th to the 57th, the 35th to the 55th, the 36th to the 57th, the 36th to the 55th, the 36th to the 57th, the 36th to the 55th, the 36th to the 57th and the 36th to the 55th, the 36th to the 57th and the 36th to the 58th nucleotides, from the 5' end of exon 53.

TABLE 1

Target sequence ir exon 53	ı Complementary nucleotide sequence	SEQ	ID	NO:	
31-53	5'-CCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	2
31-54	5'-TCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	3
31-55	5'-CTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	4
31-56	5'-CCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	5
31-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	6
31-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	7
32-53	5'-CCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	8
32-54	5'-TCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	9

9

TABLE 1 -continued

	TABLE 1 -CONCINUEA	
Target sequence in		
exon 53	Complementary nucleotide sequence	SEQ ID NO:
32-55	5'-CTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ ID NO: 10
32-56	5'-CCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ ID NO: 11
32-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ ID NO: 12
32-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ ID NO: 13
33-53	5'-CCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 14
33-54	5'-TCCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 15
33-55	5'-CTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 16
33-56	5'-CCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 17
33-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 18
33-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ ID NO: 19
34-53	5'-CCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 20
34-54	5'-TCCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 21
34-55	5'-CTCCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 22
34-56	5'-CCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 23
34-57	5'-GCCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 24
34-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ ID NO: 25
35-53	5'-CCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 26
35-54	5'-TCCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 27
35-55	5'-CTCCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 28
35-56	5'-CCTCCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 29
35-57	5'-GCCTCCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 30
35-58	5'-TGCCTCCGGTTCTGAAGGTGTTCT-3'	SEQ ID NO: 31
36-53	5'-CCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 32
36-54	5'-TCCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 33
36-55	5'-CTCCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 34
36-56	5'-CCTCCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 35
36-57	5'-GCCTCCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 36
36-58	5'-TGCCTCCGGTTCTGAAGGTGTTC-3'	SEQ ID NO: 37

It is preferred that the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th, the 33rd to the 56th, the 34th to the 56th, the 35th to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29 or SEQ ID NO: 35), from the 5' end of the 53rd exon in the human dystrophin gene.

Preferably, the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11 or SEQ ID NO: 35), from the 5' end of the 53rd exon in the human dystrophin gene.

The term "cause skipping of the 53rd exon in the human dystrophin gene" is intended to mean that by binding of the

oligomer of the present invention to the site corresponding to exon 53 of the transcript (e.g., pre-mRNA) of the human dystrophin gene, for example, the nucleotide sequence corresponding to the 5' end of exon 54 is spliced at the 3' side of the nucleotide sequence corresponding to the 3' end of exon 51 in DMD patients with deletion of, exon 52 when the transcript undergoes splicing, thus resulting in formation of mature mRNA which is free of codon frame shift.

Accordingly, it is not required for the oligomer of the present invention to have a nucleotide sequence 100% complementary to the target sequence, as far as it causes exon 53 skipping in the human dystrophin gene. The oligomer of the present invention may include, for example, 1 to 3, 1 or 2, or one nucleotide non-complementary to the target sequence.

Herein, the term "binding" described above is intended to mean that when the oligomer of the present invention is mixed

10

25

11

with the transcript of human dystrophin gene, both are hybridized under physiological conditions to form a double strand nucleic acid. The term "under physiological conditions" refers to conditions set to mimic the in vivo environment in terms of pH, salt composition and temperature. The conditions are, for example, 25 to 40° C., preferably 37° C., pH 5 to 8, preferably pH 7.4 and 150 mM of sodium chloride concentration.

Whether the skipping of exon 53 in the human dystrophin gene is caused or not can be confirmed by introducing the 10 oligomer of the present invention into a dystrophin expression cell (e.g., human rhabdomyosarcoma cells), amplifying the region surrounding exon 53 of mRNA of the human dystrophin gene from the total RNA of the dystrophin expression cell by RT-PCR and performing nested PCR or sequence 15 analysis on the PCR amplified product.

The skipping efficiency can be determined as follows. The mRNA for the human dystrophin gene is collected from test cells; in the mRNA, the polynucleotide level "A" of the band where exon 53 is skipped and the polynucleotide level "B" of 20 the band where exon 53 is not skipped are measured. Using these measurement values of "A" and "B," the efficiency is calculated by the following equation:

Skipping efficiency (%)= $A/(A+B)\times 100$

The oligomer of the present invention includes, for example, an oligonucleotide, morpholino oligomer or peptide nucleic acid (PNA), having a length of 18 to 28 nucleotides. The length is preferably from 21 to 25 nucleotides and morpholino oligomers are preferred.

The oligonucleotide described above (hereinafter referred to as "the oligonucleotide of the present invention") is the oligomer of the present invention composed of nucleotides as constituent units. Such nucleotides may be any of ribonucleotides, deoxyribonucleotides and modified nucleotides.

The modified nucleotide refers to one having fully or partly modified nucleobases, sugar moieties and/or phosphate-binding regions, which constitute the ribonucleotide or deoxyribonucleotide.

The nucleobase includes, for example, adenine, guanine, 40 hypoxanthine, cytosine, thymine, uracil, and modified bases thereof. Examples of such modified nucleobases include, but not limited to, pseudouracil, 3-methyluracil, dihydrouracil, 5-alkylcytosines (e.g., 5-methylcytosine), 5-alkyluracils (e.g., 5-ethyluracil), 5-halouracils (5-bromouracil), 6-azapyrimidine, 6-alkylpyrimidines (6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5'-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine, 50 2-methylguanine, N6-methyladenine, 2-methyladenine, 5-methoxyaminomethyl-2-thiouracil, 7-methylguanine, $5-methyl aminomethyl uracil, \\ 5-methyl carbonyl methyl uracil,$ 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N6isopentenyladenine, uracil-5-oxyacetic acid, 2-thiocytosine, 55 purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imidazole, xanthine, etc.

Modification of the sugar moiety may include, for example, modifications at the 2'-position of ribose and modifications of the other positions of the sugar. The modification $_{60}$ at the 2'-position of ribose includes replacement of the 2'-OH of ribose with OR, R, R'OR, SH, SR, NH2, NHR, NR2, N3, CN, F, Cl, Br or I, wherein R represents an alkyl or an aryl and R' represents an alkylene.

The modification for the other positions of the sugar 65 includes, for example, replacement of O at the 4' position of ribose or deoxyribose with S, bridging between 2' and 4'

12

positions of the sugar, e.g., LNA (locked nucleic acid) or ENA (2'-O,4'-C-ethylene-bridged nucleic acids), but is not limited thereto

A modification of the phosphate-binding region includes, for example, a modification of replacing phosphodiester bond with phosphorothioate bond, phosphorodithioate bond, alkyl phosphonate bond, phosphoroamidate bond or boranophosphate bond (Enya et al: Bioorganic & Medicinal Chemistry, 2008, 18, 9154-9160) (cf., e.g., Japan Domestic Re-Publications of PCT Application Nos. 2006/129594 and 2006/038608).

The alkyl is preferably a straight or branched alkyl having 1 to 6 carbon atoms. Specific examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl and isohexyl. The alkyl may optionally be substituted. Examples of such substituents are a halogen, an alkoxy, cyano and nitro. The alkyl may be substituted with 1 to 3 substituents.

The cycloalkyl is preferably a cycloalkyl having 5 to 12 carbon atoms. Specific examples include cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclodecyl and cyclododecyl.

The halogen includes fluorine, chlorine, bromine and jodine.

The alkoxy is a straight or branched alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy, isohexyloxy, etc. Among others, an alkoxy having 1 to 3 carbon atoms is preferred.

The aryl is preferably an aryl having 6 to 10 carbon atoms. Specific examples include phenyl, α -naphthyl and β -naphthyl. Among others, phenyl is preferred. The aryl may optionally be substituted. Examples of such substituents are an alkyl, a halogen, an alkoxy, cyano and nitro. The aryl may be substituted with one to three of such substituents.

The alkylene is preferably a straight or branched alkylene having 1 to 6 carbon atoms. Specific examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 2-(ethyl) trimethylene and 1-(methyl) tetramethylene.

The acyl includes a straight or branched alkanoyl or aroyl. Examples of the alkanoyl include formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, hexanoyl, etc. Examples of the aroyl include benzoyl, toluoyl and naphthoyl. The aroyl may optionally be substituted at substitutable positions and may be substituted with an alkyl(s).

Preferably, the oligonucleotide of the present invention is the oligomer of the present invention containing a constituent unit represented by general formula below wherein the —OH group at position 2' of ribose is substituted with methoxy and the phosphate-binding region is a phosphorothioate bond:

wherein Base represents a nucleobase.

10

15

20

25

13

The oligonucleotide of the present invention may be easily synthesized using various automated synthesizer (e.g., AKTA oligopilot plus 10/100 (GE Healthcare)). Alternatively, the synthesis may also be entrusted to a third-party organization (e.g., Promega Inc., or Takara Co.), etc.

The morpholino oligomer of the present invention is the oligomer of the present invention comprising the constituent unit represented by general formula below:

wherein Base has the same significance as defined above, and, W represents a group shown by any one of the following groups:

$$Z=P-X$$
 $Z=P-X$ Y_1 $Z=P-X$
 Y_2

wherein X represents $-CH_2R^1$, $-O-CH_2R'$, 35 $-S-CH_2R^1$, $-NR_2R^3$ or F;

R1 represents H or an alkyl;

R² and R³, which may be the same or different, each represents H, an alkyl, a cycloalkyl or an aryl;

Y₁ represents O, S, CH₂ or NR¹;

Y₂ represents O, S or NR¹;

Z represents O or S.

Preferably, the morpholino oligomer is an oligomer comprising a constituent unit represented by general formula below (phosphorodiamidate morpholino oligomer (hereinafter referred to as "PMO")).

wherein Base, R^2 and R^3 have the same significance as defined above.

The morpholino oligomer may be produced in accordance with, e.g., WO 1991/009033 or WO 2009/064471. In particular, PMO can be produced by the procedure described in WO 2009/064471 or produced by the process shown below.

14

[Method for Producing PMO]

An embodiment of PMO is, for example, the compound represented by general formula (I) below (hereinafter PMO (I)).

wherein Base, R² and R³ have the same significance as defined above; and,

n is a given integer of 1 to 99, preferably a given integer of 18 to 28.

PMO (I) can be produced in accordance with a known method, for example, can be produced by performing the procedures in the following steps.

The compounds and reagents used in the steps below are not particularly limited so long as they are commonly used to prepare PMO.

Also, the following steps can all be carried out by the liquid phase method or the solid phase method (using manuals or commercially available solid phase automated synthesizers). In producing PMO by the solid phase method, it is desired to use automated synthesizers in view of simple operation procedures and accurate synthesis.

(1) Step A:

50

The compound represented by general formula (II) below (hereinafter referred to as Compound (II)) is reacted with an acid to prepare the compound represented by general formula (III) below (hereinafter referred to as Compound (III)):

wherein n, R² and R³ have the same significance as defined above:

each \boldsymbol{B}^{P} independently represents a nucleobase which may $\ _{20}$ optionally be protected;

T represents trityl, monomethoxytrityl or dimethoxytrityl; and,

L represents hydrogen, an acyl or a group represented by general formula (IV) below (hereinafter referred to as group 25 (IV)).

The "nucleobase" for B^P includes the same "nucleobase" as in Base, provided that the amino or hydroxy group in the nucleobase shown by B^P may be protected.

Such protective group for amino is not particularly limited so long as it is used as a protective group for nucleic acids. Specific examples include benzoyl, 4-methoxybenzoyl, acetyl, propionyl, butyryl, isobutyryl, phenylacetyl, phenoxyacetyl, 4-tert-butylphenoxyacetyl, 4-isopropylphenoxyacetyl and (dimethylamino)methylene. Specific examples of the protective group for the hydroxy group include 2-cyanoethyl, 4-nitrophenethyl, phenylsulfonylethyl, methylsulfonylethyl and trimethylsilylethyl, and phenyl, which may be substituted by 1 to 5 electron-withdrawing group at optional substitutable positions, diphenylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylphenylcarbamoyl, 1-pyrrolidinylcarbamoyl, morpholinocarbamoyl, 4-(tert-butylcarboxy) benzyl, 4-[(dimethylamino)carboxyl]benzyl and 4-(phenylcarboxy)benzyl, (cf., e.g., WO 2009/064471).

The "solid carrier" is not particularly limited so long as it is a carrier usable for the solid phase reaction of nucleic acids. It is desired for the solid carrier to have the following properties: 50 e.g., (i) it is sparingly soluble in reagents that can be used for the synthesis of morpholino nucleic acid derivatives (e.g., dichloromethane, acetonitrile, tetrazole, N-methylimidazole, pyridine, acetic anhydride, lutidine, trifluoroacetic acid); (ii) it is chemically stable to the reagents usable for the synthesis 55 of morpholino nucleic acid derivatives; (iii) it can be chemically modified; (iv) it can be charged with desired morpholino nucleic acid derivatives; (v) it has a strength sufficient to withstand high pressure through treatments; and (vi) it has a uniform particle diameter range and distribution. Specifi- 60 cally, swellable polystyrene (e.g., aminomethyl polystyrene resin 1% dibenzylbenzene crosslinked (200-400 mesh) (2.4-3.0 mmol/g) (manufactured by Tokyo Chemical Industry), Aminomethylated Polystyrene Resin.HCl [dibenzylbenzene 1%, 100-200 mesh] (manufactured by Peptide Institute, 65 Inc.)), non-swellable polystyrene (e.g., Primer Support (manufactured by GE Healthcare)), PEG chain-attached

16

polystyrene (e.g., NH₂—PEG resin (manufactured by Watanabe Chemical Co.), TentaGel resin), controlled pore glass (controlled pore glass; CPG) (manufactured by, e.g., CPG), oxalyl-controlled pore glass (cf., e.g., Alul et al., Nucleic Acids Research, Vol. 19, 1527 (1991)), TentaGel support-aminopolyethylene glycol-derivatized support (e.g., Wright et al., cf., Tetrahedron Letters, Vol. 34, 3373 (1993)), and a copolymer of Poros-polystyrene/divinylbenzene.

A "linker" which can be used is a known linker generally used to connect nucleic acids or morpholino nucleic acid derivatives. Examples include 3-aminopropyl, succinyl, 2,2'-diethanolsulfonyl and a long chain alkyl amino (LCAA).

This step can be performed by reacting Compound (II) with an acid.

The "acid" which can be used in this step includes, for example, trifluoroacetic acid, dichloroacetic acid and trichloroacetic acid. The acid used is appropriately in a range of, for example, 0.1 mol equivalent to 1000 mol equivalents based on 1 mol of Compound (II), preferably in a range of 1 mol equivalent to 100 mol equivalents based on 1 mol of Compound (II).

An organic amine can be used in combination with the acid described above. The organic amine is not particularly limited and includes, for example, triethylamine. The amount of the organic amine used is appropriately in a range of, e.g., 0.01 mol equivalent to 10 mol equivalents, and preferably in a range of 0.1 mol equivalent to 2 mol equivalents, based on 1 mol of the acid.

When a salt or mixture of the acid and the organic amine is used in this step, the salt or mixture includes, for example, a salt or mixture of trifluoroacetic acid and triethylamine, and more specifically, a mixture of 1 equivalent of triethylamine and 2 equivalents of trifluoroacetic acid.

The acid which can be used in this step may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, dichloromethane, acetonitrile, an alcohol (ethanol, isopropanol, trifluoroethanol, etc.), water, or a mixture thereof.

The reaction temperature in the reaction described above is preferably in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35° C.

The reaction time may vary depending upon kind of the acid used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

After completion of this step, a base may be added, if necessary, to neutralize the acid remained in the system. The "base" is not particularly limited and includes, for example, diisopropylamine. The base may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% (v/v) to 30% (v/v).

The solvent used in this step is not particularly limited so long as it is inert to the reaction, and includes dichloromethane, acetonitrile, an alcohol (ethanol, isopropanol, trifluoroethanol, etc.), water, and a mixture thereof. The reaction temperature is preferably in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35° C.

The reaction time may vary depending upon kind of the base used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

17

In Compound (II), the compound of general formula (IIa) below (hereinafter Compound (IIa)), wherein n is 1 and L is a group (IV), can be produced by the following procedure.

wherein $B^{\mathcal{F}}$, T, linker and solid carrier have the same significance as defined above. Step 1:

The compound represented by general formula (V) below is reacted with an acylating agent to prepare the compound ²⁰ represented by general formula (VI) below (hereinafter referred to as Compound (VI)).

wherein B^P , T and linker have the same significance as defined above; and, R^4 represents hydroxy, a halogen or $_{45}$ amino.

This step can be carried out by known procedures for introducing linkers, using Compound (V) as the starting material.

In particular, the compound represented by general formula (VIa) below can be produced by performing the method known as esterification, using Compound (V) and succinic anhydride.

18

wherein B^P and T have the same significance as defined above.

Step 2:

 $Compound \, (VI) \, is \, reacted \, with \, a \, solid \, career \, by \, a \, condensing \, agent \, to \, prepare \, Compound \, (IIa).$

$$\mathbb{R}^4$$
 linker \mathbb{R}^P \mathbb{R}^P

$$\begin{array}{c|c} \text{solid carrier} & & \\ & &$$

wherein B^P , R^4 , T, linker and solid carrier have the same significance as defined above.

This step can be performed using Compound (VI) and a solid carrier in accordance with a process known as condensation reaction.

In Compound (II), the compound represented by general formula (IIa2) below wherein n is 2 to 99 and L is a group represented by general formula (IV) can be produced by using Compound (IIa) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

wherein B^P , R^2 , R^3 , T, linker and solid carrier have the same significance as defined above; and,

n' represents 1 to 98.

65 In Compound (II), the compound of general formula (IIb) below wherein n is 1 and L is hydrogen can be produced by the procedure described in, e.g., WO 1991/009033.

19

wherein B^P and T have the same significance as defined above

In Compound (II), the compound represented by general formula (IIb2) below wherein n is 2 to 99 and L is hydrogen can be produced by using Compound (IIb) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

$$\begin{array}{c|c} \mathbf{H} & & & \\$$

wherein B^{P} , n', R^{2} , R^{3} and T have the same significance as defined above.

In Compound (II), the compound represented by general formula (IIc) below wherein n is 1 and L is an acyl can be produced by performing the procedure known as acylation reaction, using Compound (IIb).

$$\mathbb{R}^{5}$$
 O
 \mathbb{B}^{p}
 \mathbb{N}
 $\mathbb{$

wherein $\mathbf{B}^{\mathcal{F}}$ and T have the same significance as defined above; and,

R5 represents an acyl.

In Compound (II), the compound represented by general formula (IIc2) below wherein n is 2 to 99 and L is an acyl can be produced by using Compound (IIc) as the starting material and repeating step A and step B of the PMO production 65 method described in the specification for a desired number of times.

$$\begin{array}{c}
\mathbb{R}^{5} \\
 & \\
\mathbb{R}^{2} \\
 & \\
\mathbb{R}^{3} \\
 & \\
\mathbb{Q}
\end{array}$$
(IIc2)

20

wherein $B^{P}, n^{t}, R^{2}, R^{3}, R^{5}$ and T have the same significance as $_{20}$ defined above.

(2) Step B

(IIb2)

35

45

60

Compound (III) is reacted with a morpholino monomer compound in the presence of a base to prepare the compound represented by general formula (VII) below (hereinafter referred to as Compound (VII)):

wherein B^{P} , L, n, R^{2} , R^{3} and T have the same significance as defined above.

21

This step can be performed by reacting Compound (III) with the morpholino monomer compound in the presence of a base.

The morpholino monomer compound includes, for example, compounds represented by general formula (VIII) 5 below:

wherein B^P , R^2 , R^3 and T have the same significance as defined above.

The "base" which can be used in this step includes, for example, diisopropylamine, triethylamine and N-ethylmorpholine. The amount of the base used is appropriately in a range of 1 mol equivalent to 1000 mol equivalents based on 1 mol of Compound (III), preferably, 10 mol equivalents to 100 mol equivalents based on 1 mol of Compound (III).

The morpholino monomer compound and base which can 30 be used in this step may also be used as a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, N,N-dimethylimidazolidone, N-methylpiperidone, DMF, dichloromethane, acetonitrile, tetrahydrofuran, or a mixture thereof.

The reaction temperature is preferably in a range of e.g., 0° C. to 100° C., and more preferably, in a range of 10° C. to 50° C

The reaction time may vary depending upon kind of the 40 base used and reaction temperature, and is appropriately in a range of 1 minute to 48 hours in general, and preferably in a range of 30 minutes to 24 hours.

Furthermore, after completion of this step, an acylating agent can be added, if necessary. The "acylating agent" 45 includes, for example, acetic anhydride, acetyl chloride and phenoxyacetic anhydride. The acylating agent may also be used as a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, 50 dichloromethane, acetonitrile, an alcohol(s) (ethanol, isopropanol, trifluoroethanol, etc.), water, or a mixture thereof.

If necessary, a base such as pyridine, lutidine, collidine, triethylamine, diisopropylethylamine, N-ethylmorpholine, etc. may also be used in combination with the acylating agent. 55 The amount of the acylating agent is appropriately in a range of 0.1 mol equivalent to 10000 mol equivalents, and preferably in a range of 1 mol equivalent to 1000 mol equivalents. The amount of the base is appropriately in a range of, e.g., 0.1 mol equivalent to 100 mol equivalents, and preferably in a form of 1 mol equivalent to 10 mol equivalents, based on 1 mol of the acylating agent.

The reaction temperature in this reaction is preferably in a range of 10° C. to 50° C., more preferably, in a range of 10° C. to 50° C., much more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35° C. The reaction time may vary depending upon kind of the acylating

22

agent used and reaction temperature, and is appropriately in a range of $0.1\,$ minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

(3) Step C:

In Compound (VII) produced in Step B, the protective group is removed using a deprotecting agent to prepare the compound represented by general formula (IX).

wherein Base, B^P , L, n, R^2 , R^3 and T have the same significance as defined above.

This step can be performed by reacting Compound (VII) with a deprotecting agent.

The "deprotecting agent" includes, e.g., conc. ammonia water and methylamine. The "deprotecting agent" used in this step may also be used as a dilution with, e.g., water, methanol, ethanol, isopropyl alcohol, acetonitrile, tetrahydrofuran, DMF, N,N-dimethylimidazolidone, N-methylpiperidone, or a mixture of these solvents. Among others, ethanol is preferred. The amount of the deprotecting agent used is appropriately in a range of, e.g., 1 mol equivalent to 100000 mol equivalents, and preferably in a range of 10 mol equivalents to 1000 mol equivalents, based on 1 mol of Compound (VII).

The reaction temperature is appropriately in a range of 15° C. to 75° C., preferably, in a range of 40° C. to 70° C., and more preferably, in a range of 50° C. to 60° C. The reaction time for deprotection may vary depending upon kind of Compound (VII), reaction temperature, etc., and is appropriately in a range of 10 minutes to 30 hours, preferably 30 minutes to 24 hours, and more preferably in a range of 5 hours to 20 hours.

(4) Step D:

PMO (I) is produced by reacting Compound (IX) produced in step C with an acid:

10

15

 $\begin{array}{c|c} & & & & \\ & &$

wherein Base, n, R^2 , R^3 and T have the same significance as defined above.

This step can be performed by adding an acid to Compound (IX).

The "acid" which can be used in this step includes, for example, trichloroacetic acid, dichloroacetic acid, acetic acid, phosphoric acid, hydrochloric acid, etc. The acid used is ⁴⁰ appropriately used to allow the solution to have a pH range of 0.1 to 4.0, and more preferably, in a range of pH 1.0 to 3.0. The solvent is not particularly limited so long as it is inert to the reaction, and includes, for example, acetonitrile, water, or a mixture of these solvents thereof.

The reaction temperature is appropriately in a range of 10° C. to 50° C., preferably, in a range of 20° C. to 40° C., and more preferably, in a range of 25° C. to 35° C. The reaction time for deprotection may vary depending upon kind of Compound (IX), reaction temperature, etc., and is appropriately in a range of 0.1 minute to 5 hours, preferably 1 minute to 1 hour, and more preferably in a range of 1 minute to 30 minutes.

PMO (I) can be obtained by subjecting the reaction mixture obtained in this step to conventional means of separation and $_{55}$ purification such as extraction, concentration, neutralization, filtration, centrifugal separation, recrystallization, reversed phase column chromatography $\rm C_8$ to $\rm C_{18}$, cation exchange column chromatography, anion exchange column chromatography, gel filtration column chromatography, high performance liquid chromatography, dialysis, ultrafiltration, etc., alone or in combination thereof. Thus, the desired PMO (I) can be isolated and purified (cf., e.g., WO 1991/09033).

In purification of PMO (I) using reversed phase chromatography, e.g., a solution mixture of 20 mM triethylamine/ 65 acetate buffer and acetonitrile can be used as an elution solvent

24

In purification of PMO (I) using ion exchange chromatography, e.g., a solution mixture of 1 M saline solution and 10 mM sodium hydroxide aqueous solution can be used as an elution solvent.

A peptide nucleic acid is the oligomer of the present invention having a group represented by the following general formula as the constituent unit:

wherein Base has the same significance as defined above.

Peptide nucleic acids can be prepared by referring to, e.g., the following literatures.

- P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science, 254, 1497 (1991)
- M. Egholm, O. Buchardt, P. E. Nielsen, R. H. Berg, Jacs., 114, 1895 (1992)
- 3) K. L. Dueholm, M. Egholm, C. Behrens, L. Christensen, H. F. Hansen, T. Vulpius, K. H. Petersen, R. H. Berg, P. E. Nielsen, O. Buchardt, J. Org. Chem., 59, 5767 (1994)
- L. Christensen, R. Fitzpatrick, B. Gildea, K. H. Petersen,
 H. F. Hansen, T. Koch, M. Egholm, O. Buchardt, P. E. Nielsen, J. Coull, R. H. Berg, J. Pept. Sci., 1, 175 (1995)
 - 5) T. Koch, H. F. Hansen, P. Andersen, T. Larsen, H. G. Batz, K. Otteson, H. Orum, J. Pept. Res., 49, 80 (1997)

In the oligomer of the present invention, the 5' end may be any of chemical structures (1) to (3) below, and preferably is (3)-OH.

Hereinafter, the groups shown by (1), (2) and (3) above are referred to as "Group (1)," "Group (2)" and "Group (3)," respectively.

2. Pharmaceutical Composition

The oligomer of the present invention causes exon 53 skipping with a higher efficiency as compared to the prior art antisense oligomers. It is thus expected that conditions of muscular dystrophy can be relieved with high efficience by 5 administering the pharmaceutical composition comprising the oligomer of the present invention to DMD patients. For example, when the pharmaceutical composition comprising the oligomer of the present invention is used, the same therapeutic effects can be achieved even in a smaller dose than that 10 of the oligomers of the prior art. Accordingly, side effects can be alleviated and such is economical.

25

In another embodiment, the present invention provides the pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the oligomer of 15 the present invention, a pharmaceutically acceptable salt or hydrate thereof (hereinafter referred to as "the composition of the present invention").

Examples of the pharmaceutically acceptable salt of the oligomer of the present invention contained in the composi- 20 tion of the present invention are alkali metal salts such as salts of sodium, potassium and lithium; alkaline earth metal salts such as salts of calcium and magnesium; metal salts such as salts of aluminum, iron, zinc, copper, nickel, cobalt, etc.; ammonium salts; organic amine salts such as salts of t-octylamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, guanidine, diethylamine, triethylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzylphenethylamine, piperazine, tet- 30 ramethylammonium, tris(hydroxymethyl)aminomethane; hydrohalide salts such as salts of hydrofluorates, hydrochlorides, hydrobromides and hydroiodides; inorganic acid salts such as nitrates, perchlorates, sulfates, phosphates, etc.; lower alkane sulfonates such as methanesulfonates, trifluo- 35 romethanesulfonates and ethanesulfonates; arylsulfonates such as benzenesulfonates and p-toluenesulfonates; organic acid salts such as acetates, malates, fumarates, succinates, citrates, tartarates, oxalates, maleates, etc.; and, amino acid salts such as salts of glycine, lysine, arginine, ornithine, 40 glutamic acid and aspartic acid. These salts may be produced by known methods. Alternatively, the oligomer of the present invention contained in the composition of the present invention may be in the form of a hydrate thereof.

Administration route for the composition of the present 45 invention is not particularly limited so long as it is pharmaceutically acceptable route for administration, and can be chosen depending upon method of treatment. In view of easiness in delivery to muscle tissues, preferred are intravenous administration, intraarterial administration, intramuscular 50 administration, subcutaneous administration, oral administration, etc. Also, dosage forms which are available for the composition of the present invention are not particularly limited, and include, for example, various injections, oral agents, drips, 55 inhalations, ointments, lotions, etc.

In administration of the oligomer of the present invention to patients with muscular dystrophy, the composition of the present invention preferably contains a carrier to promote delivery of the oligomer to muscle tissues. Such a carrier is 60 not particularly limited as far as it is pharmaceutically acceptable, and examples include cationic carriers such as cationic liposomes, cationic polymers, etc., or carriers using viral envelope. The cationic liposomes are, for example, liposomes composed of 2-O-(2-diethylaminoethyl)carabamoyl-1,3-O-65 dioleoylglycerol and phospholipids as the essential constituents (hereinafter referred to as "liposome A"), Oligo-

26

fectamine (registered trademark) (manufactured by Invitrogen Corp.), Lipofectin (registered trademark) (manufactured by Invitrogen Corp.), Lipofectamine (registered trademark) (manufactured by Invitrogen Corp.), Lipofectamine 2000 (registered trademark) (manufactured by Invitrogen Corp.), DMRIE-C (registered trademark) (manufactured by Invitrogen Corp.), GeneSilencer (registered trademark) (manufactured by Gene Therapy Systems), Trans-Messenger (registered trademark) (manufactured by QIAGEN, Inc.), TransIT TKO (registered trademark) (manufactured by Minis) and Nucleofector II (Lonza). Among others, liposome A is preferred. Examples of cationic polymers are JetSI (registered trademark) (manufactured by Qbiogene, Inc.) and Jet-PEI (registered trademark) (polyethylenimine, manufactured by Qbiogene, Inc.). An example of carriers using viral envelop is GenomeOne (registered trademark) (HVJ-E liposome, manufactured by Ishihara Sangyo). Alternatively, the medical devices described in Japanese Patent No. 2924179 and the cationic carriers described in Japanese Domestic Re-Publication PCT Nos. 2006/129594 and 2008/ 096690 may be used as well.

A concentration of the oligomer of the present invention contained in the composition of the present invention may vary depending on kind of the carrier, etc., and is appropriately in a range of 0.1 nM to $100\,\mu\text{M}$, preferably in a range of $1\,\text{nM}$ to $10\,\mu\text{M}$, and more preferably in a range of $10\,\text{nM}$ to $1\,\mu\text{M}$. A weight ratio of the oligomer of the present invention contained in the composition of the present invention and the carrier (carrier/oligomer of the present invention) may vary depending on property of the oligomer, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 1 to 50, and more preferably in a range of 10 to 20.

In addition to the oligomer of the present invention and the carrier described above, pharmaceutically acceptable additives may also be optionally formulated in the composition of the present invention. Examples of such additives are emulsification aids (e.g., fatty acids having 6 to 22 carbon atoms and their pharmaceutically acceptable salts, albumin and dextran), stabilizers (e.g., cholesterol and phosphatidic acid), isotonizing agents (e.g., sodium chloride, glucose, maltose, lactose, sucrose, trehalose), and pH controlling agents (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide and triethanolamine). One or more of these additives can be used. The content of the additive in the composition of the present invention is appropriately 90 wt % or less, preferably 70 wt % or less and more preferably, 50 wt % or less.

The composition of the present invention can be prepared by adding the oligomer of the present invention to a carrier dispersion and adequately stirring the mixture. Additives may be added at an appropriate step either before or after addition of the oligomer of the present invention. An aqueous solvent that can be used in adding the oligomer of the present invention is not particularly limited as far as it is pharmaceutically acceptable, and examples are injectable water or injectable distilled water, electrolyte fluid such as physiological saline, etc., and sugar fluid such as glucose fluid, maltose fluid, etc. A person skilled in the art can appropriately choose conditions for pH and temperature for such matter.

The composition of the present invention may be prepared into, e.g., a liquid form and its lyophilized preparation. The lyophilized preparation can be prepared by lyophilizing the composition of the present invention in a liquid form in a conventional manner. The lyophilization can be performed, for example, by appropriately sterilizing the composition of the present invention in a liquid form, dispensing an aliquot

27

into a vial container, performing preliminary freezing for 2 hours at conditions of about -40 to -20° C., performing a primary drying at 0 to 10° C. under reduced pressure, and then performing a secondary drying at about 15 to 25° C. under reduced pressure. In general, the lyophilized preparation of the composition of the present invention can be obtained by replacing the content of the vial with nitrogen gas and capping.

The lyophilized preparation of the composition of the present invention can be used in general upon reconstitution by adding an optional suitable solution (reconstitution liquid) and redissolving the preparation. Such a reconstitution liquid includes injectable water, physiological saline and other infusion fluids. A volume of the reconstitution liquid may vary 15 depending on the intended use, etc., is not particularly limited, and is suitably 0.5 to 2-fold greater than the volume prior to lyophilization or no more than 500 mL.

It is desired to control a dose of the composition of the present invention to be administered, by taking the following factors into account: the type and dosage form of the oligomer of the present invention contained; patients' conditions including age, body weight, etc.; administration route; and the characteristics and extent of the disease. A daily dose calculated as the amount of the oligomer of the present invention is generally in a range of 0.1 mg to 10 g/human, and preferably 1 mg to 1 g/human. This numerical range may vary occasionally depending on type of the target disease, administration route and target molecule. Therefore, a dose lower than the range may be sufficient in some occasion and conversely, a dose higher than the range may be required occasionally. The composition can be administered from once to several times daily or at intervals from one day to several days

In still another embodiment of the composition of the present invention, there is provided a pharmaceutical composition comprising a vector capable of expressing the oligonucleotide of the present invention and the carrier described above. Such an expression vector may be a vector capable of expressing a plurality of the oligonucleotides of the present invention. The composition may be formulated with pharma- 45 ceutically acceptable additives as in the case with the composition of the present invention containing the oligomer of the present invention. A concentration of the expression vector contained in the composition may vary depending upon type of the career, etc., and is appropriately in a range of 0.1 nM to 100 μM, preferably in a range of 1 nM to 10 μM, and more preferably in a range of 10 nM to 1 µM. A weight ratio of the expression vector contained in the composition and the carrier (carrier/expression vector) may vary depending on 55 property of the expression vector, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 1 to 50, and more preferably in a range of 10 to 20. The content of the carrier contained in the composition is the same as in the case with the composition of the present invention $\ ^{60}$ containing the oligomer of the present invention, and a method for producing the same is also the same as in the case with the composition of the present invention.

Hereinafter, the present invention will be described in more 65 detail with reference to EXAMPLES and TEST EXAMPLES below, but is not deemed to be limited thereto.

28 EXAMPLES

Reference Example 1

4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

Step 1: Production of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl] methoxy}-4-oxobutanoic acid

Under argon atmosphere, 22.0 g of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide and 7.04 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 269 mL of dichloromethane, and 5.76 g of succinic anhydride was added to the suspension, followed by stirring at room temperature for 3 hours. To the reaction solution was added 40 mL of methanol, and the mixture was concentrated under reduced pressure. The residue was extracted using ethyl acetate and 0.5M aqueous potassium dihydrogenphosphate solution. The resulting organic layer was washed sequentially with 0.5M aqueous potassium dihydrogenphosphate solution, water and brine in the order mentioned. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure to give 25.9 g of the product.

Step 2: Production of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

After $23.5 \text{ g of } 4-\{[(2S,6R)-6-(4-\text{benzamido-}2-\text{oxopyrimi-}$ din-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid was dissolved in 336 mL of pyridine (dehydrated), 4.28 g of 4-DMAP and 40.3 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to the solution. Then, 25.0 g of Aminomethyl Polystyrene Resin cross-linked with 1% DVB (manufactured by Tokyo Chemical Industry Co., Ltd., A1543) and 24 mL of triethylamine were added to the mixture, followed by shaking at room temperature for 4 days. After completion of the reaction, the resin was taken out by filtration. The resulting resin was washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure. To the resulting resin were added 150 mL of tetrahydrofuran (dehydrate), 15 mL of acetic anhydride and 15 mL of 2,6-lutidine, and the mixture was shaken at room temperature for 2 hours. The resin was taken out by filtration, washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure to give 33.7 g of the product.

The loading amount of the product was determined by measuring UV absorbance at 409 nm of the molar amount of the trityl per g resin using a known method. The loading amount of the resin was 397.4 µmol/g.

Conditions of UV measurement Device: U-2910 (Hitachi, Ltd.) Solvent: methanesulfonic acid

Wavelength: 265 nm ∈ Value: 45000

29

Reference Example 2

4-Oxo-4-{[(2S,6R)-6-(6-oxo-2-[2-phenoxyacetamido]-1H-purin-9-yl)-4-tritylmorpholin-2-yl] methoxy butanoic acid loaded onto 2-aminomethylpolystyrene resin

Step 1: Production of N²-(phenoxyacetyl)guanosine

Guanosine, 100 g, was dried at 80° C. under reduced pressure for 24 hours. After 500 mL of pyridine (anhydrous) and 500 mL of dichloromethane (anhydrous) were added thereto, 401 mL of chlorotrimethylsilane was dropwise added to the mixture under an argon atmosphere at $\hat{0}^{\circ}$ C., followed by stirring at room temperature for 3 hours. The mixture was 15 again ice-cooled and 66.3 g of phenoxyacetyl chloride was dropwise added thereto. Under ice cooling, the mixture was stirred for further 3 hours. To the reaction solution was added 500 mL of methanol, and the mixture was stirred at room temperature overnight. The solvent was then removed by 20 distillation under reduced pressure. To the residue was added 500 mL of methanol, and concentration under reduced pressure was performed 3 times. To the residue was added 4 L of water, and the mixture was stirred for an hour under ice cooling. The precipitates formed were taken out by filtration, washed sequentially with water and cold methanol and then dried to give 150.2 g of the objective compound (yield: 102%) (cf.: Org. Lett. (2004), Vol. 6, No. 15, 2555-2557).

Step 2

N-{9-[(2R,6S)-6-(hydroxymethyl)-4-morpholin-2yll-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide p-toluenesulfonate

In 480 mL of methanol was suspended 30 g of the compound obtained in Step 1, and 130 mL of 2N hydrochloric acid was added to the suspension under ice cooling. Subsequently, 56.8 g of ammonium tetraborate tetrahydrate and 16.2 g of sodium periodate were added to the mixture in the order mentioned and stirred at room temperature for 3 hours. 40 The reaction solution was ice cooled and the insoluble matters were removed by filtration, followed by washing with 100 mL of methanol. The filtrate and washing liquid were combined and the mixture was ice cooled. To the mixture was added 11.52 g of 2-picoline borane. After stirring for 20 minutes, 45 54.6 g of p-toluenesulfonic acid monohydrate was slowly added to the mixture, followed by stirring at 4° C. overnight. The precipitates were taken out by filtration and washed with 500 mL of cold methanol and dried to give 17.7 g of the objective compound (yield: 43.3%).

¹H NMR (6, DMSO-d6): 9.9-9.2 (2H, br), 8.35 (1H, s), 7.55 (2H, m), 7.35 (2H, m), 7.10 (2H, d, J=7.82 Hz), 7.00 (3H, m), 5.95 (1H, dd, J=10.64, 2.42 Hz), 4.85 (2H, s), 4.00 (1H, m), 3.90-3.60 (2H, m), 3.50-3.20 (5H, m), 2.90 (1H, m), 2.25 (3H, s)

Step 3: Production of N-{9-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide

In 30 mL of dichloromethane was suspended 2.0 g of the compound obtained in Step 2, and 13.9 g of triethylamine and 18.3 g of trityl chloride were added to the suspension under ice cooling. The mixture was stirred at room temperature for an hour. The reaction solution was washed with saturated sodium bicarbonate aqueous solution and then with water, and dried. The organic layer was concentrated under reduced pressure. To the residue was added 40 mL of 0.2M sodium 30

citrate buffer (pH 3)/methanol (1:4 (v/v)), and the mixture was stirred. Subsequently, 40 mL of water was added and the mixture was stirred for an hour under ice cooling. The mixture was taken out by filtration, washed with cold methanol and dried to give 1.84 g of the objective compound (yield: 82.0%).

Step 4: Production of 4-oxo-4-{[(2S,6R)-6-(6-oxo-2-[2-phenoxyacetamido]-1H-purin-9-yl)-4-tritylmorpholin-2-yl]methoxy}butanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that N-{9-[2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4yl}benzamide used in Step 1 of REFERENCE EXAMPLE 1.

Reference Example 3

4-{[(2S,6R)-6-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine- $_{30}$ 2,4(1H,3H)-dione was used in this step, instead of N- $\{1-[(2R,$ 6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2dihydropyrimidin-4-yl}benzamide used in Step 1 of REFERENCE EXAMPLE 1.

Reference Example 4

1,12-Dioxo-1-(4-tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-tritylpiperazine-1-carboxylic acid (the compound described in WO 2009/064471) was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4yl}benzamide.

According to the descriptions in EXAMPLES 1 to 12 and REFERENCE EXAMPLES 1 to 3 below, various types of PMO shown by PMO Nos. 1-11 and 13-16 in TABLE 2 were synthesized. The PMO synthesized was dissolved in injectable water (manufactured by Otsuka Pharmaceutical Factory, Inc.). PMO No. 12 was purchased from Gene Tools, LLC.

TABLE 2

55	TABLE 2			
	PMO No.	Target sequence in exon 53	Note	SEQ ID NO:
60	1 2	31-55 32-53	5' end: group (3) 5' end: group (3)	SEQ ID NO: 4 SEQ ID NO: 8
	3	32-56	5' end: group (3)	SEQ ID NO: 11
	4	33-54	5' end: group (3)	SEQ ID NO: 15
	5	34-58	5' end: group (3)	SEQ ID NO: 25
	6	36-53	5' end: group (3)	SEQ ID NO: 32
	7	36-55	5' end: group (3)	SEQ ID NO: 34
65	8	36-56	5' end: group (3)	SEQ ID NO: 35
	9	36-57	5' end: group (3)	SEQ ID NO: 36

31 TABLE 2-continued

PMO No.	Target sequence in exon 53	Note	SEQ ID NO:
10	33-57	5' end: group (3)	SEQ ID NO: 18
11	39-69	Sequence corresponding to H53A(+39 + 69) (cf. Table 1) in Non-Patent Document 3, 5' end: group (3)	SEQ ID NO: 38
12	30-59	Sequence corresponding to h53A30/1 (cf. Table 1) in Non-Patent Document 5, 5' end: group (2)	SEQ ID NO: 39
13	32-56	5' end: group (1)	SEQ ID NO: 11
14	36-56	5' end: group (1)	SEO ID NO: 35
15	30-59	Sequence corresponding to h53A30/1 (cf. Table 1) in Non-Patent Document 5 5' end: group (3)	SEQ ID NO: 39
16	23-47	Sequence corresponding to SEQ ID NO: 429 described in Patent Document 4, 5' end: group (3)	SEQ ID NO: 47

Example 1

PMO No. 8

4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid, loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 1), 2 g (800 μmol) was transferred to a reaction vessel, and 30 mL of dichloromethane was added thereto. The mixture was allowed to stand for 30 minutes. After the mixture was further washed twice with 30 mL of dichloromethane, the following synthesis cycle was started. The desired morpholino monomer compound was added in each cycle to give the nucleotide sequence of the title compound.

TABLE 3

Step	Reagent	Volume (mL)	Time (min)
1	deblocking solution	30	2.0
2	deblocking solution	30	2.0
3	deblocking solution	30	2.0
4	deblocking solution	30	2.0
5	deblocking solution	30	2.0
6	deblocking solution	30	2.0
7	neutralizing solution	30	1.5
8	neutralizing solution	30	1.5
9	neutralizing solution	30	1.5
10	neutralizing solution	30	1.5
11	neutralizing solution	30	1.5
12	neutralizing solution	30	1.5
13	dichloromethane	30	0.5
14	dichloromethane	30	0.5
15	dichloromethane	30	0.5
16	coupling solution B	20	0.5
17	coupling solution A	6-11	90.0
18	dichloromethane	30	0.5
19	dichloromethane	30	0.5
20	dichloromethane	30	0.5
21	capping solution	30	3.0
22	capping solution	30	3.0
23	dichloromethane	30	0.5
24	dichloromethane	30	0.5
25	dichloromethane	30	0.5

The deblocking solution used was a solution obtained by dissolving a mixture of trifluoroacetic acid (2 equivalents)

32

and triethylamine (1 equivalent) in a dichloromethane solution containing 1% (v/v) ethanol and 10% (v/v) 2,2,2-trifluoroethanol to be 3% (w/v). The neutralizing solution used was a solution obtained by dissolving N,N-diisopropylethylamine in a dichloromethane solution containing 25% (v/v) 2-propanol to be 5% (v/v). The coupling solution A used was a solution obtained by dissolving the morpholino monomer compound in 1,3-dimethyl-2-imidazolidinone containing 10% (v/v) N,N-diisopropylethylamine to be 0.15M. The coupling solution B used was a solution obtained by dissolving N,N-diisopropylethylamine in 1,3-dimethyl-2-imidazolidinone to be 10% (v/v). The capping solution used was a solution obtained by dissolving 20% (v/v) acetic anhydride and 30% (v/v) 2,6-lutidine in dichloromethane.

The aminomethyl polystyrene resin loaded with the PMO synthesized above was recovered from the reaction vessel and dried at room temperature for at least 2 hours under reduced pressure. The dried PMO loaded onto aminomethyl polystyrene resin was charged in a reaction vessel, and 200 mL of 28% ammonia water-ethanol (1/4) was added thereto. The mixture was stirred at 55° C. for 15 hours. The aminomethyl polystyrene resin was separated by filtration and washed with 50 mL of water-ethanol (1/4). The resulting filtrate was concentrated under reduced pressure. The resulting residue was dissolved in 100 mL of a solvent mixture of 20 mM acetic acid-triethylamine buffer (TEAA buffer) and acetonitrile (4/1) and filtered through a membrane filter. The filtrate obtained was purified by reversed phase HPLC. The conditions used are as follows.

TABLE 4

Column	XTerra MS18 (Waters, φ50x 100 mm, 1CV = 200 mL)
Flow rate	60 mL/min
Column temperature	room temperature
Solution A	20 mM TEAA buffer
Solution B	CH ₃ CN
Gradient	(B) conc. 20→50%/9CV

Each fraction was analyzed and the product was recovered in 100 mL of acetonitrile-water (1/1), to which 200 mL of ethanol was added. The mixture was concentrated under reduced pressure. Further drying under reduced pressure gave a white solid. To the resulting solid was added 300 mL of 10 mM phosphoric acid aqueous solution to suspend the solid. To the suspension was added 10 mL of 2M phosphoric acid aqueous solution, and the mixture was stirred for 15 minutes. Furthermore, 15 mL of 2M sodium hydrate aqueous solution was added for neutralization. Then, 15 mL of 2M sodium hydroxide aqueous solution was added to make the mixture alkaline, followed by filtration through a membrane filter (0.45 μ m). The mixture was thoroughly washed with 100 mL of 10 mM sodium hydroxide aqueous solution to give the product as an aqueous solution.

The resulting aqueous solution containing the product was purified by an anionic exchange resin column. The conditions used are as follows.

TABLE 5

0	Column	Source 30Q (GE Healthcare, φ40x 150 mm, 1CV = 200 mL)	-
	Flow rate	80 mL/min	
	Column temp.	room temperature	
	Solution A	10 mM sodium hydroxide aqueous solution	
	Solution B	10 mM sodium hydroxide aqueous solution,	
		1M sodium chloride aqueous solution	
5	Gradient	(B) conc. 5→35%/15CV	

60

10

25

40

50

33

Each fraction was analyzed (on HPLC) and the product was obtained as an aqueous solution. To the resulting aqueous solution was added 225 mL of 0.1M phosphate buffer (pH 6.0) for neutralization. The mixture was filtered through a membrane filter (0.45 μm). Next, ultrafiltration was performed under the conditions described below.

TABLE 6

Filter	PELLICON2 MINI FILTER PLBC 3K	_
Size	Regenerated Cellulose, Screen Type C 0.1 m ²	

The filtrate was concentrated to give approximately 250 mL of an aqueous solution. The resulting aqueous solution $_{15}$ was filtered through a membrane filter (0.45 $\mu m).$ The aqueous solution obtained was freeze-dried to give 1.5 g of the objective compound as a white cotton-like solid.

ESI-TOF-MS Calcd.: 6924.82.

Found: 6923.54.

Example 2

PMO. No. 1

The title compound was produced in accordance with the procedure of EXAMPLE $1. \,$

MALDI-TOF-MS Calcd.: 8291.96.

Found: 8296.24.

Example 3

PMO. No. 2

The title compound was produced in accordance with the $\,^{35}$ procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 7310.13.

Found: 7309.23.

Example 4

PMO. No. 3

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.55.

Example 5

PMO. No. 4

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-(((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-trityl-morpholin-2-yl)methoxy)-4-oxobutanoic acid (REFER-ENCE EXAMPLE 3) loaded onto aminomethyl polystyrene resin was used as the starting material.

ESI-TOF-MS Calcd.: 7310.13.

Found: 7310.17.

Example 6

PMO. No. 5

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-(((2S,6R)-6-(5-

34

methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-trityl-morpholin-2-yl)methoxy)-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 3) was used as the starting material.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.20.

Example 7

PMO. No. 6

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 5964.01.

Found: 5963.68.

Example 8

PMO. No. 7

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 6609.55.

Found: 6608.85.

Example 9

PMO. No. 9

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-6-(6-oxo-2-(2-phenoxyacetamido)-1H-purin-9(6H)-yl)-4-tritylmorpholin-2-yl)methoxy)butanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 2) was used as the starting material.

ESI-TOF-MS Calcd.: 7280.11.

Found: 7279.42.

Example 10

PMO. No. 10

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-6-(6-oxo-2-(2-phenoxyacetamido)-1H-purin-9(6H)-yl)-4-tritylmorpholin-2-yl)methoxy)butanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 2) was used as the starting material.

ESI-TOF-MS Calcd.: 8295.95.

Found: 8295.91.

Example 11

PMO. No. 13

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4-tri-tylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 7276.15.

Found: 7276.69.

Example 12

PMO. No. 14

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4-tri-

25

35

35

tylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 8622.27.

Found: 8622.29.

Comparative Example 1

PMO. No. 11

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 10274.63.

Found: 10273.71.

Comparative Example 2

PMO. No. 15

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 9941.33.

Found: 9940.77.

Comparative Example 3

PMO. No. 16

The title compound was produced in accordance with the 30 procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 8238.94.

Found: 8238.69.

Test Example 1

In Vitro Assay

Using an Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza), 10 μM of the oligomers PMO Nos. 1 to 8 of 40 the present invention and the antisense oligomer PMO No. 11 were transfected with 4×10⁵ of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used.

After transfection, the cells were cultured overnight in 2 mL of Eagle's minimal essential medium (EMEM) (manu- 45 factured by Sigma, hereinafter the same) containing 10% fetal calf serum (FCS) (manufactured by Invitrogen) under conditions of 37° C. and 5% CO₂. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 µl of ISOGEN (manufactured by Nippon 50 TIG-119 cells (human normal tissue-derived fibroblasts, Gene) was added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lyse the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined 55 using a NanoDrop ND-1000 (manufactured by LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a Titan One Tube RT-PCR Kit (manufactured by Roche). A reaction solution was prepared in accordance with the protocol attached to the kit. A PTC- 60 100 (manufactured by MJ Research) was used as a thermal cycler. The RT-PCR program used is as follows.

50° C., 30 mins: reverse transcription

94° C., 2 mins: thermal denaturation

[94° C., 10 seconds; 58° C., 30 seconds; 68° C., 45 sec- 65 onds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

36

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

```
(SEQ ID NO: 40)
Forward primer: 5'-AGGATTTGGAACAGAGGCGTC-3'
```

(SEQ ID NO: 41) Reverse primer: 5'-GTCTGCCACTGGCGAGGTC-3'

Next, a nested PCR was performed with the product amplified by RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program used is as follows.

94° C., 2 mins: thermal denaturation

[94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given

```
(SEQ ID NO: 42)
Forward primer: 5'-CATCAAGCAGAAGGCAACAA-3'
```

(SEO ID NO: 43)

Reverse primer: 5'-GAAGTTTCAGGGCCAAGTCA-3'

The reaction product, 1 of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)=A/(A+B)×100

Experimental Results

The results are shown in FIG. 1. This experiment revealed that the oligomers PMO Nos. 1 to 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the antisense oligomer PMO No. 11. In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than four times higher exon skipping efficiency than that of the antisense oligomer PMO No. 11.

Test Example 2

In Vitro Assay Using Human Fibroblasts

Human myoD gene (SEQ ID NO: 44) was introduced into National Institute of Biomedical Innovation) or 5017 cells (human DMD patient-derived fibroblasts, Coriell Institute for Medical Research) using a ZsGreen1 coexpression retroviral

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblasts were collected by FACS and plated at 5×10^4 /cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM.F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12 to 14 days to differentiate into myotubes.

37

Subsequently, the differentiation medium was replaced by a differentiation medium containing 6 µM Endo-Porter (Gene Tools), and the morpholino oligomer was added thereto in a final concentration of 10 μM. After incubation for 48 hours, total RNA was extracted from the cells using a TRIzol (manufactured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR 10 program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation [94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: PCR amplification 72° C., 7 mins: final extension

The primers used were hEX51F and hEX55R.

hEX51F: 5'-CGGGCTTGGACAGAACTTAC-3 (SEO ID NO: 46) hEx55R: 5'-TCCTTACGGGTAGCATCCTG-3

The reaction product of RT-PCR above was separated by 2% agarose gel electrophoresis and gel images were captured with a GeneFlash (Syngene). The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured using an Image J (manufactured by National Institutes of Health). Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skipping efficiency (%)=A/(A+B)×100

Experimental Results

The results are shown in FIGS. 2 and 3. This experiment revealed that in TIG-119 cells, the oligomers PMO Nos. 3, 8 and 9 of the present invention (FIG. 2) all caused exon 53 skipping with a higher efficiency than the antisense oligomer 40 PMO No. 12 (FIG. 2). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than twice higher exon skipping efficiency than that of the antisense oligomer PMO No. 12 (FIG. 2).

Furthermore, this experiment revealed that the oligomers 45 Experimental Results PMO Nos. 3 and 8 to 10 of the present invention (FIG. 3) all caused exon 53 skipping with a higher efficiency than the antisense oligomer PMO No. 12 (FIG. 3). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than seven times higher exon skipping efficiency 50 than that of the antisense oligomer PMO No. 12 (FIG. 3).

Test Example 3

In Vitro Assay Using Human Fibroblasts

The skin fibroblast cell line (fibroblasts from human DMD patient (exons 45-52 or exons 48-52)) was established by biopsy from the medial left upper arm of DMD patient with deletion of exons 45-52 or DMD patient with deletion of 60 exons 48-52. Human myoD gene (SEQ ID NO: 44) was introduced into the fibroblast cells using a ZsGreen1 coexpression retroviral vector.

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblasts were collected by FACS and plated at 65 5×10^4 /cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium:

38

Nutrient Mixture F-12 (DMEM/F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by a differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12, 14 or 20 days to differentiate into myotubes.

Subsequently, the differentiation medium was replaced by a differentiation medium containing 6 µM Endo-Porter (Gene Tools), and a morpholino oligomer was added thereto at a final concentration of 10 µM. After incubation for 48 hours, total RNA was extracted from the cells using a TRIzol (manufactured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR (SEQ ID NO: 45) 20 program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation [94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: PCR amplification

72° C., 7 mins: final extension The primers used were hEx44F and h55R.

> (SEO ID NO: 48) hEx44F: 5'-TGTTGAGAAATGGCGGCGT-3 (SEQ ID NO: 46) hEx55R: 5'-TCCTTACGGGTAGCATCCTG-3

The reaction product of RT-PCR above was separated by 35 2% agarose gel electrophoresis and gel images were captured with a GeneFlash (Syngene). The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured using an Image J (manufactured by National Institutes of Health). Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skipping efficiency (%)=A/(A+B)×100

The results are shown in FIGS. 4 and 5. This experiment revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with an efficiency as high as more than 80% in the cells from DMD patient with deletion of exons 45-52 (FIG. 4) or deletion of exons 48-52 (FIG. 5). Also, the oligomers PMO Nos. 3 and 8 of the present invention were found to cause exon 53 skipping with a higher efficiency than that of the antisense oligomer PMO No. 15 in the cells from DMD patient with deletion of exons 45-52 55 (FIG. 4).

Test Example 4

Western Blotting

The oligomer PMO No. 8 of the present invention was added to the cells at a concentration of 10 µM, and proteins were extracted from the cells after 72 hours using a RIPA buffer (manufactured by Thermo Fisher Scientific) containing Complete Mini (manufactured by Roche Applied Science) and quantified using a BCA protein assay kit (manufactured by Thermo Fisher Scientific). The proteins were

3

4

39

electrophoresed in NuPAGE Novex Tris-Acetate Gel 3-8% (manufactured by Invitrogen) at 150V for 75 minutes and transferred onto a PVDF membrane (manufactured by Millipore) using a semi-dry blotter. The PVDF membrane was blocked with a 5% ECL Blocking agent (manufactured by GE 5 Healthcare) and the membrane was then incubated in a solution of anti-dystrophin antibody (manufactured by NCL-Dysl, Novocastra). After further incubation in a solution of peroxidase-conjugated goat-antimouse IgG (Model No. 170-6516, Bio-Rad), the membrane was stained with ECL Plus 10 Western blotting system (manufactured by GE Healthcare). Immunostaining

The oligomer PMO No. 3 or 8 of the present invention was added to the cells. The cells after 72 hours were fixed in 3% paraformaldehyde for 10 minutes, followed by incubation in 10% Triton-X for 10 minutes. After blocking in 10% goat serum-containing PBS, the membrane was incubated in a solution of anti-dystrophin antibody (NCL-Dysl, Novocastra). The membrane was further incubated in a solution of anti-mouse IgG antibody (manufactured by Invitrogen). The membrane was mounted with Pro Long Gold Antifade reagent (manufactured by Invitrogen) and observed with a fluorescence microscope.

Experimental Results

The results are shown in FIGS. 6 and 7. In this experiment 2 it was confirmed by western blotting (FIG. 6) and immunostaining (FIG. 7) that the oligomers PMO Nos. 3 and 8 of the present invention induced expression of the dystrophin protein.

Test Example 5

In Vitro Assay Using Human Fibroblasts

The experiment was performed as in TEST EXAMPLE 3. $_{\rm 3}$ Experimental Results

The results are shown in FIG. 8. This experiment revealed that in the cells from DMD patients with deletion of exons 45-52, the oligomers PMO Nos. 3 to 8 of the present invention caused exon 53 skipping with a higher efficiency than the 4 oligomers PMO Nos. 13 and 14 of the present invention (FIG.

Test Example 6

In Vitro Assay

Experiments were performed using the antisense oligomers of 2'-O-methoxy-phosphorothioates (2'-OMe-S-RNA) shown by SEQ ID NO: 49 to SEQ ID NO: 123. Various antisense oligomers used for the assay were purchased from Japan Bio Services. The sequences of various antisense oligomers are given below.

TABLE 7

oligomer Antisense	Nucleotide sequence	SEQ ID NO:
H53_39-69	CAUUCAACUGUUGCCUCCGGUUCUGAAGGUG	49
H53_1-25	UCCCACUGAUUCUGAAUUCUUUCAA	50
H53_6-30	CUUCAUCCCACUGAUUCUGAAUUCU	51
H53_11-35	UUGUACUUCAUCCCACUGAUUCUGA	52
H53_16-40	UGUUCUUGUACUUCAUCCCACUGAU	53

40

mant r	7	-continued
TABLE	-/-	-continuec

	oligomer Antisense	Nucleotide sequence	SEQ II NO:
5	H53_21-45	GAAGGUGUUCUUGUACUUCAUCCCA	54
	H53_26-50	GUUCUGAAGGUGUUCUUGUACUUCA	55
	H53_31-55	CUCCGGUUCUGAAGGUGUUCUUGUA	56
0	H53_36-60	GUUGCCUCCGGUUCUGAAGGUGUUC	57
	H53_41-65	CAACUGUUGCCUCCGGUUCUGAAGG	58
	H53_46-70	UCAUUCAACUGUUGCCUCCGGUUCU	59
15	H53_51-75	ACAUUUCAUUCAACUGUUGCCUCCG	60
	H53_56-80	CUUUAACAUUUCAUUCAACUGUUGC	61
	H53_61-85	GAAUCCUUUAACAUUUCAUUCAACU	62
20	H53_66-90	GUGUUGAAUCCUUUAACAUUUCAUU	63
	H53_71-95	CCAUUGUGUUGAAUCCUUUAACAUU	64
	H53_76-100	UCCAGCCAUUGUGUUGAAUCCUUUA	65
٠.	H53_81-105	UAGCUUCCAGCCAUUGUGUUGAAUC	66
25	H53_86-110	UUCCUUAGCUUCCAGCCAUUGUGUU	67
	H53_91-115	GCUUCUUCCUUAGCUUCCAGCCAUU	68
	H53_96-120	GCUCAGCUUCUUCCUUAGCUUCCAG	69
30	H53_101-125	GACCUGCUCAGCUUCUUCCUUAGCU	70
	H53_106-130	CCUAAGACCUGCUCAGCUUCUUCCU	71
	H53_111-135	CCUGUCCUAAGACCUGCUCAGCUUC	72
35	H53_116-140	UCUGGCCUGUCCUAAGACCUGCUCA	73
	H53_121-145	UUGGCUCUGGCCUGUCCUAAGACCU	74
	H53_126-150	CAAGCUUGGCUCUGGCCUGUCCUAA	75
10	H53_131-155	UGACUCAAGCUUGGCUCUGGCCUGU	76
	H53_136-160	UUCCAUGACUCAAGCUUGGCUCUGG	77
	H53_141-165	CCUCCUUCCAUGACUCAAGCUUGGC	78
15	H53_146-170	GGGACCCUCCUUCCAUGACUCAAGC	79
	H53_151-175	GUAUAGGGACCCUCCUUCCAUGACU	80
	H53_156-180	CUACUGUAUAGGGACCCUCCUUCCA	81
50	H53_161-185	UGCAUCUACUGUAUAGGGACCCUCC	82
	H53_166-190	UGGAUUGCAUCUACUGUAUAGGGAC	83
	H53_171-195	UCUUUUGGAUUGCAUCUACUGUAUA	84
55	H53_176-200	GAUUUUCUUUUGGAUUGCAUCUACU	85
	H53_181-205	UCUGUGAUUUUCUUUUGGAUUGCAU	86
	H53_186-210	UGGUUUCUGUGAUUUUCUUUUGGAU	87
sn.	H53_84-108	CCUUAGCUUCCAGCCAUUGUGUUGA	88
50	H53_88-112	UCUUCCUUAGCUUCCAGCCAUUGUG	89
	H53_119-143	GGCUCUGGCCUGUCCUAAGACCUGC	90
	H53_124-148	AGCUUGGCUCUGGCCUGUCCUAAGA	91
55	H53_128-152	CUCAAGCUUGGCUCUGGCCUGUCCU	92

25

45

41
TABLE 7 -continued

oligomer Antisense	Nucleotide sequence	SEQ ID NO:
H53_144-168	GACCCUCCUUCCAUGACUCAAGCUU	93
H53_149-173	AUAGGGACCCUCCUUCCAUGACUCA	94
H53_153-177	CUGUAUAGGGACCCUCCUUCCAUGA	95
H53_179-203	UGUGAUUUUCUUUUGGAUUGCAUCU	96
H53_184-208	GUUUCUGUGAUUUUCUUUUGGAUUG	97
H53_188-212	CUUGGUUUCUGUGAUUUUCUUUUGG	98
H53_29-53	CCGGUUCUGAAGGUGUUCUUGUACU	99
H53_30-54	UCCGGUUCUGAAGGUGUUCUUGUAC	100
H53_32-56	CCUCCGGUUCUGAAGGUGUUCUUGU	101
H53_33-57	GCCUCCGGUUCUGAAGGUGUUCUUG	102
H53_34-58	UGCCUCCGGUUCUGAAGGUGUUCUU	103
H53_35-59	UUGCCUCCGGUUCUGAAGGUGUUCU	104
H53_37-61	UGUUGCCUCCGGUUCUGAAGGUGUU	105
H53_38-62	CUGUUGCCUCCGGUUCUGAAGGUGU	106
H53_39-63	ACUGUUGCCUCCGGUUCUGAAGGUG	107
H53_40-64	AACUGUUGCCUCCGGUUCUGAAGGU	108
H53_32-61	UGUUGCCUCCGGUUCUGAAGGUGUUCUUGU	109
H53_32-51	GGUUCUGAAGGUGUUCUUGU	110
H53_35-54	UCCGGUUCUGAAGGUGUUCU	111
H53_37-56	CCUCCGGUUCUGAAGGUGUU	112
H53_40-59	UUGCCUCCGGUUCUGAAGGU	113
H53_42-61	UGUUGCCUCCGGUUCUGAAG	114
H53_32-49	UUCUGAAGGUGUUCUUGU	115
H53_35-52	CGGUUCUGAAGGUGUUCU	116
H53_38-55	CUCCGGUUCUGAAGGUGU	117
H53_41-58	UGCCUCCGGUUCUGAAGG	118
H53_44-61	UGUUGCCUCCGGUUCUGA	119
H53_35-49	UUCUGAAGGUGUUCU	120
H53_40-54	UCCGGUUCUGAAGGU	121
H53_45-59	UUGCCUCCGGUUCUG	122
H53_45-62	cnenneccacceenncae	123

RD cells (human rhabdomyosarcoma cell line) were plated at 3×10^5 in a 6-well plate and cultured in 2 mL of Eagle's minimal essential medium (EMEM) (manufactured by Sigma, Inc., hereinafter the same) containing 10% fetal calf serum (FCS) (manufactured by Invitrogen Corp.) under conditions of 37° C. and 5% CO $_2$ overnight. Complexes of various antisense oligomers (Japan Bio Services) (1 μ M) for exon 53 skipping and Lipofectamine 2000 (manufactured by Invitrogen Corp.) were prepared and 200 μ l was added to RD cells where 1.8 mL of the medium was exchanged, to reach the final concentration of 100 nM.

42

After completion of the addition, the cells were cultured overnight. The cells were washed twice with PBS (manufactured by Nissui, hereafter the same) and then 500 μl of ISOGEN (manufactured by Nippon Gene) were added to the cells. After the cells were allowed to stand at room temperature for a few minutes for cell lysis, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a Titan One Tube RT-PCR Kit (manufactured by Roche). A reaction solution was prepared in accordance with the protocol attached to the kit. A PTC-100 (manufactured by MJ Research) was used as a thermal cycler. The RT-PCR program used is as follows.

 $50^{\rm o}$ C., 30 mins: reverse transcription

94° C., 2 mins: thermal denaturation

[94° C., 10 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

Subsequently, a nested PCR was performed with the amplified product of RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program used is as follows

94° C., 2 mins: thermal denaturation

[94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given 40 below.

```
(SEQ ID NO: 40)
Forward primer: 5'-AGGATTTGGAACAGAGGCGTC-3'

(SEQ ID NO: 41)
Reverse primer: 5'-GTCTGCCACTGGCGGAGGTC-3'
```

The reaction product, 1 μ l, of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)= $A/(A+B)\times100$

Experimental Results

The results are shown in FIGS. 9 to 17. These experiments revealed that, when the antisense oligomers were designed at exons 31-61 from the 5' end of exon 53 in the human dystrophin gene, exon 53 skipping could be caused with a high efficiency.

Test Example 7

Using an Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza), 0.3 to $30~\mu M$ of the antisense oligomers

43

were transfected with 3.5×10^5 of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used.

After the transfection, the cells were cultured overnight in 2 mL of Eagle's minimal essential medium (EMEM) (manufactured by Sigma, Inc., hereinafter the same) containing 5 10% fetal calf serum (FCS) (manufactured by Invitrogen Corp.) under conditions of 37° C. and 5% CO $_2$. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 μ l of ISOGEN (manufactured by Nippon Gene) was then added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lyse the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by 15 LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit (manufactured by Qiagen, Inc.). A reaction solution was prepared in accordance with the protocol attached to the kit. The ²⁰ thermal cycler used was a PTC-100 (manufactured by MJ Research). The RT-PCR program used is as follows.

 50° C., 30 mins: reverse transcription

95° C., 15 mins: thermal denaturation

 $[94^{\circ}\,\text{C.}, 30\,\text{seconds}; 60^{\circ}\,\text{C.}, 30\,\text{seconds}; 72^{\circ}\,\text{C.}, 1\,\text{mins}] \times 35^{-25}$ cycles: PCR amplification

72° C., 10 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

(SEQ ID NO: 42)
Forward primer: 5'-CATCAAGCAGAAGGCAACAA-3'

(SEQ ID NO: 43)
Reverse primer: 5'-GAAGTTTCAGGGCCAAGTCA-3'

The reaction product, 1 µl, of the PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)= $A/(A+B)\times 100$

Experimental Results

The results are shown in FIGS. **18** and **19**. These experiments revealed that the oligomer PMO No. 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the antisense oligomers PMO Nos. 15 and 16 (FIG. **18**). It was also revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the oligomers PMO Nos. 13 and 14 of the present invention (FIG. 55 **19**). These results showed that the sequences with —OH group at the 5' end provide a higher skipping efficiency even in the same sequences.

INDUSTRIAL APPLICABILITY

60

Experimental results in TEST EXAMPLES demonstrate that the oligomers of the present invention (PMO Nos. 1 to 10) all caused exon 53 skipping with a markedly high efficiency under all cell environments, as compared to the oligomers (PMO Nos. 11, 12, 15 and 16) in accordance with the prior art. The 5017 cells used in TEST EXAMPLE 2 are the

44

cells isolated from DMD patients, and the fibroblasts used in TEST EXAMPLES 3 and 5 are exon 53 skipping target cells from DMD patients. Particularly in TEST EXAMPLES 3 and 5, the oligomers of the present invention show the exon 53 skipping efficiency of 90% or higher in the cells from DMD patients that are the target for exon 53 skipping. Consequently, the oligomers of the present invention can induce exon 53 skipping with a high efficiency, when DMD patients are administered.

Therefore, the oligomers of the present invention are extremely useful for the treatment of DMD. Sequence Listing Free Text

SEQ ID NO: 2: synthetic nucleic acid SEQ ID NO: 3: synthetic nucleic acid SEQ ID NO: 4: synthetic nucleic acid SEQ ID NO: 5: synthetic nucleic acid SEQ ID NO: 6: synthetic nucleic acid SEQ ID NO: 7: synthetic nucleic acid SEQ ID NO: 8: synthetic nucleic acid SEQ ID NO: 9: synthetic nucleic acid SEQ ID NO: 10: synthetic nucleic acid SEQ ID NO: 11: synthetic nucleic acid SEQ ID NO: 12: synthetic nucleic acid SEQ ID NO: 13: synthetic nucleic acid SEQ ID NO: 14: synthetic nucleic acid SEQ ID NO: 15: synthetic nucleic acid SEQ ID NO: 16: synthetic nucleic acid SEQ ID NO: 17: synthetic nucleic acid SEQ ID NO: 18: synthetic nucleic acid SEQ ID NO: 19: synthetic nucleic acid SEQ ID NO: 20: synthetic nucleic acid SEQ ID NO: 21: synthetic nucleic acid SEQ ID NO: 22: synthetic nucleic acid SEO ID NO: 23: synthetic nucleic acid SEQ ID NO: 24: synthetic nucleic acid SEQ ID NO: 25: synthetic nucleic acid SEQ ID NO: 26: synthetic nucleic acid SEQ ID NO: 27: synthetic nucleic acid SEQ ID NO: 28: synthetic nucleic acid SEQ ID NO: 29: synthetic nucleic acid SEQ ID NO: 30: synthetic nucleic acid SEQ ID NO: 31: synthetic nucleic acid SEQ ID NO: 32: synthetic nucleic acid SEQ ID NO: 33: synthetic nucleic acid SEQ ID NO: 34: synthetic nucleic acid SEQ ID NO: 35: synthetic nucleic acid SEQ ID NO: 36: synthetic nucleic acid SEQ ID NO: 37: synthetic nucleic acid SEQ ID NO: 38: synthetic nucleic acid SEQ ID NO: 39: synthetic nucleic acid SEQ ID NO: 40: synthetic nucleic acid SEQ ID NO: 41: synthetic nucleic acid SEQ ID NO: 42: synthetic nucleic acid SEQ ID NO: 43: synthetic nucleic acid SEQ ID NO: 45: synthetic nucleic acid SEO ID NO: 46: synthetic nucleic acid SEQ ID NO: 47: synthetic nucleic acid SEQ ID NO: 48: synthetic nucleic acid SEQ ID NO: 49: synthetic nucleic acid SEQ ID NO: 50: synthetic nucleic acid SEQ ID NO: 51: synthetic nucleic acid SEQ ID NO: 52: synthetic nucleic acid SEQ ID NO: 53: synthetic nucleic acid SEQ ID NO: 54: synthetic nucleic acid SEQ ID NO: 55: synthetic nucleic acid SEQ ID NO: 56: synthetic nucleic acid SEQ ID NO: 57: synthetic nucleic acid

45 46 SEO ID NO: 58: synthetic nucleic acid SEQ ID NO: 91: synthetic nucleic acid SEQ ID NO: 59: synthetic nucleic acid SEQ ID NO: 92: synthetic nucleic acid SEQ ID NO: 93: synthetic nucleic acid SEQ ID NO: 60: synthetic nucleic acid SEQ ID NO: 94: synthetic nucleic acid SEQ ID NO: 61: synthetic nucleic acid SEQ ID NO: 95: synthetic nucleic acid SEQ ID NO: 62: synthetic nucleic acid SEQ ID NO: 96: synthetic nucleic acid SEQ ID NO: 63: synthetic nucleic acid SEQ ID NO: 97: synthetic nucleic acid SEQ ID NO: 64: synthetic nucleic acid SEO ID NO: 98: synthetic nucleic acid SEQ ID NO: 65: synthetic nucleic acid SEQ ID NO: 99: synthetic nucleic acid SEQ ID NO: 66: synthetic nucleic acid SEQ ID NO: 100: synthetic nucleic acid SEQ ID NO: 67: synthetic nucleic acid SEQ ID NO: 101: synthetic nucleic acid SEQ ID NO: 68: synthetic nucleic acid SEQ ID NO: 102: synthetic nucleic acid SEQ ID NO: 69: synthetic nucleic acid SEQ ID NO: 103: synthetic nucleic acid SEQ ID NO: 70: synthetic nucleic acid SEQ ID NO: 104: synthetic nucleic acid SEQ ID NO: 71: synthetic nucleic acid SEQ ID NO: 105: synthetic nucleic acid SEQ ID NO: 72: synthetic nucleic acid SEQ ID NO: 106: synthetic nucleic acid SEQ ID NO: 73: synthetic nucleic acid SEQ ID NO: 107: synthetic nucleic acid SEQ ID NO: 74: synthetic nucleic acid SEQ ID NO: 108: synthetic nucleic acid SEQ ID NO: 75: synthetic nucleic acid SEQ ID NO: 109: synthetic nucleic acid SEQ ID NO: 76: synthetic nucleic acid SEQ ID NO: 110: synthetic nucleic acid SEQ ID NO: 77: synthetic nucleic acid SEQ ID NO: 111: synthetic nucleic acid SEQ ID NO: 78: synthetic nucleic acid SEQ ID NO: 112: synthetic nucleic acid SEQ ID NO: 79: synthetic nucleic acid SEQ ID NO: 113: synthetic nucleic acid SEQ ID NO: 80: synthetic nucleic acid SEQ ID NO: 114: synthetic nucleic acid SEQ ID NO: 81: synthetic nucleic acid SEQ ID NO: 115: synthetic nucleic acid SEQ ID NO: 82: synthetic nucleic acid SEQ ID NO: 116: synthetic nucleic acid SEQ ID NO: 83: synthetic nucleic acid SEQ ID NO: 117: synthetic nucleic acid SEQ ID NO: 84: synthetic nucleic acid SEQ ID NO: 118: synthetic nucleic acid SEQ ID NO: 85: synthetic nucleic acid SEQ ID NO: 119: synthetic nucleic acid SEQ ID NO: 86: synthetic nucleic acid SEQ ID NO: 120: synthetic nucleic acid SEQ ID NO: 87: synthetic nucleic acid SEQ ID NO: 121: synthetic nucleic acid SEQ ID NO: 122: synthetic nucleic acid SEQ ID NO: 88: synthetic nucleic acid SEQ ID NO: 89: synthetic nucleic acid SEQ ID NO: 123: synthetic nucleic acid SEQ ID NO: 90: synthetic nucleic acid Sequence Listing:

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 123
<210> SEO ID NO 1
<211> LENGTH: 212
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 1
                                                                        60
ttgaaagaat tcagaatcag tgggatgaag tacaagaaca ccttcagaac cggaggcaac
agttgaatga aatgttaaag gattcaacac aatggctgga agctaaggaa gaagctgagc
                                                                       120
aggtcttagg acaggccaga gccaagcttg agtcatggaa ggagggtccc tatacagtag
                                                                       180
atgcaatcca aaagaaaatc acagaaacca ag
                                                                       212
<210> SEQ ID NO 2
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 2
ccggttctga aggtgttctt gta
                                                                        23
<210> SEQ ID NO 3
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
```

47

-continu	ued	
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 3		
tooggttotg aaggtgttot tgta	24	
<210> SEQ ID NO 4 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 4		
ctccggttct gaaggtgttc ttgta	25	
<pre><210> SEQ ID NO 5 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>		
<400> SEQUENCE: 5	26	
cctccggttc tgaaggtgtt cttgta	26	
<210> SEQ ID NO 6 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 6		
geeteeggtt etgaaggtgt tettgta	27	
<210> SEQ ID NO 7 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 7		
tgcctccggt tctgaaggtg ttcttgta	28	
<210> SEQ ID NO 8 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 8		
ccggttctga aggtgttctt gt	22	
<210> SEQ ID NO 9 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 9		
teeggttetg aaggtgttet tgt	23	

49 50

-continued <210> SEQ ID NO 10 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 10 ctccggttct gaaggtgttc ttgt 24 <210> SEQ ID NO 11 <211> LENGTH: 25 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 11 25 cctccggttc tgaaggtgtt cttgt <210> SEQ ID NO 12 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 12 gcctccggtt ctgaaggtgt tcttgt 26 <210> SEQ ID NO 13 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 13 tgcctccggt tctgaaggtg ttcttgt 27 <210> SEQ ID NO 14 <211> LENGTH: 21 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 14 ccggttctga aggtgttctt g 21 <210> SEQ ID NO 15 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 15 tccggttctg aaggtgttct tg 22 <210> SEQ ID NO 16 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid

51 52 -continued <400> SEQUENCE: 16 ctccggttct gaaggtgttc ttg 23 <210> SEQ ID NO 17 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 17 cctccggttc tgaaggtgtt cttg 24 <210> SEQ ID NO 18 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 18 gcctccggtt ctgaaggtgt tcttg 25 <210> SEQ ID NO 19 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 19 tgcctccggt tctgaaggtg ttcttg <210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 20 ccggttctga aggtgttctt 20 <210> SEQ ID NO 21 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 21 tccggttctg aaggtgttct t 21 <210> SEQ ID NO 22 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 22 22 ctccggttct gaaggtgttc tt <210> SEQ ID NO 23 <211> LENGTH: 23

53

-continued <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 23 23 cctccggttc tgaaggtgtt ctt <210> SEQ ID NO 24 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 24 gcctccggtt ctgaaggtgt tctt 24 <210> SEQ ID NO 25 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 25 25 tgcctccggt tctgaaggtg ttctt <210> SEQ ID NO 26 <211> LENGTH: 19 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 26 19 ccggttctga aggtgttct <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 27 tccggttctg aaggtgttct 20 <210> SEQ ID NO 28 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 28 ctccggttct gaaggtgttc t 21 <210> SEQ ID NO 29 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 29

55 56 -continued cctccggttc tgaaggtgtt ct <210> SEQ ID NO 30 <211> LENGTH: 23 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 30 gcctccggtt ctgaaggtgt tct 23 <210> SEQ ID NO 31 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 31 tgcctccggt tctgaaggtg ttct 24 <210> SEQ ID NO 32 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 32 ccqqttctqa aqqtqttc 18 <210> SEQ ID NO 33 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 33 tccggttctg aaggtgttc 19 <210> SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 34 ctccggttct gaaggtgttc <210> SEQ ID NO 35 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 35 cctccggttc tgaaggtgtt c 21 <210> SEQ ID NO 36 <211> LENGTH: 22 <212> TYPE: DNA

<213 > ORGANISM: Artificial

57 58

-cc	ontinued
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 36	
gcctccggtt ctgaaggtgt tc	22
<210> SEQ ID NO 37 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 37	
tgcctccggt tctgaaggtg ttc	23
<pre><210> SEQ ID NO 38 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 38	
cattcaactg ttgcctccgg ttctgaaggt g	31
<210> SEQ ID NO 39 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 39	
ttgcctccgg ttctgaaggt gttcttgtac	30
<210> SEQ ID NO 40 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 40	
aggatttgga acagaggcgt c	21
<pre><210> SEQ ID NO 41 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 41</pre>	
gtotgocact ggoggaggto	20
<pre><210> SEQ ID NO 42 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 42	
catcaagcag aaggcaacaa	20

59 -continued

20

```
<210> SEQ ID NO 43
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 43
gaagtttcag ggccaagtca
                                                                       20
<210> SEO ID NO 44
<211> LENGTH: 963
<212> TYPE: DNA
<213> ORGANISM: Homo sapiens
<400> SEQUENCE: 44
atggagetae tgtegeeace geteegegae gtagaeetga eggeeeeega eggetetete
                                                                       60
                                                                      120
tgctcctttg ccacaacgga cgacttctat gacgacccgt gtttcgactc cccggacctg
cgcttcttcg aagacctgga cccgcgcctg atgcacgtgg gcgcgctcct gaaacccgaa
gagcactege actteccege ggeggtgeac ceggeecegg gegeaegtga ggaegageat
                                                                      240
gtgcgcgcgc ccagcgggca ccaccaggcg ggccgctgcc tactgtgggc ctgcaaggcg
                                                                      300
tqcaaqcqca aqaccaccaa cqccqaccqc cqcaaqqccq ccaccatqcq cqaqcqqcqc
                                                                      360
cgcctgagca aagtaaatga ggcctttgag acactcaagc gctgcacgtc gagcaatcca
                                                                      420
aaccagcggt tgcccaaggt ggagatcctg cgcaacgcca tccgctatat cgagggcctg
                                                                      480
caggetetge tgegegacca ggaegeegeg ecceetggeg eegeageege ettetatgeg
                                                                      540
                                                                      600
cogggeocge tgecccoggg cogcggogg gagcactaca goggegacte cgacgogtee
agcccgcgct ccaactgctc cgacggcatg atggactaca gcggcccccc gagcggcgcc
                                                                      660
cggcggcgga actgctacga aggcgcctac tacaacgagg cgcccagcga acccaggccc
                                                                      720
                                                                      780
gggaagagtg cggcggtgtc gagcctagac tgcctgtcca gcatcgtgga gcgcatctcc
accgagagee etgeggegee egeceteetg etggeggaeg tgeettetga gtegeeteeg
cgcaggcaag aggctgccgc ccccagcgag ggagagagca gcggcgaccc cacccagtca
                                                                      900
                                                                      960
ceggaegeeg ceeegeagtg ceetgegggt gegaaceeea accegatata ceaggtgete
                                                                      963
tqa
<210> SEQ ID NO 45
<211> LENGTH: 20
<212> TYPE: DNA
<213 > ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 45
                                                                       20
cgggcttgga cagaacttac
<210> SEQ ID NO 46
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 46
```

tccttacggg tagcatcctg

61 62

-continued <210> SEQ ID NO 47 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic DNA <400> SEQUENCE: 47 ctgaaggtgt tcttgtactt catcc 25 <210> SEQ ID NO 48 <211> LENGTH: 19 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic DNA <400> SEQUENCE: 48 tgttgagaaa tggcggcgt 19 <210> SEQ ID NO 49 <211> LENGTH: 31 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 49 cauucaacug uugccuccgg uucugaaggu g 31 <210> SEQ ID NO 50 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 50 ucccacugau ucugaauucu uucaa 25 <210> SEQ ID NO 51 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 51 cuucauccca cuqauucuqa auucu 25 <210> SEQ ID NO 52 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 52 uuguacuuca ucccacugau ucuga 25 <210> SEQ ID NO 53 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid

63 64 -continued <400> SEQUENCE: 53 uguucuugua cuucauccca cugau 25 <210> SEQ ID NO 54 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 54 25 qaaqququuc uuquacuuca uccca <210> SEQ ID NO 55 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 55 guucugaagg uguucuugua cuuca 25 <210> SEQ ID NO 56 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 56 cuccgguucu gaagguguuc uugua 25 <210> SEQ ID NO 57 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 57 25 guugecuceg guucugaagg uguuc <210> SEQ ID NO 58 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 58 caacuguugc cuccgguucu gaagg 25 <210> SEQ ID NO 59 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 59 25 ucauucaacu guugccuccg guucu <210> SEQ ID NO 60 <211> LENGTH: 25

65 66 -continued

-continued	
<pre><212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE:</pre>	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 60	
acauuucauu caacuguugc cuccg	25
<210> SEQ ID NO 61 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 61	
cuuuaacauu ucauucaacu guugc	25
<210> SEQ ID NO 62 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 62	
gaauccuuua acauuucauu caacu	25
<210> SEQ ID NO 63 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 63	
guguugaauc cuuuaacauu ucauu	25
<210> SEQ ID NO 64 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 64	
ccauuguguu gaauccuuua acauu	25
<210> SEQ ID NO 65 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 65	
uccagccauu guguugaauc cuuua	25
<210> SEQ ID NO 66 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 66	

67 68 -continued 25 uagcuuccag ccauuguguu gaauc <210> SEQ ID NO 67 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 67 25 uuccuuagcu uccagccauu guguu <210> SEQ ID NO 68 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 68 gcuucuuccu uagcuuccag ccauu 25 <210> SEQ ID NO 69 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 69 qcucaqcuuc uuccuuaqcu uccaq 25 <210> SEQ ID NO 70 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 70 gaccugcuca gcuucuuccu uagcu 25 <210> SEQ ID NO 71 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 71 ccuaagaccu gcucagcuuc uuccu 25 <210> SEQ ID NO 72 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 72 ccuguccuaa gaccugcuca gcuuc 25 <210> SEQ ID NO 73

<211> LENGTH: 25 <212> TYPE: RNA

<213 > ORGANISM: Artificial

69 70 -continued <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 73 25 ucuggccugu ccuaagaccu gcuca <210> SEQ ID NO 74 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 74 uuggcucugg ccuguccuaa gaccu 25 <210> SEQ ID NO 75 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 75 25 caagcuuggc ucuggccugu ccuaa <210> SEQ ID NO 76 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 76 ugacucaagc uuggcucugg ccugu 25 <210> SEQ ID NO 77 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 77 25 uuccaugacu caagcuuggc ucugg <210> SEQ ID NO 78 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 78 ccuccuucca ugacucaagc uuggc 25 <210> SEQ ID NO 79 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 79

gggacccucc uuccaugacu caagc

25

71 72

-continued <210> SEQ ID NO 80 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 80 guauagggac ccuccuucca ugacu 25 <210> SEQ ID NO 81 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 81 25 cuacuguaua gggacccucc uucca <210> SEQ ID NO 82 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 82 ugcaucuacu guauagggac ccucc 25 <210> SEQ ID NO 83 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 83 uggauugcau cuacuguaua gggac 25 <210> SEO ID NO 84 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 84 25 ucuuuuggau ugcaucuacu guaua <210> SEQ ID NO 85 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 85 gauuuucuuu uggauugcau cuacu 25 <210> SEQ ID NO 86 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid

73 74 -continued <400> SEQUENCE: 86 ucugugauuu ucuuuuggau ugcau 25 <210> SEQ ID NO 87 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 87 25 ugguuucugu gauuuucuuu uggau <210> SEQ ID NO 88 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 88 ccuuagcuuc cagccauugu guuga 25 <210> SEQ ID NO 89 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 89 ucuuccuuag cuuccagcca uugug 25 <210> SEO ID NO 90 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 90 25 ggcucuggcc uguccuaaga ccugc <210> SEQ ID NO 91 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 91 agcuuggcuc uggccugucc uaaga 25 <210> SEQ ID NO 92 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 92 cucaagcuug gcucuggccu guccu 25

<210> SEQ ID NO 93

75 -continued

-continued		
<pre><211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>		
<400> SEQUENCE: 93		
gacccuccuu ccaugacuca agcuu	25	
<210> SEQ ID NO 94 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 94		
auagggaccc uccuuccaug acuca	25	
<210> SEQ ID NO 95 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 95		
cuguauaggg acccuccuuc cauga	25	
<210> SEQ ID NO 96 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 96		
ugugauuuuc uuuuggauug caucu	25	
<210> SEQ ID NO 97 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 97 guuucuguga uuuucuuuug gauug	25	
<210> SEQ ID NO 98 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 98		
cuugguuucu gugauuuucu uuugg	25	
<210> SEQ ID NO 99 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 99		

77 78 -continued 25 ccgguucuga agguguucuu guacu <210> SEQ ID NO 100 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 100 25 uccgguucug aagguguucu uguac <210> SEQ ID NO 101 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 101 ccuccgguuc ugaagguguu cuugu 25 <210> SEQ ID NO 102 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 102 25 gccuccgguu cugaaggugu ucuug <210> SEQ ID NO 103 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 103 ugccuccggu ucugaaggug uucuu 25 <210> SEQ ID NO 104 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 104 uugccuccgg uucugaaggu guucu 25 <210> SEQ ID NO 105 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 105 uguugccucc gguucugaag guguu 25 <210> SEQ ID NO 106 <211> LENGTH: 25 <212> TYPE: RNA

79 80

-continued	
<pre></pre> <pre><213> ORGANISM: Artificial</pre>	
<213> ORGANISM: AFCIFICIAT <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 106	
cuguugccuc cgguucugaa ggugu	25
<210> SEQ ID NO 107	
<211> LENGTH: 25	
<212> TYPE: RNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 107	
acuguugccu ccgguucuga aggug	25
<210> SEQ ID NO 108	
<211> LENGTH: 25	
<212> TYPE: RNA <213> ORGANISM: Artificial	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 108	
aacuguugcc uccgguucug aaggu	25
<210> SEQ ID NO 109	
<211> LENGTH: 30	
<212> TYPE: RNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 109	
uguugccucc gguucugaag guguucuugu	30
<210> SEQ ID NO 110	
<211> LENGTH: 20	
<212> TYPE: RNA	
<213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 110	
gguucugaag guguucuugu	20
<210> SEQ ID NO 111	
<211> LENGTH: 20 <212> TYPE: RNA	
<212> TYPE: RNA <213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 111	
uccgguucug aagguguucu	20
300	
<210> SEQ ID NO 112	
<211> LENGTH: 20	
<212> TYPE: RNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 112	
ccuccgguuc ugaagguguu	20

81

-continued <210> SEQ ID NO 113 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 113 uugccuccgg uucugaaggu 20 <210> SEO ID NO 114 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 114 20 uguugccucc gguucugaag <210> SEQ ID NO 115 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 115 uucugaaggu guucuugu 18 <210> SEQ ID NO 116 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 116 18 cgguucugaa gguguucu <210> SEO ID NO 117 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 117 18 cuccgguucu gaaggugu <210> SEQ ID NO 118 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 118 ugccuccggu ucugaagg 18 <210> SEQ ID NO 119 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid

83 -continued

<400> SEQUENCE: 119 18 uguugccucc gguucuga <210> SEO ID NO 120 <211> LENGTH: 15 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 120 15 uucugaaggu guucu <210> SEQ ID NO 121 <211> LENGTH: 15 <212 > TYPE · RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 121 uccgguucug aaggu 15 <210> SEQ ID NO 122 <211> LENGTH: 15 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 122 uugccuccgg uucug 15 <210> SEO ID NO 123 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEOUENCE: 123 18 cuguugccuc cgguucug

The invention claimed is:

1. An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of the nucleotide sequence of SEQ ID NO: 35, wherein the antisense 50 oligomer is an oligonucleotide having the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide modified, or a morpholino oligomer.

2. The antisense oligomer according to claim 1, wherein the antisense oligomer is a morpholino oligomer.

- 3. The antisense oligomer according to claim 1, wherein the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group is replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R' is an alkylene).
- 4. The antisense oligomer according to claim 1, wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond and a boranophosphate bond.

- **5**. The antisense oligomer according to claim **2**, wherein the morpholino oligomer is a phosphorodiamidate morpholino oligomer.
- 6. The antisense oligomer according to claim 2, wherein the 5 end of the morpholino oligomer is one of the groups of chemical formulae (1) to (3) below:

15

85

-continued (2)
$$O \longrightarrow NH_2 \qquad (5)$$

$$O \longrightarrow P \longrightarrow N \qquad (5)$$

$$O \longrightarrow P \longrightarrow N \qquad (7)$$

$$OH \qquad (3)$$

7. A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active, ingredient the antisense oligomer according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof.

* * * *

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 9,079,934 B2 Page 1 of 1

APPLICATION NO. : 13/819520 DATED : July 14, 2015

INVENTOR(S) : Naoki Watanabe et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

At Column 84, Line 51, replace "the 5 end of" with --the 5' end of--.

Signed and Sealed this Twenty-third Day of June, 2020

Andrei Iancu

Director of the United States Patent and Trademark Office

EXHIBIT AB

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 67 of 250 PageID #: 20035

Atty. Docket No.: 209658-0001-00-US-495293 (PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent No. 9,079,934

Issued: July 14, 2015

To: Naoki WATANABE et al.

Assignees: NIPPON SHINYAKU CO., LTD. AND NATIONAL CENTER OF NEUROLOGY AND

PSYCHIATRY

For: ANTISENSE NUCLEIC ACIDS

APPLICATION FOR EXTENSION OF PATENT TERM UNDER 35 U.S.C. § 156

MAIL STOP HATCH-WAXMAN PTE

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant, NIPPON SHINYAKU CO., LTD., represents that it is the Assignee of an undivided interest in the entirety in and to United States Patent No. 9,079,934 granted to Naoki Watanabe et al. on the July 14, 2015, for ANTISENSE NUCLEIC ACIDS by virtue of an assignment from the inventors to NIPPON SHINYAKU CO., LTD., recorded in the U.S. Patent and Trademark Office at Reel 030185, Frame 0302 on April 10, 2013.

By the Power of Attorney submitted April 10, 2013, the inventors appoint the registered practitioners associated with Customer Number 055694, including Mercedes K. Meyer and Zhengyu Feng, as attorneys with regard to this application for extension of the patent term of U.S. Patent No. 9,079,934 and to transact all business in the U.S. Patent and Trademark Office in connection therewith.

Docket No.: 209658-0001-00-US-495293

Information Required Under 37 C.F.R. § 1.740

Applicant hereby submits this application for extension of the patent term under 35 U.S.C. § 156 by providing the following information required by the rules promulgated by the U.S. Patent and Trademark Office (37 C.F.R. § 1.740). For the convenience of the Patent and Trademark Office, the information contained in this application will be presented in a format that follows the requirements of Section 1.740 of Title 37 of the Code of Federal Regulations.

(1) The approved product, VILTEPSOTM (viltolarsen), is a small molecule. A chemical name of viltolarsen is: all-P-ambo-[2',3'-azanediyl-P,2',3'-trideoxy-P-(dimethylamino)-2',3'-seco](2'-N→5')(CCTCCGGTTC TGAAGGTGTT C). Viltolarsen is represented by the following structural formula:

CCTCCGGTTC TGAAGGTGTT C

- (2) The approved product, VILTEPSOTM (viltolarsen), is subject to regulatory review under the Federal Food, Drug and Cosmetic Act Section 505, Part (b)(1).
- (3) The approved product, VILTEPSO[™] (viltolarsen), received approval for commercial marketing or use under Section 505, Part (b)(1) of the Federal Food, Drug and Cosmetic Act from the Food and Drug Administration on <u>August 12, 2020</u>.
- (4) The active ingredient in VILTEPSOTM is viltolarsen, which on information and belief, has not been previously approved for commercial marketing or use under the Federal Food, Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act. A copy of the package insert describing the approved product is attached (Attachment A).

Docket No.: 209658-0001-00-US-495293

- (5) This application for extension of patent term under 35 U.S.C. § 156 is being submitted within the permitted 60-day period pursuant to 37 C.F.R. § 1.720(f) (i.e., 60 days from August 12, 2020), said period will expire on October 11, 2020.
- (6) The complete identification of the patent for which a term extension is being sought is as follows:

Inventors: Naoki Watanabe; Youhei Satou; Shin'ichi Takeda; and Tetsuya

Nagata

Patent No.: 9,079,934

Application Serial No.: 13/819,520

Filing Date: August 31, 2011

Issue Date: July 14, 2015

Expiration Date: August 31, 2031

- (7) A true copy of U.S. Patent 9,079,934 is attached (Attachment B).
- (8) No disclaimer, reexamination certificate, or certificate of correction has been issued on this patent. A copy of the maintenance fee statement indicating payment of the fourth year maintenance fee on January 3, 2019 is attached (Attachment C).
- (9) Claims 1-2 and 5-7 of U.S. Patent No. 9,079,934 read upon the approved product, VILTEPSOTM (viltolarsen).

Claim 1 reads as follows:

1. An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of the nucleotide sequence of SEQ ID NO: 35, wherein the antisense oligomer is an oligonucleotide having the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide modified, or a morpholino oligomer.

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 70 of 250 PageID #: 20038

Docket No.: 209658-0001-00-US-495293

Viltolarsen is an antisense phosphorodiamidate morpholino oligomer. Viltolarsen is 21 nucleobases in length and has the following sequence: 5'- CCTCCGGTTC TGAAGGTGTT C - 3', which corresponds to SEQ ID NO: 35 in U.S. Patent No. 9,079,934.

- (10) The relevant dates and information pursuant to 35 U.S.C. § 156(g) to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:
 - Investigational New Drug Application (IND 127474) for VILTEPSO™
 (viltolarsen) became effective on March 25, 2016.
 - New Drug Application (NDA 212154) for VILTEPSO™ (viltolarsen) was filed on February 1, 2019.
 - New Drug Application (NDA 212154) was approved on <u>August 12, 2020</u>.
- (11) A brief description of the significant activities undertaken by the marketing applicant during the applicable regulatory review period with respect to the approved product and the dates applicable to these significant activities are set forth in a chronology of events in Attachment D.

Docket No.: 209658-0001-00-US-495293

(12)(i) Applicant is of the opinion that U.S. Patent No. 9,079,934 is eligible for extension of the patent term under 35 U.S.C. § 156.

(12)(ii) Applicant respectfully submits that the length of the extension of patent term for U.S. Patent No. 9,079,934 is **1,077** days pursuant to 35 U.S.C. § 156(c) (i.e., the difference between Aug. 31, 2031 and 14 years from the NDA approval date). The length of the extension was determined pursuant to 37 C.F.R. § 1.775(a) to (d) as follows:

1.775(c)(1)and (c)(2)

- (a) The regulatory review period under 35 U.S.C. § 156(g)(1)(B) is a total of 1,603 days, which is the sum of (1) and (2) below:
 - (1) The period of review under 35 U.S.C. § 156(g)(1)(B)(i), the "Testing Period," began on March 25, 2016. The date the NDA was initially submitted is February 1, 2019. The difference between these dates is 1,044 days (1.775(c)(1)); and
 - (2) The period of review under 35 U.S.C. § 156(g)(1)(B)(ii), the "Approval Period," began on February 1, 2019, and ended on August 12, 2020, which is a total of 559 days (1.775(c)(2)).

1.775(d)(1)(i)-(iii)

- (b) The regulatory review period upon which the period of extension is calculated is the entire regulatory review period as determined in subparagraph 12(ii)(a) above (1,603 days) less:
- (1) The number of days in the regulatory review period which were before or on the date on which the patent issued (July 14, 2015), which is <u>0 days</u> pursuant to 37 C.F.R. §1.775(d)(1)(i); there are no days known to applicant during the periods of 1.775(c)(1) and (2) above that applicant failed to act diligently, thus <u>0 days</u> pursuant to 37 C.F.R. §1.775(d)(1)(ii);
- (2) One-half the number of days determined in subparagraph (12)(ii)(a)(1) above after the patent issued which is (1044 days 0 days)/2 or $\underline{522 \text{ days}}$; the sum

Docket No.: 209658-0001-00-US-495293

results in a total regulatory review period upon which the period of extension is calculated of (1,603 days minus <u>0</u> days minus <u>522 days</u>) or <u>1,081 days</u>.

- (c) The number of days as determined in subparagraph (12)(ii)(b) (i.e., 1,081 days) when added to the original term of the patent (August 31, 2031) would result in the expiration date of <u>August 16, 2034</u>. 37 C.F.R. 1.755(d)(2).
- (d) Fourteen (14) years when added to the date of the NDA approval date (i.e., August 12, 2020 plus 14 years) would result in the expiration date of <u>August 12, 2034</u>. 37 C.F.R. 1.755(d)(3).
- (e) The earlier date as determined in subparagraphs (12)(ii)(c) and (12)(ii)(d) is August 12, 2034. 37 C.F.R. 1.755(d)(4).
- (f) Since U.S. Patent No. 9,079,934 issued after September 24, 1984, the period of extension may not exceed five years from the original expiration date of August 31, 2031 (The application was filed August 31, 2011 and there are 0 days added under 35 U.S.C. 154). Five years when added to the original expiration date of the patent would result in the date of August 31, 2036. 37 C.F.R. 1.755(d)(5).
- (g) The earlier date as determined by subparagraphs (12)(ii)(e) and (12)(ii)(f) is August 12, 2034.
- (13) Applicant acknowledges a duty to disclose to the Director of the United States Patent and Trademark Office and the Secretary of Health and Human Services any information which is material to the determination of entitlement to the extension sought pursuant to §§1.704(a)(13) and 1.765.
- (14) Please charge the prescribed fee for receiving and acting upon this application in the amount of \$1,180.00 to Deposit Account No. 50-0573. The Director is authorized to charge any additional fees required by this application to Deposit Account No. 50-0573.
- (15) (A) All correspondence and inquiries may be directed to the undersigned at the correspondence address associated with Customer No. 055694.
- (15) (B) This is a certification that the application for extension of patent term under 35 U.S.C. § 156 including its attachments and supporting papers is being submitted via EFS-Web given the USPTO's official notice of May 29, 2020 (https://www.uspto.gov/about-us/news-

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 73 of 250 PageID #: 20041

Docket No.: 209658-0001-00-US-495293

updates/uspto-allow-filing-initial-patent-term-extension-applications-patent). The notice of May 29th waived the requirement of submitting one original application and two copies for the total of three copies under 1.740(a)(12) given the 2020 coronavirus pandemic. The submitted EFS application can also be considered as having been submitted in triplicate for purposes of intent.

Applicant submits based on the above calculations that Applicant is entitled to 1,077 days of patent term extension.

Dated: October 9, 2020 Respectfully submitted,

Customer Number: 055694 By: Mercedes K. Meyer

Mercedes K. Meyer, Ph.D., J.D.

Registration No.: 44,939

202.842.8465 (Fax)

FAEGRE DRINKER BIDDLE & REATH LLP

1500 K Street, N.W., Suite 1100 Washington, DC 20005-1209 202.842.8821 (Phone)

mercedes.meyer@faegredrinker.com Attorneys/Agents For Applicant

Attachments:

Approved Package Insert (Attachment A)
U.S. Patent No. 9,079,934 (Attachment B)
Maintenance Fee Statement (Attachment C)

Chronology of Regulatory Review Period (Attachment D)

ATTACHMENT A

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 75 of 250 PageID #: 20043

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use
VILTEPSO™ safely and effectively. See full prescribing
information for VILTEPSO.

VILTEPSO (viltolarsen) injection, for intravenous use Initial U.S. Approval: 2020

----INDICATIONS AND USAGE---

VILTEPSO is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (1)

---DOSAGE AND ADMINISTRATION---

- Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. (2.1)
- Recommended dosage is 80 milligrams per kilogram of body weight once weekly. (2.2)
- Administer as an intravenous infusion over 60 minutes. (2.2, 2.4)
- If the volume of VILTEPSO required is less than 100 mL, dilution in 0.9% Sodium Chloride Injection, USP, is required. (2.3)

------WARNINGS AND PRECAUTIONS-----

Kidney Toxicity: Based on animal data, may cause kidney toxicity. Kidney function should be monitored; creatinine may not be a reliable measure of renal function in DMD patients. (5.1, 13.2)

------ADVERSE REACTIONS------

The most common adverse reactions (incidence ≥15% in patients treated with VILTEPSO) were upper respiratory tract infection, injection site reaction, cough, and pyrexia. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact NS Pharma at 1-866 NSPHARM (1-866-677-4276) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION

Revised: 8/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

- 1 INDICATIONS AND USAGE
- 2 DOSAGE AND ADMINISTRATION
- 2.1 Monitoring to Assess Safety
- 2.1 Dosing Information
- 2.2 Preparation instructions
- 2.3 Administration Instructions
- 3 DOSAGE FORMS AND STRENGTHS
- 4 CONTRAINDICATIONS
- 5 WARNINGS AND PRECAUTIONS
 - 5.1 Kidney Toxicity
- 6 ADVERSE REACTIONS
 - 6.1 Clinical Trials Experience
- 6.2 Immunogenicity
- 8 USE IN SPECIFIC POPULATIONS
 - 8.1 Pregnancy
 - 8.2 Lactation
 - 8.4 Pediatric Use

- 8.5 Geriatric Use
- 8.6 Patients with Renat Impairment
- 11 DESCRIPTION
- 12 CLINICAL PHARMACOLOGY
 - 12.1 Mechanism of Action
 - 12.2 Pharmacodynamics
 - 12.3 Pharmacokinetics
- 13 NONCLINICAL TOXICOLOGY
 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
- 14 CLINICAL STUDIES
- 16 HOW SUPPLIED/STORAGE AND HANDLING
 - 16.1 How Supplied
 - 16.2 Storage and Handling
- * Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

2 DOSAGE AND ADMINISTRATION

2.1 Monitoring to Assess Safety

Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider measurement of glomerular filtration rate prior to initiation of VILTEPSO. Monitoring for kidney toxicity during treatment is recommended [see Warnings and Precautions (5.1)].

2.2 Dosing Information

The recommended dosage of VILTEPSO is 80 mg/kg administered once weekly as a 60-minute intravenous infusion.

If a dose of VILTEPSO is missed, it should be administered as soon as possible after the scheduled dose time.

2.3 Preparation Instructions

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Prepare the VILTEPSO dose using aseptic technique.

- a. Calculate the total dose of VILTEPSO to be administered based on the patient's weight and the recommended dosage of 80 mg/kg. Determine the volume of VILTEPSO needed and the correct number of vials to supply the full calculated dose.
- b. Allow vials to warm to room temperature. Mix the contents of each vial by gently inverting 2 to 3 times. Do not shake.
- c. Visually inspect each vial of VILTEPSO. VILTEPSO is a clear and colorless solution. Do not use if the solution in the vials is discolored or particulate matter is present.
- d. Withdraw the calculated volume of VILTEPSO from the appropriate number of vials.
 - i. If the volume of VILTEPSO required is less than 100 mL, dilution in 0.9% Sodium Chloride Injection, USP is required. Withdraw from the 100-mL infusion bag a volume of 0.9% Sodium Chloride Injection, USP, equivalent to the calculated volume of VILTEPSO and inject the VILTEPSO into the infusion bag, such that the total volume in the bag is 100 mL.
 - ii. If the volume of VILTEPSO required is 100 mL or more, dilution is not required, and the required amount of VILTEPSO should be placed into an empty infusion bag.

- e. Visually inspect the infusion bag containing the solution for particulates. Gently invert the infusion bag to ensure equal distribution of product. Do not shake.
- f. VILTEPSO contains no preservatives. Infusion should begin as soon as possible, but no more than 5 hours after preparation of VILTEPSO, and be completed within 6 hours of preparation (allowing for 1 hour of infusion time), if diluted solution is stored at 20°C to 26°C (68°F to 79°F). If immediate use is not possible, the solution may be stored for up to 24 hours at 2°C to 8°C (36°F to 46°F). Do not freeze.
- g. VILTEPSO is supplied in single-dose vials. Discard unused VILTEPSO.

2.4 Administration Instructions

VILTEPSO is administered via intravenous infusion using a peripheral or central venous catheter. Flush the intravenous access line with 0.9% Sodium Chloride Injection, USP, after infusion. Filtration of VILTEPSO is not required.

Infuse VILTEPSO over 60 minutes. Do not mix other medications with VILTEPSO or infuse other medications concomitantly via the same intravenous access line. VILTEPSO should be mixed with 0.9% Sodium Chloride Injection, USP, only.

3 DOSAGE FORMS AND STRENGTHS

VILTEPSO is a clear and colorless solution available as follows:

• Injection: 250 mg/5 mL (50 mg/mL) solution in a single-dose vial

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Kidney Toxicity

Kidney toxicity was observed in animals who received viltolarsen [see Use in Specific Populations (8.4)]. Although kidney toxicity was not observed in the clinical studies with VILTEPSO, the clinical experience with VILTEPSO is limited, and kidney toxicity, including potentially fatal glomerulonephritis, has been observed after administration of some antisense oligonucleotides. Kidney function should be monitored in patients taking VILTEPSO. Because of the effect of reduced skeletal muscle mass on creatinine measurements, serum creatinine may not be a reliable measure of kidney function in DMD patients. Serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio should be measured before starting VILTEPSO. Consider also measuring glomerular filtration rate using an exogenous filtration marker before starting VILTEPSO. During treatment, monitor urine dipstick every month, and serum cystatin C and urine protein-to-creatinine ratio every three months. If a persistent increase in serum cystatin C or proteinuria is detected, refer to a pediatric nephrologist for further evaluation.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials with VILTEPSO, 32 patients have been exposed to VILTEPSO once weekly, ranging between 40 mg/kg (0.5 times the recommended dosage) and 80 mg/kg (the recommended dosage), including 16 patients treated for greater than 12 months and 8 patients treated for greater than 24 months as part of an ongoing open-label extension study. All patients were male and had genetically confirmed DMD.

Study 1 was a multicenter, 2-period, dose-finding study conducted in the United States and Canada in males 4 years to less than 10 years of age on a stable corticosteroid regimen for at least 3 months. During the initial period (first 4 weeks) of Study 1, patients were randomized (double-blind) to VILTEPSO or placebo. All patients then received 20 weeks of VILTEPSO 40 mg/kg once weekly (0.5 times the recommended dose) (N=8), or 80 mg/kg once weekly (N=8) [see Clinical Studies (14)].

Study 2 was a multicenter, parallel-group, open-label, dose-finding study conducted in Japan. Eligible patients included ambulatory and non-ambulatory males 5 years to less than 18 years of age who were assigned to receive intravenous VILTEPSO 40 mg/kg once weekly (0.5 times the recommended dose) (N=8) or 80 mg/kg once weekly (N=8) for 24 weeks.

Adverse reactions reported in ≥10% of patients treated with VILTEPSO 80 mg/kg/wk in pooled Studies 1 and 2 are displayed in Table 1. The most common adverse reactions (incidence ≥15% in patients treated with VILTEPSO) were upper respiratory tract infection, injection site reaction, cough, and pyrexia. Patients in the pooled analysis were treated with VILTEPSO for 20 to 24 weeks.

Table 1: Adverse Reactions Reported in ≥10% of DMD Patients Treated with VILTEPSO 80 mg/kg Once Weekly (Pooled Studies 1 and 2)

Adverse Reaction	VILTEPSO 80 mg/kg Once Weekly (n=16) %
Upper respiratory tract infection*	63
Injection site reaction**	25
Cough	19
Pyrexia	19
Contusion	13
Arthralgia	13
Diarrhea	13
Vomiting	13
Abdominal pain	13
Ejection fraction decreased	13
Urticaria	13

- * Upper respiratory tract infection includes the following terms: upper respiratory tract infection, nasopharyngitis, and rhinorrhea.
- ** Injection site reaction includes the following terms: injection site bruising, injection site erythema, injection site reaction, and injection site swelling.

6.2 Immunogenicity

As with all oligonucleotides, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies in the studies described below with the incidence of antibodies in other studies may be misleading.

For Study 1, samples collected from all 16 patients at Day 1 (pre-dose), Week 5, Week 13, and Week 24 were assessed for anti-viltolarsen antibodies. All samples were determined to be antibody negative. For the same study, serum samples collected from all 16 patients at Day 1 (pre-dose), Week 13, and Week 24 were analyzed for anti-dystrophin antibodies. Anti-dystrophin antibodies were detected in 1 out of 16 patients (6.25%) at Weeks 13 and 24; however, at Weeks 37, 49, 73, and 97, no anti-dystrophin antibodies were detected in the same patient. Further, this patient achieved a change from baseline in dystrophin levels that was comparable to the mean change in his dosage group (80 mg/kg/week) and there were no adverse events reported with this antibody production. For Study 2, all samples collected from the 16 patients were determined to be both anti-viltolarsen antibody and anti-dystrophin antibody negative. Overall, there was a lack of observed immunogenicity, which indicates that viltolarsen is not highly immunogenic.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Risk Summary

There are no human or animal data available to assess the use of VILTEPSO during pregnancy. In the U.S. general population, major birth defects occur in 2 to 4%, and miscarriage occurs in 15 to 20% of clinically recognized pregnancies.

8.2 Lactation

Risk Summary

There are no human or animal data to assess the effect of VILTEPSO on milk production, the presence of viltolarsen in milk, or the effects of VILTEPSO on the breastfed infant.

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VILTEPSO and any potential adverse effects on the breastfed infant from VILTEPSO or from the underlying maternal condition.

8.4 Pediatric Use

VILTEPSO is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping, including pediatric patients [see Clinical Studies (14)].

Juvenile Animal Toxicity Data

Viltolarsen (0, 15, 60, 240, or 1200 mg/kg) was administered to juvenile male mice by subcutaneous injection on postnatal day (PND) 7 and by intravenous injection weekly from PND 14 to PND 70. The highest dose resulted in deaths because of renal toxicity. In surviving animals at 240 and 1200 mg/kg, there was a dose-dependent increase in the incidence and severity of renal tubular effects (including degeneration), which were not accompanied by clinical pathology correlates. Reduced body weight gain and delayed sexual maturation were observed at the highest dose tested. At the no-effect dose for renal toxicity (60 mg/kg), plasma exposures were similar to that in humans at the recommended human dose of 80 mg/kg/week.

8.5 Geriatric Use

DMD is largely a disease of children and young adults; therefore, there is no geriatric experience with VILTEPSO.

8.6 Patients with Renal Impairment

VILTEPSO has not been studied in patients with renal impairment. Viltolarsen is mostly excreted unchanged in the urine, and renal impairment may increase its exposure. However, because of the effect of reduced skeletal muscle mass on creatinine measurements in DMD patients, no specific dosage adjustment can be recommended for DMD patients with renal impairment based on estimated glomerular filtration rate. Patients with known renal function impairment should be closely monitored during treatment with VILTEPSO.

11 DESCRIPTION

VILTEPSO (viltolarsen) injection is a sterile, preservative-free, aqueous solution for intravenous administration. VILTEPSO is a clear and colorless solution. VILTEPSO is supplied in single-dose vials containing 250 mg/5 mL viltolarsen (50 mg/mL) in 0.9% sodium chloride. Each milliliter of VILTEPSO contains 50 mg viltolarsen and 9 mg sodium chloride in water for injection. The final product is adjusted to a pH ranging between 7.0 and 7.5 using hydrochloric acid and/or sodium hydroxide.

Viltolarsen is an antisense oligonucleotide of the phosphorodiamidate morpholino oligomer (PMO) subclass. PMOs are synthetic molecules in which the five-membered ribofuranosyl rings found in natural DNA and RNA are replaced by a six-membered morpholino ring. Each morpholino ring is linked through an uncharged phosphorodiamidate moiety rather than the negatively charged phosphate linkage that is present in natural DNA and RNA. Each phosphorodiamidate morpholino subunit contains one of the heterocyclic bases found in DNA (adenine, cytosine, guanine, or thymine). Viltolarsen contains 21 linked subunits. The molecular formula of viltolarsen is C₂₄₄H₃₈₁N₁₁₃O₈₈P₂₀ and the molecular weight is 6924.82 daltons. The structure and base sequence of viltolarsen are shown in Figure 1.

Figure 1: Structural Formula of Viltolarsen

CCTCCGGTTC TGAAGGTGTT C

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

VILTEPSO is designed to bind to exon 53 of dystrophin pre-mRNA resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping. Exon 53 skipping is intended to allow for production of an internally truncated dystrophin protein in patients with genetic mutations that are amenable to exon 53 skipping.

12.2 Pharmacodynamics

After treatment with VILTEPSO 80 mg/kg once weekly, all patients evaluated (N=8) were found to produce mRNA for a truncated dystrophin protein, as measured by reverse transcription polymerase chain reaction (RT-PCR), and demonstrated exon 53 skipping, as measured by DNA sequence analysis.

In Study 1, all patients who received VILTEPSO 80 mg/kg once weekly for 20 to 24 weeks showed an increase from baseline in dystrophin protein expression, as quantified by a validated Western blot method (mean 5.3%; median 3.8%; range 0.7% to 13.9% of normal levels when normalized to myosin heavy chain; p-value 0.01). Mass spectrometry, immunofluorescence staining, and RT-PCR results were supportive of the Western blot data [see Clinical Studies (14)]. Expected localization of truncated dystrophin to the sarcolemma in muscle fibers of patients treated with viltolarsen was confirmed by immunofluorescence staining.

12.3 Pharmacokinetics

The pharmacokinetics of viltolarsen was evaluated in DMD patients following administration of intravenous (IV) doses ranging from 1.25 mg/kg/week (0.016 times the recommended dosage) to 80 mg/kg/week (the recommended dosage). Viltolarsen exposure increased proportionally with dose, with minimal accumulation with once-weekly dosing. Inter-subject variability (as %CV) for C_{max} and AUC ranged from 16% to 27% respectively.

VILTEPSO is administered as an IV infusion over 60 minutes. Bioavailability is assumed to be 100%, and median T_{max} was around 1 hour (end of infusion).

Distribution

The mean viltolarsen steady-state volume of distribution was 300 mL/kg (%CV=14 at a dose of 80 mg/kg. Viltolarsen plasma protein binding ranged from 39% to 40% and is not concentration dependent.

Elimination

Metabolism

Data from in vitro metabolism indicate that viltolarsen is metabolically stable. No metabolites were detected in plasma or urine.

Excretion

VILTEPSO is excreted mainly as an unchanged drug in the urine. Viltolarsen elimination half-life was 2.5 (%CV=8) hours, and plasma clearance was 217 mL/hr/kg (%CV=22).

Specific Populations

Age, Sex & Race

The pharmacokinetics of viltolarsen have been evaluated only in male pediatric DMD patients. There is no experience with VILTEPSO in patients 65 years of age or older. No marked differences in any PK parameters were observed between White and Asian patients.

Patients with Renal or Hepatic Impairment

VILTEPSO has not been studied in patients with renal or hepatic impairment. Viltolarsen was found to be metabolically stable, and hepatic metabolism does not contribute to the elimination of viltolarsen. In addition, viltolarsen was mainly excreted unchanged in the urine. Viltolarsen is eliminated renally, and renal impairment is expected to result in increasing exposure of viltolarsen. However, because of the effect of reduced skeletal muscle mass on creatinine measurements in DMD patients, no specific dosage adjustment can be recommended for DMD patients with renal impairment based on glomerular filtration rate estimated by serum creatinine [see Use in Specific Populations (8.6)].

In Vitro Drug Interaction Studies

Viltolarsen did not inhibit CYP3A4/5, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, UGT1A1, or UGT2B7. Viltolarsen did not induce CYP1A2, CYP2B6, or CYP3A4.

Viltolarsen is not metabolized by CYP enzymes and is not a substrate of transporters BCRP, BSEP, MDR1, OAT1, OAT3, OCT1, OCT2, MATE1, or MATE2-K. Viltolarsen did not inhibit the transporters tested (OATP1B1, OATP1B3, OAT3, BCRP, MDR1, BSEP, OAT1, OCT1, OCT2, MATE1, and MATE2-K).

Based on in vitro data, viltolarsen has a low potential for drug-drug interactions with major CYP enzymes and drug transporters in humans.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies of viltolarsen have not been conducted.

Mutagenesis

Viltolarsen was negative for genotoxicity in *in vitro* (bacterial reverse mutation, chromosomal aberration in Chinese hamster lung cells) and *in vivo* (mouse bone marrow micronucleus) assays.

Impairment of Fertility

Intravenous administration of viltolarsen (0, 60, 240, or 1000 mg/kg) to male mice weekly prior to and during mating to untreated females did not have adverse effects on fertility. Plasma exposure (AUC) at the highest dose was approximately 18 times that in humans at the recommended human dose of 80 mg/kg/week.

14 CLINICAL STUDIES

The effect of VILTEPSO on dystrophin production was evaluated in one study in DMD patients with a confirmed mutation of the DMD gene that is amenable to exon 53 skipping (Study 1; NCT02740972).


Study 1 was a multicenter, 2-period, dose-finding study conducted in the United States and Canada. During the initial period (first 4 weeks) of Study 1, patients were randomized (double blind) to VILTEPSO or placebo. All patients then received 20 weeks of open-label VILTEPSO 40 mg/kg once weekly (0.5 times the recommended dosage) (N=8) or 80 mg/kg once weekly (N=8). Study 1 enrolled ambulatory male patients 4 years to less than 10 years of age (median age 7 years) on a stable corticosteroid regimen for at least 3 months.

Efficacy was assessed based on change from baseline in dystrophin protein level (measured as % of the dystrophin level in healthy subjects, i.e., % of normal) at Week 25. Muscle biopsies (left or right biceps brachii) were collected from patients at baseline and following 24 weeks of VILTEPSO treatment, and analyzed for dystrophin protein level by Western blot normalized to myosin heavy chain (primary endpoint) and mass spectrometry (secondary endpoint).

In patients who received VILTEPSO 80 mg/kg once weekly, mean dystrophin levels increased from 0.6% (SD 0.8) of normal at baseline to 5.9% (SD 4.5) of normal by Week 25, with a mean change in dystrophin of 5.3% (SD 4.5) of normal levels (p=0.01) as assessed by validated Western blot (normalized to myosin heavy chain); the median change from baseline was 3.8%. All patients demonstrated an increase in dystrophin levels over their baseline values. As assessed by mass spectrometry (normalized to filamin C), mean dystrophin levels increased from 0.6% (SD 0.2) of normal at baseline to 4.2% (SD 3.7) of normal by Week 25, with a mean change in dystrophin of 3.7% (SD 3.8) of normal levels (nominal p=0.03, not adjusted for multiple comparisons); the median change from baseline was 1.9%.

Individual patient dystrophin levels in patients evaluated in Study 1 are shown in Figure 2 and Table 2.

Figure 2: Dystrophin Expression in Individual Patients (Study 1)



Note: Solid lines represent individual patient data. Dystrophin was measured using Western blot and normalized to myosin heavy chain.

Table 2: Dystrophin Expression in Individual Patients (Study 1)

Patient	Western Blot % Normal Dystrophin ^a		
Number	Baseline	Week 25	Change from
			Baseline
1	0.46	1.14	0.69
2	0.40	3.97	3.57
3	0.46	2.97	2.51
4	0.09	10.40	10.31
5	0.51	14.42	13.91
6	2.61	7.40	4.79
7	0.43	3.06	2.63
8	0.09	4.07	3.98

^a Data were normalized by myosin heavy chain

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 85 of 250 PageID #: 20053

VILTEPSO injection is supplied in single-dose vials. The solution is clear and colorless.

Single-dose vials containing 250 mg/5 mL (50 mg/mL) viltolarsen NDC 73292-011-01

16.2 Storage and Handling

Store VILTEPSO at 2°C to 8°C (36°F to 46°F). Do not freeze.

17 Patient Counseling Information

Kidney Toxicity

Inform patients nephrotoxicity has occurred with drugs similar to VILTEPSO. Advise patients of the importance of monitoring for kidney toxicity by their healthcare providers during treatment with VILTEPSO [see Warnings and Precautions (5.1)].

Manufactured for: NS Pharma, Inc. Paramus, NJ 07652 Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 86 of 250 Ragala ##ge 1 of 1 20054

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/ -----

WILLIAM H Dunn 08/12/2020 12:57:38 PM

ATTACHMENT B

(12) United States Patent

Watanabe et al.

(10) Patent No.:

US 9,079,934 B2

(45) Date of Patent:

Jul. 14, 2015

(54) ANTISENSE NUCLEIC ACIDS

(75) Inventors: Naoki Watanabe, Tsukuba (JP); Youhei Satou, Tsukuba (JP); Shin'ichi Takeda,

Tokyo (JP); Tetsuya Nagata, Tokyo (JP)

(73) Assignees: NIPPON SHINYAKU CO., LTD.,

Kyoto-shi, Kyoto (JP); NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, Kodaira-shi, Tokyo (JP)

Notice: Subject to any disclaimer, the term of this

patent is extended or adjusted under 35

U.S.C. 154(b) by 0 days.

13/819,520 (21) Appl. No.:

(22) PCT Filed: Aug. 31, 2011

(86) PCT No.: PCT/JP2011/070318

§ 371 (c)(1),

Apr. 10, 2013 (2), (4) Date:

(87) PCT Pub. No.: WO2012/029986

PCT Pub. Date: Mar. 8, 2012

(65)**Prior Publication Data**

US 2013/0211062 A1 Aug. 15, 2013

(30)Foreign Application Priority Data

Sep. 1, 2010 (JP) 2010-196032

(51)	Int. Cl.	
	C07H 21/02	(2006.01)
	C07H 21/04	(2006.01)
	A61K 31/70	(2006.01)
	C12N 15/11	(2006.01)
	C12N 15/113	(2010.01)
	C07H 21/00	(2006.01)
	C12O 1/68	(2006.01)

(52) U.S. Cl.

CPC C07H 21/04 (2013.01); C07H 21/00 (2013.01); C12N 15/111 (2013.01); C12N **15/113** (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/3525 (2013.01); C12N 2320/33 (2013.01)

(58) Field of Classification Search

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

6,653,467 2010/0130591			Matsuo et al. Sazani et al.	514/44 A
2010/0168212	A1*	7/2010	Popplewell et al	514/44 R
2012/0190728 2013/0109091			Bennett et al	

FOREIGN PATENT DOCUMENTS

ъ	2002-10790	1/2002
WO	2004/048570	6/2004
WO	2006/000057	1/2006
WO	2008/036127	3/2008
WO	2010/048586	4/2010
WO	2011/057350	5/2011

OTHER PUBLICATIONS

Linda J. Popplewell et al., "Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene," Mol. Ther., vol. 17, No. 3, Mar. 2009, pp. 554-561.

Linda J. Popplewell et al., "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials," Neuromuscular Disorders, vol. 20, No. 2, Feb. 2010, pp. 102-110.

Annemieke Aartsma-Rus et al., "Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy," Neuromuscular Disorders, vol. 12, 2002, pp. S71-S77

Steve D. Wilton et al., "Antisense Oligonucleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript," Mol Ther., vol. 15, No. 7, Jul. 2007, pp. 1288-1296.

Anthony P. Monaco et al., "An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus," Genomics, 1988; 2, pp. 90-95.

Masafumi Matsuo, "Duchenne / Becker muscular dystrophy: from molecular diagnosis to gene therapy," Brain & Development, 1996; 18, pp. 167-172.

International Search Report dated Oct. 11, 2011 in PCT/JP2011/ 070318 filed Aug. 31, 2011.

* cited by examiner


Primary Examiner — Sean McGarry (74) Attorney, Agent, or Firm - Drinker Biddle & Reath LLP

ABSTRACT (57)

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.


7 Claims, 19 Drawing Sheets

U.S. Patent Jul. 14, 2015 Sheet 1 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 2 of 19 US 9,079,934 B2


Figure 2



U.S. Patent Jul. 14, 2015


Sheet 3 of 19

Figure 3



US 9,079,934 B2


U.S. Patent Jul. 14, 2015 Sheet 4 of 19



U.S. Patent Jul. 14, 2015 Sheet 5 of


Sheet 5 of 19 US 9,079,934 B2

Figure 5




U.S. Patent Jul. 14, 2015 Sheet 6 of 19 US 9,079,934 B2

Figure 6



U.S. Patent Jul. 14, 2015 Sheet 7 of 19 US 9,079,934 B2



Highre 7

U.S. Patent Jul. 14, 2015 Sheet 8 of 19 US 9,079,934 B2

Figure 8


100

(%) 80


60

No.8 No.14 No.3 No.13


U.S. Patent Jul. 14, 2015 Sheet 9 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 10 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 11 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 12 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 13 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet 14 of 19 US 9,079,934 B2




U.S. Patent Jul. 14, 2015 Sheet 15 of 19 US 9,079,934 B2



U.S. Patent Jul. 14, 2015 Sheet


Sheet 16 of 19



U.S. Patent

Jul. 14, 2015

Sheet 17 of 19



U.S. Patent

Jul. 14, 2015

Sheet 18 of 19




Figure 18

U.S. Patent

Jul. 14, 2015

Sheet 19 of 19




Figure 19

US 9,079,934 B2

1 ANTISENSE NUCLEIC ACIDS

CROSS REFERENCE TO RELATED APPLICATIONS

This application is the National Stage of International Application No. PCT/JP2011/070318, filed Aug. 31, 2011, and claims benefit of Japanese Application No. 2010-196032, filed on Sep. 1, 2010, all of which are herein incorporated by reference in their entirety.

SEQUENCE LISTING

The instant application contains a sequence listing which has been submitted in ASCII format via EFS-Web and is 15 hereby incorporated by reference in its entirety. Said ASCII copy, created on Mar. 29, 2013, is named G12_0074_Seq_Listing_revised_Sq_No_64.txt and is 24,294 bytes in size.

TECHNICAL FIELD

The present invention relates to an antisense oligomer which causes skipping of exon 53 in the human dystrophin gene, and a pharmaceutical composition comprising the oli-25 gomer.

BACKGROUND ART

Duchenne muscular dystrophy (DMD) is the most frequent 30 form of hereditary progressive muscular dystrophy that affects one in about 3,500 newborn boys. Although the motor functions are rarely different from healthy humans in infancy and childhood, muscle weakness is observed in children from around 4 to 5 years old. Then, muscle weakness progresses to 35 the loss of ambulation by about 12 years old and death due to cardiac or respiratory insufficiency in the twenties. DMD is such a severe disorder. At present, there is no effective therapy for DMD available, and it has been strongly desired to develop a novel therapeutic agent.

DMD is known to be caused by a mutation in the dystrophin gene. The dystrophin gene is located on X chromosome and is a huge gene consisting of 2.2 million DNA nucleotide pairs. DNA is transcribed into mRNA precursors, and introns are removed by splicing to synthesize mRNA in which 79 45 exons are joined together. This mRNA is translated into 3,685 amino acids to produce the dystrophin protein. The dystrophin protein is associated with the maintenance of membrane stability in muscle cells and necessary to make muscle cells less fragile. The dystrophin gene from patients with DMD 50 contains a mutation and hence, the dystrophin protein, which is functional in muscle cells, is rarely expressed. Therefore, the structure of muscle cells cannot be maintained in the body of the patients with DMD, leading to a large influx of calcium ions into muscle cells. Consequently, an inflammation-like 55 response occurs to promote fibrosis so that muscle cells can be regenerated only with difficulty.

Becker muscular dystrophy (BMD) is also caused by a mutation in the dystrophin gene. The symptoms involve muscle weakness accompanied by atrophy of muscle but are 60 typically mild and slow in the progress of muscle weakness, when compared to DMD. In many cases, its onset is in adulthood. Differences in clinical symptoms between DMD and BMD are considered to reside in whether the reading frame for amino acids on the translation of dystrophin mRNA into 65 the dystrophin protein is disrupted by the mutation or not (Non-Patent Document 1). More specifically, in DMD, the

2

presence of mutation shifts the amino acid reading frame so that the expression of functional dystrophin protein is abolished, whereas in BMD the dystrophin protein that functions, though imperfectly, is produced because the amino acid reading frame is preserved, while a part of the exons are deleted by

Exon skipping is expected to serve as a method for treating DMD. This method involves modifying splicing to restore the amino acid reading frame of dystrophin mRNA and induce expression of the dystrophin protein having the function partially restored (Non-Patent Document 2). The amino acid sequence part, which is a target for exon skipping, will be lost. For this reason, the dystrophin protein expressed by this treatment becomes shorter than normal one but since the amino acid reading frame is maintained, the function to stabilize muscle cells is partially retained. Consequently, it is expected that exon skipping will lead DMD to the similar symptoms to that of BMD which is milder. The exon skipping approach has 20 passed the animal tests using mice or dogs and now is currently assessed in clinical trials on human DMD patients.

The skipping of an exon can be induced by binding of antisense nucleic acids targeting either 5' or 3' splice site or both sites, or exon-internal sites. An exon will only be included in the mRNA when both splice sites thereof are recognized by the spliceosome complex. Thus, exon skipping can be induced by targeting the splice sites with antisense nucleic acids. Furthermore, the binding of an SR protein to an exonic splicing enhancer (ESE) is considered necessary for an exon to be recognized by the splicing mechanism. Accordingly, exon skipping can also be induced by targeting ESE.

Since a mutation of the dystrophin gene may vary depending on DMD patients, antisense nucleic acids need to be designed based on the site or type of respective genetic mutation. In the past, antisense nucleic acids that induce exon skipping for all 79 exons were produced by Steve Wilton, et al., University of Western Australia (Non-Patent Document 3), and the antisense nucleic acids which induce exon skip-40 ping for 39 exons were produced by Annemieke Aartsma-Rus, et al., Netherlands (Non-Patent Document 4).

It is considered that approximately 8% of all DMD patients may be treated by skipping the 53rd exon (hereinafter referred to as "exon 53"). In recent years, a plurality of research organizations reported on the studies where exon 53 in the dystrophin gene was targeted for exon skipping (Patent Documents 1 to 4; Non-Patent Document 5). However, a technique for skipping exon 53 with a high efficiency has not yet been established.

Patent Document 1: International Publication WO 2006/ 000057

Patent Document 2: International Publication WO 2004/ 048570

Patent Document 3: US 2010/0168212

Patent Document 4: International Publication WO 2010/ 048586

Non-Patent Document 1: Monaco A. P. et al., Genomics 1988; 2: p. 90-95

Non-Patent Document 2: Matsuo M., Brain Dev 1996; 18: p. 167-172

Non-Patent Document 3: Wilton S. D., et al., Molecular Therapy 2007: 15: p. 1288-96

Non-Patent Document 4: Annemieke Aartsma-Rus et al., (2002) Neuromuscular Disorders 12: S71-S77

Non-Patent Document 5: Linda J. Popplewell et al., (2010) Neuromuscular Disorders, vol. 20, no. 2, p. 102-10

3

DISCLOSURE OF THE INVENTION

Under the foregoing circumstances, antisense oligomers that strongly induce exon 53 skipping in the dystrophin gene and muscular dystrophy therapeutics comprising oligomers thereof have been desired.

As a result of detailed studies of the structure of the dystrophin gene, the present inventors have found that exon 53 skipping can be induced with a high efficiency by targeting the sequence consisting of the 32nd to the 56th nucleotides from the 5' end of exon 53 in the mRNA precursor (hereinafter referred to as "pre-mRNA") in the dystrophin gene with antisense oligomers. Based on this finding, the present inventors have accomplished the present invention.

That is, the present invention is as follows.

[1] An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a 20 nucleotide sequence complementary to any one of the sequences consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 56th, the 31st to the 57th, the 31st to the 58th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 58th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 53rd, the 34th to the 54th, the 34th to the 55th, the 34th to the 56th, the 34th to the 57th, the 34th to the 58th, the 35th to the 53rd, the 35th to the 54th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 58th, the 36th to the 53rd, the 36th to the 54th, the 36th to the 55th, the 36th to the 56th, the 36th to the 35 57th, or the 36th to the 58th nucleotides, from the 5' end of the 53rd exon in the human dystrophin gene.

- [2] The antisense oligomer according to [1] above, which is an oligonucleotide.
- [3] The antisense oligomer according to [2] above, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified.
- [4] The antisense oligomer according to [3] above, wherein the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group is replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R' is an alkylene).
- [5] The antisense oligomer according to [3] or [4] above, wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond and a boranophosphate bond.
- [6] The antisense oligomer according to [1] above, which is a morpholino oligomer.
- [7] The antisense oligomer according to [6] above, which is a phosphorodiamidate morpholino oligomer.
- [8] The antisense oligomer according to any one of [1] to 65 [7] above, wherein the 5' end is any one of the groups of chemical formulae (1) to (3) below:

4

[9] The antisense oligomer according to any one of [1] to [8] above, consisting of a nucleotide sequence complementary to the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides from the 5' end of the 53rd exon in the human dystrophin gene.

[10] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 2 to 37.

[11] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 11, 17, 23, 29 and 35.

[12] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by SEQ ID NO: 11 or 35.

[13] A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the antisense oligomer according to any one of [1] to [12] above, or a pharmaceutically acceptable salt or hydrate thereof.

The antisense oligomer of the present invention can induce exon 53 skipping in the human dystrophin gene with a high efficiency. In addition, the symptoms of Duchenne muscular dystrophy can be effectively alleviated by administering the pharmaceutical composition of the present invention.

BRIEF DESCRIPTION OF DRAWINGS

- FIG. 1 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cell line (RD cells).
- FIG. 2 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into human normal tissue-derived fibroblasts (TIG-119 cells) to induce differentiation into muscle cells.
- FIG. 3 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into human DMD patient-derived fibroblasts (5017 cells) to induce differentiation into muscle cells.

5

- FIG. 4 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle cells
- FIG. 5 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells
- FIG. 6 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells
- FIG. 7 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52 or deletion of exons 48-52) to induce 20 differentiation into muscle cells.
- FIG. 8 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle ²⁵ cells
- FIG. 9 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhab-domyosarcoma cells (RD cells).
- FIG. 10 shows the efficiency of exon 53 skipping (T-OMe-30 S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 11 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 12 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 13 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyo-40 sarcoma cells (RD cells).
- FIG. 14 shows the efficiency of exon 53 skipping (T-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 15 shows the efficiency of exon 53 skipping (2'-OMe-45 S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 16 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 17 shows the efficiency of exon 53 skipping (T-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).
- FIG. 18 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cells 55 (RD cells) at the respective concentrations of the oligomers.
- FIG. 19 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells) at the respective concentrations of the oligomers.

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention is described in detail. The embodiments described below are intended to be presented by way of example merely to describe the invention but not limited only to the following embodiments. The

6

present invention may be implemented in various ways without departing from the gist of the invention.

All of the publications, published patent applications, patents and other patent documents cited in the specification are herein incorporated by reference in their entirety. The specification hereby incorporates by reference the contents of the specification and drawings in the Japanese Patent Application (No. 2010-196032) filed Sep. 1, 2010, from which the priority was claimed.

10 1. Antisense Oligomer

The present invention provides the antisense oligomer (hereinafter referred to as the "oligomer of the present invention") which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to any one of the sequences (hereinafter also referred to as "target sequences") consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 56th, the 31st to the 57th, the 31st to the 58th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 58th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 53rd, the 34th to the 54th, the 34th to the 55th, the 34th to the 56th, the 34th to the 57th, the 34th to the 58th, the 35th to the 53rd, the 35th to the 54th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 58th, the 36th to the 53rd, the 36th to the 54th, the 36th to the 55th, the 36th to the 56th, the 36th to the 57th, or the 36th to the 58th nucleotides, from the 5' end of the 53rd exon in the human dystrophin gene. [Exon 53 in Human Dystrophin Gene]

In the present invention, the term "gene" is intended to mean a genomic gene and also include cDNA, mRNA precursor and mRNA. Preferably, the gene is mRNA precursor, i.e., pre-mRNA.

In the human genome, the human dystrophin gene locates at locus Xp21.2. The human dystrophin gene has a size of 3.0 Mbp and is the largest gene among known human genes. However, the coding regions of the human dystrophin gene are only 14 kb, distributed as 79 exons throughout the human dystrophin gene (Roberts, R.G., et al., Genomics, 16: 536-538 (1993)). The pre-mRNA, which is the transcript of the human dystrophin gene, undergoes splicing to generate mature mRNA of 14 kb. The nucleotide sequence of human wild-type dystrophin gene is known (GenBank Accession No. NM_004006).

The nucleotide sequence of exon 53 in the human wildtype dystrophin gene is represented by SEQ ID NO: 1.

The oligomer of the present invention is designed to cause skipping of exon 53 in the human dystrophin gene, thereby modifying the protein encoded by DMD type of dystrophin gene into the BMD type of dystrophin protein. Accordingly, exon 53 in the dystrophin gene that is the target of exon skipping by the oligomer of the present invention includes both wild and mutant types.

Specifically, exon 53 mutants of the human dystrophin gene include the polynucleotides defined in (a) or (b) below.

- (a) A polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of SEQ 60 ID NO: 1; and,
 - (b) A polynucleotide consisting of a nucleotide sequence having at least 90% identity with the nucleotide sequence of SEQ ID NO: 1.

As used herein, the term "polynucleotide" is intended to 65 mean DNA or RNA.

As used herein, the term "polynucleotide that hybridizes under stringent conditions" refers to, for example, a poly-

7

nucleotide obtained by colony hybridization, plaque hybridization, Southern hybridization or the like, using as a probe all or part of a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of, e.g., SEQ ID NO: 1. The hybridization method which may be used 5 includes methods described in, for example, "Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor, Laboratory Press 2001," "Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997," etc.

As used herein, the term "complementary nucleotide sequence" is not limited only to nucleotide sequences that form Watson-Crick pairs with target nucleotide sequences, but is intended to also include nucleotide sequences which form Wobble base pairs. As used herein, the term Watson- 15 Crick pair refers to a pair of nucleobases in which hydrogen bonds are formed between adenine-thymine, adenine-uracil or guanine-cytosine, and the term Wobble base pair refers to a pair of nucleobases in which hydrogen bonds are formed between guanine-uracil, inosine-uracil, inosine-adenine or 20 inosine-cytosine. As used herein, the term "complementary nucleotide sequence" does not only refers to a nucleotide sequence 100% complementary to the target nucleotide sequence but also refers to a complementary nucleotide sequence that may contain, for example, 1 to 3, 1 or 2, or one nucleotide non-complementary to the target nucleotide sequence.

As used herein, the term "stringent conditions" may be any of low stringent conditions, moderate stringent conditions or high stringent conditions. The term "low stringent condi- 30 tions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 32° C. The term "moderate stringent conditions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 42° C., or 5×SSC, 1% SDS, 50 mM Tris-HCl (pH 7.5), 50% formamide at 42° C. The term 35 "high stringent conditions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 50° C. or 0.2×SSC, 0.1% SDS at 65° C. Under these conditions, polynucleotides with higher homology are expected to be obtained efficiently at higher temperatures, although multiple 40 factors are involved in hybridization stringency including temperature, probe concentration, probe length, ionic strength, time, salt concentration and others, and those skilled in the art may appropriately select these factors to achieve similar stringency.

When commercially available kits are used for hybridization, for example, an Alkphos Direct Labeling and Detection System (GE Healthcare) may be used. In this case, according to the attached protocol, after cultivation with a labeled probe overnight, the membrane is washed with a primary wash buffer containing 0.1% (w/v) SDS at 55° C., thereby detecting hybridized polynucleotides. Alternatively, in producing a probe based on the entire or part of the nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO: 1, hybridization can be detected with a DIG Nucleic Acid Detection Kit (Roche Diagnostics) when the probe is labeled with digoxigenin (DIG) using a commercially available reagent (e.g., a PCR Labeling Mix (Roche Diagnostics), etc.).

8

In addition to the polynucleotides described above, other polynucleotides that can be hybridized include polynucleotides having 90% or higher, 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 96% or higher, 97% or higher, 98% or higher, 99% or higher, 99.1% or higher, 99.2% or higher, 99.3% or higher, 99.4% or higher, 99.5% or higher, 99.6% or higher, 99.7% or higher, 99.8% or higher or 99.9% or higher identity with the polynucleotide of SEQ ID NO: 1, as calculated by homology search software BLAST using the default parameters.

The identity between nucleotide sequences may be determined using algorithm BLAST (Basic Local Alignment Search Tool) by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc. Natl. Acad. Sci. USA 90: 5873, 1993). Programs called BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul S F, et al: J. Mol. Biol. 215: 403, 1990). When a nucleotide sequence is sequenced using BLASTN, the parameters are, for example, score=100 and wordlength=12. When BLAST and Gapped BLAST programs are used, the default parameters for each program are employed.

Examples of the nucleotide sequences complementary to the sequences consisting of the 31st to the 53rd, the 31st to the 54th, the 31st to the 55th, the 31st to the 56th, the 31st to the 57th, the 31st to the 55th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 55th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 57th, the 34th to the 55th, the 34th to the 56th, the 34th to the 57th, the 34th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 55th, the 36th to the 56th, the 36th to the 57th, the 36th to the 58th, the 36th to the 56th, the 36th to the 57th and the 36th to the 58th nucleotides, from the 5' end of exon 53.

TABLE 1

Target sequence in exon 53	n Complementary nucleotide sequence	SEQ	ID	NO:	
31-53	5'-CCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	2
31-54	5'-TCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	3
31-55	5'-CTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	4
31-56	5'-CCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	5
31-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	6
31-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTGTA-3'	SEQ	ID	NO:	7
32-53	5'-CCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	8
32-54	5'-TCCGGTTCTGAAGGTGTTCTTGT-3'	SEO	ID	NO:	9

9

TABLE 1 -continued

Target					
sequence in exon 53	Complementary nucleotide sequence	SEQ	ID	NO:	
32-55	5'-CTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	10
32-56	5'-CCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	11
32-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	12
32-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	13
33-53	5'-CCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	14
33-54	5'-TCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	15
33-55	5'-CTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	16
33-56	5'-CCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	17
33-57	5'-GCCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	18
33-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	19
34-53	5'-CCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	20
34-54	5'-TCCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	21
34-55	5'-CTCCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	22
34-56	5'-CCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	23
34-57	5'-GCCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	24
34-58	5'-TGCCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ	ID	NO:	25
35-53	5'-CCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	26
35-54	5'-TCCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	27
35-55	5'-CTCCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	28
35-56	5'-CCTCCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	29
35-57	5'-GCCTCCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	30
35-58	5'-TGCCTCCGGTTCTGAAGGTGTTCT-3'	SEQ	ID	NO:	31
36-53	5'-CCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	32
36-54	5'-TCCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	33
36-55	5'-CTCCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	34
36-56	5'-CCTCCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	35
36-57	5'-GCCTCCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	36
36-58	5'-TGCCTCCGGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	37

It is preferred that the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th, the 33rd to the 56th, the 34th to the 56th, the 35th to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29 or SEQ ID NO: 35), from the 5' end of the 53rd exon in the human dystrophin gene.

Preferably, the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11 or SEQ ID NO: 35), from the 5' end of the 53rd exon in the human dystrophin gene.

The term "cause skipping of the 53rd exon in the human dystrophin gene" is intended to mean that by binding of the

oligomer of the present invention to the site corresponding to exon 53 of the transcript (e.g., pre-mRNA) of the human dystrophin gene, for example, the nucleotide sequence corresponding to the 5' end of exon 54 is spliced at the 3' side of the nucleotide sequence corresponding to the 3' end of exon 51 in DMD patients with deletion of, exon 52 when the transcript undergoes splicing, thus resulting in formation of mature mRNA which is free of codon frame shift.

Accordingly, it is not required for the oligomer of the present invention to have a nucleotide sequence 100% complementary to the target sequence, as far as it causes exon 53 skipping in the human dystrophin gene. The oligomer of the present invention may include, for example, 1 to 3, 1 or 2, or one nucleotide non-complementary to the target sequence.

Herein, the term "binding" described above is intended to mean that when the oligomer of the present invention is mixed

10

11

with the transcript of human dystrophin gene, both are hybridized under physiological conditions to form a double strand nucleic acid. The term "under physiological conditions" refers to conditions set to mimic the in vivo environment in terms of pH, salt composition and temperature. The 5 conditions are, for example, 25 to 40° C., preferably 37° C., pH 5 to 8, preferably pH 7.4 and 150 mM of sodium chloride concentration.

Whether the skipping of exon 53 in the human dystrophin gene is caused or not can be confirmed by introducing the 10 oligomer of the present invention into a dystrophin expression cell (e.g., human rhabdomyosarcoma cells), amplifying the region surrounding exon 53 of mRNA of the human dystrophin gene from the total RNA of the dystrophin expression cell by RT-PCR and performing nested PCR or sequence 15 analysis on the PCR amplified product.

The skipping efficiency can be determined as follows. The mRNA for the human dystrophin gene is collected from test cells; in the mRNA, the polynucleotide level "A" of the band where exon 53 is skipped and the polynucleotide level "B" of 20 the band where exon 53 is not skipped are measured. Using these measurement values of "A" and "B," the efficiency is calculated by the following equation:

Skipping efficiency (%)=A/(A+B)×100

The oligomer of the present invention includes, for example, an oligonucleotide, morpholino oligomer or peptide nucleic acid (PNA), having a length of 18 to 28 nucleotides. The length is preferably from 21 to 25 nucleotides and morpholino oligomers are preferred.

The oligonucleotide described above (hereinafter referred to as "the oligonucleotide of the present invention") is the oligomer of the present invention composed of nucleotides as constituent units. Such nucleotides may be any of ribonucleotides, deoxyribonucleotides and modified nucleotides.

The modified nucleotide refers to one having fully or partly modified nucleobases, sugar moieties and/or phosphate-binding regions, which constitute the ribonucleotide or deoxyribonucleotide.

The nucleobase includes, for example, adenine, guanine, 40 hypoxanthine, cytosine, thymine, uracil, and modified bases thereof. Examples of such modified nucleobases include, but not limited to, pseudouracil, 3-methyluracil, dihydrouracil, 5-alkylcytosines (e.g., 5-methylcytosine), 5-alkyluracils (e.g., 5-ethyluracil), 5-halouracils (5-bromouracil), 6-azapy- 45 rimidine, 6-alkylpyrimidines (6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5'-carboxymethylaminomethyl-2-thiouracil, 5-carboxymethylaminomethyluracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine, 50 2-methyladenine, 2-methylguanine, N6-methyladenine, 7-methylguanine, 5-methoxyaminomethyl-2-thiouracil, 5-methylaminomethyluracil, 5-methylcarbonylmethyluracil, 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N6isopentenyladenine, uracil-5-oxyacetic acid, 2-thiocytosine, 55 purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imidazole, xanthine, etc.

Modification of the sugar moiety may include, for example, modifications at the 2'-position of ribose and modifications of the other positions of the sugar. The modification 60 at the 2'-position of ribose includes replacement of the 2'-OH of ribose with OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br or I, wherein R represents an alkyl or an aryl and R' represents an alkylene.

The modification for the other positions of the sugar 65 includes, for example, replacement of O at the 4' position of ribose or deoxyribose with S, bridging between 2' and 4'

12

positions of the sugar, e.g., LNA (locked nucleic acid) or ENA (2'-O,4'-C-ethylene-bridged nucleic acids), but is not limited thereto.

A modification of the phosphate-binding region includes, for example, a modification of replacing phosphodiester bond with phosphorothioate bond, phosphorodithioate bond, alkyl phosphonate bond, phosphoroamidate bond or boranophosphate bond (Enya et al: Bioorganic & Medicinal Chemistry, 2008, 18, 9154-9160) (cf., e.g., Japan Domestic Re-Publications of PCT Application Nos. 2006/129594 and 2006/038608).

The alkyl is preferably a straight or branched alkyl having 1 to 6 carbon atoms. Specific examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-hexyl and isohexyl. The alkyl may optionally be substituted. Examples of such substituents are a halogen, an alkoxy, cyano and nitro. The alkyl may be substituted with 1 to 3 substituents.

The cycloalkyl is preferably a cycloalkyl having 5 to 12 carbon atoms. Specific examples include cyclopentyl, cyclohexyl, cycloheptyl, cycloactyl, cyclodecyl and cyclododecyl.

The halogen includes fluorine, chlorine, bromine and iodine.

The alkoxy is a straight or branched alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy, isohexyloxy, etc. Among others, an alkoxy having 1 to 3 carbon atoms is preferred.

The aryl is preferably an aryl having 6 to 10 carbon atoms. Specific examples include phenyl, α-naphthyl and β-naphthyl. Among others, phenyl is preferred. The aryl may optionally be substituted. Examples of such substituents are an alkyl, a halogen, an alkoxy, cyano and nitro. The aryl may be substituted with one to three of such substituents.

The alkylene is preferably a straight or branched alkylene having 1 to 6 carbon atoms. Specific examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 2-(ethyl) trimethylene and 1-(methyl) tetramethylene.

The acyl includes a straight or branched alkanoyl or aroyl. Examples of the alkanoyl include formyl, acetyl, 2-methylacetyl, 2,2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, hexanoyl, etc. Examples of the aroyl include benzoyl, toluoyl and naphthoyl. The aroyl may optionally be substituted at substitutable positions and may be substituted with an alkyl(s).

Preferably, the oligonucleotide of the present invention is the oligomer of the present invention containing a constituent unit represented by general formula below wherein the —OH group at position 2' of ribose is substituted with methoxy and the phosphate-binding region is a phosphorothioate bond:

wherein Base represents a nucleobase.

10

15

20

13

The oligonucleotide of the present invention may be easily synthesized using various automated synthesizer (e.g., AKTA oligopilot plus 10/100 (GE Healthcare)). Alternatively, the synthesis may also be entrusted to a third-party organization (e.g., Promega Inc., or Takara Co.), etc.

The morpholino oligomer of the present invention is the oligomer of the present invention comprising the constituent unit represented by general formula below:

wherein Base has the same significance as defined above, and, W represents a group shown by any one of the following groups:

$$Z = P - X \qquad Z = P - X \qquad Y_1 \qquad Z = P - X$$

$$Y_1 \qquad Y_2 \qquad Y_2 \qquad Y_2 \qquad Y_3 \qquad Y_4 \qquad Y_4 \qquad Y_5 \qquad Y_5$$

wherein X represents $--CH_2R^1$, $--O--CH_2R'$, 35 $--S--CH_2R^1$, $--NR_2R^3$ or F:

R¹ represents H or an alkyl;

R² and R³, which may be the same or different, each represents H, an alkyl, a cycloalkyl or an aryl;

Y, represents O, S, CH2 or NR1;

 Y_2 represents O, S or NR¹;

Z represents O or S.

Preferably, the morpholino oligomer is an oligomer comprising a constituent unit represented by general formula below (phosphorodiamidate morpholino oligomer (hereinafter referred to as "PMO")).

wherein Base, R^2 and R^3 have the same significance as defined above.

The morpholino oligomer may be produced in accordance with, e.g., WO 1991/009033 or WO 2009/064471. In particular, PMO can be produced by the procedure described in WO 2009/064471 or produced by the process shown below.

14

[Method for Producing PMO]

An embodiment of PMO is, for example, the compound represented by general formula (I) below (hereinafter PMO (I)).

wherein Base, R² and R³ have the same significance as defined above: and.

n is a given integer of 1 to 99, preferably a given integer of 18 to 28.

PMO (I) can be produced in accordance with a known method, for example, can be produced by performing the procedures in the following steps.

The compounds and reagents used in the steps below are not particularly limited so long as they are commonly used to prepare PMO.

Also, the following steps can all be carried out by the liquid phase method or the solid phase method (using manuals or commercially available solid phase automated synthesizers). In producing PMO by the solid phase method, it is desired to use automated synthesizers in view of simple operation procedures and accurate synthesis.

(1) Step A:

50

The compound represented by general formula (II) below (hereinafter referred to as Compound (II)) is reacted with an acid to prepare the compound represented by general formula (III) below (hereinafter referred to as Compound (III)):

-continued (III)

wherein n, R² and R³ have the same significance as defined

each B^P independently represents a nucleobase which may 20 optionally be protected:

T represents trityl, monomethoxytrityl or dimethoxytrityl;

L represents hydrogen, an acyl or a group represented by general formula (IV) below (hereinafter referred to as group 25 (IV)).

The "nucleobase" for BP includes the same "nucleobase" as in Base, provided that the amino or hydroxy group in the nucleobase shown by B^P may be protected.

Such protective group for amino is not particularly limited so long as it is used as a protective group for nucleic acids. 35 Specific examples include benzoyl, 4-methoxybenzoyl, acetyl, propionyl, butyryl, isobutyryl, phenylacetyl, phenoxyacetyl, 4-tert-butylphenoxyacetyl, 4-isopropylphenoxyacetyl and (dimethylamino)methylene. Specific examples of the protective group for the hydroxy group include 2-cyanoethyl, 4-nitrophenethyl, phenylsulfonylethyl, methylsulfonylethyl and trimethylsilylethyl, and phenyl, which may be substituted by 1 to 5 electron-withdrawing group at optional substitutable positions, diphenylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylphenylcarbamoyl, 1-pyrrolidinylcarbamoyl, morpholinocarbamoyl, 4-(tert-butylcar- 45 boxy) benzyl, 4-[(dimethylamino)carboxyl]benzyl and 4-(phenylcarboxy)benzyl, (cf., e.g., WO 2009/064471).

The "solid carrier" is not particularly limited so long as it is a carrier usable for the solid phase reaction of nucleic acids. It is desired for the solid carrier to have the following properties: 50 a range of 1 minute to 5 hours. e.g., (i) it is sparingly soluble in reagents that can be used for the synthesis of morpholino nucleic acid derivatives (e.g., dichloromethane, acetonitrile, tetrazole, N-methylimidazole, pyridine, acetic anhydride, lutidine, trifluoroacetic acid); (ii) it is chemically stable to the reagents usable for the synthesis 55 of morpholino nucleic acid derivatives; (iii) it can be chemically modified; (iv) it can be charged with desired morpholino nucleic acid derivatives; (v) it has a strength sufficient to withstand high pressure through treatments; and (vi) it has a uniform particle diameter range and distribution. Specifi- 60 cally, swellable polystyrene (e.g., aminomethyl polystyrene resin 1% dibenzylbenzene crosslinked (200-400 mesh) (2.4-3.0 mmol/g) (manufactured by Tokyo Chemical Industry), Aminomethylated Polystyrene Resin.HCl [dibenzylbenzene 1%, 100-200 mesh] (manufactured by Peptide Institute, 65 Inc.)), non-swellable polystyrene (e.g., Primer Support (manufactured by GE Healthcare)), PEG chain-attached

16

polystyrene (e.g., NH2-PEG resin (manufactured by Watanabe Chemical Co.), TentaGel resin), controlled pore glass (controlled pore glass; CPG) (manufactured by, e.g., CPG), oxalyl-controlled pore glass (cf., e.g., Alul et al., Nucleic Acids Research, Vol. 19, 1527 (1991)), TentaGel support-aminopolyethylene glycol-derivatized support (e.g., Wright et al., cf., Tetrahedron Letters, Vol. 34, 3373 (1993)). and a copolymer of Poros-polystyrene/divinylbenzene.

A "linker" which can be used is a known linker generally used to connect nucleic acids or morpholino nucleic acid derivatives. Examples include 3-aminopropyl, succinyl, 2,2'diethanolsulfonyl and a long chain alkyl amino (LCAA).

This step can be performed by reacting Compound (II)

The "acid" which can be used in this step includes, for example, trifluoroacetic acid, dichloroacetic acid and trichloroacetic acid. The acid used is appropriately in a range of, for example, 0.1 mol equivalent to 1000 mol equivalents based on 1 mol of Compound (II), preferably in a range of 1 mol equivalent to 100 mol equivalents based on 1 mol of Compound (II).

An organic amine can be used in combination with the acid described above. The organic amine is not particularly limited and includes, for example, triethylamine. The amount of the organic amine used is appropriately in a range of, e.g., 0.01 mol equivalent to 10 mol equivalents, and preferably in a range of 0.1 mol equivalent to 2 mol equivalents, based on 1 mol of the acid.

When a salt or mixture of the acid and the organic amine is used in this step, the salt or mixture includes, for example, a salt or mixture of trifluoroacetic acid and triethylamine, and more specifically, a mixture of 1 equivalent of triethylamine and 2 equivalents of trifluoroacetic acid.

The acid which can be used in this step may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, dichloromethane, acetonitrile, an alcohol (ethanol, isopropanol, trifluoroethanol, etc.), water, or a mixture thereof.

The reaction temperature in the reaction described above is preferably in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35° C.

The reaction time may vary depending upon kind of the acid used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in

After completion of this step, a base may be added, if necessary, to neutralize the acid remained in the system. The "base" is not particularly limited and includes, for example, diisopropylamine. The base may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% (v/v) to 30% (v/v).

The solvent used in this step is not particularly limited so long as it is inert to the reaction, and includes dichloromethane, acetonitrile, an alcohol (ethanol, isopropanol, trifluoroethanol, etc.), water, and a mixture thereof. The reaction temperature is preferably in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35° C.

The reaction time may vary depending upon kind of the base used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

17

In Compound (II), the compound of general formula (IIa) below (hereinafter Compound (IIa)), wherein n is 1 and L is a group (IV), can be produced by the following procedure.

wherein B^P , T, linker and solid carrier have the same significance as defined above.

Step 1:

The compound represented by general formula (V) below is reacted with an acylating agent to prepare the compound ²⁰ represented by general formula (VI) below (hereinafter referred to as Compound (VI)).

wherein B^P , T and linker have the same significance as defined above; and, R^4 represents hydroxy, a halogen or $_{45}$ amino.

This step can be carried out by known procedures for introducing linkers, using Compound (V) as the starting material.

In particular, the compound represented by general formula (VIa) below can be produced by performing the method known as esterification, using Compound (V) and succinic anhydride.

18

wherein B^P and T have the same significance as defined above.

Step 2:

5 Compound (VI) is reacted with a solid career by a condensing agent to prepare Compound (IIa).

wherein B^P , R^4 , T, linker and solid carrier have the same significance as defined above.

This step can be performed using Compound (VI) and a solid carrier in accordance with a process known as condensation reaction.

In Compound (II), the compound represented by general formula (IIa2) below wherein n is 2 to 99 and L is a group 40 represented by general formula (IV) can be produced by using Compound (IIa) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

wherein B^P , R^2 , R^3 , T, linker and solid carrier have the same significance as defined above; and,

n' represents 1 to 98.

60

In Compound (II), the compound of general formula (IIb) below wherein n is 1 and L is hydrogen can be produced by the procedure described in, e.g., WO 1991/009033.

10

45

60

19

$$\begin{array}{c} \text{OH} \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \end{array}$$

wherein B^{P} and T have the same significance as defined above.

In Compound (II), the compound represented by general formula (IIb2) below wherein n is 2 to 99 and L is hydrogen can be produced by using Compound (IIb) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

$$\begin{array}{c} H = \begin{array}{c} O \\ \\ \end{array} \\ \begin{array}{c} B^{P} \\ \end{array} \\ \begin{array}{c} N \\ \end{array} \\ \begin{array}{c} P \\ \end{array} \\ \begin{array}{c} O \\ \end{array} \\ \begin{array}{c} B^{P} \\ \end{array} \\ \begin{array}{c} O \\ \end{array} \\ \begin{array}{c} O \\ \end{array} \\ \begin{array}{c} B^{P} \\ \end{array} \\ \begin{array}{c} O \\ \end{array} \\ \begin{array}{c} O$$

wherein B^{P} , n^{t} , R^{2} , R^{3} and T have the same significance as defined above.

In Compound (II), the compound represented by general formula (IIc) below wherein n is 1 and L is an acyl can be produced by performing the procedure known as acylation reaction, using Compound (IIb).

$$\mathbb{R}^5$$
 (He)
$$0$$

$$1$$

$$1$$

$$1$$

$$1$$

$$55$$

wherein B^P and T have the same significance as defined above; and,

R5 represents an acyl.

In Compound (II), the compound represented by general formula (IIc2) below wherein n is 2 to 99 and L is an acyl can be produced by using Compound (IIc) as the starting material and repeating step A and step B of the PMO production 65 method described in the specification for a desired number of times.

20

wherein B^P , n^t , R^2 , R^3 , R^5 and T have the same significance as defined above.

(2) Step B

Compound (III) is reacted with a morpholino monomer compound in the presence of a base to prepare the compound represented by general formula (VII) below (hereinafter referred to as Compound (VII)):

$$\mathbb{L} = 0$$

$$\mathbb{R}^{2}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{3}$$

$$\mathbb{R}^{4}$$

wherein B^F , L, n, R^2 , R^3 and T have the same significance as defined above.

21

This step can be performed by reacting Compound (III) with the morpholino monomer compound in the presence of a base.

The morpholino monomer compound includes, for example, compounds represented by general formula (VIII) $\,^5$ below:

wherein B^P , R^2 , R^3 and T have the same significance as defined above.

The "base" which can be used in this step includes, for example, diisopropylamine, triethylamine and N-ethylmorpholine. The amount of the base used is appropriately in a range of 1 mol equivalent to 1000 mol equivalents based on 1 mol of Compound (III), preferably, 10 mol equivalents to 100 mol equivalents based on 1 mol of Compound (III).

The morpholino monomer compound and base which can 30 be used in this step may also be used as a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, N,N-dimethylimidazolidone, N-methylpiperidone, DMF, dichloromethane, acetoni-35 trile, tetrahydrofuran, or a mixture thereof.

The reaction temperature is preferably in a range of e.g., 0° C. to 100° C., and more preferably, in a range of 10° C. to 50° C.

The reaction time may vary depending upon kind of the 40 base used and reaction temperature, and is appropriately in a range of 1 minute to 48 hours in general, and preferably in a range of 30 minutes to 24 hours.

Furthermore, after completion of this step, an acylating agent can be added, if necessary. The "acylating agent" 45 includes, for example, acetic anhydride, acetyl chloride and phenoxyacetic anhydride. The acylating agent may also be used as a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, 50 dichloromethane, acetonitrile, an alcohol(s) (ethanol, isopropanol, trifluoroethanol, etc.), water, or a mixture thereof.

If necessary, a base such as pyridine, lutidine, collidine, triethylamine, diisopropylethylamine, N-ethylmorpholine, etc. may also be used in combination with the acylating agent. 55 The amount of the acylating agent is appropriately in a range of 0.1 mol equivalent to 10000 mol equivalents, and preferably in a range of 1 mol equivalent to 1000 mol equivalents. The amount of the base is appropriately in a range of, e.g., 0.1 mol equivalent to 100 mol equivalents, and preferably in a 60 range of 1 mol equivalent to 10 mol equivalents, based on 1 mol of the acylating agent.

The reaction temperature in this reaction is preferably in a range of 10° C. to 50° C., more preferably, in a range of 10° C. to 50° C., much more preferably, in a range of 20° C. to 40° C., 65 and most preferably, in a range of 25° C. to 35° C. The reaction time may vary depending upon kind of the acylating

22

agent used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

(3) Step C:

In Compound (VII) produced in Step B, the protective group is removed using a deprotecting agent to prepare the compound represented by general formula (IX).

wherein Base, B^P, L, n, R², R³ and T have the same significance as defined above.

(IX)

This step can be performed by reacting Compound (VII) with a deprotecting agent.

The "deprotecting agent" includes, e.g., conc. ammonia water and methylamine. The "deprotecting agent" used in this step may also be used as a dilution with, e.g., water, methanol, ethanol, isopropyl alcohol, acetonitrile, tetrahydrofuran, DMF, N,N-dimethylimidazolidone, N-methylpiperidone, or a mixture of these solvents. Among others, ethanol is preferred. The amount of the deprotecting agent used is appropriately in a range of, e.g., 1 mol equivalent to 100000 mol equivalents, and preferably in a range of 10 mol equivalents to 1000 mol equivalents, based on 1 mol of Compound (VII).

The reaction temperature is appropriately in a range of 15° C. to 75° C., preferably, in a range of 40° C. to 70° C., and more preferably, in a range of 50° C. to 60° C. The reaction time for deprotection may vary depending upon kind of Compound (VII), reaction temperature, etc., and is appropriately in a range of 10 minutes to 30 hours, preferably 30 minutes to 24 hours, and more preferably in a range of 5 hours to 20 hours.

(4) Step D:

PMO (I) is produced by reacting Compound (IX) produced in step C with an acid:

10

15

wherein Base, n, R^2 , R^3 and T have the same significance as defined above.

This step can be performed by adding an acid to Compound (IX).

The "acid" which can be used in this step includes, for example, trichloroacetic acid, dichloroacetic acid, acetic acid, phosphoric acid, hydrochloric acid, etc. The acid used is appropriately used to allow the solution to have a pH range of 0.1 to 4.0, and more preferably, in a range of pH 1.0 to 3.0. The solvent is not particularly limited so long as it is inert to the reaction, and includes, for example, acetonitrile, water, or a mixture of these solvents thereof.

The reaction temperature is appropriately in a range of 10° C. to 50° C., preferably, in a range of 20° C. to 40° C., and more preferably, in a range of 25° C. to 35° C. The reaction time for deprotection may vary depending upon kind of Compound (IX), reaction temperature, etc., and is appropriately in a range of 0.1 minute to 5 hours, preferably 1 minute to 1 hour, and more preferably in a range of 1 minute to 30 minutes.

PMO (I) can be obtained by subjecting the reaction mixture obtained in this step to conventional means of separation and purification such as extraction, concentration, neutralization, filtration, centrifugal separation, recrystallization, reversed phase column chromatography C₈ to C₁₈, cation exchange column chromatography, anion exchange column chromatography, anion exchange column chromatography, gel filtration column chromatography, high performance liquid chromatography, dialysis, ultrafiltration, etc., alone or in combination thereof. Thus, the desired PMO (I) can be isolated and purified (cf., e.g., WO 1991/09033).

In purification of PMO (I) using reversed phase chromatography, e.g., a solution mixture of 20 mM triethylamine/ 65 acetate buffer and acetonitrile can be used as an elution solvent.

24

In purification of PMO (I) using ion exchange chromatography, e.g., a solution mixture of 1 M saline solution and 10 mM sodium hydroxide aqueous solution can be used as an elution solvent.

A peptide nucleic acid is the oligomer of the present invention having a group represented by the following general formula as the constituent unit:

wherein Base has the same significance as defined above.

Peptide nucleic acids can be prepared by referring to, e.g., the following literatures.

- P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt, Science, 254, 1497 (1991)
- M. Egholm, O. Buchardt, P. E. Nielsen, R. H. Berg, Jacs., 114, 1895 (1992)
- 3) K. L. Dueholm, M. Egholm, C. Behrens, L. Christensen, H. F. Hansen, T. Vulpius, K. H. Petersen, R. H. Berg, P. E. Nielsen, O. Buchardt, J. Org. Chem., 59, 5767 (1994)
- 4) L. Christensen, R. Fitzpatrick, B. Gildea, K. H. Petersen, H. F. Hansen, T. Koch, M. Egholm, O. Buchardt, P. E. Nielsen, J. Coull, R. H. Berg, J. Pept. Sci., 1, 175 (1995)
- T. Koch, H. F. Hansen, P. Andersen, T. Larsen, H. G. Batz, K. Otteson, H. Orum, J. Pept. Res., 49, 80 (1997)

In the oligomer of the present invention, the 5' end may be any of chemical structures (1) to (3) below, and preferably is (3)-OH.

Hereinafter, the groups shown by (1), (2) and (3) above are referred to as "Group (1)," "Group (2)" and "Group (3)," respectively.

2. Pharmaceutical Composition

The oligomer of the present invention causes exon 53 skipping with a higher efficiency as compared to the prior art antisense oligomers. It is thus expected that conditions of muscular dystrophy can be relieved with high efficience by 5 administering the pharmaceutical composition comprising the oligomer of the present invention to DMD patients. For example, when the pharmaceutical composition comprising

25

the oligomer of the present invention is used, the same therapeutic effects can be achieved even in a smaller dose than that of the oligomers of the prior art. Accordingly, side effects can be alleviated and such is economical.

In another embodiment, the present invention provides the pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the oligomer of 15 the present invention, a pharmaceutically acceptable salt or hydrate thereof (hereinafter referred to as "the composition of the present invention").

Examples of the pharmaceutically acceptable salt of the oligomer of the present invention contained in the composi- 20 tion of the present invention are alkali metal salts such as salts of sodium, potassium and lithium; alkaline earth metal salts such as salts of calcium and magnesium; metal salts such as salts of aluminum, iron, zinc, copper, nickel, cobalt, etc.; ammonium salts; organic amine salts such as salts of t-octy- 25 lamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, guanidine, diethylamine, triethylamine, dicyclohexylamine, N,N'-dibenzylethylenediamine, chloroprocaine, procaine, diethanolamine, N-benzylphenethylamine, piperazine, tetramethylammonium, tris(hydroxymethyl)aminomethane; hydrohalide salts such as salts of hydrofluorates, hydrochlorides, hydrobromides and hydroiodides; inorganic acid salts such as nitrates, perchlorates, sulfates, phosphates, etc.; lower alkane sulfonates such as methanesulfonates, trifluo- 35 romethanesulfonates and ethanesulfonates; arylsulfonates such as benzenesulfonates and p-toluenesulfonates; organic acid salts such as acetates, malates, fumarates, succinates, citrates, tartarates, oxalates, maleates, etc.; and, amino acid salts such as salts of glycine, lysine, arginine, ornithine, 40 glutamic acid and aspartic acid. These salts may be produced by known methods. Alternatively, the oligomer of the present invention contained in the composition of the present invention may be in the form of a hydrate thereof.

Administration route for the composition of the present 45 invention is not particularly limited so long as it is pharmaceutically acceptable route for administration, and can be chosen depending upon method of treatment. In view of easiness in delivery to muscle tissues, preferred are intravenous administration, intraarterial administration, intramuscular 50 administration, subcutaneous administration, oral administration, tissue administration, transdermal administration, etc. Also, dosage forms which are available for the composition of the present invention are not particularly limited, and include, for example, various injections, oral agents, drips, 55 inhalations, ointments, lotions, etc.

In administration of the oligomer of the present invention to patients with muscular dystrophy, the composition of the present invention preferably contains a carrier to promote delivery of the oligomer to muscle tissues. Such a carrier is 60 not particularly limited as far as it is pharmaceutically acceptable, and examples include cationic carriers such as cationic liposomes, cationic polymers, etc., or carriers using viral envelope. The cationic liposomes are, for example, liposomes composed of 2-O-(2-diethylaminoethyl)carabamoyl-1,3-O- 65 dioleoylglycerol and phospholipids as the essential constituents (hereinafter referred to as "liposome A"), Oligo26

fectamine (registered trademark) (manufactured by Invitrogen Corp.), Lipofectin (registered trademark) (manufactured by Invitrogen Corp.), Lipofectamine (registered trademark) (manufactured by Invitrogen Corp.), Lipofectamine 2000 (registered trademark) (manufactured by Invitrogen Corp.), DMRIE-C (registered trademark) (manufactured by Invitrogen Corp.), GeneSilencer (registered trademark) (manufactured by Gene Therapy Systems), Trans-Messenger (registered trademark) (manufactured by QIAGEN, Inc.), TransIT TKO (registered trademark) (manufactured by Minis) and Nucleofector II (Lonza). Among others, liposome A is preferred. Examples of cationic polymers are JetSI (registered trademark) (manufactured by Qbiogene, Inc.) and Jet-PEI (registered trademark) (polyethylenimine, manufactured by Qbiogene, Inc.). An example of carriers using viral envelop is GenomeOne (registered trademark) (HVJ-E liposome, manufactured by Ishihara Sangyo). Alternatively, the medical devices described in Japanese Patent No. 2924179 and the cationic carriers described in Japanese Domestic Re-Publication PCT Nos. 2006/129594 and 2008/ 096690 may be used as well.

A concentration of the oligomer of the present invention contained in the composition of the present invention may vary depending on kind of the carrier, etc., and is appropriately in a range of 0.1 nM to 100 µM, preferably in a range of 1 nM to 10 μM, and more preferably in a range of 10 nM to 1 μM. A weight ratio of the oligomer of the present invention contained in the composition of the present invention and the carrier (carrier/oligomer of the present invention) may vary depending on property of the oligomer, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 1 to 50, and more preferably in a range of 10 to 20.

In addition to the oligomer of the present invention and the carrier described above, pharmaceutically acceptable additives may also be optionally formulated in the composition of the present invention. Examples of such additives are emulsification aids (e.g., fatty acids having 6 to 22 carbon atoms and their pharmaceutically acceptable salts, albumin and dextran), stabilizers (e.g., cholesterol and phosphatidic acid), isotonizing agents (e.g., sodium chloride, glucose, maltose, lactose, sucrose, trehalose), and pH controlling agents (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide and triethanolamine). One or more of these additives can be used. The content of the additive in the composition of the present invention is appropriately 90 wt % or less, preferably 70 wt % or less and more preferably, 50 wt % or less.

The composition of the present invention can be prepared by adding the oligomer of the present invention to a carrier dispersion and adequately stirring the mixture. Additives may be added at an appropriate step either before or after addition of the oligomer of the present invention. An aqueous solvent that can be used in adding the oligomer of the present invention is not particularly limited as far as it is pharmaceutically acceptable, and examples are injectable water or injectable distilled water, electrolyte fluid such as physiological saline, etc., and sugar fluid such as glucose fluid, maltose fluid, etc. A person skilled in the art can appropriately choose conditions for pH and temperature for such matter.

The composition of the present invention may be prepared into, e.g., a liquid form and its lyophilized preparation. The lyophilized preparation can be prepared by lyophilizing the composition of the present invention in a liquid form in a conventional manner. The lyophilization can be performed, for example, by appropriately sterilizing the composition of the present invention in a liquid form, dispensing an aliquot

27

into a vial container, performing preliminary freezing for 2 hours at conditions of about -40 to -20° C., performing a primary drying at 0 to 10° C. under reduced pressure, and then performing a secondary drying at about 15 to 25° C. under reduced pressure. In general, the lyophilized preparation of 5 the composition of the present invention can be obtained by replacing the content of the vial with nitrogen gas and capping.

The lyophilized preparation of the composition of the present invention can be used in general upon reconstitution by adding an optional suitable solution (reconstitution liquid) and redissolving the preparation. Such a reconstitution liquid includes injectable water, physiological saline and other infusion fluids. A volume of the reconstitution liquid may vary 15 depending on the intended use, etc., is not particularly limited, and is suitably 0.5 to 2-fold greater than the volume prior to lyophilization or no more than 500 mL.

It is desired to control a dose of the composition of the present invention to be administered, by taking the following factors into account: the type and dosage form of the oligomer of the present invention contained; patients' conditions including age, body weight, etc.; administration route; and the characteristics and extent of the disease. A daily dose 25 calculated as the amount of the oligomer of the present invention is generally in a range of 0.1 mg to 10 g/human, and preferably 1 mg to 1 g/human. This numerical range may vary occasionally depending on type of the target disease, admin-30 istration route and target molecule. Therefore, a dose lower than the range may be sufficient in some occasion and conversely, a dose higher than the range may be required occasionally. The composition can be administered from once to several times daily or at intervals from one day to several days.

In still another embodiment of the composition of the present invention, there is provided a pharmaceutical composition comprising a vector capable of expressing the oligo- $^{40}\,$ nucleotide of the present invention and the carrier described above. Such an expression vector may be a vector capable of expressing a plurality of the oligonucleotides of the present invention. The composition may be formulated with pharma- 45 ceutically acceptable additives as in the case with the composition of the present invention containing the oligomer of the present invention. A concentration of the expression vector contained in the composition may vary depending upon type of the career, etc., and is appropriately in a range of 0.1 nM to 100 μM, preferably in a range of 1 nM to 10 μM, and more preferably in a range of 10 nM to 1 µM. A weight ratio of the expression vector contained in the composition and the carrier (carrier/expression vector) may vary depending on 55 property of the expression vector, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 1 to 50, and more preferably in a range of 10 to 20. The content of the carrier contained in the composition is the same as in the case with the composition of the present invention $\ ^{60}$ containing the oligomer of the present invention, and a method for producing the same is also the same as in the case with the composition of the present invention.

Hereinafter, the present invention will be described in more 65 detail with reference to EXAMPLES and TEST EXAMPLES below, but is not deemed to be limited thereto.

28 EXAMPLES

Reference Example 1

4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

Step 1: Production of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl] methoxy}-4-oxobutanoic acid

Under argon atmosphere, 22.0 g of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl] benzamide and 7.04 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 269 mL of dichloromethane, and 5.76 g of succinic anhydride was added to the suspension, followed by stirring at room temperature for 3 hours. To the reaction solution was added 40 mL of methanol, and the mixture was concentrated under reduced pressure. The residue was extracted using ethyl acetate and 0.5M aqueous potassium dihydrogenphosphate solution. The resulting organic layer was washed sequentially with 0.5M aqueous potassium dihydrogenphosphate solution, water and brine in the order mentioned. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure to give 25.9 g of the product.

Step 2: Production of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

After 23.5 g of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid was dissolved in 336 mL of pyridine (dehydrated). 4.28 g of 4-DMAP and 40.3 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to the solution. Then, 25.0 g of Aminomethyl Polystyrene Resin cross-linked with 1% DVB (manufactured by Tokyo Chemical Industry Co., Ltd., A1543) and 24 mL of triethylamine were added to the mixture, followed by shaking at room temperature for 4 days. After completion of the reaction, the resin was taken out by filtration. The resulting resin was washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure. To the resulting resin were added 150 mL of tetrahydrofuran (dehydrate), 15 mL of acetic anhydride and 15 mL of 2,6-lutidine, and the mixture was shaken at room temperature for 2 hours. The resin was taken out by filtration, washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure to give 33.7 g of the product.

The loading amount of the product was determined by measuring UV absorbance at 409 nm of the molar amount of the trityl per g resin using a known method. The loading amount of the resin was 397.4 µmol/g.

Conditions of UV measurement

Device: U-2910 (Hitachi, Ltd.) Solvent: methanesulfonic acid Wavelength: 265 nm

€ Value: 45000

29

Reference Example 2

4-Oxo-4-{[(2S,6R)-6-(6-oxo-2-[2-phenoxyaceta-mido]-1H-purin-9-yl)-4-tritylmorpholin-2-yl] methoxy}butanoic acid loaded onto 2-aminometh-ylpolystyrene resin

Step 1: Production of N2-(phenoxyacetyl)guanosine

Guanosine, 100 g, was dried at 80° C. under reduced pressure for 24 hours. After 500 mL of pyridine (anhydrous) and 500 mL of dichloromethane (anhydrous) were added thereto, 401 mL of chlorotrimethylsilane was dropwise added to the mixture under an argon atmosphere at 0° C., followed by stirring at room temperature for 3 hours. The mixture was 15 again ice-cooled and 66.3 g of phenoxyacetyl chloride was dropwise added thereto. Under ice cooling, the mixture was stirred for further 3 hours. To the reaction solution was added 500 mL of methanol, and the mixture was stirred at room temperature overnight. The solvent was then removed by 20 distillation under reduced pressure. To the residue was added 500 mL of methanol, and concentration under reduced pressure was performed 3 times. To the residue was added 4 L of water, and the mixture was stirred for an hour under ice cooling. The precipitates formed were taken out by filtration, washed sequentially with water and cold methanol and then dried to give 150.2 g of the objective compound (yield: 102%) (cf.: Org. Lett. (2004), Vol. 6, No. 15, 2555-2557).

Step 2

N-{9-{(2R,6S)-6-(hydroxymethyl)-4-morpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyac-etamide p-toluenesulfonate

In 480 mL of methanol was suspended 30 g of the com- 35 pound obtained in Step 1, and 130 mL of 2N hydrochloric acid was added to the suspension under ice cooling. Subsequently, 56.8 g of ammonium tetraborate tetrahydrate and 16.2 g of sodium periodate were added to the mixture in the order mentioned and stirred at room temperature for 3 hours. 40 The reaction solution was ice cooled and the insoluble matters were removed by filtration, followed by washing with 100 mL of methanol. The filtrate and washing liquid were combined and the mixture was ice cooled. To the mixture was added 11.52 g of 2-picoline borane. After stirring for 20 minutes, 45 54.6 g of p-toluenesulfonic acid monohydrate was slowly added to the mixture, followed by stirring at 4° C. overnight. The precipitates were taken out by filtration and washed with 500 mL of cold methanol and dried to give 17.7 g of the objective compound (yield: 43.3%).

¹H NMR (6, DMSO-d6): 9.9-9.2 (2H, br), 8.35 (1H, s), 7.55 (2H, m), 7.35 (2H, m), 7.10 (2H, d, J=7.82 Hz), 7.00 (3H, m), 5.95 (1H, dd, J=10.64, 2.42 Hz), 4.85 (2H, s), 4.00 (1H, m), 3.90-3.60 (2H, m), 3.50-3.20 (5H, m), 2.90 (1H, m), 2.25 (3H, s)

Step 3: Production of N-{9-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide

In 30 mL of dichloromethane was suspended 2.0 g of the compound obtained in Step 2, and 13.9 g of triethylamine and 18.3 g of trityl chloride were added to the suspension under ice cooling. The mixture was stirred at room temperature for an hour. The reaction solution was washed with saturated sodium bicarbonate aqueous solution and then with water, 6 and dried. The organic layer was concentrated under reduced pressure. To the residue was added 40 mL of 0.2M sodium

30

citrate buffer (pH 3)/methanol (1:4 (v/v)), and the mixture was stirred. Subsequently, 40 mL of water was added and the mixture was stirred for an hour under ice cooling. The mixture was taken out by filtration, washed with cold methanol and dried to give 1.84 g of the objective compound (yield: 82.0%).

Step 4: Production of 4-oxo-4-{[(2S,6R)-6-(6-oxo-2-[2-phenoxyacetamido]-1H-purin-9-yl)-4-tritylmor-pholin-2-yl]methoxy} butanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that N-{9-[2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide used in Step 1 of REFERENCE EXAMPLE 1.

Reference Example 3

4-{[(2S,6R)-6-(5-Methyl-2,4-dioxo-3,4-dihydropyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide used in Step 1 of REFERENCE EXAMPLE 1.

Reference Example 4

1,12-Dioxo-1-(4-tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 2-[2-(2-hydroxyethoxy)ethoxy]ethyl 4-tritylpiperazine-1-carboxylic acid (the compound described in WO 2009/064471) was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}benzamide.

According to the descriptions in EXAMPLES 1 to 12 and REFERENCE EXAMPLES 1 to 3 below, various types of PMO shown by PMO Nos. 1-11 and 13-16 in TABLE 2 were synthesized. The PMO synthesized was dissolved in injectable water (manufactured by Otsuka Pharmaceutical Factory, Inc.). PMO No. 12 was purchased from Gene Tools, LLC.

TABLE 2

	PMO No.	Target sequence in exon 53	Note	SEQ ID NO:
	1	31-55	5' end: group (3)	SEQ ID NO: 4
0	2	32-53	5' end: group (3)	SEQ ID NO: 8
	3	32-56	5' end: group (3)	SEQ ID NO: 11
	4	33-54	5' end: group (3)	SEQ ID NO: 15
	5	34-58	5' end: group (3)	SEQ ID NO: 25
	6	36-53	5' end: group (3)	SEQ ID NO: 32
	7	36-55	5' end: group (3)	SEQ ID NO: 34
5	8	36-56	5' end: group (3)	SEQ ID NO: 35
	9	36-57	5' end: group (3)	SEQ ID NO: 36

31
TABLE 2-continued

PMO No.	Target sequence in exon 53	Note	SEQ ID NO:
10	33-57	5' end: group (3)	SEQ ID NO: 18
11	39-69	Sequence corresponding to H53A(+39 + 69) (cf. Table 1) in Non-Patent Document 3, 5' end: group (3)	SEQ ID NO: 38
12	30-59	Sequence corresponding to h53A30/1 (cf. Table 1) in Non-Patent Document 5, 5' end: group (2)	SEQ ID NO: 39
13	32-56	5' end: group (1)	SEQ ID NO: 11
14	36-56	5' end: group (1)	SEO ID NO: 35
15	30-59	Sequence corresponding to h53A30/1 (cf. Table 1) in Non-Patent Document 5 5' end: group (3)	SEQ ID NO: 39
16	23-47	Sequence corresponding to SEQ ID NO: 429 described in Patent Document 4, 5' end: group (3)	SEQ ID NO: 47

Example 1

PMO No. 8

4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid, loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 1), 2 g (800 µmol) was transferred to a reaction vessel, and 30 mL of dichloromethane was added thereto. The mixture was allowed to stand for 30 minutes. After the mixture was further washed twice with 30 mL of dichloromethane, the following synthesis cycle was started. The desired morpholino monomer compound was added in each cycle to give the nucleotide sequence of the title compound.

TABLE 3

Step	Reagent	Volume (mL)	Time (min)
1	deblocking solution	30	2.0
2	deblocking solution	30	2.0
3	deblocking solution	30	2.0
4	deblocking solution	30	2.0
5	deblocking solution	30	2.0
6	deblocking solution	30	2.0
7	neutralizing solution	30	1.5
8	neutralizing solution	30	1.5
9	neutralizing solution	30	1.5
10	neutralizing solution	30	1.5
11	neutralizing solution	30	1.5
12	neutralizing solution	30	1.5
13	dichloromethane	30	0.5
14	dichloromethane	30	0.5
15	dichloromethane	30	0.5
16	coupling solution B	20	0.5
17	coupling solution A	6-11	90.0
18	dichloromethane	30	0.5
19	dichloromethane	30	0.5
20	dichloromethane	30	0.5
21	capping solution	30	3.0
22	capping solution	30	3.0
23	dichloromethane	30	0.5
24	dichloromethane	30	0.5
25	dichloromethane	30	0.5

The deblocking solution used was a solution obtained by dissolving a mixture of trifluoroacetic acid (2 equivalents)

32

and triethylamine (1 equivalent) in a dichloromethane solution containing 1% (v/v) ethanol and 10% (v/v) 2,2,2-trifluoroethanol to be 3% (w/v). The neutralizing solution used was a solution obtained by dissolving N,N-diisopropylethylamine in a dichloromethane solution containing 25% (v/v) 2-propanol to be 5% (v/v). The coupling solution A used was a solution obtained by dissolving the morpholino monomer compound in 1,3-dimethyl-2-imidazolidinone containing 10% (v/v) N,N-diisopropylethylamine to be 0.15M. The coupling solution B used was a solution obtained by dissolving N,N-diisopropylethylamine in 1,3-dimethyl-2-imidazolidinone to be 10% (v/v). The capping solution used was a solution obtained by dissolving 20% (v/v) acetic anhydride and 30% (v/v) 2,6-lutidine in dichloromethane.

The aminomethyl polystyrene resin loaded with the PMO synthesized above was recovered from the reaction vessel and dried at room temperature for at least 2 hours under reduced pressure. The dried PMO loaded onto aminomethyl polystyrene resin was charged in a reaction vessel, and 200 mL of 20 28% ammonia water-ethanol (1/4) was added thereto. The mixture was stirred at 55° C. for 15 hours. The aminomethyl polystyrene resin was separated by filtration and washed with 50 mL of water-ethanol (1/4). The resulting filtrate was concentrated under reduced pressure. The resulting residue was 25 dissolved in 100 mL of a solvent mixture of 20 mM acetic acid-triethylamine buffer (TEAA buffer) and acetonitrile (4/1) and filtered through a membrane filter. The filtrate obtained was purified by reversed phase HPLC. The conditions used are as follows.

TABLE 4

Column		rra MS18 (Waters, φ50x 100 mm, ′ = 200 mL)
Flow rate		nL/min
Column ter	nperature roor	n temperature
Solution A	20 n	nM TEAA buffer
Solution B	CH:	CN
Gradient	(B)	conc. 20-→50%/9CV

Each fraction was analyzed and the product was recovered in 100 mL of acetonitrile-water (1/1), to which 200 mL of ethanol was added. The mixture was concentrated under reduced pressure. Further drying under reduced pressure gave a white solid. To the resulting solid was added 300 mL of 10 mM phosphoric acid aqueous solution to suspend the solid. To the suspension was added 10 mL of 2M phosphoric acid aqueous solution, and the mixture was stirred for 15 minutes. Furthermore, 15 mL of 2M sodium hydrate aqueous solution was added for neutralization. Then, 15 mL of 2M sodium hydroxide aqueous solution was added to make the mixture alkaline, followed by filtration through a membrane filter (0.45 μm). The mixture was thoroughly washed with 100 mL of 10 mM sodium hydroxide aqueous solution to give the product as an aqueous solution.

The resulting aqueous solution containing the product was purified by an anionic exchange resin column. The conditions used are as follows.

TABLE 5

		11 11 11 11
60	Column	Source 30Q (GE Healthcare, φ40x 150 mm, 1CV = 200 mL)
	Flow rate	80 mL/min
	Column temp.	room temperature
	Solution A	10 mM sodium hydroxide aqueous solution
	Solution B	10 mM sodium hydroxide aqueous solution,
		1M sodium chloride aqueous solution
65	Gradient	(B) conc. 5→35%/15CV

10

25

40

50

33

Each fraction was analyzed (on HPLC) and the product was obtained as an aqueous solution. To the resulting aqueous solution was added 225 mL of 0.1M phosphate buffer (pH 6.0) for neutralization. The mixture was filtered through a membrane filter (0.45 μ m). Next, ultrafiltration was performed under the conditions described below.

TABLE 6

Filter	PELLICON2 MINI FILTER PLBC 3K
	Regenerated Cellulose, Screen Type C
Size	0.1 m^2

The filtrate was concentrated to give approximately 250 mL of an aqueous solution. The resulting aqueous solution 15 was filtered through a membrane filter (0.45 µm). The aqueous solution obtained was freeze-dried to give 1.5 g of the objective compound as a white cotton-like solid.

ESI-TOF-MS Calcd.: 6924.82.

Found: 6923.54.

Example 2

PMO. No. 1

The title compound was produced in accordance with the procedure of EXAMPLE 1.

MALDI-TOF-MS Calcd.: 8291.96.

Found: 8296.24.

Example 3

PMO. No. 2

The title compound was produced in accordance with the ³⁵ procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 7310.13.

Found: 7309.23.

Example 4

PMO. No. 3

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.55.

Example 5

PMO. No. 4

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-(((2S.6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-trityl-morpholin-2-yl)methoxy)-4-oxobutanoic acid (REFER-ENCE EXAMPLE 3) loaded onto aminomethyl polystyrene resin was used as the starting material.

ESI-TOF-MS Calcd.: 7310.13.

Found: 7310.17.

Example 6

PMO. No. 5

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-(((2S,6R)-6-(5-

34

methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-trityl-morpholin-2-yl)methoxy)-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 3) was used as the starting material.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.20.

Example 7

PMO. No. 6

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 5964.01.

Found: 5963.68.

Example 8

PMO. No. 7

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 6609.55.

Found: 6608.85.

Example 9

PMO. No. 9

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-6-(6-oxo-2-(2-phenoxyacetamido)-1H-purin-9(6H)-yl)-4-tritylmorpholin-2-yl)methoxy)butanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 2) was used as the starting material.

ESI-TOF-MS Calcd.: 7280.11.

Found: 7279.42.

Example 10

PMO. No. 10

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-6-(6-oxo-2-(2-phenoxyacetamido)-1H-purin-9(6H)-yl)-4-tritylmorpholin-2-yl)methoxy)butanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 2) was used as the starting material.

ESI-TOF-MS Calcd.: 8295.95.

Found: 8295.91.

Example 11

PMO. No. 13

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4-tri-tylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 7276.15.

Found: 7276.69.

Example 12

PMO. No. 14

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4-tri-

25

35

35

tylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 8622.27.

Found: 8622.29.

Comparative Example 1

PMO. No. 11

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 10274.63.

Found: 10273.71.

Comparative Example 2

PMO. No. 15

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 9941.33.

Found: 9940.77.

Comparative Example 3

PMO. No. 16

The title compound was produced in accordance with the 30 procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 8238.94.

Found: 8238.69.

Test Example 1

In Vitro Assay

Using an Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza), 10 μM of the oligomers PMO Nos. 1 to 8 of 40 the present invention and the antisense oligomer PMO No. 11 were transfected with 4×10⁵ of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used.

After transfection, the cells were cultured overnight in 2 mL of Eagle's minimal essential medium (EMEM) (manu- 45 factured by Sigma, hereinafter the same) containing 10% fetal calf serum (FCS) (manufactured by Invitrogen) under conditions of 37° C. and 5% CO₂. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 µl of ISOGEN (manufactured by Nippon 50 TIG-119 cells (human normal tissue-derived fibroblasts, Gene) was added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lyse the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined 55 using a NanoDrop ND-1000 (manufactured by LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a Titan One Tube RT-PCR Kit (manufactured by Roche). A reaction solution was prepared in accordance with the protocol attached to the kit. A PTC- 60 100 (manufactured by MJ Research) was used as a thermal cycler. The RT-PCR program used is as follows.

50° C., 30 mins: reverse transcription

94° C., 2 mins: thermal denaturation

194° C., 10 seconds; 58° C., 30 seconds; 68° C., 45 sec- 65 onds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

36

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

(SEQ ID NO: 40) Forward primer: 5'-AGGATTTGGAACAGAGGCGTC-3'

(SEQ ID NO: 41)

Reverse primer: 5'-GTCTGCCACTGGCGGAGGTC-3'

Next, a nested PCR was performed with the product amplified by RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program used is as follows.

94° C., 2 mins: thermal denaturation

[94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given

(SEO ID NO: 42) Forward primer: 5'-CATCAAGCAGAAGGCAACAA-3'

(SEQ ID NO: 43)

Reverse primer: 5'-GAAGTTTCAGGGCCAAGTCA-3'

The reaction product, 1 of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)=A/(A+B)×100

Experimental Results

The results are shown in FIG. 1. This experiment revealed that the oligomers PMO Nos. 1 to 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the antisense oligomer PMO No. 11. In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than four times higher exon skipping efficiency than that of the antisense oligomer PMO No. 11.

Test Example 2

In Vitro Assay Using Human Fibroblasts

Human myoD gene (SEQ ID NO: 44) was introduced into National Institute of Biomedical Innovation) or 5017 cells (human DMD patient-derived fibroblasts, Coriell Institute for Medical Research) using a ZsGreen1 coexpression retroviral vector.

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblasts were collected by FACS and plated at 5×10^4 /cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM.F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12 to 14 days to differentiate into myotubes.

37

Subsequently, the differentiation medium was replaced by a differentiation medium containing 6 µM Endo-Porter (Gene Tools), and the morpholino oligomer was added thereto in a final concentration of 10 µM. After incubation for 48 hours, total RNA was extracted from the cells using a TRIzol (manufactured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR 10 program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation

[94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: PCR amplification

72° C., 7 mins: final extension The primers used were hEX51F and hEX55R.

> hEX51F: 5'-CGGGCTTGGACAGAACTTAC-3' (SEQ ID NO: 46) hex55R: 5'-TCCTTACGGGTAGCATCCTG-3'

The reaction product of RT-PCR above was separated by 2% agarose gel electrophoresis and gel images were captured with a GeneFlash (Syngene). The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured using an Image J (manufactured by National Institutes of $_{30}$ Health). Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skipping efficiency (%)=A/(A+B)×100

Experimental Results

The results are shown in FIGS. 2 and 3. This experiment revealed that in TIG-119 cells, the oligomers PMO Nos. 3, 8 and 9 of the present invention (FIG. 2) all caused exon 53 skipping with a higher efficiency than the antisense oligomer 40 PMO No. 12 (FIG. 2). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than twice higher exon skipping efficiency than that of the antisense oligomer PMO No. 12 (FIG. 2).

Furthermore, this experiment revealed that the oligomers 45 Experimental Results PMO Nos. 3 and 8 to 10 of the present invention (FIG. 3) all caused exon 53 skipping with a higher efficiency than the antisense oligomer PMO No. 12 (FIG. 3). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than seven times higher exon skipping efficiency 50 than that of the antisense oligomer PMO No. 12 (FIG. 3).

Test Example 3

In Vitro Assay Using Human Fibroblasts

The skin fibroblast cell line (fibroblasts from human DMD patient (exons 45-52 or exons 48-52)) was established by biopsy from the medial left upper arm of DMD patient with deletion of exons 45-52 or DMD patient with deletion of 60 exons 48-52. Human myoD gene (SEQ ID NO: 44) was introduced into the fibroblast cells using a ZsGreen1 coexpression retroviral vector.

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblasts were collected by FACS and plated at 65 5×10^4 /cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium:

38

Nutrient Mixture F-12 (DMEM/F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by a differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12, 14 or 20 days to differentiate into myotubes.

Subsequently, the differentiation medium was replaced by a differentiation medium containing 6 µM Endo-Porter (Gene Tools), and a morpholino oligomer was added thereto at a final concentration of 10 µM. After incubation for 48 hours, total RNA was extracted from the cells using a TRIzol (manu-15 factured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR (SEQ ID NO: 45) 20 program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation

[94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: PCR amplification

72° C., 7 mins: final extension The primers used were hEx44F and h55R.

> (SEQ ID NO: 48) hEx44F: 5'-TGTTGAGAAATGGCGGCGT-3 (SEQ ID NO: 46) hEx55R: 5'-TCCTTACGGGTAGCATCCTG-3

The reaction product of RT-PCR above was separated by 35 2% agarose gel electrophoresis and gel images were captured with a GeneFlash (Syngene). The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured using an Image J (manufactured by National Institutes of Health). Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skipping efficiency (%)= $A/(A+B)\times100$

The results are shown in FIGS. 4 and 5. This experiment revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with an efficiency as high as more than 80% in the cells from DMD patient with deletion of exons 45-52 (FIG. 4) or deletion of exons 48-52 (FIG. 5). Also, the oligomers PMO Nos. 3 and 8 of the present invention were found to cause exon 53 skipping with a higher efficiency than that of the antisense oligomer PMO No. 15 in the cells from DMD patient with deletion of exons 45-52 55 (FIG. 4).

Test Example 4

Western Blotting

The oligomer PMO No. 8 of the present invention was added to the cells at a concentration of 10 µM, and proteins were extracted from the cells after 72 hours using a RIPA buffer (manufactured by Thermo Fisher Scientific) containing Complete Mini (manufactured by Roche Applied Science) and quantified using a BCA protein assay kit (manufactured by Thermo Fisher Scientific). The proteins were

39

electrophoresed in NuPAGE Novex Tris-Acetate Gel 3-8% (manufactured by Invitrogen) at 150V for 75 minutes and transferred onto a PVDF membrane (manufactured by Millipore) using a semi-dry blotter. The PVDF membrane was blocked with a 5% ECL Blocking agent (manufactured by GE 5 Healthcare) and the membrane was then incubated in a solution of anti-dystrophin antibody (manufactured by NCL-Dysl, Novocastra). After further incubation in a solution of peroxidase-conjugated goat-antimouse IgG (Model No. 170-6516, Bio-Rad), the membrane was stained with ECL Plus 10 Western blotting system (manufactured by GE Healthcare). Immunostaining

The oligomer PMO No. 3 or 8 of the present invention was added to the cells. The cells after 72 hours were fixed in 3% paraformaldehyde for 10 minutes, followed by incubation in 15 10% Triton-X for 10 minutes. After blocking in 10% goat serum-containing PBS, the membrane was incubated in a solution of anti-dystrophin antibody (NCL-Dysl, Novocastra). The membrane was further incubated in a solution of anti-mouse IgG antibody (manufactured by Invitrogen). The 20 membrane was mounted with Pro Long Gold Antifade reagent (manufactured by Invitrogen) and observed with a fluorescence microscope.

Experimental Results

The results are shown in FIGS. 6 and 7. In this experiment 25 it was confirmed by western blotting (FIG. 6) and immunostaining (FIG. 7) that the oligomers PMO Nos. 3 and 8 of the present invention induced expression of the dystrophin protein.

Test Example 5

In Vitro Assay Using Human Fibroblasts

The experiment was performed as in TEST EXAMPLE 3. 35 Experimental Results

The results are shown in FIG. 8. This experiment revealed that in the cells from DMD patients with deletion of exons 45-52, the oligomers PMO Nos. 3 to 8 of the present invention caused exon 53 skipping with a higher efficiency than the 40 oligomers PMO Nos. 13 and 14 of the present invention (FIG.

Test Example 6

In Vitro Assay

Experiments were performed using the antisense oligomers of 2'-O-methoxy-phosphorothioates (2'-OMe-S-RNA) shown by SEQ ID NO: 49 to SEQ ID NO: 123. Various 50 antisense oligomers used for the assay were purchased from Japan Bio Services. The sequences of various antisense oligomers are given below.

TABLE 7

*****************		*******
oligomer Antisense	Nucleotide sequence	SEQ ID NO:
H53_39-69	CAUUCAACUGUUGCCUCCGGUUCUGAAGGUG	49
H53_1-25	UCCCACUGAUUCUGAAUUCUUUCAA	50
H53_6-30	CUUCAUCCCACUGAUUCUGAAUUCU	51
H53_11-35	UUGUACUUCAUCCCACUGAUUCUGA	52
H53_16-40	UGUUCUUGUACUUCAUCCCACUGAU	53

40 TABLE 7 -continued

	oligomer Antisense	Nucleotide sequence	SEQ ID No:
5	H53_21-45	GAAGGUGUUCUUGUACUUCAUCCCA	54
	H53_26-50	GUUCUGAAGGUGUUCUUGUACUUCA	55
	H53_31-55	CUCCGGUUCUGAAGGUGUUCUUGUA	56
10	H53_36-60	GUUGCCUCCGGUUCUGAAGGUGUUC	57
	H53_41-65	CAACUGUUGCCUCCGGUUCUGAAGG	58
	H53_46-70	UCAUUCAACUGUUGCCUCCGGUUCU	59
15	H53_51-75	ACAUUUCAUUCAACUGUUGCCUCCG	60
	H53_56-80	CUUUAACAUUUCAUUCAACUGUUGC	61
	H53_61-85	GAAUCCUUUAACAUUUCAUUCAACU	62
20	H53_66-90	GUGUUGAAUCCUUUAACAUUUCAUU	63
	H53_71-95	CCAUUGUGUUGAAUCCUUUAACAUU	64
	H53_76-100	UCCAGCCAUUGUGUUGAAUCCUUUA	65
25	H53_81-105	UAGCUUCCAGCCAUUGUGUUGAAUC	66
وي	H53_86-110	UUCCUUAGCUUCCAGCCAUUGUGUU	67
	H53_91-115	GCUUCUUCCUUAGCUUCCAGCCAUU	68
3.0	H53_96-120	GCUCAGCUUCUUCCUUAGCUUCCAG	69
30	H53_101-125	GACCUGCUCAGCUUCUUCCUUAGCU	70
	H53_106-130	CCUAAGACCUGCUCAGCUUCUUCCU	71
	H53_111-135	CCUGUCCUAAGACCUGCUCAGCUUC	72
35	H53_116-140	UCUGGCCUGUCCUAAGACCUGCUCA	73
	H53_121-145	UUGGCUCUGGCCUGUCCUAAGACCU	74
	H53_126-150	CAAGCUUGGCUCUGGCCUGUCCUAA	75
40	H53_131-155	UGACUCAAGCUUGGCUCUGGCCUGU	76
	H53_136-160	UUCCAUGACUCAAGCUUGGCUCUGG	77
	H53_141-165	CCUCCUUCCAUGACUCAAGCUUGGC	78
45	H53_146-170	GGGACCCUCCUUCCAUGACUCAAGC	79
	H53_151-175	GUAUAGGGACCCUCCUUCCAUGACU	80
	H53_156-180	CUACUGUAUAGGGACCCUCCUUCCA	81.
50	H53_161-185	UGCAUCUACUGUAUAGGGACCCUCC	82
	H53_166-190	UGGAUUGCAUCUACUGUAUAGGGAC	83
	H53_171-195	UCUUUUGGAUUGCAUCUACUGUAUA	84
55	H53_176-200	GAUUUUCUUUUGGAUUGCAUCUACU	85
	H53_181-205	UCUGUGAUUUUCUUUUGGAUUGCAU	86
	H53_186-210	UGGUUUCUGUGAUUUUUUUUUUUUUGGAU	87
60	H53_84-108	CCUUAGCUUCCAGCCAUUGUGUUGA	88
	H53_88-112	UCUUCCUUAGCUUCCAGCCAUUGUG	89
	H53_119-143	GGCUCUGGCCUGUCCUAAGACCUGC	90
65	H53_124-148	AGCUUGGCUCUGGCCUGUCCUAAGA	91
	H53_128-152	CUCAAGCUUGGCUCUGGCCUGUCCU	92

25

45

41
TABLE 7 -continued

oligomer Antisense	Nucleotide sequence	SEQ ID NO:
H53_144-168	GACCCUCCUUCCAUGACUCAAGCUU	93
H53_149-173	AUAGGGACCCUCCUUCCAUGACUCA	94
H53_153-177	CUGUAUAGGGACCCUCCUUCCAUGA	95
H53_179-203	UGUGAUUUUCUUUUGGAUUGCAUCU	96
H53_184-208	GUUUCUGUGAUUUUCUUUUGGAUUG	97
H53_188-212	CUUGGUUUCUGUGAUUUUCUUUUGG	98
H53_29-53	CCGGUUCUGAAGGUGUUCUUGUACU	99
H53_30-54	UCCGGUUCUGAAGGUGUUCUUGUAC	100
H53_32-56	CCUCCGGUUCUGAAGGUGUUCUUGU	101
H53_33-57	GCCUCCGGUUCUGAAGGUGUUCUUG	102
H53_34-58	UGCCUCCGGUUCUGAAGGUGUUCUU	103
H53_35-59	UUGCCUCCGGUUCUGAAGGUGUUCU	1.04
H53_37-61	UGUUGCCUCCGGUUCUGAAGGUGUU	105
H53_38-62	CUGUUGCCUCCGGUUCUGAAGGUGU	106
H53_39-63	ACUGUUGCCUCCGGUUCUGAAGGUG	107
H53_40-64	AACUGUUGCCUCCGGUUCUGAAGGU	108
H53_32-61	UGUUGCCUCCGGUUCUGAAGGUGUUCUUGU	109
H53_32-51	GGUUCUGAAGGUGUUCUUGU	1.1.0
H53_35-54	UCCGGUUCUGAAGGUGUUCU	111
H53_37-56	CCUCCGGUUCUGAAGGUGUU	112
H53_40-59	UUGCCUCCGGUUCUGAAGGU	1.1.3
H53_42-61	UGUUGCCUCCGGUUCUGAAG	114
H53_32-49	UUCUGAAGGUGUUCUUGU	115
H53_35-52	CGGUUCUGAAGGUGUUCU	116
H53_38-55	CUCCGGUUCUGAAGGUGU	117
H53_41-58	UGCCUCCGGUUCUGAAGG	118
H53_44-61	UGUUGCCUCCGGUUCUGA	119
H53_35-49	UUCUGAAGGUGUUCU	120
H53_40-54	UCCGGUUCUGAAGGU	121.
H53_45-59	nneccacceenacae	122
H53_45-62	cnenneccaceenacae	123

RD cells (human rhabdomyosarcoma cell line) were plated at 3×10^5 in a 6-well plate and cultured in 2 mL of Eagle's minimal essential medium (EMEM) (manufactured by Sigma, Inc., hereinafter the same) containing 10% fetal calf serum (FCS) (manufactured by Invitrogen Corp.) under conditions of 37° C. and 5% CO $_2$ overnight. Complexes of various antisense oligomers (Japan Bio Services) (1 μ M) for exon 53 skipping and Lipofectamine 2000 (manufactured by Invitrogen Corp.) were prepared and 200 μ M was added to RD cells where 1.8 mL of the medium was exchanged, to reach the final concentration of 100 nM.

42

After completion of the addition, the cells were cultured overnight. The cells were washed twice with PBS (manufactured by Nissui, hereafter the same) and then 500 μl of ISOGEN (manufactured by Nippon Gene) were added to the cells. After the cells were allowed to stand at room temperature for a few minutes for cell lysis, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a Titan One Tube RT-PCR Kit (manufactured by Roche). A reaction solution was prepared in accordance with the protocol attached to the kit. A PTC-100 (manufactured by MJ Research) was used as a thermal cycler. The RT-PCR program used is as follows.

 50° C., 30 mins: reverse transcription

94° C., 2 mins: thermal denaturation

[94° C., 10 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

Subsequently, a nested PCR was performed with the amplified product of RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program used is as follows.

94° C., 2 mins: thermal denaturation

[94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given 40 below.

The reaction product, 1 μ l, of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)= $A/(A+B)\times 100$

Experimental Results

The results are shown in FIGS. 9 to 17. These experiments revealed that, when the antisense oligomers were designed at exons 31-61 from the 5' end of exon 53 in the human dystrophin gene, exon 53 skipping could be caused with a high efficiency.

Test Example 7

Using an Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza), 0.3 to 30 µM of the antisense oligomers

45

60

43

were transfected with 3.5×10^5 of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used.

After the transfection, the cells were cultured overnight in 2 mL of Eagle's minimal essential medium (EMEM) (manufactured by Sigma, Inc., hereinafter the same) containing 5 10% fetal calf serum (FCS) (manufactured by Invitrogen Corp.) under conditions of 37° C. and 5% CO₂. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 µl of ISOGEN (manufactured by Nippon Gene) was then added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lyse the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by 15 LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit (manufactured by Qiagen, Inc.). A reaction solution was prepared in accordance with the protocol attached to the kit. The 20 thermal cycler used was a PTC-100 (manufactured by MJ Research). The RT-PCR program used is as follows.

 $50^{\rm o}$ C., 30 mins: reverse transcription $95^{\rm o}$ C., 15 mins: thermal denaturation

[94° C., 30 seconds; 60° C., 30 seconds; 72° C., 1 mins]×35 $^{-25}$ cycles: PCR amplification

72° C., 10 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

(SEQ ID NO: 42) Forward primer: 5'-CATCAAGCAGAAGGCAACAA-3'

(SEQ ID NO: 43)
Reverse primer: 5'-GAAGTTTCAGGGCCAAGTCA-3'
3

The reaction product, 1 μ l, of the PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.)

The polynucleotide level "A" of the band with exon 53 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)=A/(A+B)×100

Experimental Results

The results are shown in FIGS. 18 and 19. These experiments revealed that the oligomer PMO No. 8 of the present invention caused exon 53 skipping with a markedly high 50 efficiency as compared to the antisense oligomers PMO Nos. 15 and 16 (FIG. 18). It was also revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the oligomers PMO Nos. 13 and 14 of the present invention (FIG. 55 19). These results showed that the sequences with —OH group at the 5' end provide a higher skipping efficiency even in the same sequences.

INDUSTRIAL APPLICABILITY

Experimental results in TEST EXAMPLES demonstrate that the oligomers of the present invention (PMO Nos. 1 to 10) all caused exon 53 skipping with a markedly high efficiency under all cell environments, as compared to the oligomers (PMO Nos. 11, 12, 15 and 16) in accordance with the prior art. The 5017 cells used in TEST EXAMPLE 2 are the

44

cells isolated from DMD patients, and the fibroblasts used in TEST EXAMPLES 3 and 5 are exon 53 skipping target cells from DMD patients. Particularly in TEST EXAMPLES 3 and 5, the oligomers of the present invention show the exon 53 skipping efficiency of 90% or higher in the cells from DMD patients that are the target for exon 53 skipping. Consequently, the oligomers of the present invention can induce exon 53 skipping with a high efficiency, when DMD patients are administered.

Therefore, the oligomers of the present invention are extremely useful for the treatment of $\overline{D}MD$.

Sequence Listing Free Text

SEQ ID NO: 2: synthetic nucleic acid SEQ ID NO: 3: synthetic nucleic acid SEQ ID NO: 4: synthetic nucleic acid SEQ ID NO: 5: synthetic nucleic acid SEQ ID NO: 6: synthetic nucleic acid SEQ ID NO: 7: synthetic nucleic acid SEQ ID NO: 8: synthetic nucleic acid SEO ID NO: 9: synthetic nucleic acid SEQ ID NO: 10: synthetic nucleic acid SEQ ID NO: 11: synthetic nucleic acid SEQ ID NO: 12: synthetic nucleic acid SEQ ID NO: 13: synthetic nucleic acid SEQ ID NO: 14: synthetic nucleic acid SEQ ID NO: 15: synthetic nucleic acid SEQ ID NO: 16: synthetic nucleic acid SEQ ID NO: 17: synthetic nucleic acid SEQ ID NO: 18: synthetic nucleic acid SEQ ID NO: 19: synthetic nucleic acid SEQ ID NO: 20: synthetic nucleic acid SEQ ID NO: 21: synthetic nucleic acid SEQ ID NO: 22: synthetic nucleic acid SEQ ID NO: 23: synthetic nucleic acid SEQ ID NO: 24: synthetic nucleic acid SEQ ID NO: 25: synthetic nucleic acid SEQ ID NO: 26: synthetic nucleic acid SEQ ID NO: 27: synthetic nucleic acid SEQ ID NO: 28: synthetic nucleic acid SEQ ID NO: 29: synthetic nucleic acid SEQ ID NO: 30: synthetic nucleic acid SEQ ID NO: 31: synthetic nucleic acid SEQ ID NO: 32: synthetic nucleic acid SEQ ID NO: 33: synthetic nucleic acid SEQ ID NO: 34: synthetic nucleic acid SEQ ID NO: 35: synthetic nucleic acid SEQ ID NO: 36: synthetic nucleic acid SEQ ID NO: 37: synthetic nucleic acid SEQ ID NO: 38: synthetic nucleic acid SEQ ID NO: 39: synthetic nucleic acid SEQ ID NO: 40: synthetic nucleic acid SEQ ID NO: 41: synthetic nucleic acid SEQ ID NO: 42: synthetic nucleic acid SEQ ID NO: 43: synthetic nucleic acid SEQ ID NO: 45: synthetic nucleic acid SEQ ID NO: 46: synthetic nucleic acid SEQ ID NO: 47: synthetic nucleic acid SEQ ID NO: 48: synthetic nucleic acid SEQ ID NO: 49: synthetic nucleic acid SEQ ID NO: 50: synthetic nucleic acid SEQ ID NO: 51: synthetic nucleic acid SEQ ID NO: 52: synthetic nucleic acid SEQ ID NO: 53: synthetic nucleic acid SEQ ID NO: 54: synthetic nucleic acid SEQ ID NO: 55: synthetic nucleic acid SEQ ID NO: 56: synthetic nucleic acid

SEQ ID NO: 57: synthetic nucleic acid

45 46 SEQ ID NO: 58: synthetic nucleic acid SEQ ID NO: 91: synthetic nucleic acid SEQ ID NO: 92: synthetic nucleic acid SEQ ID NO: 59: synthetic nucleic acid SEQ ID NO: 93: synthetic nucleic acid SEQ ID NO: 60: synthetic nucleic acid SEQ ID NO: 94: synthetic nucleic acid SEQ ID NO: 61: synthetic nucleic acid SEQ ID NO: 95: synthetic nucleic acid SEO ID NO: 62: synthetic nucleic acid SEQ ID NO: 96: synthetic nucleic acid SEO ID NO: 63: synthetic nucleic acid SEQ ID NO: 97: synthetic nucleic acid SEO ID NO: 64: synthetic nucleic acid SEQ ID NO: 98: synthetic nucleic acid SEQ ID NO: 65: synthetic nucleic acid SEQ ID NO: 99: synthetic nucleic acid SEQ ID NO: 66: synthetic nucleic acid SEQ ID NO: 100: synthetic nucleic acid SEQ ID NO: 67: synthetic nucleic acid SEQ ID NO: 101: synthetic nucleic acid SEQ ID NO: 68: synthetic nucleic acid SEQ ID NO: 102: synthetic nucleic acid SEQ ID NO: 69: synthetic nucleic acid SEQ ID NO: 103: synthetic nucleic acid SEQ ID NO: 70: synthetic nucleic acid SEQ ID NO: 104: synthetic nucleic acid SEQ ID NO: 71: synthetic nucleic acid SEQ ID NO: 105: synthetic nucleic acid SEQ ID NO: 72: synthetic nucleic acid SEQ ID NO: 106: synthetic nucleic acid SEQ ID NO: 73: synthetic nucleic acid SEQ ID NO: 107: synthetic nucleic acid SEQ ID NO: 74: synthetic nucleic acid SEQ ID NO: 108: synthetic nucleic acid SEQ ID NO: 75: synthetic nucleic acid SEQ ID NO: 109: synthetic nucleic acid SEQ ID NO: 76: synthetic nucleic acid SEQ ID NO: 110: synthetic nucleic acid SEQ ID NO: 77: synthetic nucleic acid SEQ ID NO: 111: synthetic nucleic acid SEQ ID NO: 78: synthetic nucleic acid SEQ ID NO: 112: synthetic nucleic acid SEQ ID NO: 79: synthetic nucleic acid SEQ ID NO: 113: synthetic nucleic acid SEQ ID NO: 80: synthetic nucleic acid SEQ ID NO: 114: synthetic nucleic acid SEQ ID NO: 81: synthetic nucleic acid SEQ ID NO: 115: synthetic nucleic acid SEQ ID NO: 82: synthetic nucleic acid SEQ ID NO: 116: synthetic nucleic acid SEQ ID NO: 83: synthetic nucleic acid SEQ ID NO: 117: synthetic nucleic acid SEQ ID NO: 84: synthetic nucleic acid SEQ ID NO: 118: synthetic nucleic acid SEQ ID NO: 85: synthetic nucleic acid SEQ ID NO: 119: synthetic nucleic acid SEQ ID NO: 86: synthetic nucleic acid SEQ ID NO: 120: synthetic nucleic acid SEQ ID NO: 87: synthetic nucleic acid SEQ ID NO: 121: synthetic nucleic acid SEQ ID NO: 88: synthetic nucleic acid SEQ ID NO: 122: synthetic nucleic acid SEO ID NO: 89: synthetic nucleic acid SEQ ID NO: 123: synthetic nucleic acid SEQ ID NO: 90: synthetic nucleic acid Sequence Listing:

SEQUENCE LISTING

```
<160> NUMBER OF SEQ ID NOS: 123
<210> SEQ ID NO 1
<211> LENGTH: 212
<212> TYPE: DNA
<213 > ORGANISM: Homo sapiens
<400> SEQUENCE: 1
ttqaaaqaat tcaqaatcaq tqqqatqaaq tacaaqaaca cottcaqaac cqqaqqcaac
                                                                        60
agttgaatga aatgttaaag gattcaacac aatggctgga agctaaggaa gaagctgagc
                                                                       120
aggtottagg acaggocaga gocaagottg agtoatggaa ggagggtooc tatacagtag
                                                                       180
atquaatcua aaaqaaaatu acaqaaacca aq
                                                                       212
<210> SEQ ID NO 2
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 2
                                                                        23
ceggttetga aggtgttett gta
<210> SEQ ID NO 3
<211> LENGTH: 24
<212> TYPE: DNA
<213 > ORGANISM: Artificial
<220> FEATURE:
```

47 48

-continued		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 3		
teeggttetg aaggtgttet tgta	24	
<210> SEQ ID NO 4 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 4		
ctccggttct gaaggtgttc ttgta	25	
<210> SEQ ID NO 5 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 5		
cctceggttc tgaaggtgtt cttgta	26	
<pre><210> SEQ ID NO 6 <211> LENGTH: 27 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>		
<400> SEQUENCE: 6		
gccteeggtt ctgaaggtgt tcttgta	27	
<210> SEQ ID NO 7 <211> LENGTH: 28 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 7		
tgootooggt totgaaggtg ttottgta	28	
<210> SEQ ID NO 8 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 8		
coggttotga aggtgttott gt	22	
<210> SEQ ID NO 9 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 9		
teeggttetg aaggtgttet tgt	23	

49 50

-continued

-continued	
<210> SEQ ID NO 10 <211> LENGTH: 24	
<212> TYFE: DNA <213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 10	
otcoggttot gaaggtgtto ttgt	24
<210> SEQ ID NO 11	
<211> LENGTH: 25 <212> TYPE: DNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 11	
ecteeggtte tgaaggtgtt ettgt	25
<210> SEQ ID NO 12	
<211> LENGTH: 26 <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 12	
geeteeggtt etgaaggtgt tettgt	26
<210> SEQ ID NO 13	
<211> LENGTH: 27 <212> TYPE: DNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 13	
tgeeteeggt tetgaaggtg ttettgt	27
<210> SEQ ID NO 14	
<211> LENGTH: 21 <212> TYPE: DNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 14	
coggttotga aggtgttott g	21
<210> SEQ ID NO 15	
<211> LENGTH: 22 <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 15	
teeggttetg aaggtgttet tg	22
<210> SEQ ID NO 16	
<211> LENGTH: 23 <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	

51 **52**

-cont	inued
<400> SEQUENCE: 16	
ctceggttet gaaggtgtte ttg	23
<210> SEQ ID NO 17 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 17	
ectoeggtte tgaaggtgtt ettg	24
<210> SEQ ID NO 18 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 18	
gootooggtt otgaaggtgt tottg	25
<210> SEQ ID NO 19 <211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 19	
tgcctccggt tctgaaggtg ttcttg	26
<210> SEQ ID NO 20 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 20	
ccgqttctga aggtgttctt	20
<210> SEQ ID NO 21 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 21	
teeggutetg aaggtgutet t	21
<pre><210> SEQ ID NO 22 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 22	
ctccggttct gaaggtgttc tt	22
<210> SEQ ID NO 23 <211> LENGTH: 23	

53

-continued <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 23 cctccggttc tgaaggtgtt ctt 23 <210> SEQ ID NO 24 <211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 24 geeteeggtt etgaaggtgt tett <210> SEQ ID NO 25 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 25 25 tgeetceggt tetgaaggtg ttett <210> SEQ ID NO 26 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 26 ceggttetga aggtgttet 19 <210> SEQ ID NO 27 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 27 teeggttetg aaggtgttet 20 <210> SEQ ID NO 28 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 28 etceggttet gaaggtgtte t 21 <210> SEQ ID NO 29 <211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 29

55 56

<i>55</i>	50
	-continued
	22
cctccggttc tgaaggtgtt ct	2 ú
<210> SEQ ID NO 30 <211> LENGTH: 23	
<212> TYPE: DNA	
<213> ORGANISM: Artificial <220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Ac	id
<400> SEQUENCE: 30	
geeteeggtt etgaaggtgt tet	23
<210> SEQ ID NO 31 <211> LENGTH: 24	
<211> DBAGTH. 1: <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Ac</pre>	rid
.400. CROTUNCE 24	
<400> SEQUENCE: 31	
tgeeteeggt tetgaaggtg ttet	24
<210> SEQ ID NO 32	
<211> LENGTH: 18 <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Ac</pre>	rid
<400> SEQUENCE: 32	
deggttetga aggtgtte	18
<210> SEQ ID NO 33	
<211> LENGTH: 19 <212> TYPE: DNA	
<213> ORGANISM: Artificial	
<220> FEATURE:	4.a
<223> OTHER INFORMATION: Synthetic Nucleic Ac	
<400> SEQUENCE: 33	
tooggttotg aaggtgtto	1.9
<210> SEQ ID NO 34	
<211> LENGTH: 20	
<212> TYPE: DNA <213> ORGANISM: Artificial	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Ac	rid
<400> SEQUENCE: 34	
ctccggttct gaaggtgttc	20
<210> SEQ ID NO 35	
<211> LENGTH: 21	
<212> TYPE: DNA <213> ORGANISM: Artificial	
<220> FEATURE:	
<223> OTHER INFORMATION: Synthetic Nucleic Ac	rid
<400> SEQUENCE: 35	
	22
octooggito igaaggigit o	21
<210> SEQ ID NO 36 <211> LENGTH: 22	
<211> GENGTA: 22 <212> TYPE: DNA	
<213> ORGANISM: Artificial	

57 58

-continued <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 36 geeteeggtt etgaaggtgt te 22 <210> SEQ ID NO 37 <211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 37 tgeeteeggt tetgaaggtg tte 23 <210> SEQ ID NO 38 <211> LENGTH: 31 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 38 cattcaactg ttgcctccgg ttctgaaggt g 31 <210> SEQ ID NO 39 <211> LENGTH: 30 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 39 ttgcctccgg ttctgaaggt gttcttgtac 3.0 <210> SEQ ID NO 40 <211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 40 aggatttgga acagaggcgt c 21 <210> SEQ ID NO 41 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 41 2.0 gtctgccact ggcggaggtc <210> SEQ ID NO 42 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 42 20 catcaagcag aaggcaacaa

59 60

-continued <210> SEQ ID NO 43 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 43 gaagtttcag ggccaagtca 20 <210> SEQ ID NO 44 <211> LENGTH: 963 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 44 atggagetae tgtegeeaec geteegegae gtagaeetga eggeeeega eggetetete 60 tgctectttg ccacaecqqa cqacttctat qacqacccqt qtttcqactc cccqqacctq 120 cgettetteg aagacetgga ceegegeetg atgeaegtgg gegegeteet gaaaceegaa 180 gagdactogo acttocoogo ggoggtgdac coggdddogg gogdacgtga ggadgagdat 240 gtgegegege ccagegggea ccaceaggeg ggeegetgee tactgtggge etgeaaggeg 300 tgcaagegea agaecaccaa egeegacege egeaaggeeg ceaccatgeg egageggege 360 egeetgagea aagtaaatga ggeetttgag acaeteaage getgeaegte gageaateea 420 aaccageggt tgcccaaggt ggagateetg egcaaegeea teegetatat egagggeetg 480 caggetetge tgegegaeea ggaegeegeg ceeeetggeg cegeageege ettetatgeg 540 cogggecoge tgecccoggg cogeggegge gageactaca geggegaete egaegegtee 600 agocegogot ccaactgote egacggoatg atggactaca geggeeeece gageggegee 660 eggeggegga aetgetaega aggegeetae tacaaegagg egeeeagega aeceaggeee 720 gggaagagtg eggeggtgte gageetagae tgeetgteea geategtgga gegeatetee 780 accgagagec etgeggegee egeceteetg etggeggaeg tgeettetga gtegeeteeg 840 ogcaggoaag aggotgoogo occoagogag ggagagagoa goggogacoo cacocagtoa 900 960 coggacgoog coocgcagtg cootgogggt gogaaccoca accogatata coaggtgoto 963 <210> SEQ ID NO 45 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 45 egggettgga eagaacttac 20 <210> SEQ ID NO 46 <211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 46

teettaeggg tageateetg

20

61

-continued <210> SEQ ID NO 47 <211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic DNA <400> SEQUENCE: 47 ctgaaggtgt tcttgtactt catco 25 <210> SEQ ID NO 48 <211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic DNA <400> SEQUENCE: 48 tgttgagaaa tggcggcgt 19 <210> SEQ ID NO 49 <211> LENGTH: 31 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 49 31 cauucaacug uugccuccgg uucugaaggu g <210> SEQ ID NO 50 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 50 ucccacugau ucugaauucu uucaa 25 <210> SEQ ID NO 51 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 51 25 cuucauceca cugauucuga auucu <210> SEQ ID NO 52 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 52 25 uuguacuuca ucccacugau ucuga <210> SEQ ID NO 53 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE

<223> OTHER INFORMATION: Synthetic Nucleic Acid

63 64 -continued <400> SEQUENCE: 53 25 uguucuugua cuucauccca cugau <210> SEQ ID NO 54 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 54 gaagguguuc uuguacuuca uccca 25 <210> SEQ ID NO 55 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 55 25 guucugaagg uguucuugua cuuca <210> SEQ ID NO 56 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 56 cuccgguucu gaagguguuc uugua 25 <210> SEQ ID NO 57 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 57 guugecueeg guucugaagg uguuc 25 <210> SEQ ID NO 58 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 58 caacuguuge cucegguucu gaagg 25 <210> SEQ ID NO 59 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 59 25 ucauucaacu guugecuceg guucu

<210> SEQ ID NO 60 <211> LENGTH: 25

65

-continued <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 60 acauuucauu caacuguuge cuccg 25 <210> SEQ ID NO 61 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 61 cuuuaacauu ucauucaacu guugc <210> SEQ ID NO 62 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 62 gaauccuuua acauuucauu caacu 25 <210> SEQ ID NO 63 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 63 guguugaauc cuuuaacauu ucauu 25 <210> SEQ ID NO 64 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 64 ccauuguguu gaauccuuua acauu 25 <210> SEQ ID NO 65 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 65 uccagecauu guguugaauc cuuua 25 <210> SEQ ID NO 66 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 66

67

-continued		
uageuuccag ccauuguguu gaauc	25	nnanannananannannannannannannannan
<210> SEQ ID NO 67		
<211> LENGTH: 25		
<212> TYPE: RNA <213> ORGANISM: Artificial		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 67		
uuccuuageu uccageeanu guguu	25	
<210> SEQ ID NO 68		
<211> LENGTH: 25		
<212> TYPE: RNA <213> ORGANISM: Artificial		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 68		
деинсинеси наденнесад ссани	25	
<210> SEQ ID NO 69		
<211> LENGTH: 25		
<212> TYPE: DNA		
<213> ORGANISM: Artificial <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 69		
деиеадение инеспиаден несад	25	
<210> SEQ ID NO 70		
<211> LENGTH: 25 <212> TYPE: RNA		
<213> ORGANISM: Artificial		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 70		
gaccugcuca gcuucuuccu uagcu	25	
<210> SEQ ID NO 71		
<211> LENGTH: 25 <212> TYPE: RNA		
<213> ORGANISM: Artificial		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 71		
ccuaagaccu gcucagcuuc nuccu	25	
<210> SEQ ID NO 72		
<211> LENGTH: 25		
<212> TYPE: RNA <213> ORGANISM: Artificial		
<220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 72		
ccuguccuaa gaccugcuca gcuuc	25	
<210> SEQ ID NO 73		
<211> LENGTH: 25		
<212> TYPE: RNA		
<213> ORGANISM: Artificial		

69 70

	UF		/ 0	
		-continued	ā.	
	FEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		00000000000000000000000000000000000000
<400>	SEQUENCE: 73			
ucuggo	ccugu ccuaagaccu gcuca		25	
<211><212><213><220>	SEQ ID NO 74 LENGTH: 25 TYPE: RNA ORGANISM: Artificial FEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
<400>	SEQUENCE: 74			
uuggei	icugg ccuguccuaa gaccu		25	
<211><212><213><220>	SEQ ID NO 75 LENGTH: 25 TYPE: RNA ORGANISM: Artificial FEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
<400>	SEQUENCE: 75			
caagcı	lugge ucuggecugu ccuaa		25	
<211><212><213><220>	SEQ ID NO 76 LENGTH: 25 TYPE: RNA ORGANISM: Artificial FEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
< 400>	SEQUENCE: 76			
ugacu	caage uuggeweugg eeugu		25	
<211><212><213><220>	SEQ ID NO 77 LENGTH: 25 TYPE: RNA ORGANISM: Artificial PEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
<400>	SEQUENCE: 77			
uuccai	igacu caageuugge ucugg		25	
<211><212><213><220>	SEQ ID NO 78 LENGTH: 25 TYPE: RNA ORGANISM: Artificial FEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
<400>	SEQUENCE: 78			
ccucci	uucca ugacucaage uugge		25	
<211><212><213><220>	SEQ ID NO 79 LENGTH: 25 TYPE: RNA ORGANISM: Artificial PEATURE: OTHER INFORMATION: Synthetic	Nucleic Acid		
<400>	SEQUENCE: 79			
gggaco	ccucc uuccaugacu caagc		25	

71 72

-continued

<210> SEQ ID NO 80 <211> LENGTH: 25		
<212> TYPE: RNA <213> ORGANISM: Artificial		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 80		
guauagggac ccuccuucca ugacu	25	
<210> SEQ ID NO 81 <211> LENGTH: 25		
<212> TYPE: RNA		
<213> ORGANISM: Artificial <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 81		
cuacuguaua gggacccucc uucca	25	
<210> SEQ ID NO 82		
<211> LENGTH: 25		
<212> TYPE: RNA <213> ORGANISM: Artificial		
<220> PEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 82		
ngcanchacu quanaggae cence	25	
•		
<210> SEQ ID NO 83 <211> LENGTH: 25		
<212> TYPE: RNA		
<213> ORGANISM: Artificial <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 83		
uggauugcau cuacuguaua gggac	25	
<210> SEQ ID NO 84		
<211> LENGTH: 25 <212> TYPE: RNA		
<213> ORGANISM: Artificial		
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 34		
ucuuuuggau ugcaucuacu guaua	25	
<210> SEQ ID NO 85 <211> LENGTH: 25		
<212> TYPE: RNA		
<213> ORGANISM: Artificial <220> FEATURE:		
<223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 85		
gauuuucuuu uggauugcau cuacu	25	
<210> SEQ ID NO 86		
<211> LENGTH: 25 <212> TYPE: RNA		
<213> ORGANISM: Artificial		
<pre><220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>		

73

-continued		
<400> SEQUENCE: 86		
ucugugauuu ucuuuuggau ugcau	25	
<210> SEQ ID NO 87 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 87		
ugguuncugu gauuuncuuu uggau	25	
<210> SEQ ID NO 88 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 88		
ccuuagcuuc cageeauugu guuga	25	
<210> SEQ ID NO 89 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 89		
ucuuccuuag cuuccagoca uugug	25	
<pre><210> SEQ ID NO 90 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 90</pre>		
ggeusugges ugussuaaga seugs	25	
<210> SEQ ID NO 91 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 91		
ageuuggeus uggssuguss uaaga	25	
<210> SEQ ID NO 92 <211> LEMCTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 92		
cucaagcuug geucuggeeu gueeu	25	
<210> SEQ ID NO 93		

75

	-continued	
<pre><211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	Nucleic Acid	
<400> SEQUENCE: 93		
gacceuccuu ccaugacuca agcuu	25	
<210> SEQ ID NO 94 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic	Nucleic Acid	
<400> SEQUENCE: 94	0.5	
auagggaccc uccuuccaug acuca	25	
<pre><210> SEQ ID NO 95 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic</pre>	Nucleic Acid	
<400> SEQUENCE: 95		
cuguauaggg acccuccuuc cauga	25	
<pre><210> SEQ ID NO 96 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 96</pre>	Nucleic Acid	
uguqauuunc uuunggaung caucu	25	
<210> SEQ ID NO 97 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 97		
guuucuguga uuuucuuuug gauug	25	
<210> SEQ ID NO 98 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic	Nucleic Acid	
<400> SEQUENCE: 98		
cuugguuucu gugauuuucu uuugg	25	
<pre><210> SEQ ID NO 99 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic <400> SEQUENCE: 99</pre>	Nucleic Acid	

78 77 -continued

-continued		
***************************************		***************************************
cogguucuga agguguucuu guacu	25	
<pre><210> SEQ ID NO 100 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>		
<400> SEQUENCE: 100		
uccgguucug aagguguucu uguac	25	
<210> SEQ ID NO 101 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 101		
cenceggune ugaagguguu euugu	25	
<210> SEQ ID NO 102 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 102		
geeucegguu eugaaggugu ueuug	25	
<210> SEQ ID NO 103 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 103		
ugocuceggu ucugaaggug uucuu	25	
<210> SEQ ID NO 104 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 104		
uugeeucegg uucugaaggu guucu	25	
<210> SEQ ID NO 105 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid		
<400> SEQUENCE: 105		
uguugecuee gguucugaag guguu	25	
<210> SEQ ID NO 106 <211> LENGTH: 25 <212> TYPE: RNA		

79

-continued	
<213 > ORGANISM: Artificial	
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 106	
cuguugeeuc caguucugaa gaugu	25
<pre><210> SEQ ID NO 107 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 107	
acuguugecu cegguucuga aggug	25
<210> SEQ ID NO 108 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 108	25
aacuguugcc uccgguucug aaggu <210> SEQ ID NO 109	25
<pre><210 Sup</pre>	
<400> SEQUENCE: 109	
uguugeeuee gguucugaag guguucuugu	30
<pre><210> SEQ ID NO 110 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 110	
gguucugaag guguucuugu	20
<pre><210> SEQ ID NO 111 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 111	
uccgguucug aagguguucu	20
<pre><210> SEQ ID NO 112 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 112	
cenecadine nassadanan	20

81

-continued

<210> SEQ ID NO 113 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 113	
uugeeucegg uucugaaggu	20
<pre><210> SEQ ID NO 114 <211> LENGTH: 20 <212> TYPE: PNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 114	
ngungconce ggunengaag	20
<pre><210> SEQ ID NO 115 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid</pre>	
<400> SEQUENCE: 115	
nucugaaggu guucungu	18
<210> SEQ ID NO 116 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 116	
egguueugaa gguguueu	18
<210> SEQ ID NO 117 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 117	
сиосддииси дааддиди	18
<210> SEQ ID NO 118 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	
<400> SEQUENCE: 118	
ugccuccggu ucugaagg	18
<210> SEQ ID NO 119 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid	

83

-continued <400> SEQUENCE: 119 18 uguugeeuee gguueuga <210> SEQ ID NO 120 <211> LENGTH: 15 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 120 uucugaaggu guucu 1.5 <210> SEQ ID NO 121 <211> LENGTH: 15 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 121 15 uccqquucuq aaqqu <210> SEO ID NO 122 <211> LENGTH: 15 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 122 uugeeueegg uueug 15 <210> SEQ ID NO 123 <211> LENGTH: 18 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 123 18 euguugeeue egguueug

The invention claimed is:

1. An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of the nucleotide sequence of SEQ ID NO: 35, wherein the antisense 50 oligomer is an oligonucleotide having the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide modified, or a morpholino oligomer.

 The antisense oligomer according to claim 1, wherein the antisense oligomer is a morpholino oligomer.

- 3. The antisense oligomer according to claim 1, wherein the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH group is replaced by any one selected from the group consisting of OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R' is an alkylene).
- 4. The antisense oligomer according to claim 1, wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond and a boranophosphate bond.

- 5. The antisense oligomer according to claim 2, wherein the morpholino oligomer is a phosphorodiamidate morpholino oligomer.
- **6**. The antisense oligomer according to claim **2**, wherein the 5 end of the morpholino oligomer is one of the groups of chemical formulae (1) to (3) below:

ОН

US 9,079,934 B2

5

10 (3)

15

85

86

-continued (2)

$$O \longrightarrow NH_2$$
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3
 CH_3

7. A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active, ingredient the anti-

sense oligomer according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof.

Case 1:21-cv-01015-JLH Document 335-1 Filed 08/23/23 Page 151 of 250 PageID #: 20119

UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF CORRECTION

PATENT NO. : 9,079,934 B2

APPLICATION NO. : 13/819520 DATED : July 14, 2015

INVENTOR(S) : Naoki Watanabe et al.

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

At Column 84, Line 51, replace "the 5 end of" with --the 5' end of--.

Signed and Sealed this Twenty-third Day of June, 2020

Andrei Iancu

Director of the United States Patent and Trademark Office

ATTACHMENT C

Document 335-1 Filed 08/23/23 Page 153 of 250 PageID Case 1:21-cv-01015-JLH

United States Patent and Trademark Office

Office of the Commissioner for Patents

Maintenance Fee Statement

CURPENT MAINTENANCE FEE ACCRESS.

CPA GLOBAL LIMITED

ALEXANDRIA, VA 22314

CUSTOMER #

197

ENTITY STATUS

STATEMENT GENERATED

2318 MILL ROAD 12TH FLOOR

UNDISCOUNTED

09/20/2020 21:55:29

Invention

ANTISENSE NUCLEIC ACIDS

PATENT® APPLICATION# 9079934 13819520

FILING DATE: 04/10/2013

Sate III

183UE DATE 07/14/2015

Payment Details

PAYMENT DATE DATE POSTED

Fee Onde - Description

TRANSACTION ID

ATTORNEY DOCKET #

TOTAL PAYMENT

01/03/2019 01/03/2019

010319INTMTFEE00007950504623

\$1,600,00

1551 MAINTENANCE FEE DUE AT 3.5 YEARS

010319INTMTFEE00007950

\$1,600.00

According to the records of the United States Patent and Trademark Office (USPTO), the maintenance for and any necessary surcharge have been amaly paid for the patent libred allove. The payment cinown allove is subject to actual collection, if the payment is refused or charged back by a financial institution, the payment will be void and the maintenance liee and any necessary surcharge ungald.

ATTACHMENT D

Attachment D

Summary of Events VILTEPSO™ (viltolarsen)

Date ¹	Initiated By	Туре	Brief Description
20150728	NSP ²	Email	Question for pre-IND Meeting planning
20150805	NSP	Email	pre-IND meeting request
20150824	NSP	Email	pre-IND meeting request granted
20150918	NSP	Mail	pre-IND meeting information package
20151006	NSP	Email	Questions on pre-IND meeting & breakthrough
			therapy designation; FDA responded
20151019	NSP	Email	pre-IND meeting - Division preliminary
			comments & sponsor responses
20151020	NSP	Meeting	pre-IND meeting
20160325	NSP	eCTD	Submit original IND to FDA

¹ The date is provided as year, month, date.

² "NSP" refers to a US agent of the NDA applicant and holder, NS Pharma, Inc., which is an affiliate of the patent holder and NDA applicant and holder.

³ "RFI" stands for Request for Information.

⁴ "DSUR" stands for development safety update report and "DIBD" stands for development international birth date.

⁵ "AR" stands for Annual Report.

Date ¹	Initiated By	Type	Brief Description
			date & submission of ODD and RPDD granted
			letters
20170307	FDA	Email	Receive DSUR-AR revised date granted letter
20170316	FDA	Email	Response to the SN0003 request for comment
			on tox study question
20170327	NSP	Email	Provide response to FDA comment on tox study
20170328	FDA	Email	FDA comments on NSP questions on tox study
			from request for comment (SN0003)
20170420	NSP	eCTD	Type C meeting request for bioanalytical
			methods; NSP submits questions on tox study
20170501	FDA	Email	Type C meeting request granted letter
20170526	NSP	eCTD	Type C meeting information package
20170629	NSP	eCTD	Study 201 Protocol A4 and Study 202 Protocol
			A1 with investigator information
20170705	FDA	Email	Type C WR (written response)

Date ¹	Initiated By	Type	Brief Description
20170707	FDA	Email	FDA information request for nondinical study
			pathology statements
20170714	NSP	Email	Response to FDA's request for information on
			pathology statements
20170728	NSP	Email	Delivery of nonclinical study pathology
			statements in response to FDA request
20170802	NSP	eCTD	Submit nonclinical study pathology statement
			in response to FDA information request
20170804	NSP	eCTD	Request for comment on DP (drug product)
			stability & Type C WR (SN0013)
20170808	FDA	Email	Request to submit request for comment on DP
			stability (SN0013) as Type C WRO request
20170814	NSP	eCTD	Submit Type C WRO request for DP stability
20170821	NSP	eCTD	Submit Sponsor response to Type C WR
20170823	FDA	Email	FDA comments on sponsor questions for

Date ¹	Initiated By	Type	Brief Description
			clarification (Type C WR)
20170908	NSP	Email	Follow-up sponsor responses to FDA email
			feedback
20170920	NSP	eCTD	Submit Type C WRO information package
20171012	FDA	Email	Type C WR (DP stability)
20171020	NSP	eCTD	Submit Module 3 update with DP
20171024	NSP	eCTD	Submit Study 202 Protocol A2 with investigator
			information
20171221	NSP	eCTD	Submit Study 201 Protocol A5
20171221	NSP	eCTD	Study 201 Protocol A6 and Type C WR (DP
			stability)
20180123	NSP	eCTD	Submit Study 202 Protocol A3
20180123	NSP	eCTD	Submit Study 202 Protocol A4
20180215	NSP	eCTD	Submit Module 3 update for new strength
20180220	NSP	eCTD	Submit breakthrough therapy designation (BTD)

Date ¹	Initiated By	Туре	Brief Description
			request
20180222	FDA	Email	Acknowledgement of BTD request
20180227	NSP	eCTD	Submit Type C meeting request for clinical &
			CMC ⁶
20180306	FDA	Email	Notice of new FDA PM ⁷
20180309	FDA	Email	Type C meeting request granted letter
20180320	NSP	Email	Request if 2-Apr-18 receipt of Type C
			information package desk copies is acceptable;
			FDA responded
20180327	NSP	Email	Notification inquiry of carcinogenicity SPA ⁸
			request in mid/late May
20180327	NSP	eCTD	Submit Type C meeting information package for
			clinical & CMC

⁶ "CMC" stands for Chemistry Manufacturing and Controls.

⁷ "PM" stands for project manager.

⁸ "SPA" stands for Special Protocol Assessment.

Date ¹	Initiated By	Type	Brief Description
20180427	NSP	Email	Notification of NSP intent to submit
			carcinogenicity SPA
20180501	NSP	Email	Delivery of Type C meeting data supplement
20180503	NSP	eCTD	Submit data supplement to Type C meeting
			information package for clinical & CMC
20180509	FDA	Email	Delivery of FDA preliminary comments to Type
			C meeting information package
20180514	NSP	Email	Delivery of sponsor responses to the FDA's
			preliminary comments
20180514	FDA	Email	FDA inquiry about status of NSP's
			plans/questions for the Type C meeting
20180515	NSP	Meeting	Type C meeting
20180515	NSP	Email	Pre-assigned eCTD NDA number request
20180516	FDA	Email	Assignment of NDA number
20180517	NSP	eCTD	Submit request for proprietary name review

Date ¹	Initiated By	Type	Brief Description
20180601	NSP	eCTD	Submit request for carcinogenicity SPA
			(SN0029)
20180604	NSP	Email	Deliver copy of SN0029 cover letter for request
			for SPA
20180605	FDA	Email	FDA provides acknowledgement of receipt for
			SPA request
20180713	NSP	eCTD	Submit DSUR ⁹
20180720	NSP	eCTD	Submit pre-NDA meeting request
20180724	FDA	Email	FDA information request (bioanalytical
			methods)
20180730	NSP	eCTD	Submit Protocol 202 A5
20180730	NSP	eCTD	Submit Protocol 202 A5.1
20180730	NSP	eCTD	Submit Protocol 202 A6 & ICF ¹⁰ version 6
20180730	NSP	eCTD	Submit Protocol 202 A7 & ICF version 7

⁹ "DSUR" stands for development safety update report.

¹⁰ "ICF" stands for informed consent form.

Date ¹	Initiated By	Туре	Brief Description
20180801	FDA	Email	pre-NDA meeting granted letter
20180817	NSP	eCTD	Submit bioanalytical methods & nonclinical
			bridging study reports
20180822	NSP	eCTD	Submit pre-NDA meeting information package
20180913	FDA	Email	Reviewer comment and recommendation on
			bioanalytical methods
20180917	NSP	Email	Sponsor inquiry on date for FDA internal
			meeting & response to reviewer's comments on
			bioanalytical methods
20180919	FDA	Email	FDA clarification on 13-Sep-18 comment
20180926	NSP	Meeting	pre-NDA meeting
20181108	NSP	eCTD	Submit nonclinical information amendment
20181113	FDA	Email	Request for update on rolling review submission
			schedule
20181120	NSP	eCTD	Submit clinical information amendment -

Date ¹	Initiated By	Type	Brief Description
			including request for comments/advice on
			revised confirmatory study synopsis
20181128	NSP	eCTD	Submit rolling review request with updated
			NDA submission schedule
20181203	NSP	Email	Request for status update on open items at pre-
			NDA meeting; FDA responded
20181203	FDA	Email	Receipt of acknowledgement of rolling review
			request
20181214	NSP	Email	Status update follow-up to 3-Dec-18 email
			correspondence on open items
20181220	FDA	Email	FDA response to 14-Dec-18 status update
			follow-up
20190108	NSP	eCTD	Submit nonclinical information amendment &
			20-Dec-18 FDA correspondence
20190114	NSP	Email	Request status of rolling review request

Date ¹	Initiated By	Type	Brief Description
20190115	FDA	Email	Grant rolling review for NDA 212154
20190201	NSP	eCTD	Submit NDA Wave 1 (nonclinical)
20190226	FDA	Email	Acknowledgement of pre-submission letter
20190610	FDA	Email	Information request - inspection readiness &
			submission timing
20190617	NSP	Email	Response to 10-Jun-19 division information
			request
20190618	FDA	Email	FDA agreement on plan for NDA nonclinical
			information amendment
20190627	NSP	eCTD	Submit Phase 3 (Study 301) protocol, ICF, and
			SAP ¹¹
20190628	NSP	eCTD	Rat carcinogenicity SPA request
20190708	NSP	eCTD	DSUR (IND annual report)
20190813	NSP	Email	NDA status update and request for agreement

¹¹ "SAP" stands for Statistical Analysis Plan.

Date ¹	Initiated By	Type	Brief Description
			on image data, safety update report
20190820	FDA	Email	FDA comment on Phase 3 study submitted on
			27-June-19
20190820	NSP	eCTD	Submit request for comment and advice
20190822	FDA	Email	FDA responses to 13-Aug-19 email (image data)
20190827	FDA	Email	Completed FDA responses to 13-Aug-19 email
			(safety update report)
20190918	FDA	Email	Request for status of NDA 212154 submission
			completion
20190920	NSP	eCTD	Submit IND CMC amendment for Phase 3 study
20190926	NSP	eCTD	Submit IND amendment for Study 201/202 -
			change in investigators
20190927	NSP	eCTD	Submit NDA Wave 2 (clinical and quality)
20190930	FDA	Email	Request for clarification on relationship

Date ¹	Initiated By	Туре	Brief Description
			between NSP and NS HQ ¹²
20191007	FDA	Email	Courtesy copy of US NDA acknowledgement
			Letter
20191008	FDA	Email	Clinical information request
20191018	NSP	eCTD	Submit response to 8-Oct-19 clinical
			information request
20191022	FDA	Email	Clinical information request
20191023	FDA	Email	Follow-up clinical information request
20191025	NSP	eCTD	Submit proprietary name review request
20191030	NSP	eCTD	Submit response to 23-Oct-19 clinical
			information request
20191030	NSP	eCTD	Submit nonclinical information amendment -
			multimer studies
20191101	NSP	eCTD	Submit response to 22-Oct-19 clinical

¹² "NS HQ" is Nippon Shinyaku Head Quarters, the NDA applicant and holder.

Date ¹	Initiated By	Type	Brief Description
			information request
20191107	NSP	Email	Agreement to continue rolling submission
20191114	NSP	Email	Delivery of method validation plan; FDA
			responded on 15-Nov-19 and accepted on 18-
			Nov-19
20191115	NSP	eCTD	Submit Protocol 301 Amendment - version 1.1
			(ICFs)
20191119	NSP	eCTD	Submit Protocol 301 Amendment - version 1.2
			(ICFs)
20191121	NSP	eCTD	Submit 2 nd response to 22-Oct-19 information
			request – clinical information amendment with
			method validation plan
20191122	NSP	Email	Notification of applicant intention to submit
			safety update report year-end
20191122	NSP	eCTD	Submit Study 301 new investigator & financial

Date ¹	Initiated By	Type	Brief Description
			certification
20191125	NSP	Meeting	Informal tcon on request for expedited filing
20191126	NSP	Email	Email summarizing 25-Nov-19 request
			expedited filing
20191203	NSP	eCTD	Submit Protocol 202 A8 (with ICF revisions)
20191204	NSP	Email	Status of method validation & 26-Nov-19
			expedite NDA filing request; FDA responded
20191210	NSP	eCTD	Submit request for comment - Study 211
20191211	FDA	Email	Clinical information request
20191211	NSP	Email	Notification of submission of method validation
			report; FDA responded
20191212	NSP	eCTD	Submit 3 rd response to 22-Oct-19 clinical
			information request
20191214	NSP	eCTD	Submit response to 11-Dec-19 information
			request

Date ¹	Initiated By	Type	Brief Description
20191231	NSP	eCTD	Submit NDA safety update report
20200107	FDA	Email	Receive NDA 212154 acknowledgement letter
20200107	NSP	Email	NSP acknowledges receipt of acknowledgment
			letter
20200110	FDA	Email	Proprietary name request unacceptable
			/disclosure authorization request
20200113	FDA	Email	Clinical information request: QT risk assessment
20200114	NSP	Email	NSP question about purpose of 13-Jan-20
			information request; FDA responded
20200115	NSP	Email	NSP informs FDA of timing of 13-Jan-20
			information request submission
20200115	FDA	Email	Acknowledge 13-Jan-20 information request
			submission timing
20200117	NSP	Email	Inform FDA that there is delay in providing
			response

Date ¹	Initiated By	Type	Brief Description
20200117	FDA	Email	Acknowledge 13-Jan-20 information request
			submission timing
20200120	NSP	Email	Submit 13-Jan-20 information request response
			via email
20200122	FDA	Email	Request for formal submission of 13-Jan-20
			information request
20200122	NSP	eCTD	Submit response to 13-Jan-20 information
			request on QT risk assessment
20200122	FDA	Email	Request to secure email and submit disclosure
			authorization officially to NDA
20200122	NSP	eCTD	Submit response for proprietary name/response
			to disclosure authorization request
20200124	FDA	Email	Copy of fax about 22-Jan-20 communication
20200124	FDA	Email	Clinical information request
20200124	FDA	Email	Response to question about disclosure

Date ¹	Initiated By	Туре	Brief Description
			information
20200127	NSP	Email	Response to 24-Jan-20 information request
20200128	FDA	Email	CMC information request
20200130	NSP	Email	NSP question about timing of acceptance to file
			and Day 74 letter
20200204	FDA	Email	Notification that agency is preparing officially
			response regarding proprietary name
20200205	NSP	Email	Update on carcinogenicity study to FDA
20200206	FDA	Email	No filing review issues identified
20200207	NSP	eCTD	Submit Study 301 new investigators
20200210	NSP	Email	NSP request for extension on 28-Jan-20
			information request
20200210	NSP	Email	NSP question about if we can send revised draft
			PI (Package Insert)
20200211	FDA	Email	FDA grants extension on 28-Jan-20 information

Date ¹	Initiated By	Туре	Brief Description
			request timing
20200214	FDA	Email	Clinical information request: bioanalytical
			methods
20200214	NSP	eCTD	Submit response to 28-Jan-20 information
			request on CMC
20200218	NSP	Email	NSP informing FDA that CMC information
			request was submitted through the ESG ¹³
20200221	NSP	Email	NSP email response to FDA for 14-Feb-20
			information request
20200226	NSP	Email	NSP question about Day 74 letter, FDA
			responded
20200226	NSP	eCTD	Submit response to 14-Feb-20 information
			request
20200305	FDA	Email	Request for status of carcinogenicity study

¹³ "ESG" stands for electronic submissions gateway.

Date ¹	Initiated By	Type	Brief Description
20200306	NSP	Email	NSP responds to FDA request for status of
			carcinogenicity study
20200306	FDA	Email	FDA requests draft reports on carcinogenicity
			study
20200306	FDA	Email	CMC information request: DP
20200309	FDA	Email	FDA informs NSP of date of mid-cycle
			communication meeting
20200309	NSP	Email	NSP provides documents regarding
			carcinogenicity study
20200310	FDA	Email	CMC information request: DS (drug substance)
20200311	NSP	eCTD	Submit Protocol 202 A9, updated ICF and IB
			addendum
20200317	NSP	eCTD	Submit Protocol 301 A3, updated ICF & assent
			form
20200318	FDA	Email	CMC information request: DP

Date ¹	Initiated By	Туре	Brief Description
20200319	NSP	eCTD	Submit Study 301 new investigators
20200320	NSP	eCTD	Submit CMC information amendment: 10-Mar-
			20 information request
20200323	FDA	Email	Clinical information request: dosing procedure
			& exposure data
20200325	-	Meeting	Mid-cycle communication meeting
20200325	NSP	eCTD	Submit CMC information amendment: 6-Mar-20
			information request
20200327	NSP	eCTD	Submit clinical information amendment: 23-
			Mar-20 information request
20200331	FDA	Email	CMC information request: container and carton
			labeling
20200401	NSP	eCTD	Submit CMC information amendment: 18-Mar-
			20 information request
20200402	FDA	Email	Clinical information request: data file for Study

Date ¹	Initiated By	Type	Brief Description
			201
20200402	FDA	Email	Clinical information request: study manuals
20200406	FDA	Email	Clinical information request
20200407	NSP	eCTD	Submit clinical information amendment: 2-Apr-
			20 information request on study manuals
20200407	NSP	eCTD	Submit CMC information amendment: 31-Mar-
			20 information request
20200409	FDA	Email	CMC Information request: DS
20200409	NSP	eCTD	Submit CMC amendment (supporting EAP) ¹⁴
20200409	NSP	eCTD	Submit clinical information amendment: 2-Apr-
			20 information request (revised study 201
			dataset)
20200410	NSP	eCTD	Submit clinical information amendment: 6-Apr-
			20 information request

¹⁴ "EAP" stands for expanded access program.

Date ¹	Initiated By	Type	Brief Description
20200410	NSP	eCTD	Submit clinical information amendment: 20-
			Mar-20 information request (mid-cycle
			communication)
20200414	FDA	Email	CMC Information request
20200416	NSP	eCTD	Submit CMC information amendment: 9-Apr-20
			information request
20200417	FDA	Email	Clinical information request
20200420	NSP	Email	Sponsor asks for updates to proprietary name
20200422	NSP	eCTD	Submit CMC information amendment: 14-Apr-
			20 information request
20200424	NSP	eCTD	Submit clinical information amendment: 17-
			Apr-20 information request
20200424	FDA	Email	Summary of call regarding OPDP (The Office of
			Prescription Drug Promotion) questions
20200427	FDA	Email	Clinical information request: P3 study status

Date ¹	Initiated By	Type	Brief Description
20200427	FDA	Email	CMC Information request: manufacturer testing
20200429	NSP	eCTD	Submit change in regulatory contact
20200429	NSP	eCTD	Submit clinical information amendment: 27-
			Apr-20 information request
20200430	NSP	eCTD	Submit CMC information amendment: 27-Apr-
			20 information request
20200520	FDA	Email	FDA advice/information request on Study 301
20200520	NSP	eCTD	Submit clinical information amendment: 4-May-
			20 request for Study 301 status
20200529	NSP	eCTD	Submit CMC information amendment: USP
			compliance statements (resolve 14-Apr-20
			information request)
20200604	NSP	eCTD	Request for proprietary name review
20200605	NSP	eCTD	Submit applicant response to late-cycle meeting
			background package

Date ¹	Initiated By	Type	Brief Description
20200608	NSP	eCTD	Submit update to proprietary name review
			request
20200610	-	Meeting	Late-cycle meeting
20200611	FDA	Email	Submission of ECG datasets with a formal
			request for a TQT waiver to NDA 212154 ¹⁵
20200615	FDA	Email	Proprietary name request for Viltepso
			conditionally acceptable
20200619	NSP	eCTD	Submit response to 20-May-20 FDA
			advice/information request on Study 301
			(SN0060)
20200626	NSP	Email	Follow up questions on status of review of
			SN0060
20200629	NSP	eCTD	Submit Study 301 new investigators
20200710	NSP	eCTD	Submit IND annual report (DSUR format)

 $^{^{\}rm 15}\,$ "ECG" stands for electrocardiogram. "TQT" stands for Through QT.

Date ¹	Initiated By	Туре	Brief Description
20200716	FDA	Email	PMRs 1-4, general timeline inquiries ¹⁶
20200719	NSP	Email	Feedback requested on future commitment for
			additional CCIT ¹⁷
20200722	NSP	eCTD	Submit CMC information amendment: CCIT
			report in response to 28-Jan-20 information
			request
20200723	NSP	Email	Follow up questions on status of review of
			SN0060 (19-Jun-20)
20200724	FDA	Email	Immunogenicity PMR timeline
20200727	FDA	Email	FDA follow-up comments on Protocol 301 A2
			(SN0060)
20200727	NSP	Email	NSP requested teleconference with the FDA if
			clarification is needed on questions &
			comments of SN0060

¹⁶ "PMR" stands for post-marketing requirements.

 $^{^{\}rm 17}\,$ "CCIT" stands for container closure integrity testing.

Date ¹	Initiated By	Type	Brief Description
20200727	FDA/NSP	Email	Labeling comments & follow-up
20200728	FDA	Email	Email correspondence on revised carton &
			container labeling
20200728	NSP	eCTD	Submit carton & container labeling update
20200729	NSP	Email	NSP adds clarification comment on
			immunogenicity PMR
20200730	NSP	Email	NSP requests clarification comments on PMRs
			1-4
20200804	FDA	Email	2-year rat carcinogenicity study PMR
20200804	FDA/NSP	Email	Labeling comments & follow up (Round 3)
20200807	NSP	eCTD	Submit MedWatch Form for an Initial Report of
			suspected unexpected serious adverse reactions
			(SUSAR)
20200810	NSP	eCTD	Submit final PMR
20200810	FDA/NSP	Email	Labeling comments & follow up (Round 4)

Date ¹	Initiated By	Туре	Brief Description
20200811	FDA/NSP	Email	Labeling comments & follow up (Round 5)
20200812	FDA	Email	Approval of NDA 212154 for VILTEPSO™
			(viltolarsen)
20200818	NSP	eCTD	Submit MedWatch follow-up submission
20200821	NSP	eCTD	Submit Protocol 202 amendment 10 (v11) and
			ICF v10
20200911	NSP	Email	Review status update from FDA on SN0060

EXHIBIT AC



ARIO DE DE LA DESTE DE SA REAR DESCRIPTOR DE LA CORTA DELA CORTA DELA CORTA DE LA CORTA DE LA CORTA DELA CORTA DELA CORTA DE LA CORTA DELA CORTA DE LA CORTA DE LA CORTA DELA CORTA DE LA CORTA DELA CORTA DE LA CORTA DELA CORTA DELA CORTA DELA CORTA DE LA CORTA DE LA CORTA DE LA CORTA DELA CORT

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office

August 27, 2021

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THIS OFFICE OF:

U.S. PATENT: 9,708,361

ISSUE DATE: July 18, 2017

By Authority of the

Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office

T. WALLACE

Certifying Officer

EXHIBIT

Segaration

Watanabe

#2

(12) United States Patent

Watanabe et al.

(10) Patent No.:

US 9,708,361 B2

(45) Date of Patent:

Jul. 18, 2017

(54) ANTISENSE NUCLEIC ACIDS

(71) Applicants: NIPPON SHINYAKU CO., LTD., Kyoto-shi, Kyoto (JP); NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, Kodaira-shi, Tokyo

(72) Inventors: Naoki Watanabe, Tsukuba (JP); Youhei Satou, Tsukubu (JP); Shin'ichi Takeda. Kedaira (JP); Tetsuya Nagata, Kedaira

(73) Assignees: NIPPON SHINYAKU CO., LTD., Kyoto-shi, Kyoto (JP): NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY, Tokyo (JP)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: 14/615,504

(22) Filed: Feb. 6, 2015

(65) Prior Publication Data US 2015/0166995 A1 Jun. 18, 2015

Related U.S. Application Data

(63) Continuation of application No. 13/819,520, filed as application No. PCT/JP2011/070318 on Aug. 31, 2011, now Pat. No. 9,079,934.

Foreign Application Priority Data (30)

C07H 21/02 (2006.01)C07H 21/04 (2006.01)(2006.01)A61K 31/70 C12N 15/11 (2006.01)C12N 15/113 (2010.01)C07H 21/00 (2006.01) C12N 5/00 (2006.01)

(52) U.S. Cl. CPC C07H 21/04 (2013.01); C07H 21/00 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 2310/11 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3145 (2013.01); CI2N 2310/321 (2013.01); CI2N 2310/3525 (2013.01); C12N 2320/33 (2013.01)

(58) Field of Classification Search

See application file for complete search history.

(56)References Cited

U.S. PATENT DOCUMENTS

6,653,467	81	11/2003	Matsuo et al.
2010/0130591	AI	5/2010	Sazani et al.
2010/0168212	Al	7/2010	Popplewell et al.
2012/0190728	AI	7/2012	Bennett et al.
2013/0109091	Al	5/2013	Baker et al.

FOREIGN PATENT DOCUMENTS

575	2202 10700		E TO CO.
J.P	2002-10790		1/2002
WO	WO-2004/048570	AL	6/2004
WO	WO-2006/0000057	AL	1/2006
WO	WO-2008/036127	A.2	3/2008
WO	WO-2010/048586	Al	4/2010
WO	WO-2011/057350	Al	5/2011

OTHER PUBLICATIONS

Linda J. Popplewell et al., "Design of Phosphorodiamidate Morpholino Oligomers (PMOs) for the Induction of Exon Skipping of the Human DMD Gene," Mol. Ther., vol. 17, No. 3, Mar. 2009, pp. 554-561.

Linda J. Popplewell et al., "Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials," Neuromuscular Disorders, vol. 20, No. 2, Feb. 2010, pp. 102-110. Annemieke Aartsma-Rus et al., "Targeted exon skipping as a

potential gene correction therapy for Duchenne muscular dystrophy," Neuromuscular Disorders, vol. 12, 2002, pp. S71-S77.

Steve D. Wilton et al., "Antisense Oligonorleotide-induced Exon Skipping Across the Human Dystrophin Gene Transcript," Mol Ther., vol. 15, No. 7, Jul. 2007, pp. 1288-1296.

Anthony P. Monaco et al., "An Explanation for the Phenotypic Differences between Patients Bearing Partial Deletions of the DMD Locus," Genomics, 1988; 2, pp. 90-95.

Masafumi Matsuo, "Ducheane / Becker muscular dystrophy: from molecular diagnosis to gene therapy," Brian & Development, 1996; 18, pp. 167-172.

International Search Report dated Oct. 11, 2011 in PCT/JP2011/ 070318 filed Aug. 31, 2011.

Mitipant, et al., "By-passing the nonsense mutation in the 4CF mouse model of muscular dystrophy by induced exon skipping", The Journal of Gene Medicine, Jan. 2009, vol. 11, No. 1, pp. 46-56.

Primary Examiner - Sean McGarry


(74) Attorney, Agent, or Firm - Drinker Biddle & Reath LLP

(57) ABSTRACT

The present invention provides an oligomer which efficiently enables to cause skipping of the 53rd exon in the human dystrophin gene. Also provided is a pharmaceutical composition which causes skipping of the 53rd exon in the human dystrophin gene with a high efficiency.

7 Claims, 19 Drawing Sheets


Jul. 18, 2017 Sheet 1 of 19



Jul. 18, 2017

Sheet 2 of 19


Figure 2




Jul. 18, 2017

Sheet 3 of 19

Figure 3




Jul. 18, 2017 Sheet 4 of 19



Jul. 18, 2017

Sheet 5 of 19

Figure 5



Jul. 18, 2017

Sheet 6 of 19

US 9,708,361 B2

Figure 6


PMO No.8

10 μM

Dystrophin
250kDa


Jul. 18, 2017

Sheet 7 of 19




Jul. 18, 2017

Sheet 8 of 19




Jul. 18, 2017

Sheet 9 of 19




U.S. Patent Jul. 18, 2017 Sheet 10 of 19 US 9,708,361 B2




Jul. 18, 2017

Sheet 11 of 19




Jul. 18, 2017

Sheet 12 of 19




Jul. 18, 2017

Sheet 13 of 19




Jul. 18, 2017

Sheet 14 of 19




Jul. 18, 2017

Sheet 15 of 19




Jul. 18, 2017

Sheet 16 of 19



Jul. 18, 2017

Sheet 17 of 19



Jul. 18, 2017

Sheet 18 of 19





Figure 18

Jul. 18, 2017

Sheet 19 of 19



Copy provided by USPTO from the PIRS Image Database on 08-24-2021

US 9,708,361 B2

ANTISENSE NUCLEIC ACIDS

CROSS REFERENCE TO RELATED APPLICATIONS

This is a Continuation of copending application Ser. No. 13/819,520, filed Apr. 10, 2013, which is a PCT National Stage of PCT/JP2011/070318 filed Aug. 31, 2011, which claims priority to JP Application No., 2010-196032 filed Sep. 1, 2010.

SEQUENCE LISTING

A Sequence Listing containing SEQ ID NO: 1-123 is incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to an antisense oligomer which causes skipping of exon 53 in the human dystrophin 20 gene, and a phomoaceutical composition comprising the oligomer.

BACKGROUND ART

Duchenne muscular dystrophy (DMD) is the most frequent form of hereditary progressive muscular dystrophy that affects one in about 3,500 newborn boys. Although the motor functions are rarely different from healthy humans in infancy and childhood, muscle weakness is observed in 30 children from around 4 to 5 years old. Then, muscle weakness progresses to the loss of ambulation by about 12 years old and death due to cardiac or respiratory insufficiency in the twenties. DMD is such a severe disorder. At present, there is no effective therapy for DMD available, and it has 35 been strongly desired to develop a novel therapeutic agent.

DMD is known to be caused by a mutation in the dystrophin gene. The dystrophin gene is located on X chromosome and is a huge gene consisting of 2.2 million DNA nucleofide pairs. DNA is transcribed into mRNA 40 precursors, and introns are removed by splicing to synthesize mRNA in which 79 exons are joined together. This mRNA is translated into 3,685 amino acids to produce the dystrophia protein. The dystrophia protein is associated with the maintenance of membrane stability in muscle cells and 45 Patent Document 1: International Publication WO 2006/ necessary to make muscle cells less fragile. The dystrophin gene from patients with DMD contains a mutation and hence, the dystrophin protein, which is functional in muscle cells, is rarely expressed. Therefore, the structure of muscle cells cannot be maintained in the body of the patients with 50 DMD, leading to a large influx of calcium ions into muscle cells. Consequently, an inflammation-like response occurs to promote fibrosis so that muscle cells can be regenerated only

Becker muscular dystrophy (BMD) is also caused by a 55 Non-Patent Document 3: Wilton S. D., et al., Molecular mutation in the dystrophin gene. The symptoms involve muscle weakness accompanied by atrophy of muscle but are typically mild and slow in the progress of muscle weakness, when compared to DMD. In many cases, its onset is in adulthood. Differences in clinical symptoms between DMD 60 and BMD are considered to reside in whether the reading frame for amino acids on the translation of dystrophin mRNA into the dystrophin protein is disrupted by the mutation or not (Non-Patent Document 1). More specifically, in DMD, the presence of mutation shifts the amino 65 acid reading frame so that the expression of functional dystrophin protein is abolished, whereas in BMD the dys-

trophin protein that functions, though imperfectly, is produced because the amino acid reading frame is preserved, while a part of the exons are deleted by the mutation.

Exon skipping is expected to serve as a method for treating DMD. This method involves modifying splicing to restore the amino acid reading frame of dystrophin mRNA and induce expression of the dystrophin protein having the function partially restored (Non-Patent Document 2). The amino acid sequence part, which is a target for exon skipping, will be lost. For this reason, the dystrophin protein expressed by this treatment becomes shorter than normal one but since the amino acid reading frame is maintained, the function to stabilize muscle cells is partially retained. Consequently, it is expected that exon skipping will lead DMD to the similar symptoms to that of BMD which is milder. The exon skipping approach has passed the animal tests using mice or dogs and now is currently assessed in clinical trials on human DMD patients.

The skipping of an exon can be induced by binding of antisense micleic acids targeting either 5' or 3' splice site or both sites, or exon-internal sites. An exon will only be included in the mRNA when both splice sites thereof are recognized by the spliceosome complex. Thus, exon skipping can be induced by targeting the splice sites with antisense nucleic seids. Furthermore, the binding of an SR protein to an exonic splicing enhancer (ESE) is considered necessary for an exon to be recognized by the splicing mechanism. Accordingly, exon skipping can also be induced by targeting ESE.

Since a mutation of the dystrophin gene may vary depending on DMD patients, antisense nucleic acids need to be desined based on the site or type of respective genetic mutation. In the past, antisense nucleic acids that induce exon skipping for all 79 exons were produced by Steve Wilton, et al., University of Western Australia (Non-Patent Document 3), and the antisense nucleic acids which induce exon skipping for 39 exous were produced by Annemieke Aartsma-Rus, et al., Netherlands (Non-Patent Document 4).

It is considered that approximately 8% of all DMD patients may be treated by skipping the 53rd exon (hereinafter referred to as "exon 53"). In recent years, a plurality of research organizations reported on the studies where exon 53 in the dystrophin gene was targeted for exen skipping (Patent Documents 1 to 4; Non-Patent Document 5). However, a technique for skipping exon 53 with a high efficiency has not yet been established

000057

Patent Document 2: International Publication WO 2004/ 048570

Patent Document 3: US 2010/0168212

Patent Document 4: International Publication WO 2010/

Non-Patent Document 1: Monaco A. P. et al., Genomics 1988; 2: p. 90-95

Non-Patent Document 2: Matsuo M., Brain Dev 1996; 18: p. 167-172

Therapy 2007: 15: p. 1288-96

Non-Patent Document 4: Annemieke Aartsma-Rus et al., (2002) Neuromuscular Disorders 12: S71-S77

Non-Patent Document 5: Linda J. Popplewell et al., (2010) Neuromuscular Disorders, vol. 20, no. 2, p. 102-10

DISCLOSURE OF THE INVENTION

Under the foregoing circumstances, antisense oligomers that strongly induce exon 53 skipping in the dystrophin gene and muscular dystrophy therapeutics comprising oligomers thereof have been desired.

3

As a result of detailed studies of the structure of the dystrophin gene, the present inventors have found that exon 53 skipping can be induced with a high efficiency by targeting the sequence consisting of the 32nd to the 56th nucleotides from the 5' end of exon 53 in the mRNA precursor (hereinafter referred to as "pre-mRNA") in the dystrophin gene with antisense oligomers. Based on this finding, the present inventors have accomplished the present invention.

That is, the present invention is as follows.

[1] An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to any one of the sequences consisting of the 31st to the 53rd, the 31st to the 55th, the 31st to the 55th, the 31st to the 55th, the 31st to the 57th, the 31st to the 58th, the 32nd to the 55th, the 32nd to the 55th, the 32nd to the 57th, the 32nd to the 55th, the 33rd to the 53rd, the 33rd to the 57th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 55rd, the 34th to the 55th, the 34th to the 55th, the 35th to the 56th, the 35th to the 56th, the 35th to the 56th, the 36th to the 56th, the 36th to the 57th, the 36th to the 56th, the 36th to the 57th, or the 36th to the 58th anceleotides, from the 5' end of the 53rd exon in the human dystrophin gene.

[2] The antisense oligomer according to [1] above, which

is an oligonucleotide.

[3] The antisense oligomer according to [2] above, wherein the sugar moiety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified.

[4] The antisense oligomer according to [3] above, wherein the sugar moiety of at least one nucleotide constituting the oligonucleotide is a ribose in which the 2'-OH 35 group is replaced by any one selected from the group consisting of OR, R, R'OR, SiH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br and I (wherein R is an alkyl or an aryl and R' is an alkylene).

[5] The antisense oligomer according to [3] or [4] above, 40 wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of a phosphorothioate bond, a phosphorodithioate bond, an alkylphosphonate bond, a phosphoramidate bond and a boranophosphate bond.

[6] The antisense eligomer according to [1] above, which is a morpholine oligomer.

[7] The antisense oligomer according to [6] above, which is a phosphorodiamidate morpholino oligomer.

[8] The antisense oligomer according to any one of [1] to 50 [7] above, wherein the 5 end is any one of the groups of chemical formulae (1) to (3) below:

4

[9] The antisense oligamer according to any one of [1] to [8] above, consisting of a nucleotide sequence complementary to the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides from the 5' end of the 53rd exon in the human dystrophin gene.

[10] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 2 to 37.

[11] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by any one selected from the group consisting of SEQ ID NOS: 11, 17, 23, 29 and 35.

[12] The antisense oligomer according to any one of [1] to [8] above, consisting of the nucleotide sequence shown by SEQ ID NO: 11 or 35.

[13] A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the antisense oligomer according to any one of [1] to [12] above, or a pharmaceutically acceptable salt or hydrate thereof.

The antisense oligomer of the present invention can induce exon 53 skipping in the human dystrophin gene with a high efficiency. In addition, the symptoms of Duchenne muscular dystrophy can be effectively alleviated by administering the pharmaceutical composition of the present invention.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cell line (RD cells).

FIG. 2 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into human normal tissue-derived fibroblasts (TIG-119 cells) to induce differentiation into muscle cells.

FIG. 3 shows the efficiency of exon 53 skipping in the tuman dystrophin gene in the cells where human myoD gene is introduced into human DMD patient-derived fibroblasts (5017 cells) to induce differentiation into muscle cells.

FIG. 4 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD of gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle cells.

FIG. 5 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD
 gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells.

FIG. 6 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 48-52) to induce differentiation into muscle cells.

FIG. 7 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myeD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52 or deletion of exons 48-52) to induce differentiation into muscle cells.

FIG. 8 shows the efficiency of exon 53 skipping in the human dystrophin gene in the cells where human myoD gene is introduced into fibroblasts from human DMD patient (with deletion of exons 45-52) to induce differentiation into muscle cells.

FIG. 9 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 10 shows the efficiency of exon 53 skipping (2'- 20 OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 11 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 12 shows the efficiency of exon 53 skipping (2'-()Me-S-RNA) in the human dystrophia gene in human rhabdomyosarcoma cells (RD cells).

FIG. 13 shows the efficiency of exon 53 skipping (2'rhabdomyosarcoma cells (RD cells)

FIG. 14 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 15 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 16 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human 40 rhabdomyosarcoma cells (RD cells).

FIG. 17 shows the efficiency of exon 53 skipping (2'-OMe-S-RNA) in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells).

FIG. 18 shows the efficiency of exon 53 skipping in the 45 human dystrophin gene in human rhabdemyosarcoma cells (RD cells) at the respective concentrations of the oligomers.

FIG. 19 shows the efficiency of exon 53 skipping in the human dystrophin gene in human rhabdomyosarcoma cells (RD cells) at the respective concentrations of the oligomers. 50

BEST MODE FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention is described in detail. 53 The embodiments described below are intended to be presented by way of example merely to describe the invention but not limited only to the following embodiments. The present invention may be implemented in various ways without departing from the gist of the invention.

All of the publications, published patent applications, patents and other patent documents cited in the specification are herein incorporated by reference in their entirety. The specification hereby incorporates by reference the contents of the specification and drawings in the Japanese Patent 65 Application (No. 2010-196032) filed Sep. 1, 2010, from which the priority was claimed.

1. Antisense Oligomer

The present invention provides the antisense oligomer (hereinafter referred to as the "oligomer of the present invention") which causes skipping of the 53rd exon in the human dystrophia gene, consisting of a nucleotide sequence complementary to any one of the sequences (hereinafter also referred to as "target sequences") consisting of the 31 st to the 53rd, the 31 st to the 54th, the 31 st to the 55th, the 31 st to the 56th, the 31 st to the 57th, the 31st to the 58th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 32nd to the 56th, the 32nd to the 57th, the 32nd to the 58th, the 33rd to the 53rd, the 33rd to the 54th, the 33rd to the 55th, the 33rd to the 56th, the 33rd to the 57th, the 33rd to the 58th, the 34th to the 53rd, the 34th to the 54th, the 34th to the 55th, the 34th to the 56th, the 34th to the 57th, the 34th to the 58th, the 35th to the 53rd, the 35th to the 54th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 58th, the 36th to the 53rd, the 36th to the 54th, the 36th to the 55th, the 36th to the 56th, the 36th to the 57th, or the 36th to the 58th nucleotides, from the 5' end of the 53rd exon in the human dystrophin gene. [Exon 53 in Human Dystrophin Gene]

In the present invention, the term "gene" is intended to mean a genomic gene and also include cDNA, mRNA 25 precursor and inRNA. Preferably, the gene is mRNA precursor, i.e., pre-mRNA.

In the human genome, the human dystrophin gene locates at locus Xp21.2. The human dystrophin gene has a size of 3.0 Mbp and is the largest gene among known human genes. OMe-S-RNA) in the human dystrophin gene in human 30 However, the coding regions of the human dystrophin gene are only 14 kb, distributed as 79 exons throughout the human dystrophin gene (Roberts, R.G., et al., Genomics, 16: 536-538 (1993)). The pre-mRNA, which is the transcript of the human dystrophin gene, undergoes splicing to generate mature mRNA of 14 kb. The nucleotide sequence of human wild-type dystrophin gene is known (GenBank Accession No. NM_004006).

The nucleotide sequence of exon 53 in the human wildtype dystrophin gene is represented by SEQ ID NO: 1.

The oligomer of the present invention is designed to cause skipping of exon 53 in the human dystrophin gene, thereby modifying the protein encoded by DMD type of dystrophin gene into the BMD type of dystrophin protein. Accordingly, exon 53 in the dystrophin gene that is the target of exon skipping by the oligomer of the present invention includes both wild and mutant types.

Specifically, exon 53 mutants of the human dystrophin gene include the polynucleotides defined in (a) or (b) below.

(a) A polynucleotide that hybridizes under stringent conditions to a polynucleotide consisting of a nucleotide sequence complementary to the nucleatide sequence of SEQ ID NO: I; and

(b) A polymelectide consisting of a nucleotide sequence having at least 90% identity with the nucleotide sequence of SEQ ID NO: 1.

As used herein, the term "polynucleotide" is intended to mean DNA or RNA

As used herein, the term "polynucleotide that hybridizes under stringent conditions" refers to, for example, a polynucleotide obtained by colony hybridization, plaque hybridization, Southern hybridization or the like, using as a probe all or part of a polynucleotide consisting of a nucleotide sequence complementary to the nucleotide sequence of, e.g., SEQ ID NO: 1. The hybridization method which may be used includes methods described in, for example, "Sambrook & Russell, Molecular Cloning: A Laboratory Manual Vol. 3, Cold Spring Harbor, Laboratory Press 2001,"

7

"Ausubel, Current Protocols in Molecular Biology, John Wiley & Sons 1987-1997," etc.

As used herein, the term "complementary nucleotide sequence" is not limited only to mucleotide sequences that form Watson-Crick pairs with target nucleotide sequences, but is intended to also include nucleotide sequences which form Wobble base pairs. As used herein, the term Watson-Crick pair refers to a pair of nucleobases in which hydrogen bonds are formed between adenine-thymine, adenine-uracil or guanine-cytosine, and the term Wobble base pair refers to a pair of nucleobases in which hydrogen bonds are formed between guanine-uracil, inosine-uracil, inosine-adenine or inosine-cytosine. As used herein, the term "complementary nucleotide sequence" does not only refers to a nucleotide sequence 100% complementary to the target nucleotide sequence but also refers to a complementary nucleotide sequence that may contain, for example, 1 to 3, 1 or 2, or one nucleotide non-complementary to the target nucleotide

As used herein, the term "stringent conditions" may be 20 any of low stringent conditions, moderate stringent conditions or high stringent conditions. The term "low stringent conditions" are, for example, 5xSSC, 5xDenbardt's solution, 0.5% SDS, 50% formamide at 32° C. The term "moderate stringent conditions" are, for example, 5×SSC, 5×Denhardt's solution, 0.5% SDS, 50% formamide at 42° C., or 5xSSC, 1% SDS, 50 mM Tris-HCl (pH 7.5), 50% formamide at 42° C. The term "high stringent conditions" are, for example, 5xSSC, 5xDenhardt's solution, 0.5% SDS, 50% formamide at 50° C. or 0.2×SSC, 0.1% SDS at 65° C. Under these conditions, polymedeotides with higher homology are expected to be obtained efficiently at higher temperatures, although multiple factors are involved in hybridization stringency including temperature, probe concentration, probe length, ionic strength, time, salt concentration and others, and those skilled in the art may appropriately select these factors to achieve similar stringency.

When commercially available kits are used for hybridization, for example, an Alkphos Direct Labeling and Detection System (GE Healthcare) may be used. In this case, according to the attached protocol, after cultivation with a labeled probe overnight, the membrane is washed with a primary wash buffer containing 0.1% (w/v) SDS at 55° C.,

thereby detecting hybridized polynucleotides. Alternatively, in producing a probe based on the entire or part of the nucleotide sequence complementary to the nucleotide sequence of SPQ ID NO: 1, hybridization can be detected with a DIG Nucleic Acid Detection Kit (Roche Diagnostics) when the probe is labeled with digoxigenin (DIG) using a commercially available reagest (e.g., a PCR Labeling Mix (Roche Diagnostics), etc.).

In addition to the polynucleotides described above, other polynucleotides that can be hybridized include polynucleotides having 90% or higher, 91% or higher, 92% or higher, 93% or higher, 94% or higher, 95% or higher, 95% or higher, 96% or higher, 98% or higher, 99.4% or higher, 99.2% or higher, 99.2% or higher, 99.2% or higher, 99.5% or higher, 99.6% or higher, 99.6% or higher, 99.6% or higher, 99.8% or higher or 99.9% or higher identity with the polynucleotide of SEQ ID NO: 1, as calculated by homology search software BLAST using the default parameters.

The identity between nucleotide sequences may be determined using algorithm BLAST (Busic Local Alignment Search Tool) by Karlin and Altschul (Proc. Natl. Acad. Sci. USA 872264-2268, 1990; Proc. Natl. Acad. Sci. USA 90: 5873, 1993). Programs called BLASTN and BLASTX based on the BLAST algorithm have been developed (Altschul S. F., et al. J. Mol. Biol. 215: 403, 1990). When a nucleotide sequence is sequenced using BLASTN, the parameters are, for example, score=100 and wordlength=12. When BLAST and Gapped BLAST programs are used, the default parameters for each program are employed.

Examples of the nucleotide sequences complementary to the sequences consisting of the 31 st to the 53rd, the 31 st to the 55th, the 31 st to the 55th, the 31 st to the 55th, the 31st to the 55th, the 32nd to the 53rd, the 32nd to the 54th, the 32nd to the 55th, the 33rd to the 55th, the 34th to the 55th, the 35th to the 55th, the 35th to the 56th, the 35th to the 57th, the 35th to the 56th, the 36th to the 57th, the 36th to the 56th, the 36th to the 57th and the 36th to the 58th nucleotides, from the 5' end of exon 53.

TARTE 1

Target sequence in exem 53	Complementary nucleotide sequence	SEQ	ID	80:	
31-53	s'-ccoortctgaacstcttcttsta-1*	SRQ	ID	NO:	2
31-84	5'-TCCOSTTCTGAAGGTGTTCTTGTA-3'	SEQ	m	3\$D :	3
31-55	5'-CTCCGCTCTCTGAACGTGTTCTTCTA-3'	SEQ	10	NO.	3
31-56	5'-CCTCDDCTTCTNAACCTGTTCTTGTA-3'	SEQ	10	290 s	5
32-57	3 GCCLCGGGCTCLGVYGQLQLTCLLQ1V-7.	GHR	TD	NO:	ê
31 > 50	5'-FGCCTCCGGTTCTGAAGGTGTTCTTGEA-)'	SRQ	m	MD:	3
32-53	S'-CCERTTCTGAAGGTGTTCTTGT-3'	SEQ	ID	NO:	0
)2-54	5'~TCCCTTTCTGAAGGTUTTCTTCT-3*	SEQ	10	NO:	9
32-55	51-CTCCCCTCTGAAGGTGFTCTTDF-31	SEQ	to	NO:	10
32-56	5 COLOXBOTTOTGAAGGTGT7CT7DT-3	SEQ	ID	NO:	11
12-57	5'-GCCTCCCCTTCTCAACGTETTCTTGT-3'	SEQ	1D	NO:	12

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

10

Target sequence b exon 50	in Complementary nucleotide sequence	SEQ	10	NO:	
12-58	s'-receveegertergaaggrefferfgr-3'	SEQ	ID	нō:	13
33-53	S) COMPTCIGAAGGTGTTCTTG-3'	SEQ	ID	no:	14
33-54	5'-TCCGSTTCTGAAGGTGTTGTTG-3'	SEQ	10	NO:	15
33-55	5'-CTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	16
33-56	5'-CCFCCCCTTCTGAACGTGTTCTTG-3'	SEQ	ID	NO:	3.7
33-57	5*-GCCCCCCTCCCGAAOGTGTTCTTG-3'	SEQ	ID	NO:	10
33-58	5'-TOCCTCCGGTTCTGAAGGTGTTCTTG-3'	SEQ	ID	NO:	19
34-63	5ccggttctgaaggtgttctt-3'	SEQ	ID	210:	20
34-54	5°TCOUTTCTGAAGGTGTTCTT-3'	SEQ	ID	No:	21
34-55	5*-CTCCGGTTCTGAAGGTGTTCTT-3*	SEQ	ID	NO	22
34-56	5'-CCTCCGGTTCTGAACXTGTTCTT-3'	SEO	10	No:	23
34-57	5'-GCCTCCGGTTCTGAAGGTGTTCTT-3'	530	11)	no:	24
34-58	5'-TOCCTCCGGTTCTGAAGGTGTTCTT-3'	SEQ	10	NO:	25
35-53	5COGGITCIGAAGGTGFTCT .3	SEQ	10	NO:	26
35-54	51-7CCGGTTCTGAAGGTGTTET-31	SEQ	10	NO:	27
35-55	5'-CTCCGGTTCT@AAGGTGTTCT-)'	SEQ	ID	NO:	28
35-56	s'-corcocurreromosterer-3'	SEQ	ID	NO:	29
35-53	5'-dectcocgf7cTdAAggTgTfcT-3'	SEQ	10	NO:	30
35-58	S.IGCCICEGGTTCTGWWGGLGTIEI*3.	SEQ	IĎ	No:	91
36-53	5'-COMGTTCTGAACGTGTTC-3'	SEQ	TD	NO:	32
36-54	5'-7CCGGTTCTGAACGTGTTC-3'	SEQ	TD	NO:	33
36-55	51-CTCCGGTTCTGAAOGTGTTC-31	SEQ	113	NO:	34
36-56	5'-COTCORGETCTCGAAGGTGTTG-3'	SEQ	ID	MO:	35
36-57	5'-GCCTCCCGTTCTGAAGGTGTTC-3'	SEQ	ID	NO:	36
36-58	5'-TGCCTCCGGTTCTGAAGGTGTTC-3'	SEO	TD	NO:	37

It is preferred that the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th, the 33rd to the 56th, the 34th to the 56th, the 35th to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 29 or SEQ ID NO: dystrophin gene.

Preferably, the oligomer of the present invention consists of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides (e.g., SEQ ID NO: 11 or SEQ ID NO: 60 target sequence. 35), from the 5' end of the 53rd exen in the human dystrophin gene.

The term "cause skipping of the 53rd exon in the human dystrophin gene" is intended to mean that by binding of the oligomer of the present invention to the site corresponding 65 to exon 53 of the transcript (e.g., pre-mRNA) of the human dystrophin gene, for example, the nucleotidé sequence cor-

responding to the 5' end of exon 54 is spliced at the 3' side of the nucleotide sequence corresponding to the 3' end of exon 51 in DMD patients with deletion of, exon 52 when the transcript undergoes splicing, thus resulting in formation of mature mRNA which is free of codon frame shift.

Accordingly, it is not required for the oligomer of the 35), from the 5' end of the 53rd exon in the human 55 present invention to have a nucleotide sequence 100% complementary to the target sequence, as far as it causes exon 53 skipping in the human dystrophin gene. The oligomer of the present invention may include, for example, 1 to 3, 1 or 2, or one nucleotide non-complementary to the

Herein, the term "binding" described above is intended to mean that when the oligomer of the present invention is mixed with the transcript of human dystrophin gene, both are hybridized uzder physiological conditions to form a double strand nucleic acid. The term "under physiological conditions" refers to conditions set to mimic the in vivo environment in terms of pH, salt composition and temperature. The conditions are, for example, 25 to 40° C., preferably 37° C., pH 5 to 8, preferably pH 7.4 and 150 mM of sodium chloride concentration.

Whether the skipping of exon 53 in the human dystrophin gene is caused or not can be confirmed by introducing the oligomer of the present invention into a dystrophin expression cell (e.g., human rhabdomyosarcoma cells), amplifying the region surrounding exon 53 of mRNA of the human dystrophin gene from the total RNA of the dystrophin expression cell by RT-PCR and performing nested PCR or sequence analysis on the PCR amplified product.

The skipping efficiency can be determined as follows. The mRNA for the human dystrophin gene is collected from test cells; in the mRNA, the polyaneleotide level "A" of the hand where exon 53 is skipped and the polyaneleotide level "B" of the band where exon 53 is not skipped are measured. Using these measurement values of "A" and "B," the efficiency is calculated by the following equation:

Skipping efficiency (%)=A/(A+B)×100

The oligomer of the present invention includes, for example, an eligonucleotide, morpholino oligomer or peptide nucleic acid (PNA), having a length of 18 to 28 nucleotides. The length is preferably from 21 to 25 nucleotides and morpholino oligomers are preferred.

The oligonucleotide described above (hereinafter referred to as "the oligonucleotide of the present invention") is the oligomer of the present invention composed of nucleotides as constituent units. Such nucleotides may be any of ribonucleotides, deoxyribonucleotides and modified nucleotides.

The modified nucleotide refers to one having fully or partly modified nucleobases, sugar moieties and/or phosphate-binding regions, which constitute the ribonucleotide 35 or deoxyribonucleotide.

The nucleobase includes, for example, adenine, guanine, hypoxanthine, cytosine, thymine, uracil, and modified bases thereof. Examples of such modified nucleobases include, but not limited to, pseudouracil, 3-methyluracil, dihydrouracil, 40 5-alkyleytosines (e.g., 5-methyleytosine), 5-alkyluracils (e.g., 5-ethyluracil), 5-halouracils (5-bromouracil), 6-azapyrimidine, 6-alkylpyrimidinės (6-methyluracil), 2-thiouracil, 4-thiouracil, 4-acetylcytesine, 5-(carboxyhydroxymethyl) uracil, 5'-carboxymethylaminomethyl-2-thiouracil, 5-car- 45 boxymethylaminomethylaracil, 1-methyladenine, 1-methylhypoxanthine, 2,2-dimethylguanine, 3-methylcytosine, 2-methyladenine, 2-methylguanine, N6-methyladenine, 7-methylguanine, 5-methoxyaminomethyl-2-thiouracil, 5-methylaminomethyluracil, 5-methylcarbonylmethylura- 50 cil, 5-methyloxyuracil, 5-methyl-2-thiouracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid, 2-thiocytosine, purine, 2,6-diaminopurine, 2-aminopurine, isoguanine, indole, imidazole, xanthine, etc.

Modification of the sugar moiety may include, for 53 example, modifications at the 2'-position of ribose and modifications of the other positions of the sugar. The modification at the 2'-position of ribose includes replacement of the 2'-OH of ribose with OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, CI, Br or I, wherein R represents an alkyl 60 or an arryl and R' represents an alkylene.

The modification for the other positions of the sugar includes, for example, replacement of O at the 4' position of ribose or deoxyribose with S, bridging between 2' and 4' positions of the sugar, e.g., LNA (locked nucleic acid) or 65 ENA (2'-O,4'-C-ethylene-bridged nucleic acids), but is not limited thereto.

12

A modification of the phosphate-binding region includes, for example, a modification of replacing phosphodiester bond with phosphoruthicate bond, phosphorodithicate bond, alkyl phosphonate bond, phosphoroamidate bond or boranophosphate bond (Enya et al: Bicorganic & Medicinal Chemistry, 2008, 18, 9154-9160) (cf. e.g., Japan Domestic Re-Publications of PCT Application Nos. 2006/129594 and 2006/038603).

The alkyl is preferably a straight or branched alkyl having 1 to 6 carbon atoms. Specific examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, see-butyl, tertbutyl, n-pentyl, isopentyl, neopentyl, tert-pentyl, n-fiexyl and isohexyl. The alkyl may optionally be substituted. Examples of such substituents are a halogen, an alkoxy, eyano and nitro. The alkyl may be substituted with 1 to 3 substituents.

The cycloalkyl is preferably a cycloalkyl having 5 to 12 carbon atoms. Specific examples include cyclopentyl, cyclohexyl, cycloheptyl, cyclocotyl, cyclodecyl and cyclodedecyl.

The halogen includes fluorine, chlorine, bromine and indine.

The alkoxy is a straight or branched alkoxy having 1 to 6 carbon atoms such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n-pentyloxy, isopentyloxy, n-hexyloxy, isobexyloxy, etc. Among others, an alkoxy having 1 to 3 carbon atoms is preferred.

The aryl is preferably an aryl having 6 to 10 carbon atoms. Specific examples include phenyl, α -naphlhyl and β -naphthyl. Among others, phenyl is preferred. The aryl may optionally be substituted. Examples of such substitutents are an alkyl, a halogen, an alkoxy, cyano and nitro. The aryl may be substituted with one to three of such substituents.

The alkylene is preferably a straight or branched alkylene having 1 to 6 carbon atoms. Specific examples include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, 2-(ethyl)trimethylene and 1-(methyl)tetramethylene.

The acyl includes a straight or branched alkanoyl or aroyl. Examples of the alkanoyl include formyl, acetyl, 2-methylacetyl, 2.2-dimethylacetyl, propionyl, butyryl, isobutyryl, pentanoyl, 2,2-dimethylpropionyl, hexanoyl, etc. Examples of the aroyl include benzoyl, toluoyl and naphthoyl. The aroyl may optionally be substituted at substitutable positions and may be substituted with an alkyl(s).

Preferably, the oligonucleotide of the present invention is the oligomer of the present invention containing a constituent unit represented by general formula below wherein the —OH group at position 2' of ribose is substituted with methoxy and the phosphate-binding region is a phosphorothioate bond:

wherein Base represents a nucleobase

13

The oligonucleotide of the present invention may be easily synthesized using various automated synthesizer (e.g., AKTA oligopilot plus 10/100 (GE Healthcare)). Alternatively, the synthesis may also be entrusted to a third-party organization (e.g., Promega Inc., or Takara Co.), etc.

The morpholino oligomer of the present invention is the oligomer of the present invention comprising the constituent unit represented by general formula below:

wherein Base has the same significance as defined above, and.

W represents a group shown by any one of the following groups:

wherein

X represents $-CH_2R^3$, $-O-CH_2R^3$, $-S-CH_2R^3$, $-NR_2R^3$ or F;

R¹ represents H or an alkyl;

R² and R², which may be the same or different, each represents H, an alkyl, a cycloalkyl or an aryl,

Y1 represents O, S, CH2 or NR1;

Y2 represents O, S or NR1;

Z represents O or S.

Preferably, the morpholino oligomer is an oligomer comprising a constituent unit represented by general formula below (phospherodiamidate morpholino oligomer (hereinufter referred to as "PMO")).

wherein Base, R2 and R3 have the same significance as defined above.

The morpholino oligomer may be produced in accordance with, e.g., WO 1991/009033 or WO 2009/064471. In particular, PMO can be produced by the procedure described 65 in WO 2009/064471 or produced by the process shown below.

14

[Method for Producing PMO]

An embodiment of PMO is, for example, the compound represented by general formula (I) below (hereinafter PMO (I)).

25 wherein

Base, R^2 and R^3 have the same significance as defined above; and,

n is a given integer of 1 to 99, preferably a given integer of 18 to 28.

PMO (I) can be produced in accordance with a known method, for example, can be produced by performing the procedures in the following steps.

The compounds and reagents used in the steps below are not particularly limited so long as they are commonly used to prepare PMO.

Also, the following steps can all be carried out by the liquid phase method or the solid phase method (using manuals or commercially available solid phase automated synthesizers). In producing PMO by the solid phase method, it is desired to use automated synthesizers in view of simple operation procedures and accurate synthesis.

(1) Step A:


The compound represented by general formula (II) below (hereinafter referred to as Compound (II)) is reacted with an acid to prepare the compound represented by general formula (III) below (hereinafter referred to as Compound (III)):

wherein n, R2 and R3 have the same significance as defined

each BP independently represents a nucleobase which may 20 with an acid. optionally be protected;

T represents trityl, monomethoxytrityl or dimethoxytrityl;

L represents hydrogen, an acyl or a group represented by general formula (TV) below (hereinafter referred to as group (IV)).



The "nucleobase" for B^P includes the same "nucleobase" as in Base, provided that the amino or hydroxy group in the nucleobase shown by $B^{\prime\prime}$ may be protected.

Such protective group for amino is not particularly limited so long as it is used as a protective group for nucleic acids. Specific examples include benzoyl, 4-methoxybenzoyl, acetyl, propionyl, butyryl, isobutyryl, phenylacetyl, phenoxyacetyl, 4-tert-butylphenoxyacetyl, 4-isopropylphe- 40 and (dimethylamino)methylene. Specific noxyacety! examples of the protective group for the hydroxy group include 2-cyanoethyl, 4-mtrophenethyl, phenylsulfonylethyl, methylsulfonylethyl and trimethylsilylethyl, and phenyl, which may be substituted by 1 to 5 electron-withdraw- 45 group at optional substitutable diphenylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, methylphenylcarbamoyl, 1-pyrolidinylcarbamoyl, morpholinocarbamoyl, 4-(tert-butylcarboxy)benzyl, 4-[(dimethylamino)carboxylbenzyl and 4-(phenylcarboxy)benzyl, (cf., 50 preferably, in a range of 25° C. to 35° C. e.g., WO 2009/064471).

The "solid carrier" is not particularly limited so long as it is a carrier usable for the solid phase reaction of nucleic acids. It is desired for the solid carrier to have the following properties: e.g., (i) it is sparingly soluble in reagents that can 55 be used for the synthesis of morpholino nucleic acid derivatives (e.g., dichloromethane, acetonitrile, tetrazole, N-methylimidazole, pyridine, acetic anhydride, lutidine, trifluoroacetic acid); (ii) it is chemically stable to the reagents usable for the synthesis of morpholino nucleic acid derivatives; (iii) 60 it can be chemically modified; (iv) it can be charged with desired morpholino nucleic acid derivatives; (v) it has a strength sufficient to withstand high pressure through treatments; and (vi) it has a uniform particle diameter range and distribution. Specifically, swellable polystyrene (e.g., amin- 65 omethyl polystyrene resin 1% dibenzylbenzene crosslinked (200-400 mesh) (2.4-3.0 mmol/g) (manufactured by Tokyo

16

Industry), Aminomethylated Polystyrene Chemical Resin FCI [dibenzylbenzene 1%, 100-200 mesh] (manufactured by Peptide Institute, Inc.)), non-swellable polystyrene (e.g., Primer Support (manufactured by GE Healthcare)), PEG chain-attached polystyrene (e.g., NH2-PEG resin (manufactured by Watanabe Chemical Co.), TentaGel resin), controlled pore glass (controlled pere glass; CPG) (manufactured by, e.g., CPG), exalyl-controlled pore glass (cf., e.g., Alul et al., Nucleic Acids Research, Vol. 19, 1527 (1991)), TentaGel support-aminopolyethylene glycol-derivatized support (e.g., Wright et al., cf., Tetrahedron Letters, Vol. 34, 3373 (1993)), and a copolymer of Poros-polystyrene/diviny/benzene.

A "linker" which can be used is a known linker generally used to connect nucleic acids or morpholino nucleic acid derivatives. Examples include 3-aminopropyl, succinyl, 2,2'-diethanolsulfonyl and a long chain alkyl amino (LCAA).

This step can be performed by reacting Compound (11)

The "acid" which can be used in this step includes, for example, trifluoroacetic acid, dichloroacetic acid and trichloroacetic acid. The acid used is appropriately in a range of, for example, 0.1 mol equivalent to 1000 mol equivalents based on 1 mol of Compound (II), preferably in a range of 1 mol equivalent to 100 mol equivalents based on 1 mol of Compound (II)

An organic amine can be used in combination with the acid described above. The organic amine is not particularly (IV) 30 limited and includes, for example, triethylamine. The amount of the organic amine used is appropriately in a range of, e.g., 0.01 mol equivalent to 10 mol equivalents, and preferably in a range of 0.1 mol equivalent to 2 mol equivalents, based on 1 mol of the acid.

When a salt or mixture of the acid and the organic amine is used in this step, the salt or mixture includes, for example, a salt or mixture of trifluoroacetic acid and triethylamine, and more specifically, a mixture of 1 equivalent of triethylamine and 2 equivalents of trifluoroscetic acid.

The acid which can be used in this step may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, dichlosomethane, acetonitrife, an alcohol (ethanol, isopropanol, trifluoroethanel, etc.), water, or a mixture thereof.

The reaction temperature in the reaction described above is preferably in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C. to 40° C., and most

The reaction time may vary depending upon kind of the acid used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

After completion of this step, a base may be added, if necessary, to neutralize the acid remained in the system. The "hase" is not particularly limited and includes, for example, diisopropylamine. The base may also be used in the form of a dilution with an appropriate solvent in a concentration of 0.1% (v/v) to 30% (v/v).

The solvent used in this step is not particularly limited so long as it is inert to the reaction, and includes dichloromethane, acetonitrile, an alcohol (ethanol, isopropanol, triffuoroethanol, etc.), water, and a mixture thereof. The reaction temperature is prefembly in a range of, e.g., 10° C. to 50° C., more preferably, in a range of 20° C, to 40° C, and most preferably, in a range of 25° C, to 35° C.


US 9,708,361 B2

30

17

The reaction time may vary depending upon kind of the base used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

In Compound (II), the compound of general formula (IIa) 5 below (hereinafter Compound (IIa)), wherein n is 1 and L is a group (IV), can be produced by the following procedure.



wherein B^F, T, linker and solid carrier have the same ²⁰ significance as defined above.

Step 1

The compound represented by general formula (V) below 25 is reacted with an acylating agent to prepare the compound represented by general formula (VI) below (hereinafter referred to as Compound (VI)).

$$(V) \begin{picture}(100,0) \put(0,0){\line(1,0){100}} \put(0,0){\line(1,0$$

wherein B^P , T and linker have the same significance as defined above; and,

R4 represents hydroxy, a halogen or amino.

This step can be carried out by known procedures for 45 introducing linkers, using Compound (V) as the starting material.

In particular, the compound represented by general formula (VIa) below can be produced by performing the method known as esterification, using Compound (V) and 50 succinic anhydride.

wherein \mathbf{B}^P and T have the same significance as defined above.

18 Step 2

Compound (VI) is reacted with a solid career by a condensing agent to prepare Compound (IIa).

wherein B^P , R^4 , T, linker and solid carrier have the same significance as defined above.

This step can be performed using Compound (VI) and a solid carrier in accordance with a process known as condensation reaction.

In Compound (II), the compound represented by general formula (IIa2) below wherein n is 2 to 99 and L is a group represented by general formula (IV) can be produced by using Compound (IIa) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

wherein B^{F} , R^{2} , R^{3} , T, linker and solid carrier have the same significance as defined above; and,

n' represents 1 to 98.

In Compound (II), the compound of general formula (IIb) below wherein a is 1 and L is hydrogen can be produced by the procedure described in, e.g., WO 1991/009033.

US 9,708,361 B2

19

wherein B^P and T have the same significance as defined above.

In Compound (II), the compound represented by general formula (IIb2) below wherein n is 2 to 99 and L is hydrogen 15 can be produced by using Compound (IIb) as the starting material and repeating step A and step B of the PMO production method described in the specification for a desired number of times.

wherein B^P , n', R^2 , R^3 and T have the same significance as defined above.

In Compound (II), the compound represented by general formula (IIc) below wherein n is 1 and L is an acyl can be produced by performing the procedure known as acylation reaction, using Compound (IIb).

wherein B^F and T have the same significance as defined above; and,

R5 represents an acyl.

In Compound (II), the compound represented by general formula (IIc2) below wherein n is 2 to 99 and L is an acyl can be produced by using Compound (IIc) as the starting material and repeating step A and step B of the PMO 65 production method described in the specification for a desired number of times.

20

wherein B^P , n', R^2 , R^3 , R^3 and T have the same significance as defined above.

(2) Step B

(IIh2)

Compound (III) is reacted with a morpholino monomer compound in the presence of a base to prepare the compound represented by general formula (VII) below (hereinafter referred to as Compound (VII)):

$$L = 0$$

$$R^{2}$$

$$R^{2}$$

$$R^{3}$$

$$R^{3}$$

$$R^{3}$$

$$R^{4}$$

$$R^{3}$$

$$R^{4}$$

$$R^{5}$$

$$R^{5$$

wherein B^P , L, n, R^2 , R^3 and T have the same significance as defined above.

21

This step can be performed by reacting Compound (III) with the morpholino monomer compound in the presence of a base.

The morpholino monomer compound includes, for example, compounds represented by general formula (VIII) below:

wherein B^P, R², R³ and T have the same significance as defined above.

The "base" which can be used in this step includes, for example, disopropylamine, tricthylamine and N-ethylmorpholine. The amount of the base used is appropriately in a range of 1 mel equivalent to 1000 mol equivalents based on 1 mel of Compound (III), preferably, 10 mol equivalents to 100 mol equivalents based on 1 mol of Compound (III).

The morpholino mononter compound and base which can 36 be used in this step may also be used as a dilution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, N,N-dimethylimidazolidose, N-methylpiperidone, DMF, dichloromethane, acetoni-35 trile, tetrahydrofuran, or a mixture thereof.

The reaction temperature is preferably in a range of, e.g., 0° C. to 100° C., and more preferably, in a range of 10° C. to 50° C.

The reaction time may vary depending upon kind of the 40 base used and reaction temperature, and is appropriately in a range of 1 minute to 48 hours in general, and preferably in a range of 30 minutes to 24 hours.

Furthermore, after completion of this step, an acylating agent can be added, if necessary. The "acylating agent" includes, for example, acetic anhydride, acetyl chloride and phenoxyacetic anhydride. The acylating agent may also be used as a difution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly limited as far as it is inert to the reaction, and includes, for example, dichloromethane, acetonitrile, an alcohol(s) (ethanol, isopropanol, trifluoroethanol, etc.), water, or a mixture this step may also be used and, isopropanol, trifluoroethanol, etc.), water, or a mixture this step may also be used and includes the step may also be used as a difution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly with a deprotecting agent with a deprotecting agent may also be used as a difution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly the deprotecting agent may also be used as a difution with an appropriate solvent in a concentration of 0.1% to 30%. The solvent is not particularly the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agent may also be used to accompany the deprotecting agen

If necessary, a base such as pyridine, butidine, collidine, triethylamine, diisopropylethylamine, N-ethylmurpholine, 55 etc. may also be used in combination with the acylating agent. The amount of the acylating agent is appropriately in a range of 0.1 mol equivalent to 10000 mol equivalents, and preferably in a range of 1 mol equivalent to 1000 mol equivalents. The amount of the base is appropriately in a 60 range of, e.g., 0.1 mol equivalent to 100 mol equivalents, and preferably in a range of 1 mol equivalent to 10 mol equivalents, based on 1 mol of the acylating agent.

The reaction temperature in this reaction is preferably in a range of 10° C. to 50° C., more preferably, in a range of 65 10° C. to 50° C., much more preferably, in a range of 20° C. to 40° C., and most preferably, in a range of 25° C. to 35°

22

C. The reaction time may vary depending upon kind of the acylating agent used and reaction temperature, and is appropriately in a range of 0.1 minute to 24 hours in general, and preferably in a range of 1 minute to 5 hours.

(3) Step C:

In Compound (VII) produced in Step B, the protective group is removed using a deprotecting agent to prepare the compound represented by general formula (IX).

wherein Base, B^F , $n_c R^2$, R^3 and T have the same significance as defined above.

This step can be performed by reacting Compound (VII) with a deprotecting agent.

The "deprotecting agent" includes, e.g., conc. ammonia water and methylamine. The "deprotecting agent" used in this step may also be used as a dilution with, e.g., water, methanol, ethanol, isopropyl alcohol, acetonitrile, tetrahydrofuran, DMF, N,N-dimethylimidazolidoue, N-methylpiperidone, or a mixture of these solvents. Among others, ethanol is preferred. The amount of the deprotecting agent used is appropriately in a range of, e.g., 1 mal equivalent to 100000 mol equivalents, and preferably in a range of 10 mol equivalents to 1000 mol equivalents, based on 1 mol of Compound (VII).

The reaction temperature is appropriately in a range of 15° C. to 75° C., preferably, in a range of 40° C. to 70° C., and more preferably, in a range of 50° C. to 60° C. The reaction time for deprotection may vary depending upon kind of Compound (VII), reaction temperature, etc., and is appropriately in a range of 10 minutes to 30 hours, preferably 30 minutes to 24 hours, and more preferably in a range of 5 hours to 20 hours.

(4) Step D:
PMO (I) is produced by reacting Compound (IX) produced in step C with an acid:

wherein Base, n, R², R³ and T have the same significance as defined above. This step can be performed by adding an acid to Compound (IX).

The "acid" which can be used in this step includes, for example, trichloroacetic acid, dichloroacetic acid, acetic acid, phosphoric acid, hydrochloric acid, etc. The acid used is appropriately used to allow the solution to have a pH range of 0.1 to 4.0, and more preferably, in a range of pHI 1.0 to 3.0. The solvent is not particularly limited so long as it is inert to the reaction, and includes, for example, acetonitrile, water, or a mixture of these solvents thereof.

The reaction temperature is appropriately in a range of ⁴⁵ 10° C, to 50° C, preferably, in a range of 20° C to 40° C, and more preferably, in a range of 25° C to 35° C. The reaction time for deprotection may vary depending upon kind of Compound (IX), reaction temperature, etc., and is appropriately in a range of 0.1 minute to 5 hours, preferably 50 1 minute to 1 hour, and more preferably in a range of 1 minute to 30 minutes.

PMO (I) can be obtained by subjecting the reaction mixture obtained in this step to conventional means of separation and purification such as extraction, concentration, 55 neutralization, filtration, centrifugal separation recrystallization, reversed phase column chromatography anion exchange column chromatography, anion exchange column chromatography, anion exchange column chromatography, bigh performance liquid chromatography, dialysis, 60 ultrafiltration, etc., alone or in combination thereof. Thus, the desired PMO (I) can be isolated and purified (cf., e.g., WO 1991/09033).

In purification of PMO (I) using reversed phase chromatography, e.g., a solution mixture of 20 mM tricthylamine/ 65 acetate buffer and acctonitrile can be used as an elution solvent. 24

In purification of PMO (I) using ion exchange chromatography, e.g., a solution mixture of 1 M saline solution and 10 mM sodium hydroxide aqueous solution can be used as an elution solvent.

A peptide nucleic acid is the oligomer of the present invention having a group represented by the following general formula as the constituent unit:

wherein Base has the same significance as defined above. Peptide nucleic acids can be prepared by referring to, e.g., the following literatures.

P. E. Nielsen, M. Egholm, R. H. Berg, O. Buchardt,
 Science, 254, 1497 (1991)

 M. Egholm, O. Buchardt, P. E. Nielsen, R. H. Berg, Jacs., 114, 1895 (1992)

 K. L. Ducholma, M. Egholm, C. Behrens, L. Christensen, H. F. Hansen, T. Vulpius, K. H. Petersen, R. H. Berg, P. E. Nielsen, O. Buchardt, J. Org. Chem., 59, 5767 (1994)

 L. Christensen, R. Fitzpatrick, B. Gildea, K. H. Petersen, H. F. Hansen, T. Koch, M. Egholm, O. Buchardt, P. E. Nielsen, J. Coull, R. H. Berg, J. Pept. Sci., 1, 175 (1995)
 T. Koch, H. F. Hansen, P. Andersen, T. Larsen, H. G. Batz,

K. Otteson, H. Orum, J. Pept. Res., 49, 80 (1997)

In the oligomer of the present invention, the 5' end may be any of chemical structures (1) to (3) below, and preferably is (3)-OH.

Hereinafter, the groups shown by (1), (2) and (3) above are referred to as "Group (1)," "Group (2)" and "Group (3)," respectively.

2. Pharmaceutical Composition

The oligomer of the present invention causes exon 53 skipping with a higher efficiency as compared to the prior art

26

antisense oligomers. It is thus expected that conditions of muscular dystruphy can be relieved with high efficience by administering the pharmaceutical composition comprising the oligomer of the present invention to DMD patients. For example, when the pharmaceutical composition comprising the eligomer of the present invention is used, the same therapeutic effects can be achieved even in a smaller dose than that of the oligomers of the prior art. Accordingly, side effects can be alleviated and such is economical.

In another embodiment, the present invention provides to the pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the oligomer of the present invention, a pharmaceutically acceptable salt or hydrate thereof (hereinafter referred to as "the composition of the present invention").

Examples of the pharmaceutically acceptable salt of the oligomer of the present invention contained in the composition of the present invention are alkali metal salts such as salts of sodium, potassium and lithium; alkaline earth metal salts such as salts of calcium and magnesium; metal salts such as salts of aluminum, iron, zinc, copper, nickel, cobalt, etc.; ammonium salts; organic amine salts such as salts of t-octylamine, dibenzylamine, morpholine, glucosamine, phenylglycine alkyl ester, ethylenediamine, N-methylglucamine, quanidine, diethylamine, triethylamine, dicyclohex-ylamine, N,N-dibenzylethylenediamine, chloroprocaine, ²⁵ procaine, diethanolamine, N-benzylphenethylamine, piperazine, tetramethylammonium, tris(hydroxymethyl)amin-omethane; hydrehalide salts such as salts of hydrofluorates, hydrochlorides, hydrobromides and hydroiodides; inorganic acid salts such as nitrates, perchlorates, sulfates, phosphates, 30 etc.; lower alkane sulfonates such as methanesulfonates, trifluoromethanesulfonates and ethanesulfonates; arylsulfonates such as benzenesulfonates and p-toluenesulfonates; organic acid salts such as acetates, malates, fumarates, succinates, eitrates, tartarates, oxalates, maleates, etc.; and, 35 amino acid salts such as salts of glycine, lysine, arginine, ornithme, glutamic acid and aspartic acid. These salts may be produced by known methods. Alternatively, the oligomer of the present invention contained in the composition of the present invention may be in the form of a hydrate thereof.

Administration route for the composition of the present invention is not particularly limited so long as it is pharmaceutically acceptable route for administration, and can be chosen depending upon method of treatment. In view of easiness in delivery to muscle tissues, preferred are intravenous administration, intraarterial administration, intramuscular administration, subcutaneous administration, oral administration, tissue administration, transdermal administration, etc. Also, desage forms which are available for the composition of the present invention are not particularly limited, and include, for example, various injections, oral 50 agents, drips, inhalations, ointments, lotions, etc.

In administration of the oligomer of the present invention to patients with muscular dystrophy, the composition of the present invention preferably contains a carrier to promote delivery of the oligomer to muscle tissues. Such a carrier is not particularly limited as far as it is pharmaceutically acceptable, and examples include cationic carriers such as cationic liposomes, cationic polymers, etc., or carriers using viral envelope. The cationic liposomes are, for example, liposomes composed of 2-O-(2-diethylaminoethyl)carabamcyl-1,3-O-dioleoylglycerol and phospholipids as the essential constituents (hereinafter referred to as "liposome A"), Oligofectamine (registered trademark) (manufactured by Invitragen Corp.), Lipofectin (registered trademark) (manufactured by Invitrogen Corp.), Lipofectamine (registered trademark) (manufactured by Invitrogen Corp.), Lipo-65 fectamine 2000 (registered trademark) (manufactured by Invitrogen Corp.), DMRIE-C (registered trademark) (manu-

factured by Invitrogen Corp.), GeneSilencer (registered trademark) (manufactured by Gene Therapy Systems), TransMessenger (registered trademark) (manufactured by QLAGEN, Inc.), TransIT TKO (registered trademark) (manufactured by Mirus) and Nucleofector II (Lonza). Among others, liposome A is preferred. Examples of cationic polymers are JetSI (registered trademark) (manufactured by Qbiogene, Inc.) and Jet-PBI (registered trademark) (polyethylenimine, manufactured by Qbiogene, Inc.). An example of carriers using viral envelop is GenomeOne (registered trademark) (HVJ-E liposome, manufactured by Ishihara Sangyo). Alternatively, the medical devices described in Japanese Patent No. 2924179 and the cationic carriers described in Japanese Domestic Re-Publication PCT Nos. 2006/129594 and 2008/096690 may be used as well.

A concentration of the oligomer of the present invention contained in the composition of the present invention may vary depending on kind of the carrier, etc., and is appropriately in a range of 0.1 nM to 100 µM, preferably in a range of 1 nM to 10 µM, and more preferably in a range of 10 nM to 1 µM. A weight ratio of the oligomer of the present invention contained in the composition of the present invention and the carrier (carrier/oligomer of the present invention) may vary depending on property of the oligomer, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 10 to 20.

In addition to the oligomer of the present invention and the carrier described above, pharmaceutically acceptable additives may also be optionally formulated in the composition of the present invention. Examples of such additives are emulsification aids (e.g., fatty acids having 6 to 22 carbon atoms and their pharmaceutically acceptable salts, albumin and dextrain), stabilizers (e.g., cholesterol and phosphatidic acid), isotonizing agents (e.g., sodium chloride, glucose, maltose, lactose, sucrose, trehalose), and pH controlling agents (e.g., hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, sodium hydroxide, potassium hydroxide and triethanolamine). One or more of these additives can be used. The content of the additive in the composition of the present invention is appropriately 90 wt % or less, preferably 70 wt % or less and more preferably, 50 wt % or less.

The composition of the present invention can be prepared by adding the oligomer of the present invention to a carrier dispersion and adequately stirring the mixture. Additives may be added at an appropriate step either before or after addition of the oligomer of the present invention. An aqueous solvent that can be used in adding the oligomer of the present invention is not particularly limited as far as it is pharmaceutically acceptable, and examples are injectable water or injectable distilled water, electrolyte third such as physiological saline, etc., and sugar fluid such as glucose fluid, maltose fluid, etc. A person skilled in the art can appropriately choose conditions for pH and temperature for such matter.

The composition of the present invention may be prepared into, e.g., a liquid form and its lyophilized preparation. The lyophilized preparation can be prepared by lyophilizing the composition of the present invention in a liquid form in a conventional manner. The lyophilization can be performed, for example, by appropriately sterilizing the composition of the present invention in a liquid form, dispensing an aliquot into a vial container, performing preliminary freezing for 2 hours at conditions of about -40 to -20° C., performing a primary drying at 0 to 10° C. under reduced pressure, and then performing a secondary drying at about 15 to 25° C. under reduced pressure. In general, the lyophilized prepa-

ration of the composition of the present invention can be obtained by replacing the content of the vial with nitrogen

gas and eapping.

The lyophilized preparation of the composition of the present invention can be used in general upon reconstitution 5 by adding an optional suitable solution (reconstitution liquid) and redissolving the preparation. Such a reconstitution liquid includes injectable water, physiological saline and other infusion fluids. A volume of the reconstitution liquid may vary depending on the intended use, etc., is not particularly limited, and is suitably 0.5 to 2-fold greater than the volume prior to tyophilization or no more than 500 mL.

It is desired to control a dose of the composition of the present invention to be administered, by taking the following factors into account: the type and dosage form of the oligomer of the present invention contained; patients' conditions including age, body weight, etc.; administration route; and the characteristics and extent of the disease. A daily dose calculated as the amount of the oligomer of the present invention is generally in a range of 0.1 mg to 10 g/human, and preferably 1 mg to 1 g/human. This numerical 20 g/human, and preferably 1 mg to 1 g/human. This numerical 21 disease, administration route and target molecule. Therefore, a dose lower than the range may be sufficient in some occasion and conversely, a dose higher than the range may be required occasionally. The composition can be administered from once to several times daily or at intervals from one day to several days.

In still another embodiment of the composition of the present invention, there is provided a pharmaceutical composition comprising a vector capable of expressing the 30 oligonucleotide of the present invention and the carrier described above. Such an expression vector may be a vector capable of expressing a plurality of the oligonucleotides of the present invention. The compasition may be formulated with pharmaceutically acceptable additives as in the case with the composition of the present invention containing the oligomer of the present invention. A concentration of the expression vector contained in the composition may vary depending upon type of the career, etc., and is appropriately in a range of 0.1 pM to 100 µM, preferably in a range of 1 nM to $10\,\mu\text{M}$, and more preferably in a range of $10\,\text{nM}$ to $1\,\mu\text{M}$. A weight ratio of the expression vector contained in the composition and the carrier (carrier/expression vector) may vary depending on property of the expression vector, type of the carrier, etc., and is appropriately in a range of 0.1 to 100, preferably in a range of 1 to 50, and more preferably 4s in a range of 10 to 20. The content of the carrier contained in the composition is the same as in the case with the composition of the present invention containing the oligomer of the present invention, and a method for producing the same is also the same as in the case with the composition so of the present invention.

Hereinafter, the present invention will be described in more detail with reference to EXAMPLES and TEST EXAMPLES below, but is not deemed to be limited thereto.

EXAMPLES

[Reference Example 1] 4-{[(28,6R)-(4-amido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl] methoxy}-4-oxobutanoic acid laded onto aminomethyl polystyrene resin

Step 1: Production of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl] meth oxy}-4-oxobutanoic acid

Under argon atmosphere, 22.0 g of N-{1-((2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihy-

dropyrimidin-4-yl}benzamide and 7.04 g of 4-dimethylaminopyridine (4-DMAP) were suspended in 269 mL of dichloromethane, and 5.76 g of succinic anhydride was added to the suspension, followed by stirring at room temperature for 3 hours. To the reaction solution was added

40 mL of methanol, and the mixture was concentrated under reduced pressure. The residue was extracted using ethyl acetate and 0.5M aqueous potassium dihydrogenphosphate solution. The resulting organic layer was washed sequentially with 0.5M aqueous potassium dihydrogenphosphate solution, water and brine in the order mentioned. The resulting organic layer was dried over sodium sulfate and concentrated under reduced pressure to give 25.9 g of the

product.

Step 2: Production of 4-{[(2S,6R)-6-(4-beazamido-2-oxopyrimidin-1-yl)-4-tritylmorpholin-2-yl] methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

After 23.5 g of 4-{[(2S,6R)-6-(4-benzamido-2-oxopyrimidin-1(2H)-yl)-4-tritylmorpholin-2-yl]methoxy}-4oxobutanoic acid was dissolved in 336 mL of pyridine (dehydrated), 4.28 g of 4-DMAP and 40.3 g of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to the solution. Then, 25.0 g of Aminomethyl Polystyrene Resin cross-linked with 1% DVB (manufactured by Tokyo Chemical Industry Co., Ltd., A1543) and 24 mL of triethylamine were added to the mixture, followed by shaking at room temperature for 4 days. After completion of the reaction, the resin was taken out by filtration. The resulting resin was washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure. To the resulting resin were added 150 mL of tetrahydrofuran (dehydrate), 15 mL of acetic anhydride and 15 mL of 2,6-lutidine, and the mixture was shaken at room temperature for 2 hours. The resin was taken out by filtration, washed sequentially with pyridine, methanol and dichloromethane in the order mentioned, and dried under reduced pressure to give 33.7 g of the product.

The loading amount of the product was determined by measuring UV absorbance at 409 nm of the molar amount of the trityl per g resin using a known method. The loading amount of the resin was 397.4 µmol/g.

Conditions of UV Measurement
Device: U-2910 (Hitachi, Ltd.)
Solvent: methanesulfonic acid
Wavelength: 265 nm

Value: 45000

[Reference Example 2] 4-Oxo-4-{[2S,6R]-6-(6-exo-2-[2-phenoxyacetamida]-1H-purin-9-yl)-4-tritylmorpholin-2-yl]methoxy}butanoic acid loaded onto 2-aminomethylpolystyrene resin

Step 1: Production of N2-(phenoxyacetyl)guanosine

Guanosine, 100 g, was dried at 80° C. under reduced pressure for 24 hours. After 500 mL of pyridine (anhydrous) and 500 mL of dichloromethane (anhydrous) were added thereto, 401 mL of chlorotrimethylsilane was dropwise added to the mixture under an argon atmosphere at 0° C., followed by stirring at room temperature for 3 hours. The mixture was again ice-cooled and 66.3 g of phenoxyacetyl chloride was dropwise added thereto. Under ice cooling, the mixture was stirred for further 3 hours. To the reaction solution was added 500 mL of methanol, and the mixture

was started at room temperature overnight. The solvent was then removed by distillation under reduced pressure. To the residue was added 500 mi. of methanol, and concentration under reduced pressure was performed 3 times. To the residue was added 4 %, of water, and the mixture was stirred 5 for an hour under ice cooling. The precipitates formed were taken out by filtration, washed sequentially with water and cold methanol and then dried to give 150.2 g of the objective compound (yield: 102%) (cf.: Org. Lett. (2004), Vol. 6, No. 15, 2555-2557).

Step 2: N-{9-[(2R,6S)-6-(hydroxymethyl)-4-morpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl]-2phenoxyacetamide p-tolucnesulfonate

In 480 mL of methanol was suspended 30 g of the compound obtained in Step 1, and 130 mL, of 2N hydrochloric acid was added to the suspension under ice cooling. Subsequently, 56.8 g of ammonium tetraborate tetrahydrate and 16.2 g of sodium periodate were added to the mixture in 20 the order mentioned and stirred at room temperature for 3 hours. The reaction solution was ice cooled and the insoluble matters were removed by filtration, followed by washing with 100 mL of methanol. The filtrate and washing liquid were combined and the mixture was ice cooled. To the 25 mixture was added 11.52 g of 2-picoline borane. After stirring for 20 minutes, 54.6 g of p-toluenesulfonic acid monohydrate was slowly added to the mixture, followed by stirring at 4° C. overnight. The precipitates were taken out by filtration and washed with 500 mL of cold methanol and 30 [(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxodried to give 17.7 g of the objective compound (yield: 43.3%).

¹H NMR (8, DMSO-d6): 9.9-9.2 (2H, br), 8.35 (1H, s), 7.55 (2H, m), 7.35 (2H, m), 7.10 (2H, d, J=7.82 Hz), 7.00 (3H, m), 5.95 (1H, dd, J=10.64, 2.42 Hz), 4.85 (2H, s), 4.00 35 (1H, m), 3.90-3.60 (2H, m), 3.50-3.20 (5H, m), 2.90 (1H, m), 2.25 (3H, s)

Step 3: Production of N-{9-{(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide

in 30 mL of dichloromethane was suspended 2.0 g of the compound obtained in Step 2, and 13.9 g of triethylamine and 18.3 g of trityl chloride were added to the suspension 45 under ice cooling. The mixture was stirred at room temperature for an hour. The reaction solution was washed with saturated sodium bicarbonate aqueous solution and then with water, and dried. The organic layer was concentrated under reduced pressure. To the residue was added 40 mL of 0.2M sodium citrate buffer (pH 3)/methanol (1:4 (v/v)), and

the mixture was stirred. Subsequently, 40 mL of water was added and the mixture was stirred for an hour under ice coaling. The mixture was taken out by filtration, washed with cold methanol and dried to give 1.84 g of the objective compound (yield: 82.0%).

Step 4: Production of 4-axo-4-{[(2S,6R)-6-(6-exo-2-[2-phenoxyacetamide]-111-purin-9-yl)-4-tritylmorpholin-2-yl]methoxy}butanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that N-{9-[(28,68)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-6-oxo-6,9-dihydro-1H-purin-2-yl}-2-phenoxyacetamide was used in this step, instead of N-{1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4yl}benzamide used in Step 1 of REFERENCE EXAMPLE

[Reference Example 3] 4-[[(2S,6R)-6-(5-Methyl-2, 4-dioxo-3,4-dihydropyrimidin-1-yl)-4-tritylmorpholin-2-yl]methoxy}-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 1-[(2R,6S)-6-(hydroxymethyl)-4-tritylmorpholin-2-yl]-5-methylpyrimidine-2,4(1H,3H)-dione was used in this step, instead of N-{1-,2-dihydropyrimidin-4-yl}benzamide used in Step 1 of REFERENCE EXAMPLE 1.

[Reference Example 4] 1,12-Dioxo-1-(4-tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin

The title compound was produced in a manner similar to REFERENCE EXAMPLE 1, except that 2-[2-(2-hydrexy-40 ethoxyl)ethoxylethyl 4-tritylpiperazine-1-carboxylic acid (the compound described in WO 2009/064471) was used in this step, instead of N-{1-|(2R,6S)-6-(hydroxymethyl)-4tritylmorpholin-2-yl]-2-oxo-1,2-dihydropyrimidin-4yl benzamide.

According to the descriptions in EXAMPLES 1 to 12 and REFERENCE EXAMPLES 1 to 3 below, various types of PMO shown by PMO Nos. 1-11 and 13-16 in TABLE 2 were synthesized. The PMO synthesized was dissolved in injectable water (manufactured by Otsuka Pharmaceutical Factory, Inc.). PMO No. 12 was purchased from Gene Tools,

TABLE 2

PMO No.	Thirgef sequence in exon 53	Note	SEQ ID NO:
!	31-55	3' end: g20ap (3)	SEQ ID NO: 4
2	32-53	5' end: group (3)	SEQ ID NO. 8
3	32-56	5' end: group (3)	\$500 ID NO: 11
4	33-54	S' end: group (3)	SEQ ID NO: 15
5	34-58	5' end: group (3)	SEQ ID NO: 25
6	36-53	5' end: group (3)	SEQ ID NO: 37
7	36-55	S' end: group (3)	SEQ ID NO: 34
8	36-56	S' end: group (3)	SEQ ID NO: 35
§	36-57	S' and: group (3)	SEQ ID NO: 36

20

32

PMO Na.	Target sequence in exan 53	Nate	SEQ ID NO:	
10	33-57	5' cod: grasp (1)	SEQ ID NO: 18	
***	39 69	Sequence corresponding to HSSA(+38 + 69) (cf. Table 1) in Non-Patent Deciment 3, 5' end: group (3)	S≅Q ID NO; 38	
12	30-59		SEQ ID NO 39	
1.3	32-56	5' end: group (1)	SEO ID NO: 11	
14	36-56	5' cad. group (1)	SEQ ID NO: 35	
15	30-59	Sequence corresponding to h53A 35/1 of. Table 1) in Non-Patent Document 5 S' end: group (3)	SEQ ID NO: 39	
16 .	23-47	Sequence corresponding to SEQ ID NO: 429 described in Patent Document 4, 5' ent: group (3)	SEQ ID NO. 47	

Example 1

PMO No. 8

4-tritylmorpholin-2-yl[methoxy] 4-oxobutanoic acid, loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 1), 2 g (800 µmol) was transferred to a reaction vessel, and 30 mL of dichloromethane was added thereto. The mixture was allowed to stand for 30 minutes. After the mixture was further washed twice with 30 mL of dichloromethane, the following synthesis cycle was started. The desired morpholino monomer compound was added in each cycle to give the nucleotide sequence of the title compound.

TABLE 3

Step	Reagont	Volume (mL)	Time (min)
)	debjecking solution	30	2.0
2	deblecking solution	30	2.0
3	deblecking solution	30	2.0
4	deblocking solution	30	2,0
5	deblecking solution	30	2.0
6	deblocking solution	30	2.0
. 7	neutralizing solution	30	1.5
8	cautalizing solution	3/3	1.5
9	acutualizing solution	342	1.5
16	nestralizing solution	30	1.5
i i	neutralizing solution	30	1,5
12	neutralizing solution	30	1,5
13	dichloremethane	30	0.5
14	dichloromethane	.30	9.5
1.5	dichloromethane	33	0.5
16	coupling solution B	20	0.5
3.7	coupling solution A.	6-11	90.0
18	dichloremethase	30	0.5
19	dichloromethane	30	81.5
20	dichloramethace	- 30	0.5
21	capping solution	30	3.0
22	capping solution	30)	3.0
2.3	dichloromethano	30	0.5
24	dichloromethane	30	0.5
25	dichloromethans	30	0.5

The deblocking solution used was a solution obtained by dissolving a mixture of trifluoroacetic acid (2 equivalents) and triethylamine (I equivalent) in a dichloromethane solution containing 1% (v/v) ethanol and 10% (v/v) 2,2,2-trifluoroethanol to be 3% (w/v). The neutralizing solution used was a solution obtained by dissolving N,N-diisopro- 65 pylethylamine in a dichloromethane solution containing 5% (v/v) 2-propanol to be 5% (v/v). The coupling solution

A used was a solution obtained by dissolving the morpholino monomer compound in 1,3-dimethyl-2-imidazolidinone containing 10% (v/v) N,N-diisopropylethylamine to be 4-{[(2S,6R)-6-(4-Benzamido-2-oxopyrimidin-1(2H)-yl]-25 O.15M. The coupling solution B used was a solution obtained by dissolving N,N-diisopropylethylamine in 1,3dimethyl-2-imidazolidinone to be 10% (v/v). The capping solution used was a solution obtained by dissolving 20% (v/v) acetic anhydride and 30% (v/v) 2.6-lutidine in dichlonomethane.

> The aminomethyl polystyrene resin loaded with the PMO synthesized above was recovered from the reaction vessel and dried at room temperature for at least 2 hours under reduced pressure. The dried PMO loaded onto antinomethyl polystyrene resin was charged in a reaction vessel, and 200 mL of 28% ammonia water-ethanol (1/4) was added thereto. The mixture was stirred at 55° C, for 15 hours. The aminomethyl polystyrene resin was separated by filtration and washed with 50 mL of water-ethanol (1/4). The resulting filtrate was concentrated under reduced pressure. The resulting residue was dissolved in 100 mL of a solvent mixture of 20 mM acetic acid-triethylamine buffer (TEAA buffer) and acetonitrile (4/1) and filtered through a membrane filter. The filtrate obtained was purified by reversed phase HPLC. The conditions used are as follows.

TABLE 4

	Column	XTeria MS18 (Waters, φ30 × 100 льнь, 1CV = 200 mL)
-	Flow rate	60 ml. rain
	Calumn temperature	room teraperature
	Solution A	20 mM TEAA truffer
	Solution D	CH ₃ CN
	Gradient	(B) conc. 20 → 50850CV

Each fraction was analyzed and the product was recovered in 100 mL of acctonitrile-water (1/1), to which 200 mL of ethanol was added. The mixture was concentrated under reduced pressure. Further drying under reduced pressure gave a white solid. To the resulting solid was added 300 mL of 10 mM phosphoric acid aqueous solution to suspend the solid. To the suspension was added 10 mL of 2M phosphoric acid aqueous solution, and the mixture was stirred for 15 minutes. Furthermore, 15 mL of 2M sodium hydrate squeous solution was added for neutralization. Then, 15 ml. of 2M sedium hydroxide aqueous solution was added to make the mixture alkaline, followed by filtration through a membrane filter (0.45 µm). The mixture was thoroughly washed

15

33

with 100 mL of 10 mM sodium hydroxide aqueous solution to give the product as an aqueous solution.

The resulting aqueous solution containing the product was purified by an anionic exchange resin column. The conditions used are as follows.

34

morpholin-2-yl)methoxy)-4-oxobutanoic acid (RFFER-ENCE EXAMPLE 3) loaded onto aminomethyl polystyrene resin was used as the starting material.

ESI-TOF-MS Caled.: 7310.13. Found: 7310.17.

TABLE 5

Column.

Flow rate
Column-temp.
Solution A
Solution B
10 mM sodium hydroxide squeeus solution
10 mM sodium hydroxide squeeus solution
Clarateat

Gradient
(B) conc. S = 35%(15CV)

Each fraction was analyzed (on HPLC) and the product was obtained as an aqueous solution. To the resulting aqueous solution was added 225 mL of 0.1M phosphate buffer (pH 6.0) for neutralization. The mixture was filtered through a membrane filter (0.45 µm). Next, ultrafiltration 20 was performed under the conditions

TABLE 6

Filter PELLICON2 MINI FILTER PLBC 3K Regenerated Cellulose, Screen Type C Size 0.1 m²

The filtrate was concentrated to give approximately 250 mL of an aqueous solution. The resulting aqueous solution was filtered through a membrane filter (0.45 µm). The aqueous solution obtained was freeze-dried to give 1.5 g of the objective compound as a white cotton-like solid.

ESI-TOF-MS Calcd.: 6924.82.

Found: 6923.54.

Example 2

PMO. No. 1

The title compound was produced in accordance with the $_{40}$ procedure of EXAMPLE 1.

MALDI-TOF-MS Calcd.: 8291.96

Found: 8296.24.

Example 3

PMO- No. 2

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 7310.13.

Found: 7309.23.

Example 4

PMO. No. 3

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.55.

Example 5

PMO. No. 4

The title compound was produced in accordance with the 65 procedure of EXAMPLE 1, except that 4-(((28,6R)-6-(5-methyl-2,4-diexe-3,4-dihydropyrimidin-(2H)-yl)-4-trityl-

Example 6

PMO. No. 5

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-(((2S,6R)-6-(5-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-trityl-morpholin-2-yl)methoxy)-4-oxobutanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 3) was used as the starting material.

ESI-TOF-MS Calcd.: 8270.94.

Found: 8270.20.

Example 7

PMO. No. 6

The title compound was produced in accordance with the 35 procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 5964.01.

Found: 5963.68.

Example 8

PMO. No. 7

The title compound was produced in accordance with the procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 6609.55.

Found: 6608.85.

Example 9

PMO. No. 9

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-6-(6-oxo-2-(2-phenoxyacetamido)-1H-purin-9(6H)-yl)-4-tritylmorpholin-2-yl)methoxy)butanoic acid loaded onto aminomethyl polystyrene resin (REFERENCE EXAMPLE 2) was used as the starting material.

ESI-TOF-MS Caled.: 7280.11.

Found: 7279.4.

Example 10

PMO. No. 10

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 4-oxo-4-(((2S,6R)-

6-(6-oxo-2-(2-phenoxyacetamido)-HI-purin-9(6H)-yl)-4tritylmorpholia-2-yl)methoxy)butanoic acid loaded onto aminomethy) polystyrene resin (REFERENCE EXAMPLE 2) was used as the storting material.

ESI-TOF-MS Caled: 8295.95. Found: 8295.91.

Example 11

PMO. No. 13

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-15-pentadecanoic acid loaded onto aminomethyl polystyrene resin (REFER-ENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 7276.15. Found: 7275.69

Example 12

PMO, No. 14

The title compound was produced in accordance with the procedure of EXAMPLE 1, except that 1,12-dioxo-1-(4-tritylpiperazin-1-yl)-2,5,8,11-tetraoxa-5-pentadecanoic acid loaded onto antinomethy) polystyrene resin (REFERENCE EXAMPLE 4) was used as the starting material.

ESI-TOF-MS Calcd.: 8622.27. Found: 8622.29.

Comparative Example 1

PMO, No. 11

The title compound was produced in accordance with the procedure of EXAMPLE 1

ESI-TOF-MS Calcd.: 10274.63. Found: 10273.71

Comparative Example 2

PMO. No. 15

The title compound was produced in accordance with the 45 procedure of EXAMPLE 1.

ESI-TOF-MS Calcd.: 9941.33.

Found: 9940.77.

Comparative Example 3

PMO. No. 16

The title compound was produced in accordance with the procedure of EXAMPLE 1

ESI-TOP-MS Caled.: 8238.94. Found: \$238.69.

Test Example 1

In Vitro Assay

Using an Amaxa Cell Line Nucleofector Kit L on Nucleofector II (Lonza), 10 µM of the oligomers PMO Nos. 1 to 8 of the present invention and the antisense oligomer PMO 65 No. 11 were transfected with 4×105 of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used

36

After transfection, the cells were cultured overnight in 2 mL of Eagle's minimal essential medium (EMEM) (manufactured by Sigma, hereinafter the same) containing 10% fetal calf serum (PCS) (manufactured by Invitrogen) under conditions of 37° C, and 5% CO₂. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 µl of ISOGEN (manufactured by Nippon Gene) was added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lysc the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by LMS).

One-Step RT-PCR was performed with 400 ng of the extracted total RNA using a Titan One Tube RT-PCR Kit (manufactured by Roche). A reaction solution was prepared in accordance with the protocol attached to the kit. A PTC-100 (manufactured by MJ Research) was used as a thermal cycler. The RT-PCR program used is as follows.

50° C., 30 mins: reverse transcription 94° C., 2 mins: thermal denaturation [94° C., 10 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

Porward primer: (SEQ ID NO: 40) 5 '- ACCIATITOCIAACAGAGGCGTC - 3

Roverse primer:

(SEQ ID NO: 41) 5*-GECTOCCACTGGCGGAGGTC-)*

Next, a nested PCR was performed with the product amplified by RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program used is as follows.

94° C., 2 mins: thermal densturation

[94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds | x30 cycles: PCR amplification

68° C., 7 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given

Porvard primer:

(SEQ ID NO: 42)

S: CATCAAGCAGAAGGCAACAA-3

Reverse primer:

(SEQ ID NO. 41)

The reaction product, 1 µl, of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polyaucleotide level "A" of the band with exon 53 skipping and the polynacleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)~46(4+8)×100

Experimental Results

The results are shown in FIG. 1. This experiment revealed that the oligomers PMO Nos. 1 to 8 of the present invention

caused exon 53 skipping with a markedly high efficiency as compared to the antisense oligomer PMO No. 11. In particular, the oligemers PMO Nos. 3 and 8 of the present invention exhibited more than four times higher exon skipping efficiency than that of the antisense oligomer PMO No.

Test Example 2

In Vitro Assay Using Human Fibroblasts

Human myoD gene (SEQ ID NO: 44) was introduced into TIG-119 cells (human normal tissue-derived fibroblasts, National Institute of Biomedical Innovation) or 5017 cells (human DMD patient-derived fibroblasts, Coriell Institute for Medical Research) using a ZsGreen1 coexpression ret-

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblests were collected by FACS and plated 20 at 5x10⁴/cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM-F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12 to 14 days to 30 differentiate into myotubes.

Subsequently, the differentiation medium was replaced by a differentiation medium containing 6 µM Endo-Porter (Gene Tools), and the morpholino oligomer was added thereto in a final concentration of 10 µM. After incubation 35 for 48 bours, total RNA was extracted from the cells using a TRIzol (manufactured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. 40 An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation

PCR amplification

72° C., 7 mins: final extension

The primers used were hEX51F and hEX55R.

(SEQ ID NO: 45) 51-COMOCTYCGACAGAACTTAC+3

(SEQ ID NO: 461 55

The reaction product of RT-PCR above was separated by 2% agarose gel electrophoresis and gel images were captured with a GeneFlash (Syngene). The polynucleotide level "A" of the band with exon 53 skipping and the polynucle- 60 otide level "B" of the band without exon 53 skipping were measured using an Image I (manufactured by National Institutes of Health). Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skipping efficiency (%)~4(4-8)×100

38

Experimental Results

The results are shown in FIGS. 2 and 3. This experiment revealed that in TIG-119 cells, the oligomers PMO Nos. 3, 8 and 9 of the present invention (FIG. 2) all caused exon 53 skipping with a higher efficiency than the antisense oligomer PMO No. 12 (FIG. 2). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than twice higher exon skipping efficiency than that of the 10 antisense oligomer PMO No. 12 (FIG. 2).

Furthermore, this experiment revealed that the oligomers PMO Nos. 3 and 8 to 10 of the present invention (FIG. 3) all caused exon 53 skipping with a higher efficiency than the antisense aligemer PMO No. 12 (FIG. 3). In particular, the oligomers PMO Nos. 3 and 8 of the present invention exhibited more than seven times higher exon skipping efficiency than that of the antisense oligomer PMO No. 12 (FIG. 3).

Test Example 3

In Vitro Assay Using Human Fibroblasts

The skin fibroblast cell line (fibroblasts from human 25 DMD patient (exons 45-52 or exons 48-52)) was established by biopsy from the medial left upper arm of DMD patient with deletion of exons 45-52 or DMD patient with deletion of exons 48-52. Human myoD gene (SEQ ID NO: 44) was introduced into the fibroblast cells using a ZsGreen1 coexpression retroviral vector.

After incubation for 4 to 5 days, ZsGreen-positive MyoDtransformed fibroblasts were collected by FACS and plated at 5×10⁴/cm² into a 12-well plate. As a growth medium, there was used 1 mL of Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) (Invitrogen Corp.) containing 10% FCS and 1% Penicillin/Streptomycin (P/S) (Sigma-Aldrich, Inc.).

The medium was replaced 24 hours later by a differentiation medium (DMEM/F-12 containing 2% equine serum (Invitrogen Corp.), 1% P/S and ITS Liquid Media Supplement (Sigma, Inc.)). The medium was exchanged every 2 to 3 days and incubation was continued for 12, 14 or 20 days to differentiate into myotubes.

Subsequently, the differentiation medium was replaced by differentiation medium containing 6 µM Endo-Porter [94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: 45 (Gene Tools), and a morpholino oligomer was added thereto at a final concentration of 10 μM. After incubation for 48 hours, total RNA was extracted from the cells using a TRizol (manufactured by Invitrogen Corp.). RT-PCR was performed with 50 ng of the extracted total RNA using a QIAGEN OneStep RT-PCR Kit. A reaction solution was prepared in accordance with the protocol attached to the kit. An iCycler (manufactured by Bio-Rad) was used as a thermal cycler. The RT-PCR program used is as follows.

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation

[94° C., 1 mins; 60° C., 1 mins; 72° C., 1 mins]×35 cycles: PCR amplification

72° C., 7 mins: final extension

The primers used were hEx44F and h55R.

hex44F: (SEC 10 No. 48) 51 - TETTOACAAATEGEGEGET - 31 hRx55R 18EQ ID NO: 461 S' -TECTTACGGGTAGCATCCTG-1'

30

The reaction product of RT-PCR above was separated by 2% agarose gel electrophoresis and gel images were captured with a GeneFlosh (Syngene). The polymoleotide level "A" of the band with exon 53 skipping and the polymoleotide level "B" of the band without exon 53 skipping were measured using an Image J (manufactured by National Institutes of Health). Bused on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation.

Skapping officiency (%)=d/(A+B)×100

Experimental Results

The results are shown in FIGS. 4 and 5. This experiment revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with an efficiency as high as more than 80% in the cells from DMD patient with deletion of exons 45-52 (FIG. 4) or deletion of exons 48-52 20 (FIG. 5). Also, the oligomers PMO Nos. 3 and 8 of the present invention were found to cause exon 53 skipping with a higher efficiency than that of the antisense oligomer PMO No. 15 in the cells from DMD patient with deletion of exons 45-52 (FIG. 4).

Test Example 4

Western Blotting

The oligomer PMO No. 8 of the present invention was added to the cells at a concentration of 10 µM, and proteins were extracted from the cells after 72 hours using a RIPA buffer (manufactured by Thermo Fisher Scientific) containing Complete Mini (manufactured by Roche Applied Science) and quantified using a BCA protein assay kit (manufactured by Thermo Fisher Scientific). The proteins were electrophoresed in NuPAGE Novex Tris-Acetate Gel 3-8% (manufactured by Invitrogen) at 150V for 75 minutes and transferred onto a PVDF membrane (manufactured by Millipore) using a semi-dry blotter. The PVDF membrane was blocked with a 5% ECL Blocking agent (manufactured by GE Healthcare) and the membrane was then incubated in a solution of anti-dystrophin antibody (manufactured by NCL-Dys1, Novocastra). After further incubation in a solution of peroxidase-conjugated goat-antimouse IgG (Model No. 170-6516, Bio-Rad), the membrane was stained with ECL Plus Western blotting system (manufactured by GE Healthcare). Immumostaining

The oligomer PMO No. 3 or 8 of the present invention was added to the cells. The cells after 72 hours were fixed in 3% paraformaldehyde for 10 minutes, followed by incubation in 10% Tritou-X for 10 minutes. After blocking in 5 10% goat serum-containing PBS, the membrane was incubated in a solution of anti-dystrophin antibody (NCL-Dys1, Novocastra). The membrane was further incubated in a solution of anti-mouse IgG antibody (manufactured by Invitrogen). The membrane was mounted with Pro Long Gold 6 Antifade reagent (manufactured by Invitrogen) and observed with a fluorescence microscope.

Experimental Results

The results are shown in FIGS. 6 and 7. In this experiment it was confirmed by western blotting (FIG. 6) and immunestaining (FIG. 7) that the oligomers PMO Nus. 3 and 8 of the present invention induced expression of the dystrophin

Test Example 5

In Vitro Assay Using Human Fibroblasts

The experiment was performed as in TEST EXAMPLE 3.

Experimental Results

The results are shown in FIG. 8. This experiment revealed that in the cells from DMD patients with deletion of exons 45-52, the oligomers PMO Nos. 3 to 8 of the present invention caused exon 53 skipping with a higher efficiency than the oligomers PMO Nos. 13 and 14 of the present invention (PIG. 8).

Test Example 6

In Vitro Assay

Experiments were performed using the antisense oligomers of 2'-O-methoxy-phosphorothicates (2'-OMe-S-RNA) shown by SEQ ID NO: 49 to SEQ ID NO: 123, Various antisense oligomers used for the assay were purchased from Japan Bio Services. The sequences of various antisense oligomers are given below.

TABLE 7

Antidende oligomer	Nucleotide sequence	SHQ ID NO
H53_39-69	CADUCAACUGUUSCCUCCGGUUCUGAAGUUG	49
H53_1-25	UCCCACUGALUCUGAAUDCUUUCAA	50
H53_6-30	CUUCADCCCACUUAUUCUJAAUUCU	51
H53 _{cm} 11-35	UNGUACUTICAUCCCACUGAUTICUGA	52
H53_16-40	UGUUCUUGUACUUCAUCCCACUGAU	5.3
H53_21-45	GAADGUGUUGUUGDACUUGAUGGGA	54
H53_26-50	GUUCUGAAGGUGUUCUUGUAGUUCA	55
H93_31-55	CUCCGGUUCUGAAGGUGUUCUUGUA	S£
H53_36-60	GDUGCCUCCGGOUCUGAAGGOGUTC	57
((5) 41-65	CAACUSUDGCCUCCGGGUUCUXMAGG	54
H53_46-70	VCAUUCAACUGUUGGGUGGGUUGU	59
H53_51+75	ACAMUUCAUUCAACUGUUGCCUCCG	86
N53_56-80	CURBAACAUTUCAUUCAACUGUUSC	61
863 _m 61-85	GNAUCCUDUAACAUUUCAUUCAACU	\$2
H53_66-90	GUQUUGANIIOCUUUAACAUIJUCAJJU	53
1153_71 95	ecacustruccontrate and contrate	84
H53_76-100	DCCAGCCAUCGUGGAAUCCUUDA	55
HS3_81-105	UNOCUUCCAGOCAUUGUGUGUAAUC	56
H63_86-110	DUCCOURSCTUCCAGACARIXGUGUU	57
H53 91-119	OCUTOUUCCUUAGCUUCCAGCCAUU	1.14

41
TABLE 7 continued

42
TABLE 7-continued

TABLE 7 continued		TABLE 7-continued					
Anriaensa oligomer	Mucleotide sequence	SEQ ID NO		Antisense oligomer	Nacicotido sequence	SEQ ID No.	
H53_96-120	GCDCAGCCCCCUUCCCUIAGCCCCAG	6.9	5	1150 10 51	AACUGUUGCCUCCGGURCUGAACGU	108	
H53_101×125	GACCIDICTEAGCUUCUUCCUIVAGCU	70		H53_10-64			
153_106-130	CCUANGACCUGCUCAGCUUCOUCCO	71		M53_32=63	DOURGECTUCCOGUIZCUGAAOGUGT UCCUGU	109	
53_111-135	CCUGUCCUAAGACCUECUCAGCUUC	- 72	10		CHURCUCAACGUGUUCURGU	110	
63_116-140	DOUGHECOGGGCCAAGACCCGGCGCA	73		HS3_35-54	DECGGUNCOGAAGGUGUUCU	111	
83_121-149	UURGCUCUGGCCUGGCCBARGACCH	24		H53_37-56	CCUCCGGUUCUGAAGGUGUU	112	
53_126-150	CAAGCUUGGCDCDGGCCDGDCCBAA	75		HE340~E9	UUGCCUCCSGUUCUGAAGGU	113	
53_131-155	DOACUCAAGCUUGGCUCUGGCCUGU	76	13	1153_42-61	DGUUGCCDCCCCUDCUGAAG	114	
_				H53_32-49	UUCUGAAKHIGUUCUUGU	115	
5)_136-160	UDOCAUGACUCAAGCUUQGCUCUGG	27		H53_35-52	CAOUNC//AVYCCACO	116	
53_141-165	CCUCCUUCCAUGACUCAAGCUUDGC	38	20	H53_38-55	CUCCOGUUCUGAAGGUGU	117	
53_146-170	G3GACCCUCCUUCCAUGACUCAAGC	19		H53_41-58	DECCUCCERUUCUGAAGG	110	
93_151×175	GUAUNGKRACECUCCUTCCAUGACU	90		3(53_44-61	EXHIBICODECCERRIDOUGA	119	
13_156-100	CDACUGUAUACKGACCCOCCOUCCA	0.1	25	#7)			
93_161-105	DESCAUCUACIGUADAGEGACECTCC	82	23	HS3_35-49	DUCUGAAGGUGUUCU	129	
3_166-190	UGGAUUGCASCUACUGUAUAGGGAC	8.3		HS3_40-54	UCCGGUUCUGAAGGU	121	
171-195	UCCUUUGGASUGCAUCUACUGUADA	0.4		H53_45×59	UVOCCUCCIGUUCU3	122	
3)_176-200	GACUUUCUUTUGGAUUGCAUCUACU	85	30	H53_45-62	cucunaccuccacuucus	123	
	DEUGOGABUTECUPUUGGABUCZAÜ	86		DD	(Syramon shall danner annual sta		
5)_181-205					(human rhabdomyosarcomna cell lir 10 ⁸ in a 6-well plate and cultured in		
156-210	OGGUUUCUGUGAUUUKKUUUUKGAU	6.7	35	Eagle's mini	mal essential medium (EMEM) (manu	facture	
3_84-168	CCCURGCOVCCAGCCAUOGUSUUGA	8.8		by Sigma, if	ic., hereinafter the same) containing 1 CS) (manufactured by Invitrogen Con		
3_88-112	UCUUCCUUACUUCCAGCCAUUGRG	89			f 37° C. and 5% CO ₂ overnight. Comp		
0_119-143	GRZUCIKIGOCUGUCCUAAGACCUGC	90			ense oligomers (Japan Bio Services) (1		
63_124-149	AGC000GGC0C0GGCCUGUCCUAAGA	91	40		ping and Lipofectamine 2000 (manufactors) were prepared and 200 µl was:		
128-153	CUCAMSCUVSGCUCUGGCCUGUCCU	92		RD cells wh	ere 1.8 mL of the medium was excha		
53_144-169	GACCOUCCOUCCAUGACCCAAGCUU	93			al concentration of 100 nM. pletion of the addition, the cells were	myltroror	
- 50_149-173	AUAKKNACEEGGGGUUGGAUHAGUGA	94	415		he cells were washed twice with PBS		
3 153-177	CUGUAWAGGGACCCUCCUUCCAUCGA	95		factured by l	Nissui, hereafter the same) and then 5	00 µl o	
					unufactured by Nippon Gene) were add the cells were allowed to stand at ro		
53179-203	UGUGATUUTEUUUUUGAUTGEAUCT	96			a few minutes for cell lysis, the lys		
53_184-208	GUUDCIGUGAUUDUCUUUUGAÜÜG	97	50	A SOUND SECURE OF	n Eppendorf tube. The total RNA was		
53_198-212	COUGGEOUCHGEGAUUUUCUUUUGG	98		tration of the	the protocol attached to ISOGEN. The total RNA extracted was determined	using :	
3,29-53	CCCCUCCGGAAGGUGUUCUUGUACU	99		NapoDrop N	D-1000 (manufactured by LMS).		
3330-54	UCCGGCOCOGAAGGCGDCCGDAC	100	55		RT-PCR was performed with 400 m al RNA using a Titun One Tube RT-1		
53_32-56	CONCOGGUNGACAACAMGUUCUUGU	101			of by Roche). A reaction solution was		
53_33-57	OCCUCCOGUUCIGAACKINGUUCUUG	102		in accordance	ce with the protocol attached to the	kit. A	
93_34-59	UGCCVCCGGDTCUGAAGGUGHDCGU	103	22.2		unufactured by MI Research) was no er. The RT-PCR program used is as fo		
53_35-69	UUGEEVEEGGUUEUGAAGGUGUUEU	104	čO	50° C., 30	mins: reverse transcription		
_	UGUUCKCUECOXUUCUGAAAGGUXUU	105			mins: thermal denaturation	r 10	
3_37-61					0 seconds; 58° C., 30 seconds; 68° cycles: PCR amplification	1 _{m-15} 10,	
3_38-62	CANGUINGGAIGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGA	105	65	68° C., 7	mins: final extension		
53_39-63	ACUGRUGCCUAXTGGUICTGAAAGSG	107			otide sequences of the forward printer used for RT-PCR are given below	ner and	

reverse primer used for RT-PCR are given below.

43

Porward primer:

(880 ID NO. 42) 5 CATCAAGGAGAKKKAACAA-3

Reverse primer:

(SEQ ID NO: 63)

5'-GANTITICAGGGCCAAGTCA-3

Subsequently, a nested PCR was performed with the amplified product of RT-PCR above using a Taq DNA Polymerase (manufactured by Roche). The PCR program 16 used is as follows.

94° C., 2 mins: thermal denaturation [94° C., 15 seconds; 58° C., 30 seconds; 68° C., 45 seconds]×30 cycles: PCR amplification

68° C., 7 mins; final extension

The nucleotide sequences of the forward primer and reverse primer used for the nested PCR above are given

Forward primer

(SEQ. ID NO: 40)

5 - AGGATTTGGAACAGAGGGGTC-)

Reverse primer:

(SEQ ID NO: 41) 25

s - dictaccherosegaogre- 3

The reaction product, 1 µl, of the nested PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.).

The polynucleotide level "A" of the band with exon 53 30 skipping and the polynucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping elliciency was determined by the following equation:

Skipping efficiency (%)=4/(4+B)×100

Experimental Results

The results are shown in FIGS, 9 to 17. These experiments revealed that, when the antisense oligomers were designed 40 ciency even in the same sequences. at exons 31-61 from the 5' end of exon 53 in the human dystrophin gene, exon 53 skipping could be caused with a high efficiency.

Test Example 7

Using an Amaxa Cell Line Nucleofector Kit Lon Nucleofector II (Lonza), 0.3 to 30 µM of the antisense oligomers were transfected with 3.5×10° of RD cells (human rhabdomyosarcoma cell line). The Program T-030 was used.

After the transfection, the cells were cultured overnight in 2 mL of Fagle's minimal essential medium (EMEM) (manufactured by Sigma, Inc., hereinafter the same) containing 10% fetal calf serum (FCS) (manufactured by Invitrogen Corp.) under conditions of 37° C, and 5% CO₂. The cells were washed twice with PBS (manufactured by Nissui, hereinafter the same) and 500 µl of ISOGEN (manufactured by Nippon Gene) was then added to the cells. After the cells were allowed to stand at room temperature for a few minutes to lyse the cells, the lysate was collected in an Eppendorf tube. The total RNA was extracted according to the protocol 50 attached to ISOGEN. The concentration of the total RNA extracted was determined using a NanoDrop ND-1000 (manufactured by LMS).
One-Step RT-PCR was performed with 400 ng of the

extracted total RNA using a QIAGEN OneStep RT-PCR Kit 65 (manufactured by Qiagen, Inc.). A reaction solution was prepared in accordance with the protocol attached to the kit.

The thermal cycler used was a PTC-100 (manufactured by MJ Research). The RT-PCR program used is as follows

50° C., 30 mins: reverse transcription 95° C., 15 mins: thermal denaturation [94° C., 30 seconds; 60° C., 30 seconds; 72° C., 1

mins]×35 cycles: PCR amplification 72° C., 10 mins: final extension

The nucleotide sequences of the forward primer and reverse primer used for RT-PCR are given below.

Porward primer:

(SEQ. ID NO: 42)

5'-CATCANGCAGAAGGCAACAA-)'

Reverse primer:

(SEQ. ID NO: 431

S'-GAAGITICAGGCCAAGICA-3'

The reaction product, I µl, of the PCR above was analyzed using a Bioanalyzer (manufactured by Agilent Technologies, Inc.)

The polymucleotide level "A" of the band with exon 53 skipping and the polymucleotide level "B" of the band without exon 53 skipping were measured. Based on these measurement values of "A" and "B," the skipping efficiency was determined by the following equation:

Skipping efficiency (%)~4/(A+B)x100

Experimental Results

The results are shown in FIGS. 18 and 19. These experiments revealed that the oligomer PMO No. 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the antisense oligomers PMO Nos. 15 and 16 (FIG. 18). It was also revealed that the oligomers PMO Nos. 3 and 8 of the present invention caused exon 53 skipping with a markedly high efficiency as compared to the oligomers PMO Nos. 13 and 14 of the present invention (FIG. 19). These results showed that the sequences with OH group at the 5' and provide a higher skipping effi-

INDUSTRIAL APPLICABILITY

Experimental results in TEST EXAMPLES demonstrate 45 that the oligomers of the present invention (PMO Nos. 1 to 10) all caused exon 53 skipping with a markedly high efficiency under all cell environments, as compared to the oligomers (PMO Nos. 11, 12, 15 and 16) in accordance with the prior art. The 5017 cells used in TEST EXAMPLE 2 are the cells isolated from DMD patients, and the fibroblasts used in TEST EXAMPLES 3 and 5 are exon 53 skipping target cells from DMD patients. Particularly in TEST EXAMPLES 3 and 5, the oligomers of the present invention show the exon 53 skipping efficiency of 90% or higher in the cells from DMD patients that are the target for exon 53 skipping. Consequently, the oligomers of the present invention can induce exon 53 skipping with a high efficiency, when DMD patients are administered.

Therefore, the oligomers of the present invention are extremely useful for the treatment of DMD.

Sequence Listing Free Text

SEQ ID NO: 2: synthetic nucleic acid

SEQ ID NO: 3: synthetic nucleic acid SEQ ID NO: 4: synthetic nucleic acid

SEQ ID NO: 5: synthetic nucleic acid

SEQ ID NO: 6: synthetic nucleic acid SEQ ID NO: 7: synthetic nucleic acid

SEQ ID NO: 8: synthetic nucleic acid

45		46
SEQ ID NO: 9: synthetic nucleic acid		SEQ ID NO: 67: synthetic nucleic acid
SEQ ID NO: 10: synthetic nucleic acid		SEQ ID NO: 68: synthetic nucleic acid
SEQ ID NO: 11: synthetic nucleic acid		SEQ ID NO: 69: synthetic nucleic acid
SEQ ID NO: 12: synthetic nucleic acid		SEQ ID NO: 70: synthetic nucleic acid
SEQ ID NO: 13: synthetic nucleic acid	4	SEQ ID NO: 71: synthetic nucleic acid
		SEQ ID NO: 72: synthetic nucleic acid
SSQ ID NO: 14: synthetic nucleic acid		SEQ ID NO: 73: synthetic micleic acid
SEQ ID NO: 15: synthetic nucleic acid		SEQ ID NO: 74: synthetic nucleic acid
SEQ ID NO: 16: synthetic nucleic acid		SEQ ID NO: 75; synthetic nucleic acid
SEQ ID NO: 17: synthetic medeic acid	10	SEQ ID NO: 76: synthetic nucleic acid
SEQ ID NO: 18: synthetic nucleic acid	20	SEQ ID NO: 77: synthetic nucleic acid
SEQ ID NO: 19: synthetic nucleic acid		SEQ ID NO: 78: synthetic nucleic acid
SEQ ID NO: 20: synthetic medeic acid		SEQ ID NO: 79: synthetic nucleic acid
SEQ ID NO: 21: synthetic nucleic acid		SEQ ID NO: 80: synthetic nucleic acid
SEQ ID NO: 22: synthetic nucleic acid	; c	SEQ ID NO: 81: synthetic nucleic acid
SEQ ID NO: 23: synthetic nucleic acid	15	SEQ ID NO: 82: synthetic nucleic acid
SEQ ID NO: 24: synthetic nucleic acid		SEQ ID NO: 83: synthetic nucleic acid
SEQ ID NO: 25: synthetic nucleic acid		SEQ ID NO: 84: synthetic nucleic acid
SEQ ID NO: 26: synthetic micleic acid		SEQ ID NO: 85: synthetic nucleic acid
SEQ ID NO: 27: synthetic nucleic acid	1000	SEQ ID NO: 86: synthetic nucleic acid
SEQ ID NO: 28: synthetic nucleic acid	20	SEQ ID NO: 87: synthetic nucleic acid
SEQ ID NO: 29: synthetic nucleic acid		SEQ ID NO: 88: synthetic nucleic scid
SEQ ID NO: 30: synthetic nucleic acid		SEQ ID NO: 89: synthetic nucleic acid
SEQ ID NO: 31: synthetic nucleic acid		SEQ ID NO: 90: synthetic nucleic sold
SEQ ID NO: 32: synthetic nucleic soid		SEQ ID NO: 91: synthetic nucleic acid
SEQ ID NO: 33: synthetic nucleic acid	25	SEQ ID NO: 92: synthetic nucleic acid
SEQ ID NO: 34: synthetic nucleic acid		SEQ ID NO: 93: synthetic nucleic acid
SEQ ID NO: 35: synthetic nucleic scid		SEQ ID NO: 94: synthetic nucleic acid
SEQ ID NO: 36: synthetic nucleic acid		SEQ ID NO: 95: synthetic nucleic acid
SEQ ID NO: 37: synthetic nucleic acid		SEQ ID NO: 96: synthetic nucleic acid
SEQ ID NO: 38: synthetic nucleic acid	.30	SEQ ID NO: 97: synthetic nucleic acid
SEQ ID NO: 39: synthetic nucleic acid		SEQ ID NO: 98: synthetic nucleic acid
SEQ ID NO: 40; synthetic nucleic acid		SEQ ID NO: 99: synthetic nucleic acid
SEQ ID NO: 41: synthetic nucleic acid		SEQ ID NO: 100: synthetic nucleic acid
SEO ID NO: 42: synthetic nucleic acid		SEO ID NO: 101: synthetic nucleic acid
SEQ ID NO: 42: synthetic nucleic acid	35	SEQ ID NO: 102: synthetic nucleic acid
SEQ ID NO: 45: synthetic nucleic acid		SEQ ID NO: 102: synthetic nucleic acid
SEQ ID NO: 46: synthetic nucleic acid		SEQ ID NO: 104: synthetic nucleic acid
SEQ ID NO: 47: synthetic nucleic acid		SEQ ID NO: 105: synthetic nucleic acid
SEQ ID NO: 48: synthetic nucleic acid		SEQ ID NO: 106: synthetic nucleic acid
	40	SEQ ID NO: 100: synthetic nucleic acid
SEQ ID NO: 49: synthetic nucleic acid		SEQ ID NO: 108; synthetic nucleic acid
SEQ ID NO: 50: synthetic nucleic acid		SEQ ID NO: 109; synthetic nucleic acid
SEQ ID NO: 51: synthetic nucleic acid		SEQ ID NO: 109: synthetic nucleic acid
SEQ ID NO: 52: synthetic nucleic acid		
SEQ ID NO: 53: synthetic nucleic acid	45	SEQ ID NO: 111: synthetic nucleic acid
SEQ ID NO: 54: synthetic nucleic acid		SEQ ID NO: 112: synthetic nucleic acid
SEQ ID NO: 55: synthetic nucleic acid		SEQ ID NO: 113: synthetic nucleic acid
SEQ ID NO: 56: synthetic nucleic acid		SEQ ID NO: 114: synthetic nucleic acid
SEQ ID NO: 57: synthetic nucleic acid		SEQ ID NO: 115: synthetic nucleic acid
SEQ ID NO: 58; synthetic nucleic acid	5G	SEQ ID NO: 116: synthetic mucleic acid
SEQ ID NO: 59: synthetic nucleic acid		SEQ ID NO: 117: synthetic nucleic acid
SEQ ID NO: 60: synthetic nucleic acid		SEQ ID NO: 118: synthetic nucleic acid
SEQ ID NO: 61: synthetic nucleic acid		SEQ ID NO: 119: synthetic nucleic acid
SEQ ID NO: 62: synthetic nucleic acid		SEQ ID NO: 120: symbolic nucleic acid
SEQ ID NO: 63: synthetic nucleic acid	55	SEQ ID NO: 121: synthetic nucleic acid
SEQ ID NO: 64: synthetic nucleic acid		SEQ ID NO: 122: synthetic nucleic acid
SEQ ID NO: 65: synthetic nucleic acid		SEQ ID NO: 123; synthetic medeic acid
SEQ ID NO: 66: synthetic nucleic acid	S	equence Listing

SEQUENCE LISTING

160 NUMBER OF SEQ ID NOS: 123

<210> SEO 1D NO 1 <211> LEMMTH: 212 <212> TYPE DNA

47 48 -continued

<213> OKGANISM: Home sapiens * 400 % BEOURNCE | | Liganagest toagastoag igggaigsag ischangabbs colleagase oggaggcase actigaatça aatqıtasaq gatreaseac aatggotgga açıtaaqqaa qaaqcigaqe aggictiagg acasgocaga gocaageing agicaiggsa ggaggelece taladaging atquastera aaaqaaaate acagamacen ag *210> SEQ ID NO 2 c2115 LENGTH: 23 <212> TYPE: DNA <213> OMGANISM: Artificial <220> FRATURE: <223> OTHER IMPORMATION: Synthetic Nucleic Acid <400 > SEQUENCE: 2 oeggttotga aggtgttett gtø 23 <210 > SEQ ID NO 3 <211> LENGTH: 24 c212> TYPE: DNA <213 x ORGANISM Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400 × SEQUENCE: 3 tooggitotg aaggigitet tgta <210 > SEQ 1D NO 1 <211> LENGTH: 25 <212× TYPE: DNA <213> ORGANISM: Artificial <220 > PEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SECURNOE: 4 ctccggttet gaaqqtgtte ttgta 25 KZ1DS ERQ ID NO 5 -211 - DENGTH: 28 2212> TYPE: DNA <213 > ORGANIEM: Artificial *220° FEATURE *223 * OTHER INFORMATION Syntheric Nucleic Acid ×4005 SEQUENCE: 5 estrogette tquaggiett cingta allow SEQ ID NO 6 <211> LEM37W: 27 <212> TYPE: DNA <213 - OMGANISM: Artificial <220> FEATURE <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 6

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

gootooggit otgaaggigt tottgta

49

50

-continued

```
<210> SEQ ID NO 7
<211> LENGTH: 29
e212> TYPE: DMA
x2()> ORGANISM: Artificial
<220× PRATURE
<223> OTHER INFORMATION: Synthetic Eucleic Acid
<400> SEQUENCE: 7
tgcctccggt totgaxqqtq ttottgta
<210> SEQ ID NO 6
<211> LENGTH: 22
<212× TYPE: DNA
<213> ORGANIEM: Artificial
<220× PRATORE
<223> OTHER INFORMATION: Synthetic Mucleic Acid
<400> SEQUENCE: 6
                                                                       22
coggitetea aggigitett gi
<210× SEO ID NO 9
<211> LEMGTH: 23
<212× TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<2235 UTHER INFORMATION: Synthetic Nucleic Acid</p>
<400× SEQUENCE: 9
tacggiteig waggigitet igt
                                                                       23
<210 > SEQ ID NO 10
<211> LENGTH: 24
<212 - TYPE: DNA
e213> ORGANISM: Artificial
a220 s FRATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEÇCENCE: 10
ctocggreet gaaggigite tigt
<210> SEQ ID NO 11
<211> DENGTH: 25
<212 > TYPE: DUA
<213> ORGANISM: Arcificial
<220> FEATURE.
<223 > OTHER INFORMATION: Synthetic Mucleic Acid
<100 × SEQUENCE: 11
cotcoggite tgaaggigit citqt
                                                                      25
<210 - SEQ ID NO 12
<211> LENGTH: 26
<212> TYPE: DNA
-213> ORGANISM: Artificial
<220 - PRATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
```

51 -continued

-concinu	ea	
<4805 SEQUENCE: 12		
yestooggit olgadegigs teligi	26	
210× SEQ 10 NO 13		
211> LENGTH: 27		
212. TYPE: DWA 213. ORGANISM: Artificial		
220° FEATURE:		
2235 OTHER INPORMATION: Synthetic Nucleic Acid		
400> GEQUENCE: 13		
geotoeggt totgaaggig storigt	27	
210 s EDQ 1D NO 14		
211> LINGTH: 21		
212> TYPE: DNA		
213> CEGANISM: Artiticial		
220× FEATURE:		
2235 OTHER INFORMATION: Synthetic Nucleic Acid		
400> SEQUENCE: 14		
400% angoings: 14		
oggittetga aggigitett g	21	
3900009. 09909.0000 9		
210> SEQ ID NO 15		
Illa LENGTA: 22		
212> TYPE: DNA		
213> ORGANISM: Artificial		
220> FEATURE 223> GTHER INFORMATION: Synthetic Nucleic Acid		
2239 Visen imponention: Systhetic sucreto sera		
400> SEQUENCE: 15		
eeggttorg aaggtgtret rg	22	
RIO- SEQ ID NO 16		
Pli> LENGTH: 2)		
HIS TYPE: DNA HIS ORGANISM: Artificial		
2205 FEATURE:		
RRIS OTHER INFORMATION: Synthetic Mucleic Acid		
SSC> SROUKNCR: 18		
	23	
coggittet gasagitgite tig	2.1	
110° SEC ID NO 17		
II s LENGTH 24		
112 > TYPE: DNA		
P13 > ORGANISM: Artificial		
20 × FEATURE:		
23.5 OTHER INFORMATION: Synthetic Nucleic Acid		
GD > SEQUENCE: 17		
terggite iganggigtt ettg	24	
195 SEQ ID NO 18		
11. LENGTH: 25 12> TYPE: DNA		
12> 1192: LAN 13> CRMANISK: Artificial		
20> FEATURE:		
123> OTHER INFORMATION: Synthetic Nucleic Acid		

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

54 53 -continued <400> SEQUENCE: 13 25 geoteoggit etgaaggigt telig <210> SEQ 10 NO 19 <211> LENGTH: 26
<212> TYPE: DNA <213 > ORGANISM: Artificial <220 × FEATURE <223 * OTHER INFORMATION: Synthetic Nucleic Acid KARON SECURICE: 19 tgeotoeggt totgaaggtg ttottg 26 -210 - SEQ ID NO 20 <211> LENGTH: 20 <2125 TYPE: DNA <213 > ORGANISM: Artificial <220> FHATURE: <223 SOTHER IMPORMATION: Synthetic Nucleic Acid 4400% ENQUENCE: 20 coggittotga aggigitett 20 <210 > SEQ ID NO 21 <211> LENGTH: 21 <212> TYPE: DNA <213> CRGAMISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400 > SECURIMEE: 21 . 21 teeggttetg aaggtgttet t ~210> SEQ ID NO 22 <211> LENGTH: 22 <212> TYPE: DNA <213 - ORGANISM: Axtificial <2205 PEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 22 cteeggitet gaaggighte ii <210> SEQ ID NO 23 <211> LEBGTH: 23 <2125 TYPE: DNA <213> ORGANISM: Artificial KIZON FEATURE: <223 - OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 23 cetecggite tqsaggigti cit 23 4210 - SEG ID NO 24 <211 > DENNYTH: 24 eriza TYPE: DNA <2135 ORGANIEM: Artificial <320> PEATURE:

*2223 OTHER IMPORMATION: Symmetic Nucleic Acid

55 56 continued ×400× SEQUENCE: 24 gesteeggtt stgaaggtqL tott *211> GRNGTH: 25

*212> TTPE: DWA

*213> ORGANISM. Archifocal wages PRATIER <2235 OTHER INFORMATION: Synchetic Nucleic Acid</p> ≈480 > SEQUENCE: 25 tgesteeggt tetgaaggtg ttett 25 <210 > SEQ ID NO 26 <211> LEMUTH: 19 ≈212> TYPE: DNA <213 s ORGANISM: Artificial ≈220's FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 26 ecggttetga aggtgttet 19 -210 SEQ ID NO 27 <211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Armiticial <220> PEATURE:
<223> OTHER INFORMATION: Synthetic Ducloic Acid <400 > SEQUENCE: 27 teeggttetg aaggtgttet 20 <210% BEQ ID NO 28 <211% LENGTH: 21 <212% TYPE: DNA <213 > ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 28 21 discognited gaaggigted t <210 - SRQ TD NO 29 <211> LENGTH: 22 <212> TYPE: DNA <213 > ORGANISM: Artificial <220 > FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid c400× SEQUENCE: 29 ceteeggite Lgaaggigtt of 22 <210> 5EQ ID NO 30 22115 LENGTH: 23 <2128 TYPE: DNA
<213* ORGANISM: A:tiChelal</pre> <220> PRATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid *400% SEQUENCE: 30 geotteeggit etgaaggtgt tet 23 <210 > SEC TO NO 31

Copy provided by USPTO from the PIRS Image Database on 98-24-2021

57

58

-continued ≈211> LENGTH: 24 *212 TYPE: CMA #2135 ORGANISM: Artificial 2220 - FRATURE: x223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 31 tgectceggt tetgaaggig tiot <210> SRQ ID NO 32 <211 > LENGTH: 19
<212 > TYPE: DNA c213> ORGANISM: Artificial *220> PEATURE: x323> OTHER INFORMATION: Synthetic Mucleic Acid <400> SKOUENCE: 32 coggetetga aggegete 16 <210 > SEQ ID NO 33 <211 > LENGTH: 19 <212> TYPE: DNA <213> ORGANISM: Artificial <220> PRATURE: <223> OTHER INFORMATION: Synthetic Mucleic Acid <400 > SEQUENCE: 33 teeggttetg aaggtgtte 19 <210> SEQ ID NO 34 <211> LENGTH: 20 <212> TYPE: DNA <213 > ORGANISM: Artificial <220> FRATURE: -0233 - OTHER INFORMATION: Synthetic Nucleic Acid *400 > SHOURNER: 34 cterggttet gaaggtgtte 20 <210> EEQ ID NO 35
<211> LENGTH: 21 <212> TYPE: DNA <213 - ORGANISM: Artificial <220> FEATURE: x229> OTHER INFORMATION: Synthetic Nucleic Acid «400» SEQUENCE: 35 ectoeggine tgaaggigti c 4210× SEQ ID NO 36 <211> LEMGTH: 22 <212> TYPE: DNA <213> ORGANISM: Artificial <220 > PEATURE: <22)> OTHER INFORMATION: Synthetic Nucleic Acid *400 > SEQUENCE: 36 22 geoteogatt otgoogstat to <211> LENGTH: 23
<3125 TYPE: DMA <213> ORGANISM: Artificial <220 > FEATURE: <223> OTHER IMPORMATION: Synthetic Mucloic Acid

<400> SEQUENCE: 37

59 60 -continued tgeetcoggt tetgaaggtg ttc 23 <210 > SEQ ID NO 36 <211 > LEBSTH: 31 <212 TYPE: DNA *213 ORGANISM: Artificial *220> FENTURE <2235 OTHER INFORMATION: Synthetic Mucleic Acid <400 > SEQUENCE: 38 cattomaced electioned threquippe q 3.1 *210× SEQ ID NO 39 <211> LENGTH: 30 <212> TYPE: DNA ~213 - ORGANISM: Artificial <220 > FRATURY: -2223 - OTHER INFORMATION: Synthetic Nucleic Acid «400» SEQUENCE: 39 tigecteegg tretgaaggt girerigtae 30 <210 > SEQ ID NO 40 <211 > LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial <220> PSATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid *400 × SEQUENCE: 40 aggattiggs acagaggegt c 21 <210> SEQ ID NO 4: <211> LENGTH: 20 <212> TYPE: DDA <213> ORGANISM: Artificial «ZZO» PEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid <480 • ENOUGHCE: 41 gtetgecact ggeggaggte 20 <210> SEQ ID HG 42 <211> DENGTH: 25 <212> TYPE: DHA <213> ORGANISM: Artificial ≈330° FEATURE: <223s Office Information: Symbotic Nucleic Acid <400> SEQUENCE: 42 catcaagcag aaggeancaa <210 - SEQ ID NO 43 <211 > LENGTH: 20 <212 > TYPE: DNA e213> ORGANISM: Artificial 22205 PEATORE <223> OTHER INFORMATION: Synthetic Nucleic Acid 64005 SEQUENCE: 43 quagittems ggeomagica 20 <210 > SEQ ID NO 44 <211 > LENGIN: 963 <212> TYPE: DMA

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

61

62

-continued <213 ORGANISM: Home sapiens -400 > SEQUENCE: 44 atogagetac totogenace detengogue gragacetes eggeconega eggetetete tyckeetite ecaesaggs cyastterat gacgascoor grategante macgystorg egettetteg aagametigga compoundly atgranging gegegotimet gaamenoogaa 180 gageactege actreeeege ggeggtgeac ceggereegg gegeachiga hhachageat 240 gtgegegege ceageggges esseesgeng ggeegetgee tactgtggge etgesaggeg tucaagogca agacoacoas ogoogacogo equaaggess ceaccatges esseegges 360 430 cycctyayca aagtaaatga qquolttqaq acautowaqo gotyoaogte gagoaatosa ascragoggt torccaaggt ggagateetg equaacgera tecgetatat egagggootg 400 enggetetge tgegggamen ggangengeg encentggeg drycageoge ctictatgeg 540 600 ecgggccogc tgcccocggg ccgcggcggc qagcactaca gcggcgactc cgacgcgtcc agorogogot ocaactgots ogacygeatg atggactaca geggecoooc gagogogoc 660 eggeggegga netgetaega aggegeetae tacaacqaeg egeecagega acceaggee 720 gggaagagtg cogcogtgt: gagectagae tgeetgteea geategtgga gegeatetee 340 accessaged objected ordered objected objected objected egcaygraag aggetyrego occcagogag ggagagagea goggegaece caeccagtea 900 coggaegecg coregoraging contraggut gegaaccoca accognitate coaggingsto 960 963 tga <210> SEQ ID NO 45 <211> LENGTH: 20 <212> TYPE: DNA %213 x OPGANISM: Artificial <220> FEATURE: ~2233 OTHER INFORMATION: Synthetic Nucleic Acid <400> SRQUENCE: 45 egggettgga cagaacttac 20 <210 x SEO 10 NO 46 <211 > LENGTH: 20 =212 TYPE: DMA <213 ORGANISM: Artificial ≈220> PRATURE: <223> OTHER IMPORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 46 techtacggg tagcalcotg 20 <210> SRQ 3D NO 47 <211: DBNGTH: 35 <212 - TYPE DNA -2130 ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION. Synthetic DNA < \$00 x SEOURNCE: 47 25 ctgaaggtgt tottgteett catee ~210 > SEO ID NO 48 <211 > LENGTH: 19 <212× TYPE: DNA

<213 > ORGANIEM: Artificial

64 63 -continued <2235 OTHER INFORMATION: Synchocis DMA e400> SEQUENCE: 48 tetteaqaaa tegegeest *210 × SEQ ID NO 49 *211> LENGTH: 31 *212> TYPE: RNA <213> ORGANISM: Artificial
<220> PRATURE: <223 - OTHER INFORMATION. Synthetic Buclaic Acid 4400 > SEQUENCE: 40 саписалонд бидосноодд висидалдды д 31 <210> SEQ ID NO 50 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Axeificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 50 uneczeugau ucunaauucu uucaa <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220 > FEATURE. <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SKOURNER: %1 cuveaueccá cyganicuga acucu 26 <210 > SEQ 10 NO 52 <211 > LEWSTH: 25 <312 > TYPR: BNA <213 * ORGANISM: Attificial <220 * FEATURE <223> OTHER INPORMATION: Synthetic Mucleic Acid <400> SEQUENCE: 52 25 индивоннов неселендви исида *210 × SBQ TD NO 53 <2115 LERGIH: 25
<2125 TYPE: ENA
<2135 ORGANISM: Artificial</pre> <220> PRATURE:
<223> OFHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE 53 uguncungua cancauceca cagan <2105 SEO 3D NO S4 <211 - LENGTH: 25 <212≥ TYPE: RNA <21) > ORGANISM: Artificial <220% FEATURE: <223 > OTHER INFORMATION: Symthetic Nucleic Acid <400> SEQUENCE: 54

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

25

ganddránna nadneanna neces

-continued

65

66

<210 > SEQ 10 NO 55 <211 > LENGTH: 25 <212 > TYPE RNA
<213 > ORGANISM - Artificial <223 > OTHER INFORMATION: Synthetic Nucleic Acid -400 SEQUENCE: 55 enecucació nenculare conca <230 > SEQ TO NO SS <211> LENGTH: 25
<212> TYPE: RNA
<213> ORGANISM: Artificial <2209 PEATURE:
<223> OTHER INFORMATION: Synthatic Nucleic Acid <4005 SEQUENCE: 56 ouccaptures gaagguguus uugua 25 <210 x SRQ ID NO 57 <212> TYPE: RNA <213 > ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 57 quogeouecg guucugaagg uguuc 25 4210> SEQ 1D NO 58 <211> LENGTH: 25 <212> TYPE: RHA <213> ORGANISM: Attiticial <220× PEATURE *223 * OTHER INFORMATION: Synthetic Nucleic Acid <400> SECURNCE: Sa caacumingo cucogguneu gaagg <210× SEQ ID NO 59
<211× LENGTH: 25
<212× TYPE: RNA <21% ORGANIEM: Artificial <220 FEATURE: <223 * OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 59 desautesach dandeeneed denest 25 <210> SEQ ID NO 60
<211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400 > ERCCHNOS: 60 acautucatu caacuguuge euceg 25 <210> SEQ ID NO 81
<211> DENGTH: 25 *212> TYPE: ENA <213 - ORGANISM: Artificial <2205 FEATURE: <223× OTHER INFORMATION: Synthetic Nucleic Acid

68 67 -continued <400> SEQUENCE: 61 25 cucuascaru ucauucaace guugr <210 > SEQ 10 NS 62 <211 > LENGTH: 25 <212 > TYPE: ENA <213 > ORGANISM: Artificial <220 > FRATURE: <223> OTHER INFORMATION Synthetic Nucleic Acid <400> SEQUENCE: 62 gazuccumia acauuncama caacu <210 > SEQ ID NO 63 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <223> OTHER INFORMATION. Synthetic Nucleic Acid <400> SEQUENCE: 63 дидвидавие опицавский исали c210> SEQ 10 NO 64 <211> LEM3TH: 25 <212> TYPE: EMA <213> ORGANISM: Artificial <220> FRATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 64 ccanugugun gaauccunna acana 25 <210> SEQ ID NO 65 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> PEATURE:
<220> OTHER INFORMATION: Synthetic Nucleic Acid c400> SEQUENCE: 65 uccagocanii giiguugaane euuna <210> SEQ ID NO 66 <211> LENGTH: 25 <212> TYPE: RNA <213> DRGANIEM: Artificial <220 > FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 66 wagewweeag ecawuguguw gaxue 25 <210 > SEQ ID NO 67 ≈211> LEMNTH: 25 <212 S TYPE: ENA <213> ORGANISM: Artificial <220> FEATURE <220 * OTHER INFORMATION: Synthetic Nucleae Acid *400 * SECURNCE: 47 имеециадец песадоский дидии

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

*210> SEQ ID NO 68

69

70

continued e2115 LENGTH: 25 <212> TYPE: RMA <213> ORGANISM: Artificial ≈220° FEATURE *223> GTHER INFORMATION: Symphetic Nucleic Acid <400> SEQUENCE: 66 дениенееси наденнееад стани 25 <210- SEQ ID NO 69 <211- LENGIN: 25 <212- TYPE- DNA <213- ORGANISM: Artificial <220- FEATURE: <223> GIMER INFORMATION: Synthetic Nacleic Acid <400 > SEQUENCE: 69 geneageune unceunagen necag 25 <210 - SEQ ID NO 70 <211 > LENGTH: 25 <212 > TYPE: RNA «213» ORGANISM: Artificial <220> FRATURE: ϵ 2235 OTHER INFORMATION: Synthetic Nucleic Acid «400» SEQUENCE: 70 gaccuscuca genucunecu uageu 6210 > SEQ ID NO 71 <211> LENGTH: 25 <212> TYPE: ENA <213 > CRGANISM: Artificial <220 > FEATURE: <223> OTHER INFORMATION: Synthetic Rucleic Acid <400> SECUENCE: 71 ccuaagaccu gcucagceuc uuccu <210> SEO ID NO 72 <2105 SEQ 10 SE ...
<2115 LENGTH: 25
<2125 TYPE: RNA
<2135 ORGANISM: Artificial</pre> ×223 > OTHER INFORMATION: Synthetic Mucleic Acid e400 > SEQUENCE: 72 осифиссиаа дасендскога денис <2105 SEQ ID NO 73 <211> LENGTH: 25 <212> TYPE: PNA <213> ORGANISM: Artificial *220 > PRATURE *223 OTHER INFORMATION: Synthetic Mucleic Acid 4400 > EBQUENCE: 73 25 nemâdeendr ceravdacer derea <210 > SEQ ID NO 74 <211> LENGTH: 25
<213> TYPE: RNA <213 - ORGANISM: Artificial 6220> FEATURE: <223> CTHER INFORMATION: Synthetic Nucleic Acid «400» SEQUENCE: 74

72 71 -continued 25 unegenengg conqueensa gacen <210> SEQ 10 NO 75 <211> LENGTH: 25 <212> TYPE: RNA <213 > OKGANISM: Artificial ~220> FRATURE: <223 * OTHER INFORMATION: Synthetic Buckets Acid caagenugge uenggeeugu ecuas 25 <210> SEQ ID NO 76 <211> LENGTH: 25 €2125 TYPE: RNA <213 - ORGANISM: Artificial <220> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 76 25 ugacucaago uuqqoucuqq ocuqu <2105 SEQ ID NO 77 <211> LENGTH: 25 <212> TYPE: RNA <213 > ORGANISM: Artificial <2235 OTHER INFORMATION: Synthetic Naclete Acid 6400% SEQUENCE: 77 unecaugaou caageuugge uougg 35 <210> SEQ ID NO 78 e211s LENGTH: 25 <212 > TYPE: RNA e2135 ORGANISM: Artificial c220 > PRATURE: <223> OTHER INFORMATION: Synthetic Nocleic Acid <400× SECTENCE: 78 cenecutees agacterage augge 25 -210> SEQ ID NO 79 <211> LEDKTTH: 25 <212> TYPE: BNA <213> ORGANISM: Artificial <220> PEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid ≪400> SEQUENCE: 79 25 gggaccouce uncoaugacu caage 62105 SEQ ID NO 80 *2115 LENGTH: 25 c212> TYPE: RMA <213> ORGANISM: Artificial 62205 FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

73 74 -continued <400> SEQUENCE: 90 guauagagae ceuceuurca ugaeu 35 <210 > SEC 1D NO 81 <211 > LENGTH: 25 <212 > TYPE: RNA <213 > ORGANISM: Astificial <223> OTHER INFORMATION: Synthetic Nacleic Acid онаснована опрядосное чисся -210 > SEQ ID NO 82 *211> LEMSTH: 25

*212> TYPE: RNA

*213> ORGANISM: Artificial <220> PEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid <400 > SHOURNER: 92 ugeaucuscu guauagggac ecoco 25, <210> EEQ ID NO 93 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 00 25 uggavugsau cuacuquava gogać <210> SEQ ID NO 84 ~210> SEQ 1D M: 4
~211> LENGTH: 25
~212> TYPE: RNA
~213> ORGANISM: Artificial <400's SECUENCE: 84 исивниддац пераменаси физиа 25 <210> SEQ ID NO 85 <211> LENGTH: 25 <2125 TYPE: RNA
<2135 ORGANISM; Artificial
<2205 FRATURE: <223 % OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 85 gameuucuun ugganugcan cuaca 25 <210> SEQ ID NO 86 <211> LENGTH: 35 ~212 - TYPE: RNA «213» ORGANISM: Actificial <220× FEATURE: <223 * OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: \$5

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

ucuququutu ucuutuqqan nqcan

*210° SEQ ID NO 87

76 75 -continued ×211> LENGTH: 25 <212> TYPE: RNA
<213> ORGANISM: Artificial <220> FEATURE: <ZZ3> OTHER INFURMATION: Synthetic Nucleic Acid < 400 × SEQUENCE: 87 ичения правительной предви <210> SEQ ID NO 98 *211> LENGTH: 25 *212> TYPE: RNA <213 > CRGANISM: Artificial -2203 FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid <480 > SHOURNCE: 88 ceurageaue cagceauugu guuqa 25 *210> SEQ ID NO 89 *211> LENGTH: 25 ≈2125 TYPE: RNA <213> ORGANISM: Artificial <220> PRATURE: <223> OTHER INFORMATION: Synthetic Mucleus Acid <400> SEQUENCE: 89 ucunecunad cunceadaca anand <311 > LENGTH: 25 <312 > TYPE: RNA *213 * ORGANISM: Artificial *220> PEATURE <223% OTHER INFORMATION: Synthetic Nacletc Acid <400> SROUENCE: 90 ggenengges uguscuanga cenge 25 <210> SBQ ID NO 91 *211> LENGTH: 25 <212> TYPE: RNA <213 s ORGANISM: Artificial <223> OTHER INFORMATION: Synthetic Nucleic Acid «400» SEQUENCE: 91 agenuggeue uggeeuguer waaga <310 > SEQ ID NO 92 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial *220> FEATURE: ×223> OTHER INFORMATION: Synthetic Nucleic Acid <400× SEQUENCE: 92 encavdenné dencaddeen decen 25 <210 > SEQ ID NO 93 <211 > LENGTH: 25 <212 > TYPE: RNA <219 > ORGANISM: Artificial <2225 FEATURE: <223 > OTHER INFORMATION: Synthetic Nucleic Acid

-400> SRQUENCE: 93

US 9.708.361 B2

77 78 continued 25 gacecuceum ceaugaeuca ageum ≈210 > SEQ ID NO 94 <211> LENGTH: 25 <212 - TYPE: RMA *213 > ORGANISM: Artificial *228 × PEATURE: *223 > OTHER INFURMATION: Synthetic Mucleic Acid <400> SEQUENCE: 94 avagggaeee uecouecaug acuea <210> SEQ ID NO 95 <211> LENGTH: 25 <212> TYPE: RNA <213 - ORGANIEM: Artificial <220> FRATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <400> SEQUENCE: 95 25 cuquauaggg acconcenue cauga ×210 × SEQ ID NO 96 <211> LENGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> PEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <4000 SECURICE: 96 uguganusue numgganug cancu 25 <210> SEQ ID NO 97 <211> LENGTH: 25 <212> TYPE: PNA <213 > ORGANISM: Artificial <220 > FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid <4005 SEQUENCE: 97 gueucegaga accurrenting gaving 25 <210> SEQ ID NO 98 <211> LENGTH: 25 <212> TYPE: RMA <213> CRGANISM: Artificial <220> FEATURE: *223> CTHER INFORMATION: Synthetic Nucleic Acid <.400> SEQUENCE: 98 chaddrance dadamanea mandd <210> SEQ ID NO 99 <211> LENGTH: 35 <212> TYPE: RNA <213> ORGANISM: Artificial *223 > OTHER INFORMATION: Symphetic Nucleic Acid <400> SEQUENCE: 99 sogguieuga agguguuduu quadu <210> SEQ JD NO 100
<211> LEMSTH: 25 e2125 TYPE: RMA

Copy provided by USPTO from the PIRS Image Database on 08-24-2021

79 -cent.inued

<213> CRGANISM: Artificial			
*220> PEATURE: *223> OTHER INFORMATION: Synthetic Modleic Acid			
<4005 SEQUENCE: 100			
nacasancea wasasance adasc	44		
manager and a manager and a manager	a 1427		
<210> SEQ ID NO 101			
<211> LENGTH: 25 <212> TYPE: SYA			
<213> ORCANISM: Artificial			
<pre><220s FEATURE: <223s OTHER INFURNATION. Synthetic Sucleic Acid</pre>			
e403> SRQUENCE: 101			
cenceddine ndryddidan enndn	25		
and the second of the second o			
<210> 580 10 NG 102			
<211> LENGTH: 25 <212> TYPE: RNA			
<213> ORGANIEM: Artificial <220> FEATURE			
K223> OTHER INFORMATION: Synthetic Nucleic Acid			
<400> SEQUENCE: 192			
gesteeggat augaaggugu ucuug	25		
<210> SEG ID NO 1G3			
<211> LENGTH: 25 <212> TYPE: RNA			
*213× ORGANISM: Artificial			
<22D> FEATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid			
<465> SEQUENCE: 103			
	25		
пасапсодан полдинавали плени	23		
<210> SEQ 1D NO 104			
<211 > GEWYH: 25			
<212> TYPE: RNA			
<213 - ORGANISM: Artificial <220 - FEATURE:			
42225 OTHER INFORMATION: Synthetic Mucleic Acid		*	
<400> SEQUENCE: 104			
nndecreedd nnendwwedn annen	25		
2103 SEQ ID NO 105			
<2115 LENGTH 25 <2125 TYPE: ENA			
<213> GRGANISM: Artificial			
<220> FKATURE: <221> OTHER INFORMATION: Synthetic Nucleic Acid			
<400> SEQUENCE: 105			
	25		
ndandecree alansadave andan	25		
<210> SBQ ID NO 106			
<211> 18HGTH: 25			
*210> TYPE: PNA			
c213 > OKNANIEM: Artifácial			
<220> FEATURE: <223> OTHER INFORMATION: Synthetic Rucleic Acid			
×400> SPQUENCE: 106			
crituriaceus caduncaday aanda	25		

81

82

-continued <Z10> SEQ ID NO 167
<Z11> LEMCTH: 25
<Z12> TYPE: ENA
<Z13> ORGANIOM: Artificial
<Z20> FRATURE: <223> OTHER INFORMATION: Synthetic Nucleic Acid *400% SEQUENCE: 107 anuguegoca cegguucuga agquq <210> SEQ ID NO 106 <211> DBNGTH: 25 <212> TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <2235 OTHER INFORMATION: Synthetic Nucleic Acid <400 > ERCURNOE: 108 ascuguugee ueegguneug aaggu 28 <210 > SEQ ID NO 109 <211 > LENGTH: 30 <212 > TYPE: RNA <213 s ORGANISM: Artificial ×220 × FRATURE: <220 > OTHER INFORMATION: Synthetic Mucleic Acid <400× SEQUENCE: 109 ugungcoure gguneugaag gunnneuligu 30 <210> SEQ ID NO 113 -211> LENGTH: 20 -213> TYPE: BNA ×213> ORGANISM: Armificial <220> FEATURE: <223 CTHER INPORMATION: Synthetic Nucleic Acid e400> SEQUENCE: 110 ggtucugaag guguucungu <210> SEQ ID NO 111 <211> LENGTH: 20 <212> TYPE: RNA <213> ORGANISM: Arcificial <220> PENTURE: <223> OTHER INFORMATION: Synthetic Mucleic Acid 4400 » SECUENCE: 111 цеоддинена възданденен 20 <210> SEQ ID NO 112 <211> LENGIH: 20 <2125 TYPE: RNA <213> ORGANISM: Artificial <220> FEATURE: <223 SOTHER IMPORMATION: Synthetic Nucleic Acid 4400> SEQUENCE: 112 20 ccuccuguus bqaaqqugin <210> SEQ ID NO 113 <211> GENGTH: 20 <212> TYPE: RNA

e213 » OEGANISM: Artificial

«220» PEATURE:

83

-consisted impromation; Synthetic Backer Acid 400. SEQUENCE: 117 **CRESS CEG ID NO 114 **CRIT.** LANDING CO. **CRIT.** CO.	0.3			94	
**************************************		-continued			
**ZION SEG ID NO 114 **ZII- LENTH. 20 **ZII- TEPR. ENN **ZII- SERVENTE INSPRINTATION. Symmetic Nucleic Acid **ZII- SERVENTE IN **ZII- SERVENTE ENN **ZII- SERVENTE EN	<223s OTHER INFORMATION: Synthetic Mucleic Aci	d			-
CHION SEQ ID NO 114	2400 × SEQUENCE: 213				
*2112 TEMPER 20 *2120 FEMALURE *2120	uugecucegg uucugaaggu		2.0		
Alls Deform 20 Alls Trye RNA Alls ORGANISM. Actificial Actos SECURIOR: SYMEMOTION SymEmotic Recisic Acid Actos SECURIOR: 134 Unquangeous opquicuspang Allo SEO IN NO 115 Alls Limburt 18 Alls Limburt 18 Alls Committee RNA Alls Organism Actificial Actos SECURIOR: 115 Watergaaging queucuspu Actos SECURIOR: 115 Actic Trye: RNA Acti					
Alls Generals. Artificial 4200 SEQUENCE: 114 Ugangeouse ggutougwag 210 4100 SEQUENCE: 114 Ugangeouse ggutougwag 210 4100 SEQ ID No 118 4110 LEMBER: 18 4120 FEATURE: 4213 FEATURE: 4213 FEATURE: 4214 FEATURE: 4215 FEATURE: 4215 FEATURE: 4216 FEATURE: 4217 FEATURE: 4218 FEATURE: 4219 FEATURE: 4219 FEATURE: 4210 SEQ ID No 118 4210 SEQ ID No 118 4210 SEQUENCE: 116 4211 SEQUENCE: 116 4212 TERE: NEAT 4213 CONCANTEN: Artificial 4210 SEQUENCE: 116 4210 SEQUENCE: 117 4210 SEQUENCE: 118 4211 SEQUENCE: 118 4211 SEQUENCE: 118 4212 SEQUENCE: 118 4213 SEQUENCE: 118 4214 SEQUENCE: 118 4215 SEQUENCE: 118 4216 SEQUENCE: 118 4217 SEQUENCE: 118 4218 SEQUENCE: 118 4219 SEQUENCE: 118 4210 SEQU					
200 FRATURE: *200* SEQUENCE: 114 Ugungecucc iguncugsag *210* SEC ID NO 118 *211* LENDTH: 18 *212* TYPE: RAT. *213* GUENCE: 115 UCCOGRAGGING GUENCUGL *210* SECUENCE: 116 *210* SECUENCE: 117 *210* SECUENCE: 117 *210* SECUENCE: 117 *210* SECUENCE: 118 *210* SECUENCE: 11					
### ### ##############################					
uguagecuc qquacuqsaq 410		ci.			
### ### ##############################	<400> SIXJUIMCE: 114				
### ### ### ### ### ### ### ### ### ##	идвидесиет уфицендаму		20		
2112 - LENTH: 18 2112 - SEQUENCE: 115 220 - FEATURE: 2212 - OTHER INFORMATION: Synthetic Encisic Acid 220 - SEQUENCE: 115 2210 - SEQUENCE: 116 2210 - SEQUENCE: 117 2210 - SEQUENCE: 118 2210 - SEQUEN					
### ### #### #########################					
*220> FTATURE: *221> OTHER INFORMATION: Synthetic Nucleic Acid *200> SEQUENCE: 115 *** *******************************	<212> TYPE: ENA				
### ### ##############################					
PROCESSED IN NO 118 **210	<22)> OTHER INFORMATION: Synthetic Nucleic Acad	di.			
210> SPQ ID NO 116 2115- LENGTH: 16 2125- CRGANISM: Astificial 2210- SPATURE: CRESS OTHER INSCRPATION: Synthetic Bucleic Acid 2400- SPEQUENCE: 116 2500- SPEQUENCE: 116 2500- SPEQUENCE: 116 2510- SPEQ ID NO 117 2511- LENGTH: 16 2512- TYPE: RNA 2510- SPEQUENCE: 117 2500- SPEQUENCE: 118 2511- LENGTH: 16 2511- LENGTH: 16 2511- SPEQUENCE: 118 2511- SPEQUENCE: 118 2512- SPEQUENCE: 118 2513- ORGANISM: Astificial 2513- ORGANISM: Astificial 2510- SPEQUENCE: 118 2510- SPEQUENCE: Astificial 2520- SPEQUENCE: Astificial	<400 > SEQUENCE: 115				
### ### ##############################	รทอดสิขาสีสิท นักกระกลัก		1.0		
### ### ##############################					
### ### ##############################					
### PROPRESS OF THE PROPRATION: Synthetic Nucleic Acid ###################################					
ACCES OTHER INFORMATION: Synthetic Nucleic Acid ACCES TYPE: RNA ACCES TY					
2210 SEQ ID NO 117 2213 DENGTH: 16 2223 TOPES REA 2213 ORGANISM: Artificial 2214 OTHER IMPORMATION: Syminetic Nucleic Acid 400> SEQUENCE: 317 2225 TOPES REA 2213 DENGTH: 16 2213 DENGTH: 16 2213 DENGTH: 16 2213 DENGTH: 16 2213 TOPES REA 2213 ORGANISM: Artificial 2200 FEATURE: 2215 TOPES IMPORMATION: Syminetic Nucleic Acid 400> SEQUENCE: 116 2210 TOPES IMPORMATION: Syminetic Nucleic Acid 400> SEQUENCE: 116 2210 TOPES INDA 2210 SEC ID NO 119 2213 DENGTH: 16 2230 FEATURE: 2230 FEATURE: 2230 FEATURE:		1			
C210 SEQ ID NO 117 C2113 DENSTH: 18 C2123 TYPE: RNA C2130 ORGANISM: Artificial C2203 OFFERTURE: C2203 OFFERT	:400 - SPQUENCE: 116				
C210 SEQ ID NO 117 C2113 DENSTH: 18 C2123 TYPE: RNA C2130 ORGANISM: Artificial C2203 OFFERTURE: C2203 OFFERT	equinuas quucuci		18		
C211> LENGTH: 18 C212> CTCANISM: Artificial C240> FEATURE: C223> OTHER INFORMATION: Synthetic Nucleic Acid C400> SEQUENCE: 317 CCCCGGGUUCU GAAGGGUGU C210> SEQ ID NO 118 C211> LENGTH: 16 C212> TYPE: RNA C213> ORGANISM: Artificial C20> FEATURE: C213> OTHER INFORMATION: Synthetic Nucleic Acid 400> SEQUENCE: 118 GCCUCCGGGU UCUGAAGG C10> SEQ ID NO 119 C210> LENGTH: 16 C210> SEQ ID NO 119 C210> LENGTH: 16 C210> SEQ ID NO 119 C210> LENGTH: 16 C210> SEQ ID NO 119 C210> LENGTH: 18 C220> SEQ ID NO 119 C210> LENGTH: 18 C220> SEQ ID NO 119 C220> SEQ					
### ### ##############################					
### PROCESS OF STATES OF S					
223's OTHER INFORMATION: Synthetic Nucleic Acid 2400's SPGUINCI: 117 2400's SPGUINCI: 117 2410's SPG ID NO 118 2411's LENGTH: 16 2412's TYPZ: RNA 113's ORGANISM: Antificial 1200's FRATURE: 2213's OTHER INFORMATION: Synthetic Nucleic Acid 400's SPGUINCI: 118 90000000000000000000000000000000000					
### 18 ################################		1			
TRICOGGUNER GAAGGUGN 118 FRIO. SEQ TO NO 118 FRIO. SEQ TO NO 118 FRIO. SEQ TYPE, RNA FRIO. SECTIVE. FRIO.					
210 SEQ ID NO 118 211 DENOTH: 16 212 TYPE: RNA 213 ORGANISM: Artificial 220 FEATURE: 221 OTHER IMPORMATION: Synthetic Macleic Acid 400 SEQUENCE: 118 geouceggu unugsagg 18 210 SEQ ID NO 119 211 LENTH: 16 212 TYPE: RNA 213 ORGANISM: Artificial 220 FEATURE: 223 OTHER IMPORMATION: Synthetic Nucleic Acid				*	
211> LEMSTH: 16 212> TYP2: RNA 713> ORGANISM: Artificial 1220> FEATURE: 222> OTHER IMPORMATION: Synthetic Macleic Acid 400> SEQUENCE: 118 99ccucceggu unugmagg 18 210> SEQ ID NO 119 211> LEMSTH: 16 212> TYPE: RNA 213> GREANISM: Artificial 220> FEATURE: 223> OTHER IMPORMATION: Synthetic Nucleic Acid	receddings dweddings		18		
211> LEMSTH: 16 212> TYP2: RNA 713> ORGANISM: Artificial 1220> FEATURE: 222> OTHER IMPORMATION: Synthetic Macleic Acid 400> SEQUENCE: 118 99ccucceggu unugmagg 18 210> SEQ ID NO 119 211> LEMSTH: 16 212> TYPE: RNA 213> GREANISM: Artificial 220> FEATURE: 223> OTHER IMPORMATION: Synthetic Nucleic Acid	510 - 610 TO 10 TO 11				
212% TTP2: RRA 213% ORGANISM: Antificial 220% PEATURE: 221% OTHER IMPORMATION: Synthetic Nucleic Acid 400% SECURICE: 116 geouceggu unugmagg 18 210% SEC ID NO 119 211% LENGTH: 16 213% ORGANISM: Artificial 220% PEATURE: 223% OTHER IMPORMATION: Synthetic Nucleic Acid					
220° PEATURE: 221° OTHER INFORMATION: Synthetic Nucleic Acid 400° SEQUENCE: 118 geouceggu unugmagg 18 210° SEQ ID NO 119 211° LERGIH: 18 212° TYR: RNA 213° CHEANISE: Artificial 220° PEATURE: 223° OTHER INFORMATION: Synthetic Nucleic Acid					
223% OTHER INFORMATION: Synthetic Nucleic Acid 400% SECURICE: 116 geouceggu unugmagg 18 210% SEC ID NO 119 211% LENGTH: 16 213% TYPE: RNA 213% GEGANISM: Artificial 220% FEATURE: 223% OTHER INFORMATION: Synthetic Nucleic Acid					
gccuccggu unugwagg 18 210> SEQ ID NO 119 211> LENGTH: 16 212> TYPE: ENA 211> GRGANISM: Artificial 220> FEATURE: 223> OTHER INFORMATION Synthetic Nucleic Acid					
210> SEQ ID NO 119 211> LERGIH: 16 212> TYPE: RNA 213> ORGANISM: Artificial 220> FEATURE: 223> OTHER INFORMATION Synthetic Nucleic Acid	400> SEQUENCE: 118				
211> LENGTH: 16 212> TYPE: RNA 213> GEGANISE: Artificial 220> FEATURE: 221> UTHER INFORMATION: Synthetic Nucleic Acid	igeeteeegu tieteaagg		18		
211> LENGTH: 16 212> TYPE: RNA 213> GEGANISE: Artificial 220> FEATURE: 221> UTHER INFORMATION: Synthetic Nucleic Acid					
213> CHEMANISH: Artificial 220> PEATURE: 223> OTHER INFORMATION: Synthetic Nucleic Acid	210× SEQ ID NO 119				
213 ORGANISM: Artificial 220 FEATURE: 223 OTHER INFORMATION Synthetic Nucleic Acid					
220> FEATURE: 223> OTHER INFORMATION Synthetic Mucleic Acid					
2232 OTHER INFORMATION Synthetic Mucleic Acid					
A A A A A A A A A A A A A A A A A A A					
ands viglorack: 113	400> SPQUENCE: 119				
geogeouse, gguveuga 18	geogeouee, ggoueug a		18		

continued

85

86

```
<210 > SEQ ID NO 120
<211> LENGTH: 15
<212> TYPS: RNA
<213> CRGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400 > SEQUENCE: 120
uncuganggu guucu
<210 > SEQ ID NO 121
<211 > LENGTH: 15
<212 > TYPE: F2A
<213> ORGANISM: Artificial
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 121
uceggaueug aaggu
                                                                                       15
<210> SEQ ID NO 122
<211> LEMSTH: 15
<212> TYPE: RNA
<213> ORGANISM: Artificial <220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<400> SEQUENCE: 122
                                                                                       15
ungecucegg uneng
<210 > SEC ID NO 123
<211> LEMMTH: 18
<212> TYPE: RNA
<211> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: Synthetic Nucleic Acid
<460> SEQUENCE: 123
```

The invention claimed is:

cuguugccuc cgguucug

I. An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of the nucleotide sequence of SEQ ID NO: 57, wherein the antisense oligomer is an oligomucleotide in which the sugar mojety and/or the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is modified, or a morpholino oligomer.

2. The antisense oligomer according to claim 1, wherein the sugar moiety of at least one nucleotide constituting the oligomedeotide is a ribose in which the 2'-OH group is replaced by any one selected from the group consisting of: OR, R, R'OR, SH, SR, NH₂, NHR, NR₂, N₃, CN, F, Cl, Br, and I, wherein R is an alkyl or an aryl and R' is an alkylene.

3. The antisense oligomer according to claim 1, wherein the phosphate-binding region of at least one nucleotide constituting the oligonucleotide is any one selected from the group consisting of: a phosphorothicate bond, a phosphoredithicate bond, an alkylphosphonate bond, a phosphoramidate bond, and a boranophosphate bond.

ramidate bond, and a boranophosphate bond.

4. The antisense oligomer according to claim 1, which is a morpholino oligomer.

The antisense oligomer according to claim 4, which is a phosphorediamidate morpholino oligomer.

6. The antisense oligomer according to claim 4, wherein 65 the 5' end is any one of the groups of chemical formulae (1) to (3) below:

(3)

87
-continued

88

OH

 A pharmaceutical composition for the treatment of muscular dystrophy, comprising as an active ingredient the antisense oligomer according to claim 1, or a pharmaceutically acceptable salt or hydrate thereof.